
<html lang="en"     class="pb-page"  data-request-id="ea39e96f-e746-4fb5-ad67-aeedf51937dc"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2013.56.issue-13;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/jm3017706;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Targeting Mutant KRAS for Anticancer Therapeutics: A Review of Novel Small Molecule Modulators" /></meta><meta name="dc.Creator" content="Yuanxiang  Wang" /></meta><meta name="dc.Creator" content="Christine E.  Kaiser" /></meta><meta name="dc.Creator" content="Brendan  Frett" /></meta><meta name="dc.Creator" content="Hong-yu  Li" /></meta><meta name="dc.Description" content="The RAS proteins play a role in cell differentiation, proliferation, and survival. Aberrant RAS signaling has been found to play a role in 30% of all cancers. KRAS, a key member of the RAS protein ..." /></meta><meta name="Description" content="The RAS proteins play a role in cell differentiation, proliferation, and survival. Aberrant RAS signaling has been found to play a role in 30% of all cancers. KRAS, a key member of the RAS protein ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 23, 2013" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm3017706" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2013 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm3017706" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm3017706" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm3017706" /></link>
        
    
    

<title>Targeting Mutant KRAS for Anticancer Therapeutics: A Review of Novel Small Molecule Modulators | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm3017706" /></meta><meta property="og:title" content="Targeting Mutant KRAS for Anticancer Therapeutics: A Review of Novel Small Molecule Modulators" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0017.jpeg" /></meta><meta property="og:description" content="The RAS proteins play a role in cell differentiation, proliferation, and survival. Aberrant RAS signaling has been found to play a role in 30% of all cancers. KRAS, a key member of the RAS protein family, is an attractive cancer target, as frequent point mutations in the KRAS gene render the protein constitutively active. A number of attempts have been made to target aberrant KRAS signaling by identifying small molecule compounds that (1) are synthetic lethal to mutant KRAS, (2) block KRAS/GEF interactions, (3) inhibit downstream KRAS effectors, or (4) inhibit the post-translational processing of RAS proteins. In addition, inhibition of novel targets outside the main KRAS signaling pathway, specifically the cell cycle related kinase PLK1, has been shown have an effect in cells that harbor mutant KRAS. Herein we review the use of various high-throughput screening assays utilized to identify new small-molecule compounds capable of targeting mutant KRAS-driven cancers." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm3017706"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm3017706">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm3017706&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm3017706&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm3017706&amp;href=/doi/10.1021/jm3017706" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2013</span><span class="cit-fg-volume">, 56</span><span class="cit-fg-issue">, 13</span><span class="cit-fg-pageRange">, 5219-5230</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/56/13" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/jm400282d" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Targeting Mutant KRAS for Anticancer Therapeutics: A Review of Novel Small Molecule Modulators</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yuanxiang++Wang">Yuanxiang Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christine+E.++Kaiser">Christine E. Kaiser</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brendan++Frett">Brendan Frett</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hong-yu++Li">Hong-yu Li</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Department of Pharmacoloy and Toxicology, College of Pharmacy, The University of Arizona, Tucson, Arizona 85721, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">BIO5 Oro Valley, The University of Arizona, 1580 Hanley Boulevard, Oro Valley, Arizona 85737, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 1-520-626-0083. E-mail: <a href="/cdn-cgi/l/email-protection#20484f4e4759554c4960504841524d4143590e4152495a4f4e410e454455"><span class="__cf_email__" data-cfemail="a2cacdccc5dbd7cecbe2d2cac3d0cfc3c1db8cc3d0cbd8cdccc38cc7c6d7">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm3017706&amp;href=/doi/10.1021%2Fjm3017706" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2013</span></span><span class="cit-volume">, 56</span><span class="cit-issue">, 13</span><span class="cit-pageRange">, 5219–5230</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 8, 2013</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>31 December 2012</li><li><span class="item_label"><b>Published</b> online</span>23 April 2013</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 July 2013</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm3017706" title="DOI URL">https://doi.org/10.1021/jm3017706</a></div><div class="article_header-article-copyright"><strong>Copyright © 2013 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5219%26pageCount%3D12%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYuanxiang%2BWang%252C%2BChristine%2BE.%2BKaiser%252C%2BBrendan%2BFrett%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D56%26issueNum%3D13%26contentID%3Djm3017706%26title%3DTargeting%2BMutant%2BKRAS%2Bfor%2BAnticancer%2BTherapeutics%253A%2BA%2BReview%2Bof%2BNovel%2BSmall%2BMolecule%2BModulators%26numPages%3D12%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5230%26publicationDate%3DJuly%2B2013">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm3017706"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">6666</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">76</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm3017706" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Targeting Mutant KRAS for Anticancer Therapeutics: A Review of Novel Small Molecule Modulators&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yuanxiang&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Christine&quot;,&quot;last_name&quot;:&quot;E. Kaiser&quot;},{&quot;first_name&quot;:&quot;Brendan&quot;,&quot;last_name&quot;:&quot;Frett&quot;},{&quot;first_name&quot;:&quot;Hong-yu&quot;,&quot;last_name&quot;:&quot;Li&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2013&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;23&quot;,&quot;issue&quot;:&quot;13&quot;,&quot;volume&quot;:&quot;56&quot;,&quot;pages&quot;:&quot;5219-5230&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm3017706&quot;},&quot;abstract&quot;:&quot;The RAS proteins play a role in cell differentiation, proliferation, and survival. Aberrant RAS signaling has been found to play a role in 30% of all cancers. KRAS, a key member of the RAS protein family, is an attractive cancer target, as frequent point mutations in the KRAS gene render the protein constitutively active. A number of attempts have been made to target aberrant KRAS signaling by identifying small molecule compounds that (1) are synthetic lethal to mutant KRAS, (2) block KRAS/GEF interactions, (3) inhibit downstream KRAS effectors, or (4) inhibit the post-translational processing of RAS proteins. In addition, inhibition of novel targets outside the main KRAS signaling pathway, specifically the cell cycle related kinase PLK1, has been shown have an effect in cells that harbor mutant KRAS. Herein we review the use of various high-throughput screening assays utilized to identify new small-molecule compounds capable of targeting mutant KRAS-driven cancers.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm3017706&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm3017706" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm3017706&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm3017706" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm3017706&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm3017706" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm3017706&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm3017706&amp;href=/doi/10.1021/jm3017706" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm3017706" /></input><a href="/doi/pdf/10.1021/jm3017706" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm3017706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm3017706%26sid%3Dliteratum%253Aachs%26pmid%3D23566315%26genre%3Darticle%26aulast%3DWang%26date%3D2013%26atitle%3DTargeting%2BMutant%2BKRAS%2Bfor%2BAnticancer%2BTherapeutics%253A%2BA%2BReview%2Bof%2BNovel%2BSmall%2BMolecule%2BModulators%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D56%26issue%3D13%26spage%3D5219%26epage%3D5230%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=291297" title="Cell signaling">Cell signaling</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/56/13" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jmcmar.2013.56.issue-13/production/jmcmar.2013.56.issue-13.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_null" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/medium/jm-2012-017706_0017.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The RAS proteins play a role in cell differentiation, proliferation, and survival. Aberrant RAS signaling has been found to play a role in 30% of all cancers. KRAS, a key member of the RAS protein family, is an attractive cancer target, as frequent point mutations in the KRAS gene render the protein constitutively active. A number of attempts have been made to target aberrant KRAS signaling by identifying small molecule compounds that (1) are synthetic lethal to mutant KRAS, (2) block KRAS/GEF interactions, (3) inhibit downstream KRAS effectors, or (4) inhibit the post-translational processing of RAS proteins. In addition, inhibition of novel targets outside the main KRAS signaling pathway, specifically the cell cycle related kinase PLK1, has been shown have an effect in cells that harbor mutant KRAS. Herein we review the use of various high-throughput screening assays utilized to identify new small-molecule compounds capable of targeting mutant KRAS-driven cancers.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18465" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18465" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The RAS (rat sarcoma) protein family members are all low-molecular-weight GTP-binding proteins that play a role in regulating cell differentiation, proliferation, and survival.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> There are three main members of the RAS family: HRAS, NRAS, and KRAS, all of which have been found to drive cancer formation and progression.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1-3)</a> Mutations in RAS are found in approximately 30% of human cancers.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> In the absence of a RAS mutation, increased RAS activity in human tumors has been shown to be the result of gene amplification, overexpression, or increased upstream activation.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Single point mutations of the RAS gene, affecting residues G12 and G13, abolish GAP-induced GTP hydrolysis through steric hindrance, while mutations of residue Q61 interfere with the coordination of a water molecule necessary for GTP hydrolysis.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> These mutations render the protein constitutively active, and the persistence of active GTP-bound RAS leads to the constant activation of its downstream effector pathways. KRAS is the most frequently mutated RAS isoform, having been shown to be mutated in 90% of pancreatic adenocarcinomas, 45% of colorectal cancers, and 35% of lung adenocarcinomas.<a onclick="showRef(event, 'ref2 ref6'); return false;" href="javascript:void(0);" class="ref ref2 ref6">(2, 6)</a> KRAS mutations have been associated with increased tumorigenicity and poor prognosis.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Additionally, the inhibition of activated RAS has been shown to revert malignant cells to a nonmalignant phenotype and cause tumor regression both in vitro and in vivo.<a onclick="showRef(event, 'ref4 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref4 ref7 ref8">(4, 7, 8)</a> Thus, KRAS is an attractive therapeutic target for a number of cancers.</div><div class="NLM_p last">While the development of a small molecule inhibitor of the constitutively active KRAS protein would be ideal as a cancer therapeutic, 25 years of work on drugs targeting the GTP binding pocket of mutant KRAS have thus far proven to be unsuccessful. To date, no effective therapy that specifically targets mutant KRAS is available. Targeting the constitutively active molecular switch of KRAS is quite difficult because the role of GDP or GTP is to stabilize inactive or active states of the RAS protein.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> This is in contrast to protein kinases in which phosphoryl transfer from ATP to a substrate is a rapid, catalytic process.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Additionally, because of picomolar affinity between KRAS and GTP, as well as the micromolar concentration of GTP in the cell, a competitive inhibitor is not particularly feasible.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Furthermore, KRAS activation and signaling are accomplished through protein–protein interactions (PPIs) with guanine nucleotide exchange factors (GEFs), GTPase activating proteins (GAPs), and the various KRAS effector proteins.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> PPIs are challenging to target because of the relatively featureless topologies of the surfaces involved.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> In spite of these issues, a number of attempts have been made to target aberrant KRAS signaling at different levels.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">KRAS Signaling Pathway</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78580" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78580" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Gaining a comprehensive understanding of the life cycle of the KRAS protein is essential to mounting a successful drug discovery effort. After RAS proteins are translated, they must undergo a series of post-translational modifications (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).<a onclick="showRef(event, 'ref2 ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref2 ref12 ref13 ref14">(2, 12-14)</a> Initially, the thiol group of the terminal cysteine in KRAS is farnesylated by farnesyltransferase (FTase).<a onclick="showRef(event, 'ref15 ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17 ref18">(15-18)</a> Next, the CAAX (C = cysteine; A = isoleucine; X = serine or methionine)<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19, 20)</a> protease RAS-converting enzyme 1 (RCE1) cleaves the terminal AAX amino acids, and the carboxy group of the cysteine is methylated by isoprenylcysteine carboxylmethyltransferase 1 (ICMT1).<a onclick="showRef(event, 'ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23">(21-23)</a> Finally, palmitoyl transferase (PTase) transfers a palmitoyl moiety to cysteine residues located just upstream of the C-terminus of HRAS, NRAS, and the KRAS-4A isoform.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The RAS protein then forms a stable interaction with the cell membrane via its farnesyl and palmitoyl groups as well as the positively charged C-terminal lysine residues. Thus, the post-translational modification of KRAS offers several possible drug targets: (1) FTase,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> (2) CAAX endopeptidase,<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25, 26)</a> (3) methyltransferase,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> and (4) palmitoyl transferase.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/medium/jm-2012-017706_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Post-translational processing of RAS proteins. Farnesyltransferase (FTase) catalyzes the transfer of a farnesyl group to the terminal cysteine of new synthesized RAS proteins. Next, the three C-terminal amino acids are cleaved by the endopeptidase RAS-converting enzyme 1 (RCE1). Carboxymethylation of of the terminal cysteine residue is accomplished by isoprenylcysteine carboxylmethyltransferase 1 (ICMT1). Finally, palmitoyl transferase (PTase) transfers a palmitoyl group to C-terminal cysteine residues of HRAS, NRAS, and the KRAS-4A isoform.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">RAS proteins cycle between the inactive GDP-bound form and the active GTP-bound form. This activation state is regulated by GEFs and GAPs (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>).<a onclick="showRef(event, 'ref6 ref28 ref29 ref30 ref31 ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref6 ref28 ref29 ref30 ref31 ref32 ref33">(6, 28-33)</a> When a growth factor binds to a tyrosine kinase receptor, it forms an active homodimer that undergoes autophosphorylation. This leads to binding of the adaptor proteins SHC and growth factor receptor bound 2 (GRB2). GRB2 then associates with GEFs through its SH3 domain.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> GEFs exchange bound GDP for GTP, thereby activating the RAS protein and initiating a signaling cascade. To terminate signaling, GAPs stimulate the intrinsic GTPase activity of RAS proteins, causing the hydrolysis of GTP to GDP, leading to deactivation of the RAS protein. Thus, upstream targets for KRAS inhibition include (1) tyrosine kinases,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> (2) the GRB2/GEF interaction,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> and (3) GEFs.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/medium/jm-2012-017706_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Upstream signaling of RAS. Activated growth-factor-recptor tyrosine kinases undergo autophosphorylation and interact with the adaptor proteins SHC and GRB2. These proteins associate with various GEFs which exchange GDP for GTP, thereby activating the RAS protein. GAPs stimulate the RAS protein’s intrinsic GTPase activity, causing the hydrolysis of GTP to GDP, thereby inactivating the protein.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">KRAS has many downstream effector proteins that it can interact with to alter cell survival and proliferation (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>).<a onclick="showRef(event, 'ref3 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref3 ref37 ref38">(3, 37, 38)</a> Active GTP-bound KRAS predominantly signals through RAF protein kinases, phosphoinositide 3-kinases (PI3K), guanine nucleotide exchange factors for the RAS-related protein Ral (RalGDS), and phospholipase Cε (PLCε). RAF initiates the mitogen-activated protein (MAP) kinase cascade, which activates extracellular signal-regulated kinase (ERK). This active kinase has numerous targets, including the transcription factor ELK1, which regulates the expression of cell-cycle progression genes.<a onclick="showRef(event, 'ref39 ref40 ref41 ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref39 ref40 ref41 ref42 ref43">(39-43)</a> The PI3K pathway activates AKT and leads to the transcription of prosurvival genes, cytoskeletal remodeling, and the activation of numerous transcription-factor pathways, most notably NF-κB.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44, 45)</a> RalGDS activation leads to the activation of the RAL1 binding protein: this in turn leads the inhibition of FOX transcription factors<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> which are involved in cell growth, proliferation, and differentiation. RalGDS can also signal through the JNK pathway to stimulate the transcription of prosurvival and cell-cycle progression genes.<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47, 48)</a> The activation of PLCε results in protein kinase C (PKC) activation and the mobilization of calcium from intracellular stores.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> It is clear from this brief overview that there are numerous downstream targets that can be inhibited in order to try and overcome aberrant KRAS signaling.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/medium/jm-2012-017706_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Downstream signaling of RAS. Ras interacts with a number of downstream effectors. The main ones include RAF protein kinases, phosphoinositide 3-kinases (PI3Ks), guanine nucleotide exchange factors for the RAS-related protein Ral (RalGDS), and phospholipase Cε (PLCε).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">High-Throughput Screening</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70662" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70662" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The screening of chemical compounds for pharmacological activity has been ongoing in various forms for the past 40 years. The recent advances in molecular biology, computer science, robotics, instrumentation, and overall process engineering have established high-throughput screening as a predominant tool in the field of drug discovery to identify compounds that are active against various biological targets or phenotypes. High-throughput screening (HTS) has been used to identify structurally diverse chemical compounds that are capable of blocking different stages of KRAS signaling in order to inhibit the proliferation of mutant KRAS-driven cancer cells both in vitro and in vivo.</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Synthetic Lethality Screening</h3><div class="NLM_p">Synthetic lethality screening aims to identify small molecules that selectively kill oncogene-expressing engineered cell lines.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Different groups have performed HTS screening, using different cell line models, in an attempt to find compounds that are lethal to mutant KRAS-driven cell lines. A few such examples and their successes are discussed below.</div><div class="NLM_p">Torrance et al. utilized DLD-1 colon cancer cells that harbor mutant KRAS and an isogenic derivative in which the mutant KRAS allele was deleted (KO cells).<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> A yellow fluorescent protein expression vector was introduced into the DLD-1 cells, while a blue fluorescent protein was introduced into the isogenic derivative. Equal volumes of the two cell lines were cocultured and tested against 29 440 compounds from the ChemBridge and NCI libraries, and results were assessed by analyzing the differential fluorescence intensity for blue and yellow fluorescent protein. Positive hits were then screened as above but over a range of drug concentrations. The main hits from this screen were a sulfinyl cytidine (<b>1</b>) derivative (<b>2</b> or <b>3</b>) and triphenyltetrazolium (<b>4</b>) (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>).<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> A mixture of the isomers <b>2</b> and <b>3</b> on DLD-1 and KO cells demonstrated IC<sub>50</sub> values of 125 and ∼750 ng/mL, respectively, while the IC<sub>50</sub> values for <b>4</b> on DLD-1 and KO cells were ∼2 and ∼12 μg/mL. Both compounds demonstrated a 6-fold selectivity for the mutant KRAS-cell-lines-containing DLD-1 cells over the KO cells. Further research demonstrated that the mixture of isomers <b>2</b> and <b>3</b> selectively inhibited the growth of the KRAS<sup>G12 V</sup>-transformed rat kidney epithelial cells compared to the parental RK3E cell line, while compound <b>4</b> had no effect in these two assays. The antitumor activity of the mixture of isomers <b>2</b> and <b>3</b> was also assessed in vivo using HCT116 and DLD-1 xenograft models, both of which harbor a single G13D point mutation in the KRAS gene; at 150 mg/kg, tumor volumes were reduced by approximately 65% and 45%, respectively.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/medium/jm-2012-017706_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structures of <b>1</b>, <b>2</b>, <b>3</b>, and <b>4</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Guo et al. utilized human ovarian surface epithelial cells that were immortalized with human telomerase reverse transcriptase (hTERT) and SV40 (T29) transformed with either mutant KRAS (T29Kt1) or mutant HRAS (T29Ht1).<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Ten-thousand compounds from the ChemBridge library were screened against the three cell lines, and a sulforhodamine B (SRB) colorimetric assay was used to determine cytotoxicity. Initial hits found to inhibit >50% of cell growth were confirmed by two more SRB dose–response tests. The hit identified was oncrasin 1 (<b>5</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). Compound <b>5</b> induced cytotoxicity in T29Ktl cells in a dose-dependent manner, with an IC<sub>50</sub> of 4.81 μM. However, no cytotoxicity was detected in T29 or T29Ht1 cells. Further research demonstrated that <b>5</b> effectively killed KRAS mutant lung cancer cells (H460, H2122, H2887, and A549) with an IC<sub>50</sub> of ≤3 μM but had little effect on the cell viability of lung cancer cells with wild-type RAS (H322 and H1395) or lung cancer cells that harbor mutant NRAS (H1299 and H2087). These results illustrate that <b>5</b> is highly selective for cells transformed with mutant KRAS. The in vivo antitumor activity of <b>5</b> was assessed using an H460 lung cancer xenograft model with daily intraperitoneal (ip) injections of 100 mg/kg. Compound <b>5</b> inhibited tumor growth by 75.4% compared to a solvent control, prolonged survival from 24 to 32 days and was well tolerated as evidenced by no weight loss. Additionally, the researchers noted that <b>5</b> was also synthetically lethal to protein kinase Cι; but the biological mechanisms behind this dual synthetic lethality remain to be determined.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/medium/jm-2012-017706_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Structure of <b>5</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Shaw et al. utilized mouse embryonic fibroblasts (MEFs) that expressed oncogenic KRAS<sup>G12D</sup> to identify effective therapeutic agents for patients with KRAS mutant tumors.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Over 50 000 compounds were screened against KRAS wild-type and mutant expressing MEF cell lines using a high-throughput ATP-based cell viability assay (CellTiter-Glo (Promega)). This assay identified tolperisone (<b>6</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>) as a lead, which showed significant differential activity in the KRAS WT cell line compared to the KRAS<sup>G12D</sup> cell line in the viability assays, as well as in a bromodeoxyuridine (BrdU) incorporation assay. Subsequently, 10 derivatives of <b>6</b> were examined to explore structure–activity relationships. The derivative lanperisone (<b>7</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>)<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> showed the most potent and selective activity against KRAS<sup>G12D</sup> MEFs, with an IC<sub>50</sub> of 4 μM in an ATP-based cell viability assay. Compound <b>7</b>, a single isomer with a minor structural modification from <b>6</b>, was shown to induce reactive oxygen species that are inefficiently scavenged in KRAS mutant cells leading to apoptosis. This increase in oxidative stress is the putative mechanism of action for compound <b>7</b>. In vivo pharmacological studies were carried out using compound mutant MEFs carrying KRAS<sup>G12D</sup> in a p53-null background. Results showed that tumors from mice treated with <b>7</b> were 24% smaller (by volume) and 37% smaller (by weight) compared to tumors from control animals. With human safety and pharmacokinetic data already completed, <b>7</b> is poised for rapid clinical development.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/medium/jm-2012-017706_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structures of <b>6</b> and <b>7</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In summary, researchers have identified several lead compounds to treat KRAS driven cancer using synthetic lethality screening. However, it should be noted that the synthetic lethality screening approach is based on a phenotype, not a molecule target. Thus, while there is selectivity based on the expression of mutant KRAS, the exact target at a molecular level is unknown. This fact can limit the full understanding of the biology involved in the selectivity of the compounds and accordingly the design of more druglike analogues.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Blocking KRAS/GEF Interactions</h3><div class="NLM_p">While PPIs are challenging to target because they often lack a defined binding pocket for small molecules, fragment-based screening is well-suited for this endeavor.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Outside the guanine nucleotide-binding domain, the KRAS protein has no known allosteric sites for potential modulation.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Several RAS-GEFs have been identified, and most research efforts have been focused on son of sevenless (SOS). The pockets adjacent to the KRAS/SOS contact surface are amenable to small-molecule binding.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> In 2012, two groups at Genentech and Vanderbilt independently utilized NMR-based fragment screening to identify small molecules that bind to the pocket adjacent to the KRAS/SOS interaction surface and subsequently interfere with the KRAS/SOS interaction.<a onclick="showRef(event, 'ref10 ref53'); return false;" href="javascript:void(0);" class="ref ref10 ref53">(10, 53)</a></div><div class="NLM_p">Fragments are defined as low molecular weight (120–250 Da), moderately lipophilic (clogP < 3), highly soluble organic molecules that typically bind to their target protein with low affinity (100 μM to millimolar).<a onclick="showRef(event, 'ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref54 ref55">(54, 55)</a> In order to identify fragments that bind to KRAS<sup>G12D</sup>, both groups utilized a target-based NMR method, measuring the changes in the chemical shift of a labeled target protein upon ligand binding, with <sup>15</sup>N-labeled GDP-bound KRAS<sup>12D</sup>. Fragment binding was assessed by changes in the resonance position of cross-peaks in the <sup>1</sup>H/<sup>15</sup>N two-dimensional heteronuclear single-quantum coherence spectra.<a onclick="showRef(event, 'ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref56 ref57">(56, 57)</a> The Genentech group also used the ligand-based approach of saturation transfer difference.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> In this approach, the protein is selectively irradiated and magnetization is transferred from the protein to the bound ligand. The magnetized ligand is then detected in the free solution, and difference spectroscopy (with an unirradiated protein reference spectrum) is utilized to identify the bound ligand. Although these methods are not considered to be a high-throughput methodology, NMR automation and the pooling of test fragments for screening allowed for large fragment libraries to be screened relatively quickly.</div><div class="NLM_p">DCAI (<b>8</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>a), identified by Genentech, was found to bind in the hydrophobic pocket located between the α2 helix (of the switch II region) and the core β-sheet of the KRAS protein and thereby interrupt KRAS/SOS association.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Titration studies with <b>8</b> indicated that it blocked both nucleotide exchange and release reactions, with IC<sub>50</sub> values of 342 ± 22 and 155 ± 36 μM, respectively. It was also noted that a secondary electronegative binding cleft is formed in the protein upon fragment binding. It is proposed that <b>8</b> blocks the first phase of the exchange reaction by inhibiting nucleotide release from KRAS.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/medium/jm-2012-017706_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (a) Structures of compounds shown to interfere with the KRAS/SOS interaction. (b) Overlay of <b>8</b> (pink) and a compound similar to <b>11</b> (teal) in the hydrophobic binding pocket of KRAS. Reproduced with permission of D. Erlanson.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The Vanderbilt group<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> screened 11 000 fragments of which 140 were shown to bind to GDP-bound KRAS<sup>G12D</sup>. Indole derivative <b>9</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>a) is a representative example of the hits that exhibit binding affinity to KRAS<sup>G12D</sup> at 1.3–2 mM. Furthermore, compound <b>9</b> was shown to inhibit SOS-mediated nucleotide exchange, thereby preventing the activation of KRAS. Using structure-based design, the Vanderbilt group added functionality to their original fragment hit in order to target the secondary electronegative binding cleft formed upon fragment binding. The resulting <i>S</i>-isoleucin derivative <b>10</b> and <span class="smallcaps smallerCapital">d</span>-proline analogue <b>11</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>a)<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> displayed improved binding affinity (190 and 340 μM, respectively) and were capable of inhibiting a greater percent of SOS-catalyzed nucleotide exchange. Additionally, a molecular modeling overlay indicates that compound <b>11</b> binds to the same hydrophobic pocket as <b>8</b>; however, they appear to make very different contacts (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>b).<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Inhibiting KRAS Effectors</h3><div class="NLM_p">Because of the difficulty of targeting KRAS directly, efforts have been put into targeting the downstream effector pathways, particularly the Raf-MEK-ERK<a onclick="showRef(event, 'ref59 ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref59 ref60 ref61">(59-61)</a> and PI3K pathways.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44, 45)</a> Raf kinase inhibitors, such as sorafenib (<b>12</b>)<a onclick="showRef(event, 'ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref62 ref63">(62, 63)</a> and vemurafenib (<b>13</b>)<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>), have shown impressive antitumor activity. However, the use of Raf inhibitors in RAS mutant cancer cells has been shown, paradoxically, to promote Raf-MEK-ERK signaling, thus precluding their use.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Furthermore, data suggest that RAS mutant tumors are insensitive to single-agent PI3K inhibitors.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> On the other hand, certain inhibitors of MEK, such as selumetinib (<b>14</b>)<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> and GDC-0973 (<b>15</b>)<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>), have shown antiproliferative efficacy in RAS mutant cancers.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/medium/jm-2012-017706_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Structures of <b>12</b>, <b>13</b>, <b>14</b>, and <b>15</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Daouti et al. recently screened compounds in an IMAP kinase assay (Molecular Devices) with a cRaf/MEK/ERK cascade.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> This unique assay detects phosphorylation by the binding of an FITC-labeled ERK substrate peptide to a proprietary binding reagent bead.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> To determine MEK specificity, secondary assays with Caliper LabChip mobility shift kinase kits were utilized with cRaf and MEK/ERK cascades independently.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> These assays measure the conversion of a fluorescent peptide substrate to a phosphorylated product on a microfluidic chip by separating the nonphosphorylated substrate from the phosphorylated product via electrophoresis and detection via laser-induced fluorescence.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Of the compounds screened, a new class of potent and selective MEK1/2 inhibitors, represented by RO4927350 (<b>16</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>) was identified.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> In a cRaf/MEK/ERK cascade assay, compound <b>16</b> potently inhibited MEK1 kinase activity with an IC<sub>50</sub> of 23 nM. Interestingly, it also showed consistent MEK inhibition with ATP concentrations ranging from 2 to 250 μM, which suggests that <b>16</b> is a non-ATP-competitive inhibitor and induces or stabilizes a novel fold in the MEK kinase. Compound <b>16</b> showed activity in the cRaf/MEK/ERK and MEK/ERK assays (with <i>K</i><sub>i</sub> values of 53 and 184 nM, respectively) but was not active in the cRaf assay (<i>K</i><sub>i</sub> > 50 μM) when the compound was tested in the Caliper cRaf assay. Ambit’s proprietary kinase profiling platform was used to assess the effects of <b>16</b> (10 μM) on 227 different kinases, and it was found to be inactive against all other kinases, including cRaf and bRaf. The antitumor activity of <b>16</b> was investigated in vivo in a LOX human melanoma xenograft model in nude mice, containing the most common activating bRaf mutation (V600E). When <b>16</b> was administered orally to LOX tumor-bearing mice twice daily with doses ranging from 12.5 to 200 mg/kg for 11 days, dose-dependent antitumor activity was observed and partial or complete tumor regression was elicited at doses above 50 mg/kg. This compound was determined to have a unique mechanism of action: inhibiting both MEK and ERK phosphorylation simultaneously.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/medium/jm-2012-017706_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Structures of <b>16</b>, <b>17</b>, and <b>18</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Lead optimization to improve the potency and PK–PD profile of <b>16</b> resulted in RO5068760 (<b>17</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>),<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> which contains a phenyl group in place of the thiazole in <b>16</b>. In vitro, <b>17</b> demonstrates MEK1 kinase inhibitory activity with an IC<sub>50</sub> of 0.025 ± 0.012 μM in a cRaf/MEK/ERK cascade assay, a 2-fold improvement in potency compared to <b>16</b>. In vivo characterization of MEK 1/2 inhibition (as measured by ERK phosphorylation) in LOX melanoma and HT-29 colorectal cancer models gave estimated EC<sub>50</sub> values in plasma of 1.36 and 3.35 μM, respectively. Furthermore, to produce ≥90% of tumor inhibition in vivo, plasma concentrations of <b>17</b> needed to be 0.65 or 5.23 μM for bRafV600E or mutant KRAS tumor models, respectively. These data were similar to the IC<sub>95</sub> values (0.64 or 4.1 μM) determined for cellular growth inhibition in vitro. Compound <b>17</b> is currently in preclinical development.</div><div class="NLM_p last">Tumor cell lines that harbor oncogenic mutation in both RAS and PIK3CA have been shown to be resistant to MEK inhibition.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Thus, dual combinations of cRaf-MEK-ERK and PI3K inhibitors may be needed to effectively treat RAS mutant cancers. Indeed, combined inhibition of MEK and PI3K signaling showed good antitumor activity in mice with mutant KRAS-driven lung tumors.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> For example, when NVP-BEZ235 (<b>18</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>),<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> a potent dual inhibitor of PI3K and mTOR, was combined with the MEK inhibitor <b>14</b>, there was marked synergy in shrinking mutant KRAS lung cancers.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Additionally, after 2 days of the combination treatment, there was notable down-regulation of PI3K and ERK.</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Inhibiting the Post-Translational Processing of KRAS</h3><div class="NLM_p">As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>, RAS proteins undergo a four-stage post-translational lipid modification: (1) farnesylation by FTase, (2) proteolytic cleavage of the terminal AAX motif by the CAAX protease RCE1, (3) carboxymethylation of the terminal cysteine by ICMT1, and (4) palmitoylation of cysteine residues close to the C-terminus of the protein.<a onclick="showRef(event, 'ref4 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref6">(4, 6)</a> As membrane localization is required for the signaling and transforming capabilities of KRAS,<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> any of these points represent viable targets for therapeutic intervention.</div><div class="NLM_p">FTase is an essential enzyme that attaches a 15-carbon isoprenoid farnesyl group to KRAS and is required for its proper localization and activity. Farnesyltransferase inhibitors (FTIs)<a onclick="showRef(event, 'ref74 ref75'); return false;" href="javascript:void(0);" class="ref ref74 ref75">(74, 75)</a> fall into two categories: the CAAX peptidomimetics, including FTI-276 (<b>19</b>),<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> FTI-277 (<b>20</b>),<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> L-744832 (<b>21</b>),<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> B956 (<b>22</b>),<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> and FTI-2153 (<b>23</b>)<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>), and the non-peptidomimetics, which include tipifarnib (<b>24</b>),<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> lonafarnib (<b>25</b>),<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> and BMS-214662 (<b>26</b>)<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>). A number of recent publications have described their preclinical efficacy.<a onclick="showRef(event, 'ref4 ref75 ref84 ref85'); return false;" href="javascript:void(0);" class="ref ref4 ref75 ref84 ref85">(4, 75, 84, 85)</a> In the case of compound <b>26</b>, the mean IC<sub>50</sub> values for HRAS farnesylation and KRAS farnesylation were determined to be 1.3 and 8.4 nM, respectively. Intravenous administration at 75 mg/kg compound <b>26</b> for 24 h led to 90% tumor cell kill in HCT-116 xenograft models.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> While compound <b>26</b> was able to reverse the HRAS-transformed phenotype in vivo, it was unable to do the same for the KRAS-transformed phenotype, likely because of the potential geranylation of KRAS as an alternative to farnesylation. In fact, in the presence of FTIs the geranylation of KRAS is able to rescue its processing.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a></div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/medium/jm-2012-017706_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Structures of selected farnesyltransferse inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>24</b> has displayed clinical efficacy as a single agent in elderly patients with acute myeloid leukemia (AML),<a onclick="showRef(event, 'ref87 ref88 ref89'); return false;" href="javascript:void(0);" class="ref ref87 ref88 ref89">(87-89)</a> myeloproliferative disorders,<a onclick="showRef(event, 'ref90 ref91'); return false;" href="javascript:void(0);" class="ref ref90 ref91">(90, 91)</a> high-risk myelodysplasia,<a onclick="showRef(event, 'ref92 ref93 ref94'); return false;" href="javascript:void(0);" class="ref ref92 ref93 ref94">(92-94)</a> and multiple myeloma.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> It has also been investigated in combination with etoposide for the treatment of AML: in a phase I trial 21 of 84 patients (25%) achieved complete remission, with a median complete remission duration of 9.8 months.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> Additionally, compound <b>24</b> was investigated in combination with gemcitabine for the treatment of advanced pancreatic cancer: while the combination gave a favorable toxicity profile, overall survival was not prolonged compared to gemcitabine as a single agent.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> Compound <b>25</b> has not shown promising clinical acitivty as a monotherapy for solid tumors, as phase II monotherpy trials for advanced pancreatic,<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> advanced colorectal,<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> and head and neck cancers<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> indicated single-agent activity to be <10%.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> However, <b>25</b> has shown some single agent activity in advanced hematologic malignancies.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> Combination of <b>25</b> and gemcitabine in a phase II trial as a second line treatment for advanced urothetial cancer gave a good response rate,<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> but a randomized phase III trial will be needed to assess the contribution of <b>25</b>.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a></div><div class="NLM_p">The loss of RCE1 has been shown to cause a mislocalization of RAS proteins and to reduce RAS-induced transformation in cells.<a onclick="showRef(event, 'ref9 ref104'); return false;" href="javascript:void(0);" class="ref ref9 ref104">(9, 104)</a> In an effort to find small-molecule inhibitors of RCE1, Manandhar et al. screened the National Cancer Institute Diversity Set compound library in an in vitro assay utilizing yeast Rce1p.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> In this high-throughput assay, diluted yeast (SM3164) membranes overexpressing the CAAX protease Rce1p were incubated with the compounds prior to the addition of a quenched fluorogenic substrate based on the KRAS C-terminal sequence. Results were determined by measuring the fluorescence every 30–60 s over a 60 min time-course. Of the almost 2000 compounds screened, 46 inhibitors were initially identified in a RAS-based assay and 9 compounds (selected examples <b>27</b>–<b>30</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>)<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> were effective in a secondary assay with a yeast a-factor mating pheromone substrate peptide. The IC<sub>50</sub> values of these nine compounds were in the low micromolar range for both yeast (6–35 μM) and human Rce1p (0.4–46 μM). Additionally, copper complex <b>30</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>) showed good selectivity for Rce1p compared to the competitive CAAX protease Ste24p.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/medium/jm-2012-017706_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Structures of RCE1 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Disruption of ICMT1 results in a significant mislocalization of RAS proteins and has been shown to inhibit cell growth and KRAS-induced oncogenic transformation in nude mice.<a onclick="showRef(event, 'ref9 ref27'); return false;" href="javascript:void(0);" class="ref ref9 ref27">(9, 27)</a> Using a radioactive HTS, Winter-Vann et al. discovered a small-molecule inhibitor of ICMT1.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The assay used measured ICMT1 activity by the incorporation of an [<sup>3</sup>H]methyl group into a farnesylated RCE1-proteolyzed KRAS substrate. In this assay, Sf9 insect cell membranes containing either recombinant RCE1 or ICMT1 were prepared and incubated with the library compounds. Results were assessed by the incorporation of a [<sup>3</sup>H]methyl group into a farnesylated, Rce1-proteolyzed KRAS substrate. Compounds displaying >50% inhibition of ICMT were screened in a secondary assay with an ICMT substrate biotin <i>S</i>-farnesyl-<span class="smallcaps smallerCapital">l</span>-cysteine (BFC). The most potent compound was determined to be cysmethynil (<b>31</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a>),<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> which gave an IC<sub>50</sub> of 2.4 μM in the BFC assay. This compound was also shown to inhibit cell growth in an ICMT1-dependent fashion, cause mislocalization of RAS, and impair epidermal growth factor-induced MAPK signaling. Additionally, compound <b>31</b> displayed high specificity for ICMT, as it did not inhibit other enzymes in the prenylation pathway at 50 μM including FTase, geranylgeranyltransferase type I, RCE1, an AdoMet-dependent DNA methyltransferase, and an unrelated protein methyltransferase.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/medium/jm-2012-017706_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Structure of <b>31</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As membrane localization is essential for KRAS activity, van der Hoeven et al.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> developed a high-content assay to identify compounds capable of inhibiting KRAS membrane localization. The Prestwick chemical library was screened against wild-type Madin–Darby canine kidney epithelial (MDCK) cells or MDCK cells expressing green fluorescent protein (GFP) attached to the C-terminal 24 or 25 amino acids of KRAS (GFP-CTK) or HRAS (GFP-CTH). The cell lines were seeded in 96-well plates and exposed to the chemical library compounds for 48 h at 4 μg/mL. Plates were imaged to assess the compounds’ ability to displace the GFP-CTK or GFP-CTH from the plasma membrane. The hit identified was fendiline (<b>32</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a>), which selectively and significantly mislocalized GFP-CTK compared to GFP-CTH. GFP-CTK was shown to be redistributed to endomembranes including the endoplasmic reticulum, Golgi apparatus, and cytosol. Furthermore, compound <b>32</b> inhibited downstream KRAS signaling and was able to block the proliferation of pancreatic, colon, lung, and endometrial cells. Compound <b>32</b> is a known L-type calcium channel blocker; however, as other classes of L-type calcium channel blockers were not shown to mislocalize KRAS, it is likely that the mechanism of disrupting KRAS membrane localization is not related to calcium channel blockade.</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/medium/jm-2012-017706_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0014.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Structures of <b>32</b>, <b>33</b>, and <b>34</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The farnesyl isoprenoid-containing small molecules salirasib (<b>33</b>) and TLN-4601 (<b>34</b>) (Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a>) have also been shown to disrupt RAS membrane anchorage, leading to an inhibition of tumor cell growth.<a onclick="showRef(event, 'ref107 ref108 ref109'); return false;" href="javascript:void(0);" class="ref ref107 ref108 ref109">(107-109)</a> More specifically, these compounds are proposed to act as antagonist of RAS function by competing for membrane-bound farnesyl-binding proteins located in the cell membrane.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> These compounds have been evaluated in a number of clinical trials with varying results.<a onclick="showRef(event, 'ref111 ref112 ref113'); return false;" href="javascript:void(0);" class="ref ref111 ref112 ref113">(111-113)</a></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Emerging Targets and Novel Mechanisms</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22632" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22632" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Many attempts to target mutant KRAS have been made; however, KRAS-related treatments have proved challenging in the clinic. Inhibitors of the upstream target epidermal growth factor receptor (EGFR), gefitinib (<b>35</b>) and erlotinib (<b>36</b>) (Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a>), can significantly block KRAS signaling,<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> but their effect is brief because of the rapid development of drug resistance. This often leads patients to develop a tumor recurrence that is generally refractory to chemotherapy and/or targeted therapy.</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/medium/jm-2012-017706_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0015.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Structures that are active in the KRAS mutant synthetic lethal assays.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To elucidate the biological mechanisms that play a role in regulating aberrant KRAS signaling but that are independent from the KRAS signaling cascade, RNAi screening has been the technique of choice.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> RNAi research can be completed in a high-throughput manner and aims to identify a novel synthetically lethal interaction. Using this technique, Luo et al.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a>found KRAS mutant cells to be hypersensitive to the inhibition of the mitotic kinase polo-like kinase 1 (PLK1).<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> PLK1 plays an important role in the G2/M and M phases of the cell cycle and has been reported to have deregulated activity in various cancer cells.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> The PLK1 inhibitor BI-2536 (<b>37</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a>)<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> was shown to inhibit the proliferation of KRAS mutant DLD-1 cells at 25 nM by >50%. In contrast, wild-type KRAS DLD-1 cells were unaffected by the treatment. Compound <b>37</b> also showed a statistically significant reduction in tumor volume in a KRAS mutants DLD-1 xenograft model.</div><div class="NLM_p">Luo et al. also showed that KRAS mutant cells are sensitive to proteasome inhibition.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> By use of the proteasome inhibitors MG132 (<b>38</b>) and bortezomib (<b>39</b>) (Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a>), proteasome inhibition was shown to exhibit synthetic lethality in cells that harbor mutant KRAS.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> Additionally, researchers showed that paclitaxel (<b>40</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a>)<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> produced a specific and marked reduction in cell fitness for mutant KRAS cells. This indicates that cells harboring mutant KRAS are hypersensitive to mitotic disruption, as the mitotic cycle of wild-type KRAS cells was not statistically affected.</div><div class="NLM_p last">Kumar et al.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> identified the transcription factor GATA binding protein 2 (GATA2) as being essential for the survival of non-small-cell lung carcinomas (NSCLC) that harbor mutant KRAS. Indeed, deletion of GATA2 in KRAS mutant NSCLC xenografts models (via tamoxifen induction of GATA2<sup>Flox/Flox</sup> mice) led to near-complete tumor regression. In another study investigating NSCLC, Puyol et al.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> identified cyclin-dependent kinase 4 (CDK4) as essential for propagating the survival of lung cells harboring mutant KRAS, as deletion of CDK4 led to immediate senescence and halted tumor progression in mouse models.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Future Prospects</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44213" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44213" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">HTS has been used to identify numerous compounds capable of disrupting the KRAS signaling pathway. However, no therapy capable of specifically and effectively targeting mutant KRAS is currently available. The problem is not due to a lack of therapeutic targets but rather due to a lack of a comprehensive understanding of the biology underlying the disease. Cell signaling is often depicted as a linear cascade, and this model is used to identify potential therapeutic targets. However, the linear depiction of cell signaling is an oversimplification. In reality, cell signaling is complex and dynamic, in which one protein interacts with many others in a nonlinear, circuit-like fashion. Cancer is not caused by just one genetic mutation or aberrant protein that drives the disease. Instead, multiple mutations existing together form and drive the progression of cancer. Thus, effective treatment will require the regulation of many targets to attain a sustained response. Therefore, a therapy capable of inhibiting multiple pathways/targets is likely the best option for treating mutant KRAS-driven cancers.</div><div class="NLM_p">KRAS can activate both PI3K and RAF, which lie in different signaling cascades. If only one pathway is inhibited, the cell can circumvent this event by overexpressing the other pathway and thereby create a resistant phenotype. For example, treatment with just the multikinase inhibitor PP-121 (<b>41</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a>),<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> which is active against PI3K without blocking the RAS/RAF pathway, will likely be ineffective in patients. A better treatment option would be blocking both the PI3K and the RAS/RAF pathways, which could be achieved by the combination of a MEK inhibitor, such as <b>14</b>, with an AKT inhibitor, such as MK-2206 (<b>42</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a>).<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> Inhibition of both pathways simultaneously may be able to produce better efficacy in mutant KRAS-driven cancers, as opposed to the inhibition of only one pathway.</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/medium/jm-2012-017706_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0016.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Structures of <b>41</b> and <b>42</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The design of a successful cancer therapeutic relies on an understanding of the biology underlying the disease. The idea that cells signal in a linear fashion is quickly becoming antiquated and is being replaced with circuit-type models. Likewise, cancer treatments need to be designed under the notion of circuit signaling. We expect that employing this rationale will lead to better treatments, more effective drug combinations, and better outcomes for patients.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/jm3017706" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32786" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32786" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong-yu Li</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacoloy and Toxicology, College of Pharmacy, The
University of Arizona, Tucson, Arizona 85721, United
States</span>; 
    <span class="hlFld-Affiliation affiliation">BIO5 Oro Valley, The University of Arizona, 1580 Hanley Boulevard, Oro
Valley, Arizona 85737, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#7e16111019070b12173e0e161f0c131f1d07501f0c170411101f501b1a0b"><span class="__cf_email__" data-cfemail="543c3b3a332d21383d14243c35263935372d7a35263d2e3b3a357a313021">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuanxiang Wang</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacoloy and Toxicology, College of Pharmacy, The
University of Arizona, Tucson, Arizona 85721, United
States</span>; 
    <span class="hlFld-Affiliation affiliation">BIO5 Oro Valley, The University of Arizona, 1580 Hanley Boulevard, Oro
Valley, Arizona 85737, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christine E. Kaiser</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacoloy and Toxicology, College of Pharmacy, The
University of Arizona, Tucson, Arizona 85721, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brendan Frett</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacoloy and Toxicology, College of Pharmacy, The
University of Arizona, Tucson, Arizona 85721, United
States</span>; 
    <span class="hlFld-Affiliation affiliation">BIO5 Oro Valley, The University of Arizona, 1580 Hanley Boulevard, Oro
Valley, Arizona 85737, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Y.W. and C.E.K. contributed equally. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72862" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72862" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Yuanxiang Wang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=BIO-d7e1245-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Yuanxiang Wang</b> obtained his Ph.D. in Medicinal Chemistry from Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China, under the supervision of Professor Ao Zhang in 2012. He is currently in a postdoctoral position under the direction of Professor Hong-yu Li at the University of Arizona. His main areas of expertise are development of novel synthetic methods to produce druglike heterocyclic chemical scaffolds, kinase inhibitor design, and total synthesis of bioactive natural products.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Christine E. Kaiser</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=BIO-d7e1250-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Christine E. Kaiser</b> is currently persuing a Ph.D. degree in the Drug Discovery and Development program at the University of Arizona under the advisement of Professor Laurence Hurley. She has an interest in targeting novel DNA secondary structures to regulate the transcription of various oncogenes. Her expertise is in the characterization of DNA secondary structures, computational modeling, and optimization of in vitro and in vivo biological assays for use in high-throughput screening.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Brendan Frett</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=BIO-d7e1255-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Brendan Frett</b> is currently perusing a Ph.D. degree in the Drug Discovery and Development program at the University of Arizona under the advisement of Professor Hong-yu Li. He has a strong interest in small molecule inhibitors for novel oncology-related targets. His expertise is in the development and synthesis of druglike compounds, developing biological assays for high-throughput compound screening, computational modeling, kinase inhibitor design, and the discovery of unique synthetic methodologies.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Hong-yu Li</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=BIO-d7e1260-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Hong-yu Li</b> is currently an Associate Professor of Medicinal Chemistry at the College of Pharmacy at the University of Arizona. He received his Ph.D. degree from the University of Tokyo, Japan, and did his postdoctoral trainings at Columbia University, NY (with Professor Koji Nakanishi), and Harvard University, MA (with Professor Yoshito Kishi). He previously worked at Eli Lilly where he focused on oncology drug discovery. His current research interests are in chemical biology and drug discovery, especially for oncology related targets and phenotypes. In his lab at the University of Arizona, a highly potent (picomolar activity in an oncogene-driven cancer cell line), selective, and orally bioavailable small molecule drug inhibitor was discovered and is currently ready for preclinical development and further IND filing.</p></figure></div><div class="ack" id="ACK-d7e1265-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08077" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08077" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We are grateful to Professor Laurence Hurley of the University of Arizona College of Pharmacy for his critical reading and suggestions.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i17" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i17"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i18" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i18"> Abbreviations Used</h2><tr><td class="NLM_term">RAS</td><td class="NLM_def"><p class="first last">rat sarcoma</p></td></tr><tr><td class="NLM_term">GTP</td><td class="NLM_def"><p class="first last">guanosine triphosphate</p></td></tr><tr><td class="NLM_term">GDP</td><td class="NLM_def"><p class="first last">guanosine diphosphate</p></td></tr><tr><td class="NLM_term">PPI</td><td class="NLM_def"><p class="first last">protein–protein interaction</p></td></tr><tr><td class="NLM_term">GEF</td><td class="NLM_def"><p class="first last">guanine nucleotide exchange factor</p></td></tr><tr><td class="NLM_term">GAP</td><td class="NLM_def"><p class="first last">guanosine triphosphatase activating protein</p></td></tr><tr><td class="NLM_term">FTase</td><td class="NLM_def"><p class="first last">farnesyltransferase</p></td></tr><tr><td class="NLM_term">RCE1</td><td class="NLM_def"><p class="first last">RAS-converting enzyme 1</p></td></tr><tr><td class="NLM_term">ICMT1</td><td class="NLM_def"><p class="first last">isoprenylcysteine carboxylmethyltransferase 1</p></td></tr><tr><td class="NLM_term">PTase</td><td class="NLM_def"><p class="first last">palmitoyl transferase</p></td></tr><tr><td class="NLM_term">SH2</td><td class="NLM_def"><p class="first last">sarcoma homology 2</p></td></tr><tr><td class="NLM_term">GRB2</td><td class="NLM_def"><p class="first last">growth factor receptor bound 2</p></td></tr><tr><td class="NLM_term">RAF</td><td class="NLM_def"><p class="first last">rapidly accelerated fibrosarcoma</p></td></tr><tr><td class="NLM_term">MAP</td><td class="NLM_def"><p class="first last">mitogen-activated protein</p></td></tr><tr><td class="NLM_term">MEK</td><td class="NLM_def"><p class="first last">also known as MAPK, mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">ERK</td><td class="NLM_def"><p class="first last">extracellular signal-regulated kinase</p></td></tr><tr><td class="NLM_term">ELK1</td><td class="NLM_def"><p class="first last">E twenty-six (ETS)-like transcription factor 1</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphoinositide 3-kinase</p></td></tr><tr><td class="NLM_term">AKT</td><td class="NLM_def"><p class="first last">protein kinase B</p></td></tr><tr><td class="NLM_term">NF-κB</td><td class="NLM_def"><p class="first last">nuclear factor κ light-chain enhancer of activated B cells</p></td></tr><tr><td class="NLM_term">RalGDS</td><td class="NLM_def"><p class="first last">Ral guanine nucleotide dissociation stimulator</p></td></tr><tr><td class="NLM_term">FOX</td><td class="NLM_def"><p class="first last">Forkhead box</p></td></tr><tr><td class="NLM_term">PLC</td><td class="NLM_def"><p class="first last">phospholipase C</p></td></tr><tr><td class="NLM_term">HTS</td><td class="NLM_def"><p class="first last">high-throughput screening</p></td></tr><tr><td class="NLM_term">SC</td><td class="NLM_def"><p class="first last">sulfinyl cytidine</p></td></tr><tr><td class="NLM_term">TPT</td><td class="NLM_def"><p class="first last">triphenyl</p></td></tr><tr><td class="NLM_term">hTERT</td><td class="NLM_def"><p class="first last">human telomerase reverse transcriptase</p></td></tr><tr><td class="NLM_term">ip</td><td class="NLM_def"><p class="first last">intraperitoneal</p></td></tr><tr><td class="NLM_term">LT</td><td class="NLM_def"><p class="first last">large T</p></td></tr><tr><td class="NLM_term">ST</td><td class="NLM_def"><p class="first last">small T</p></td></tr><tr><td class="NLM_term">HPV</td><td class="NLM_def"><p class="first last">human papillomavirus</p></td></tr><tr><td class="NLM_term">BJ</td><td class="NLM_def"><p class="first last">Bence Jones protein</p></td></tr><tr><td class="NLM_term">RB</td><td class="NLM_def"><p class="first last">retinoblastoma</p></td></tr><tr><td class="NLM_term">ROS</td><td class="NLM_def"><p class="first last">reactive oxygen species</p></td></tr><tr><td class="NLM_term">MEF</td><td class="NLM_def"><p class="first last">mouse embryonic fibroblast</p></td></tr><tr><td class="NLM_term">CTG</td><td class="NLM_def"><p class="first last">chemotaxigenesis</p></td></tr><tr><td class="NLM_term">BrdU</td><td class="NLM_def"><p class="first last">bromodeoxyuridine</p></td></tr><tr><td class="NLM_term">SOS</td><td class="NLM_def"><p class="first last">son of sevenless</p></td></tr><tr><td class="NLM_term">NMR</td><td class="NLM_def"><p class="first last">nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">NOE</td><td class="NLM_def"><p class="first last">nuclear Overhauser effect</p></td></tr><tr><td class="NLM_term">IMAP</td><td class="NLM_def"><p class="first last">immobilized metal ion affinity based fluorescence polarization</p></td></tr><tr><td class="NLM_term">FITC</td><td class="NLM_def"><p class="first last">fluorescein isothiocyanate</p></td></tr><tr><td class="NLM_term">LOX</td><td class="NLM_def"><p class="first last">lipoxygenase</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamics</p></td></tr><tr><td class="NLM_term">PIK3CA</td><td class="NLM_def"><p class="first last">phosphoinositide 3-kinase, catalytic α polypeptide</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin</p></td></tr><tr><td class="NLM_term">FTI</td><td class="NLM_def"><p class="first last">farnesyltransferse inhibitor</p></td></tr><tr><td class="NLM_term">BFC</td><td class="NLM_def"><p class="first last">biotin <i>S</i>-farnesyl-<span class="smallcaps smallerCapital">l</span>-cysteine</p></td></tr><tr><td class="NLM_term">AdoMet</td><td class="NLM_def"><p class="first last"><i>S</i>-adenosylmethionine</p></td></tr><tr><td class="NLM_term">RNAi</td><td class="NLM_def"><p class="first last">RNA interference</p></td></tr><tr><td class="NLM_term">PLK1</td><td class="NLM_def"><p class="first last">polo-like kinase 1</p></td></tr><tr><td class="NLM_term">MDCK</td><td class="NLM_def"><p class="first last">Madin–Darby canine kidney epithelial</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung cancer</p></td></tr><tr><td class="NLM_term">CDK4</td><td class="NLM_def"><p class="first last">cyclin-dependent kinase 4</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67716" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67716" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 120 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Wennerberg, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossman, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span> </span><span class="NLM_article-title">The Ras superfamily at a glance</span> <span class="citation_source-journal">J. Cell Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">843</span><span class="NLM_x">–</span> <span class="NLM_lpage">846</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1242%2Fjcs.01660" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=15731001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjs12msb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2005&pages=843-846&author=K.+Wennerbergauthor=K.+L.+Rossmanauthor=C.+J.+Der&title=The+Ras+superfamily+at+a+glance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The Ras superfamily at a glance</span></div><div class="casAuthors">Wennerberg, Krister; Rossman, Kent L.; Der, Channing J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">843-846</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  The Ras superfamily of small guanosine triphosphatases (GTPases) comprise over 150 human members, with evolutionarily conserved orthologs found in Drosophila, C. elegans, S. cerevisiae, S. pombe, Dictyostelium and plants.  The Ras oncogene proteins are the founding members of this family, which is divided into five major branches on the basis of sequence and functional similarities: Ras, Rho, Rab, Ran, and Arf.  The basic structural features of Ras proteins, with respect to specific Ras sequences, are presented to highlight the general properties of this family of proteins and discuss features that distinguish the various branches of the superfamily from Ras.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGYkOKxB2I8LVg90H21EOLACvtfcHk0lhOU80cqaKRxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjs12msb8%253D&md5=be429610b9e8581c5517194e2ebaad06</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1242%2Fjcs.01660&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.01660%26sid%3Dliteratum%253Aachs%26aulast%3DWennerberg%26aufirst%3DK.%26aulast%3DRossman%26aufirst%3DK.%2BL.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DThe%2520Ras%2520superfamily%2520at%2520a%2520glance%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2005%26volume%3D118%26spage%3D843%26epage%3D846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Adjei, A. A.</span><span> </span><span class="NLM_article-title">Blocking oncogenic Ras signaling for cancer therapy</span> <span class="citation_source-journal">J. Natl. Cancer. Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">1062</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1093%2Fjnci%2F93.14.1062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=11459867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD3MXls1Ojtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2001&pages=1062-1074&author=A.+A.+Adjei&title=Blocking+oncogenic+Ras+signaling+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Blocking oncogenic ras signaling for cancer therapy</span></div><div class="casAuthors">Adjei, Alex A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1062-1074</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  The Ras gene product is a monomeric membrane-localized G protein of 21 kd that functions as a mol. switch linking receptor and nonreceptor tyrosine kinase activation to downstream cytoplasmic or nuclear events.  Each mammalian cell contains at least 3 distinct ras proto-oncogenes encoding closely related, but distinct proteins.  Activating mutations in these Ras proteins result in constitutive signaling, thereby stimulating cell proliferation and inhibiting apoptosis.  Oncogenic mutations in the ras gene are present in approx. 30% of all human cancers.  K-ras mutations occur frequently in non-small-cell lung, colorectal, and pancreatic carcinomas; H-ras mutations are common in bladder, kidney, and thyroid carcinomas; N-ras mutations are found in melanoma, hepatocellular carcinoma, and hematol. malignancies.  The ras-signaling pathway has attracted considerable attention as a target for anticancer therapy because of its important role in carcinogenesis.  In this review, the physiol. and biochem. properties of the Ras proteins, their mechanism of cell signaling, and their relation to human cancer will be discussed.  Novel cancer therapeutic approaches based on the inhibition of Ras-mediated signaling, including inhibition of Ras processing, inhibition of Ras protein synthesis, and blockage of downstream Ras effectors, will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3KGaz7MPcrLVg90H21EOLACvtfcHk0lgBAU9dmDC_IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXls1Ojtrg%253D&md5=583d951206daaf33f2ee369eb43910a5</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F93.14.1062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F93.14.1062%26sid%3Dliteratum%253Aachs%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DBlocking%2520oncogenic%2520Ras%2520signaling%2520for%2520cancer%2520therapy%26jtitle%3DJ.%2520Natl.%2520Cancer.%2520Inst.%26date%3D2001%26volume%3D93%26spage%3D1062%26epage%3D1074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Karnoub, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, R. A.</span><span> </span><span class="NLM_article-title">Ras oncogenes: split personalities</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">517</span><span class="NLM_x">–</span> <span class="NLM_lpage">531</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1038%2Fnrm2438" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=18568040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsFGnsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=517-531&author=A.+E.+Karnoubauthor=R.+A.+Weinberg&title=Ras+oncogenes%3A+split+personalities"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Ras oncogenes: split personalities</span></div><div class="casAuthors">Karnoub, Antoine E.; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">517-531</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Extensive research over the past 30 years has revealed the involvement of Ras not only in tumorigenesis but also in many developmental disorders.  The complexity of the mol. and cell biol. mechanisms of action of Ras proteins indicates that much remains to be learns.  Extensive research on the Ras proteins and their functions in cell physiol. over the past 30 years has led to numerous insights that have revealed the involvement of Ras not only in tumorigenesis but also in many developmental disorders.  Despite great strides in our understanding of the mol. and cellular mechanisms of action of the Ras proteins, the expanding roster of their downstream effectors and the complexity of the signaling cascades that they regulate indicate that much remains to be learns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocptUdlhqaM7Vg90H21EOLACvtfcHk0lgBAU9dmDC_IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsFGnsr0%253D&md5=9de78b17b953b2560238d7a98f3bea6a</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrm2438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2438%26sid%3Dliteratum%253Aachs%26aulast%3DKarnoub%26aufirst%3DA.%2BE.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DRas%2520oncogenes%253A%2520split%2520personalities%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2008%26volume%3D9%26spage%3D517%26epage%3D531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Friday, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span> </span><span class="NLM_article-title">K-ras as a target for cancer therapy</span> <span class="citation_source-journal">Biochim. Biophys. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">1756</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">144</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1756&publication_year=2005&pages=127-144&author=B.+B.+Fridayauthor=A.+A.+Adjei&title=K-ras+as+a+target+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFriday%26aufirst%3DB.%2BB.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DK-ras%2520as%2520a%2520target%2520for%2520cancer%2520therapy%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D2005%26volume%3D1756%26spage%3D127%26epage%3D144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Pylayeva-Gupta, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grabocka, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bar-Sagi, D.</span><span> </span><span class="NLM_article-title">RAS oncogenes: weaving a tumorigenic web</span> <span class="citation_source-journal">Nat. Rev., Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">761</span><span class="NLM_x">–</span> <span class="NLM_lpage">774</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1038%2Fnrc3106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=21993244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlSkur7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=761-774&author=Y.+Pylayeva-Guptaauthor=E.+Grabockaauthor=D.+Bar-Sagi&title=RAS+oncogenes%3A+weaving+a+tumorigenic+web"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">RAS oncogenes: weaving a tumorigenic web</span></div><div class="casAuthors">Pylayeva-Gupta, Yuliya; Grabocka, Elda; Bar-Sagi, Dafna</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">761-774</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  RAS proteins are essential components of signalling pathways that emanate from cell surface receptors.  Oncogenic activation of these proteins owing to missense mutations is frequently detected in several types of cancer.  A wealth of biochem. and genetic studies indicates that RAS proteins control a complex mol. circuitry that consists of a wide array of interconnecting pathways.  In this Review, we describe how RAS oncogenes exploit their extensive signalling reach to affect multiple cellular processes that drive tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdHRt0jsiXtLVg90H21EOLACvtfcHk0lgBAU9dmDC_IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlSkur7K&md5=d1be47023ab43a30cb81e71cb92bc0aa</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrc3106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3106%26sid%3Dliteratum%253Aachs%26aulast%3DPylayeva-Gupta%26aufirst%3DY.%26aulast%3DGrabocka%26aufirst%3DE.%26aulast%3DBar-Sagi%26aufirst%3DD.%26atitle%3DRAS%2520oncogenes%253A%2520weaving%2520a%2520tumorigenic%2520web%26jtitle%3DNat.%2520Rev.%252C%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D761%26epage%3D774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Downward, J.</span><span> </span><span class="NLM_article-title">Targeting RAS signalling pathways in cancer therapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1038%2Fnrc969" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=12509763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD38XpvVertbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=11-22&author=J.+Downward&title=Targeting+RAS+signalling+pathways+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting RAS signalling pathways in cancer therapy</span></div><div class="casAuthors">Downward, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-22</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The RAS proteins control signaling pathways that are key regulators of several aspects of normal cell growth and malignant transformation.  They are aberrant in most human tumors due to activating mutations in the RAS genes themselves or to alterations in upstream or downstream signaling components.  Rational therapies that target the RAS pathways might inhibit tumor growth, survival and spread.  Several of these new therapeutic agents are showing promise in the clinic and many more are being developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwKF9JX2sXtbVg90H21EOLACvtfcHk0lgBAU9dmDC_IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpvVertbo%253D&md5=85ea9312480c3ca01f2a94faae7b84e7</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrc969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc969%26sid%3Dliteratum%253Aachs%26aulast%3DDownward%26aufirst%3DJ.%26atitle%3DTargeting%2520RAS%2520signalling%2520pathways%2520in%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2003%26volume%3D3%26spage%3D11%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Podsypanina, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beverly, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H. E.</span><span> </span><span class="NLM_article-title">Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">5242</span><span class="NLM_x">–</span> <span class="NLM_lpage">5247</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=5242-5247&author=K.+Podsypaninaauthor=K.+Politiauthor=L.+J.+Beverlyauthor=H.+E.+Varmus&title=Oncogene+cooperation+in+tumor+maintenance+and+tumor+recurrence+in+mouse+mammary+tumors+induced+by+Myc+and+mutant+Kras"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPodsypanina%26aufirst%3DK.%26aulast%3DPoliti%26aufirst%3DK.%26aulast%3DBeverly%26aufirst%3DL.%2BJ.%26aulast%3DVarmus%26aufirst%3DH.%2BE.%26atitle%3DOncogene%2520cooperation%2520in%2520tumor%2520maintenance%2520and%2520tumor%2520recurrence%2520in%2520mouse%2520mammary%2520tumors%2520induced%2520by%2520Myc%2520and%2520mutant%2520Kras%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D5242%26epage%3D5247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Chin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pomerantz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holash, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardeesy, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Hagan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pantginis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horner, J. W.,  2nd.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordon-Cardo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yancopoulos, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DePinho, R. A.</span><span> </span><span class="NLM_article-title">Essential role for oncogenic Ras in tumour maintenance</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">400</span><span class="NLM_x">, </span> <span class="NLM_fpage">468</span><span class="NLM_x">–</span> <span class="NLM_lpage">472</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=400&publication_year=1999&pages=468-472&author=L.+Chinauthor=A.+Tamauthor=J.+Pomerantzauthor=M.+Wongauthor=J.+Holashauthor=N.+Bardeesyauthor=Q.+Shenauthor=R.+O%E2%80%99Haganauthor=J.+Pantginisauthor=H.+Zhouauthor=J.+W.+Hornerauthor=C.+Cordon-Cardoauthor=G.+D.+Yancopoulosauthor=R.+A.+DePinho&title=Essential+role+for+oncogenic+Ras+in+tumour+maintenance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChin%26aufirst%3DL.%26aulast%3DTam%26aufirst%3DA.%26aulast%3DPomerantz%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DM.%26aulast%3DHolash%26aufirst%3DJ.%26aulast%3DBardeesy%26aufirst%3DN.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DO%25E2%2580%2599Hagan%26aufirst%3DR.%26aulast%3DPantginis%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DHorner%26aufirst%3DJ.%2BW.%26aulast%3DCordon-Cardo%26aufirst%3DC.%26aulast%3DYancopoulos%26aufirst%3DG.%2BD.%26aulast%3DDePinho%26aufirst%3DR.%2BA.%26atitle%3DEssential%2520role%2520for%2520oncogenic%2520Ras%2520in%2520tumour%2520maintenance%26jtitle%3DNature%26date%3D1999%26volume%3D400%26spage%3D468%26epage%3D472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Gysin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCormick, F.</span><span> </span><span class="NLM_article-title">Therapeutic strategies for targeting ras proteins</span> <span class="citation_source-journal">Genes Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">359</span><span class="NLM_x">–</span> <span class="NLM_lpage">372</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1177%2F1947601911412376" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=21779505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvFWlsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=359-372&author=S.+Gysinauthor=M.+Saltauthor=A.+Youngauthor=F.+McCormick&title=Therapeutic+strategies+for+targeting+ras+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic strategies for targeting Ras proteins</span></div><div class="casAuthors">Gysin, Stephan; Salt, Megan; Young, Amy; McCormick, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">359-372</span>CODEN:
                <span class="NLM_cas:coden">GCEAAY</span>;
        ISSN:<span class="NLM_cas:issn">1947-6019</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Ras genes are frequently activated in cancer.  Attempts to develop drugs that target mutant Ras proteins have, so far, been unsuccessful.  Tumors bearing these mutations, therefore, remain among the most difficult to treat.  Most efforts to block activated Ras have focused on pathways downstream.  Drugs that inhibit Raf kinase have shown clin. benefit in the treatment of malignant melanoma.  However, these drugs have failed to show clin. benefit in Ras mutant tumors.  It remains unclear to what extent Ras depends on Raf kinase for transforming activity, even though Raf proteins bind directly to Ras and are certainly major effectors of Ras action in normal cells and in development.  Furthermore, Raf kinase inhibitors can lead to paradoxical activation of the MAPK pathway.  MEK inhibitors block the Ras-MAPK pathway, but often activate the PI3'-kinase, and have shown little clin. benefit as single agents.  This activation is mediated by EGF-R and other receptor tyrosine kinases through relief of a neg. feedback loop from ERK.  Drug combinations that target multiple points within the Ras signaling network are likely to be necessary to achieve substantial clin. benefit.  Other effectors may also contribute to Ras signaling and provide a source of targets.  In addn., unbiased screens for genes necessary for Ras transformation have revealed new potential targets and have added to our understanding of Ras cancer biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTnzEvjaufXrVg90H21EOLACvtfcHk0lhCtTov54WAXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvFWlsbY%253D&md5=f680dda525256c8388e417d45ebe4299</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1177%2F1947601911412376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1947601911412376%26sid%3Dliteratum%253Aachs%26aulast%3DGysin%26aufirst%3DS.%26aulast%3DSalt%26aufirst%3DM.%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DMcCormick%26aufirst%3DF.%26atitle%3DTherapeutic%2520strategies%2520for%2520targeting%2520ras%2520proteins%26jtitle%3DGenes%2520Cancer%26date%3D2011%26volume%3D2%26spage%3D359%26epage%3D372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Sun, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burns, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olejniczak, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waterson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossanese, O. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fesik, S. W.</span><span> </span><span class="NLM_article-title">Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">6140</span><span class="NLM_x">–</span> <span class="NLM_lpage">6143</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1002%2Fanie.201201358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BC38Xms1entr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=6140-6143&author=Q.+Sunauthor=J.+P.+Burkeauthor=J.+Phanauthor=M.+C.+Burnsauthor=E.+T.+Olejniczakauthor=A.+G.+Watersonauthor=T.+Leeauthor=O.+W.+Rossaneseauthor=S.+W.+Fesik&title=Discovery+of+small+molecules+that+bind+to+K-Ras+and+inhibit+Sos-mediated+activation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-Mediated Activation</span></div><div class="casAuthors">Sun, Qi; Burke, Jason P.; Phan, Jason; Burns, Michael C.; Olejniczak, Edward T.; Waterson, Alex G.; Lee, Taekyu; Rossanese, Olivia W.; Fesik, Stephen W.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">6140-6143, S6140/1-S6140/17</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">K-Ras inhibition represents an attractive therapeutic strategy for many cancers.  We report on the discovery of novel small mols. that bind directly to K-Ras between switch I and switch II and inhibit Sos-catalyzed K-Ras activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpy5Cx7BSO1pLVg90H21EOLACvtfcHk0lhCtTov54WAXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xms1entr4%253D&md5=7d579523462aaf7eac1890643f91fab3</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fanie.201201358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201201358%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DBurke%26aufirst%3DJ.%2BP.%26aulast%3DPhan%26aufirst%3DJ.%26aulast%3DBurns%26aufirst%3DM.%2BC.%26aulast%3DOlejniczak%26aufirst%3DE.%2BT.%26aulast%3DWaterson%26aufirst%3DA.%2BG.%26aulast%3DLee%26aufirst%3DT.%26aulast%3DRossanese%26aufirst%3DO.%2BW.%26aulast%3DFesik%26aufirst%3DS.%2BW.%26atitle%3DDiscovery%2520of%2520small%2520molecules%2520that%2520bind%2520to%2520K-Ras%2520and%2520inhibit%2520Sos-mediated%2520activation%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2012%26volume%3D51%26spage%3D6140%26epage%3D6143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Fletcher, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, A. D.</span><span> </span><span class="NLM_article-title">Targeting protein–protein interactions by rational design: mimicry of protein surfaces</span> <span class="citation_source-journal">J. R. Soc. Interface</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">215</span><span class="NLM_x">–</span> <span class="NLM_lpage">233</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1098%2Frsif.2006.0115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=16849232" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD2sXls1Cltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=215-233&author=S.+Fletcherauthor=A.+D.+Hamilton&title=Targeting+protein%E2%80%93protein+interactions+by+rational+design%3A+mimicry+of+protein+surfaces"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting protein-protein interactions by rational design: mimicry of protein surfaces</span></div><div class="casAuthors">Fletcher, Steven; Hamilton, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Royal Society, Interface</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">215-233</span>CODEN:
                <span class="NLM_cas:coden">JRSICU</span>;
        ISSN:<span class="NLM_cas:issn">1742-5689</span>.
    
            (<span class="NLM_cas:orgname">Royal Society</span>)
        </div><div class="casAbstract">A review.  Protein-protein interactions play key roles in a range of biol. processes, and are therefore important targets for the design of novel therapeutics.  Unlike in the design of enzyme active site inhibitors, the disruption of protein-protein interactions is far more challenging, due to such factors as the large interfacial areas involved and the relatively flat and featureless topologies of these surfaces.  Nevertheless, in spite of such challenges, there has been considerable progress in recent years.  In this review, we discuss this progress in the context of mimicry of protein surfaces: targeting protein-protein interactions by rational design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxKr4YNJ6khLVg90H21EOLACvtfcHk0ljpsI-noNg82Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXls1Cltg%253D%253D&md5=e4a7eaf80e4e81291d504a9aef85ad02</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1098%2Frsif.2006.0115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frsif.2006.0115%26sid%3Dliteratum%253Aachs%26aulast%3DFletcher%26aufirst%3DS.%26aulast%3DHamilton%26aufirst%3DA.%2BD.%26atitle%3DTargeting%2520protein%25E2%2580%2593protein%2520interactions%2520by%2520rational%2520design%253A%2520mimicry%2520of%2520protein%2520surfaces%26jtitle%3DJ.%2520R.%2520Soc.%2520Interface%26date%3D2006%26volume%3D3%26spage%3D215%26epage%3D233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Ghobrial, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span> </span><span class="NLM_article-title">Inhibitors of the ras oncogene as therapeutic targets</span> <span class="citation_source-journal">Hematol. Oncol. Clin. North Am.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1065</span><span class="NLM_x">–</span> <span class="NLM_lpage">1088</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1016%2FS0889-8588%2802%2900050-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=12512383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A280%3ADC%252BD3s%252FgsleitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2002&pages=1065-1088&author=I.+M.+Ghobrialauthor=A.+A.+Adjei&title=Inhibitors+of+the+ras+oncogene+as+therapeutic+targets"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of the ras oncogene as therapeutic targets</span></div><div class="casAuthors">Ghobrial Irene M; Adjei Alex A</div><div class="citationInfo"><span class="NLM_cas:title">Hematology/oncology clinics of North America</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1065-88</span>
        ISSN:<span class="NLM_cas:issn">0889-8588</span>.
    </div><div class="casAbstract">Advances in our understanding of the molecular pathways and genetic mutations that control tumor cell proliferation and metastasis present an opportunity to develop novel, mechanism-based therapeutic strategies.  Ras mutations are the most frequently activated oncogenes in human tumors, with over 30% expressing ras mutations.  Molecular dissection of the signaling pathway and the mechanisms of ras anchorage, post-translational modification, and downstream effector signaling of ras now under intensive investigation will help us to design additional methods for ras-directed therapy in an effort to reach an optimal treatment for human tumors that will most likely comprise a combination of modalities targeted at the different underlying genetic defects.  The successes and limitations of ras-targeted therapies must be viewed in light of the increasing understanding of the complexity of the ras-signaling pathway.  Only now are we beginning to discover the many functions of this integrated pathway, such as the differences between the actions of various ras isoforms that may affect our choice of therapeutic approach.  Many of these Ras therapeutic targets have shown success in preclinical studies, and some have shown efficacy in clinical trials with minimal toxicities.  Compounds that block ras-transforming activity without affecting normal ras function seem more attractive for the future development of ras-targeted therapy.  FTIs may partially fulfill such requirements.  Based on their specific, novel, and mechanism-based action; minimal toxicity; and encouraging responses in clinical trials, the development of Ras therapeutic targets as single agents or in combination with conventional chemotherapy and radiotherapy should be pursued.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5fkskOa0PLDQLBVDQn4bCfW6udTcc2ebrdbvKqHD2NLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3s%252FgsleitA%253D%253D&md5=322dbf27931d9e5130d5df1bd2715cab</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS0889-8588%2802%2900050-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0889-8588%252802%252900050-3%26sid%3Dliteratum%253Aachs%26aulast%3DGhobrial%26aufirst%3DI.%2BM.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DInhibitors%2520of%2520the%2520ras%2520oncogene%2520as%2520therapeutic%2520targets%26jtitle%3DHematol.%2520Oncol.%2520Clin.%2520North%2520Am.%26date%3D2002%26volume%3D16%26spage%3D1065%26epage%3D1088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Adjei, A. A.</span><span> </span><span class="NLM_article-title">Farnesyltransferase inhibitors</span> <span class="citation_source-journal">Cancer Chemother. Biol. Response Modif.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">149</span><span class="NLM_x">–</span> <span class="NLM_lpage">164</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=11686012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlvVWjsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2001&pages=149-164&author=A.+A.+Adjei&title=Farnesyltransferase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Farnesyltransferase inhibitors</span></div><div class="casAuthors">Adjei, Alex A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Biological Response Modifiers</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">149-164</span>CODEN:
                <span class="NLM_cas:coden">CCBAED</span>;
        ISSN:<span class="NLM_cas:issn">0921-4410</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review discusses the development, preclin. pharmacol., mechanism of action, clin. studies, and toxicity profile of farnesyltransferase inhibitors (FTIs).  Farnesyltransferase inhibition was envisioned as a strategy for interfering with ras-dependent cell transformation, thus, various FTIs have been developed.  Four FTIs are in clin. trials worldwide, with several more at different levels of preclin. development.  Two of these, R115777 and SCH66336, are orally active heterocyclic compds. and are in phase II studies.  The other two agents, L778123 and BMS214662, are administered i.v. and are in phase I trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpkHrVNdV-arVg90H21EOLACvtfcHk0ljpsI-noNg82Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlvVWjsrc%253D&md5=43f49e89ed99f7e8b038e053a144f14b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DFarnesyltransferase%2520inhibitors%26jtitle%3DCancer%2520Chemother.%2520Biol.%2520Response%2520Modif.%26date%3D2001%26volume%3D19%26spage%3D149%26epage%3D164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Cho, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. I.</span><span> </span><span class="NLM_article-title">Chemistry and biology of Ras farnesyltransferase</span> <span class="citation_source-journal">Arch. Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">759</span><span class="NLM_x">–</span> <span class="NLM_lpage">769</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1007%2FBF02976989" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=12510823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD3sXht1answ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2002&pages=759-769&author=K.+N.+Choauthor=K.+I.+Lee&title=Chemistry+and+biology+of+Ras+farnesyltransferase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Chemistry and biology of Ras farnesyltransferase</span></div><div class="casAuthors">Cho, Kwang-Nym; Lee, Kee-In</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Pharmacal Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">759-769</span>CODEN:
                <span class="NLM_cas:coden">APHRDQ</span>;
        ISSN:<span class="NLM_cas:issn">0253-6269</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Korea</span>)
        </div><div class="casAbstract">A review.  Mutated forms of ras are found in many human tumors and the rate of incidence is significantly higher in colon and pancreatic cancers.  The protein product from the ras oncogene is a small G-protein, p21ras (Ras) that is known to play a key role in the signal transduction cascade and cell differentiation and proliferation.  Mutated Ras is unable to regulate itself and remains constantly activated, leading to uncontrolled cell growth.  The function of Ras in signal transduction requires its location near the growth factor receptor at the cell membrane.  However, Ras does not have a transmembrane domain.  Ras requires farnesylation to increase its hydrophobicity and subsequent plasma membrane assocn. for its transforming activity.  This key post-translational modification is catalyzed by the enzyme Ras farnesyltransferase (FTase), which transfers a farnesyl group from farnesylpyrophosphate to the C-terminal cysteine of the Ras protein.  The requirement has focused attention on FTase as a target for therapeutic intervention.  Selective inhibition of FTase will prevent Ras protein from assocn. with the plasma membrane, leading to a disruption of oncogenic Ras function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFTfS6GqBY1bVg90H21EOLACvtfcHk0ljpsI-noNg82Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXht1answ%253D%253D&md5=bfb36fbd490be4bf060dae517bd16735</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1007%2FBF02976989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF02976989%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DK.%2BN.%26aulast%3DLee%26aufirst%3DK.%2BI.%26atitle%3DChemistry%2520and%2520biology%2520of%2520Ras%2520farnesyltransferase%26jtitle%3DArch.%2520Pharm.%2520Res.%26date%3D2002%26volume%3D25%26spage%3D759%26epage%3D769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Casey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solski, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buss, J. E.</span><span> </span><span class="NLM_article-title">p21ras is modified by a farnesyl isoprenoid</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">8323</span><span class="NLM_x">–</span> <span class="NLM_lpage">8327</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=1989&pages=8323-8327&author=P.+J.+Caseyauthor=P.+A.+Solskiauthor=C.+J.+Derauthor=J.+E.+Buss&title=p21ras+is+modified+by+a+farnesyl+isoprenoid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCasey%26aufirst%3DP.%2BJ.%26aulast%3DSolski%26aufirst%3DP.%2BA.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26aulast%3DBuss%26aufirst%3DJ.%2BE.%26atitle%3Dp21ras%2520is%2520modified%2520by%2520a%2520farnesyl%2520isoprenoid%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1989%26volume%3D86%26spage%3D8323%26epage%3D8327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Cox, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span> </span><span class="NLM_article-title">Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?</span> <span class="citation_source-journal">Biochim. Biophys. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">1333</span><span class="NLM_x">, </span> <span class="NLM_fpage">F51</span><span class="NLM_x">–</span> <span class="NLM_lpage">F71</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1333&publication_year=1997&pages=F51-F71&author=A.+D.+Coxauthor=C.+J.+Der&title=Farnesyltransferase+inhibitors+and+cancer+treatment%3A+targeting+simply+Ras%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DA.%2BD.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DFarnesyltransferase%2520inhibitors%2520and%2520cancer%2520treatment%253A%2520targeting%2520simply%2520Ras%253F%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D1997%26volume%3D1333%26spage%3DF51%26epage%3DF71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Hancock, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magee, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Childs, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span> </span><span class="NLM_article-title">All RAS proteins are polyisoprenylated but only some are palmitoylated</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1167</span><span class="NLM_x">–</span> <span class="NLM_lpage">1177</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1016%2F0092-8674%2889%2990054-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=2661017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADyaL1MXkvFansr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1989&pages=1167-1177&author=J.+F.+Hancockauthor=A.+I.+Mageeauthor=J.+E.+Childsauthor=C.+J.+Marshall&title=All+RAS+proteins+are+polyisoprenylated+but+only+some+are+palmitoylated"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">All ras proteins are polyisoprenylated but only some are palmitoylated</span></div><div class="casAuthors">Hancock, John F.; Magee, Anthony I.; Childs, Julie E.; Marshall, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1167-77</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">The C-terminal CAAX motif of the yeast mating factors is modified by proteolysis to remove the 3 terminal amino acids (-AAX) leaving a C-terminal cysteine residue that is polyisoprenylated and carboxylmethylated.  Here it is shown that all gene ras proteins are polyisoprenylated on their C-terminal cysteine (Cys186).  Mutational anal. shows palmitoylation does not take place on Cys186 as previously thought but on cysteine residues contained in the hypervariable domain of some ras proteins.  The major expressed form of c-K-ras (exon 4B) does not have a cysteine residue immediately upstream of Cys186 and is not palmitoylated.  Polyisoprenylated but nonpalmitoylated H-ras proteins are biol. active and assoc. weakly with cell membranes.  Palmitoylation increases the avidity of this binding and enhances their transforming activity.  Polyisoprenylation is essential for biol. activity as inhibiting the biosynthesis of polyisoprenoids abolishes membrane assocn. of p21ras.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkbozglr8QdrVg90H21EOLACvtfcHk0ljoyR_oLwepXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXkvFansr8%253D&md5=0294ca0eafe10cf138ab55e5dfa294ac</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2889%2990054-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252889%252990054-8%26sid%3Dliteratum%253Aachs%26aulast%3DHancock%26aufirst%3DJ.%2BF.%26aulast%3DMagee%26aufirst%3DA.%2BI.%26aulast%3DChilds%26aufirst%3DJ.%2BE.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26atitle%3DAll%2520RAS%2520proteins%2520are%2520polyisoprenylated%2520but%2520only%2520some%2520are%2520palmitoylated%26jtitle%3DCell%26date%3D1989%26volume%3D57%26spage%3D1167%26epage%3D1177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Hancock, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span> </span><span class="NLM_article-title">A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">133</span><span class="NLM_x">–</span> <span class="NLM_lpage">139</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1016%2F0092-8674%2890%2990294-O" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=2208277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADyaK3cXmt1KltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=1990&pages=133-139&author=J.+F.+Hancockauthor=H.+Patersonauthor=C.+J.+Marshall&title=A+polybasic+domain+or+palmitoylation+is+required+in+addition+to+the+CAAX+motif+to+localize+p21ras+to+the+plasma+membrane"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane</span></div><div class="casAuthors">Hancock, John F.; Peterson, Hugh; Marshall, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">133-9</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">The C-terminal CAAX (C-cysteine, A = aliph., and X = any amino acid) motif of ras proteins undergoes a triplet of posttranslational modifications that are required for membrane assocn.  The CAAX motif lies immediately C-terminal to the hypervariable domain, a region of 20 amino acids that distinguishes the ras proteins from each other.  The hypervariable domains of p21H-ras, p21N-ras and p21K-ras(A) contain sites for palmitoylation, which are shown to combine with the CAAX motif to target specific plasma membrane localization.  Within the hypervariable domain of p21K-ras(B), which is not palmitoylated, a novel plasma membrane targeting signal consisting of a polybasic domain that also acts in combination with the CAAX motif has been identified.  One function of the hypervariable domains of p21ras is therefore to provide different signals for plasma membrane localization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmJT7cPVTh97Vg90H21EOLACvtfcHk0ljoyR_oLwepXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXmt1KltLs%253D&md5=3dceb53c12512e4e70f3c9291ac3598e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2890%2990294-O&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252890%252990294-O%26sid%3Dliteratum%253Aachs%26aulast%3DHancock%26aufirst%3DJ.%2BF.%26aulast%3DPaterson%26aufirst%3DH.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26atitle%3DA%2520polybasic%2520domain%2520or%2520palmitoylation%2520is%2520required%2520in%2520addition%2520to%2520the%2520CAAX%2520motif%2520to%2520localize%2520p21ras%2520to%2520the%2520plasma%2520membrane%26jtitle%3DCell%26date%3D1990%26volume%3D63%26spage%3D133%26epage%3D139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Boyartchuk, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashby, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rine, J.</span><span> </span><span class="NLM_article-title">Modulation of Ras and a-factor function by carboxyl-terminal proteolysis</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">275</span><span class="NLM_x">, </span> <span class="NLM_fpage">1796</span><span class="NLM_x">–</span> <span class="NLM_lpage">1800</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=1997&pages=1796-1800&author=V.+L.+Boyartchukauthor=M.+N.+Ashbyauthor=J.+Rine&title=Modulation+of+Ras+and+a-factor+function+by+carboxyl-terminal+proteolysis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoyartchuk%26aufirst%3DV.%2BL.%26aulast%3DAshby%26aufirst%3DM.%2BN.%26aulast%3DRine%26aufirst%3DJ.%26atitle%3DModulation%2520of%2520Ras%2520and%2520a-factor%2520function%2520by%2520carboxyl-terminal%2520proteolysis%26jtitle%3DScience%26date%3D1997%26volume%3D275%26spage%3D1796%26epage%3D1800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Otto, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casey, P. J.</span><span> </span><span class="NLM_article-title">Cloning and characterization of a mammalian prenyl protein-specific protease</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">274</span><span class="NLM_x">, </span> <span class="NLM_fpage">8379</span><span class="NLM_x">–</span> <span class="NLM_lpage">8382</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=8379-8382&author=J.+C.+Ottoauthor=E.+Kimauthor=S.+G.+Youngauthor=P.+J.+Casey&title=Cloning+and+characterization+of+a+mammalian+prenyl+protein-specific+protease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOtto%26aufirst%3DJ.%2BC.%26aulast%3DKim%26aufirst%3DE.%26aulast%3DYoung%26aufirst%3DS.%2BG.%26aulast%3DCasey%26aufirst%3DP.%2BJ.%26atitle%3DCloning%2520and%2520characterization%2520of%2520a%2520mammalian%2520prenyl%2520protein-specific%2520protease%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26spage%3D8379%26epage%3D8382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Clarke, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogel, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deschenes, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stock, J.</span><span> </span><span class="NLM_article-title">Posttranslational modification of the Ha-ras oncogene protein: evidence for a third class of protein carboxyl methyltransferases</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">4643</span><span class="NLM_x">–</span> <span class="NLM_lpage">4647</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=1988&pages=4643-4647&author=S.+Clarkeauthor=J.+P.+Vogelauthor=R.+J.+Deschenesauthor=J.+Stock&title=Posttranslational+modification+of+the+Ha-ras+oncogene+protein%3A+evidence+for+a+third+class+of+protein+carboxyl+methyltransferases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DClarke%26aufirst%3DS.%26aulast%3DVogel%26aufirst%3DJ.%2BP.%26aulast%3DDeschenes%26aufirst%3DR.%2BJ.%26aulast%3DStock%26aufirst%3DJ.%26atitle%3DPosttranslational%2520modification%2520of%2520the%2520Ha-ras%2520oncogene%2520protein%253A%2520evidence%2520for%2520a%2520third%2520class%2520of%2520protein%2520carboxyl%2520methyltransferases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1988%26volume%3D85%26spage%3D4643%26epage%3D4647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Hrycyna, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sapperstein, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelis, S.</span><span> </span><span class="NLM_article-title">The <i>Saccharomyces cerevisiae</i> STE14 gene encodes a methyltransferase that mediates C-terminal methylation of a-factor and RAS proteins</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1699</span><span class="NLM_x">–</span> <span class="NLM_lpage">1709</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1991&pages=1699-1709&author=C.+A.+Hrycynaauthor=S.+K.+Sappersteinauthor=S.+Clarkeauthor=S.+Michaelis&title=The+Saccharomyces+cerevisiae+STE14+gene+encodes+a+methyltransferase+that+mediates+C-terminal+methylation+of+a-factor+and+RAS+proteins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHrycyna%26aufirst%3DC.%2BA.%26aulast%3DSapperstein%26aufirst%3DS.%2BK.%26aulast%3DClarke%26aufirst%3DS.%26aulast%3DMichaelis%26aufirst%3DS.%26atitle%3DThe%2520Saccharomyces%2520cerevisiae%2520STE14%2520gene%2520encodes%2520a%2520methyltransferase%2520that%2520mediates%2520C-terminal%2520methylation%2520of%2520a-factor%2520and%2520RAS%2520proteins%26jtitle%3DEMBO%2520J.%26date%3D1991%26volume%3D10%26spage%3D1699%26epage%3D1709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Dai, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choy, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiu, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slivka, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steitz, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philips, M. R.</span><span> </span><span class="NLM_article-title">Mammalian prenylcysteine carboxyl methyltransferase is in the endoplasmic reticulum</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">273</span><span class="NLM_x">, </span> <span class="NLM_fpage">15030</span><span class="NLM_x">–</span> <span class="NLM_lpage">15034</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1998&pages=15030-15034&author=Q.+Daiauthor=E.+Choyauthor=V.+Chiuauthor=J.+Romanoauthor=S.+R.+Slivkaauthor=S.+A.+Steitzauthor=S.+Michaelisauthor=M.+R.+Philips&title=Mammalian+prenylcysteine+carboxyl+methyltransferase+is+in+the+endoplasmic+reticulum"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DQ.%26aulast%3DChoy%26aufirst%3DE.%26aulast%3DChiu%26aufirst%3DV.%26aulast%3DRomano%26aufirst%3DJ.%26aulast%3DSlivka%26aufirst%3DS.%2BR.%26aulast%3DSteitz%26aufirst%3DS.%2BA.%26aulast%3DMichaelis%26aufirst%3DS.%26aulast%3DPhilips%26aufirst%3DM.%2BR.%26atitle%3DMammalian%2520prenylcysteine%2520carboxyl%2520methyltransferase%2520is%2520in%2520the%2520endoplasmic%2520reticulum%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1998%26volume%3D273%26spage%3D15030%26epage%3D15034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Appels, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beijnen, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schellens, J. H.</span><span> </span><span class="NLM_article-title">Development of farnesyl transferase inhibitors: a review</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">565</span><span class="NLM_x">–</span> <span class="NLM_lpage">578</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=565-578&author=N.+M.+Appelsauthor=J.+H.+Beijnenauthor=J.+H.+Schellens&title=Development+of+farnesyl+transferase+inhibitors%3A+a+review"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAppels%26aufirst%3DN.%2BM.%26aulast%3DBeijnen%26aufirst%3DJ.%2BH.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26atitle%3DDevelopment%2520of%2520farnesyl%2520transferase%2520inhibitors%253A%2520a%2520review%26jtitle%3DOncologist%26date%3D2005%26volume%3D10%26spage%3D565%26epage%3D578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Wright, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philips, M. R.</span><span> </span><span class="NLM_article-title">Thematic review series: lipid posttranslational modifications. CAAX modification and membrane targeting of Ras</span> <span class="citation_source-journal">J. Lipid Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">883</span><span class="NLM_x">–</span> <span class="NLM_lpage">891</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2006&pages=883-891&author=L.+P.+Wrightauthor=M.+R.+Philips&title=Thematic+review+series%3A+lipid+posttranslational+modifications.+CAAX+modification+and+membrane+targeting+of+Ras"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWright%26aufirst%3DL.%2BP.%26aulast%3DPhilips%26aufirst%3DM.%2BR.%26atitle%3DThematic%2520review%2520series%253A%2520lipid%2520posttranslational%2520modifications.%2520CAAX%2520modification%2520and%2520membrane%2520targeting%2520of%2520Ras%26jtitle%3DJ.%2520Lipid%2520Res.%26date%3D2006%26volume%3D47%26spage%3D883%26epage%3D891" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Manandhar, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hildebrandt, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santangelo, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, W. K.</span><span> </span><span class="NLM_article-title">Chemical inhibition of CaaX protease activity disrupts yeast Ras localization</span> <span class="citation_source-journal">Yeast</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">327</span><span class="NLM_x">–</span> <span class="NLM_lpage">343</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2010&pages=327-343&author=S.+P.+Manandharauthor=E.+R.+Hildebrandtauthor=W.+H.+Jacobsenauthor=G.+M.+Santangeloauthor=W.+K.+Schmidt&title=Chemical+inhibition+of+CaaX+protease+activity+disrupts+yeast+Ras+localization"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DManandhar%26aufirst%3DS.%2BP.%26aulast%3DHildebrandt%26aufirst%3DE.%2BR.%26aulast%3DJacobsen%26aufirst%3DW.%2BH.%26aulast%3DSantangelo%26aufirst%3DG.%2BM.%26aulast%3DSchmidt%26aufirst%3DW.%2BK.%26atitle%3DChemical%2520inhibition%2520of%2520CaaX%2520protease%2520activity%2520disrupts%2520yeast%2520Ras%2520localization%26jtitle%3DYeast%26date%3D2010%26volume%3D27%26spage%3D327%26epage%3D343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Winter-Vann, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baron, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">dela Cruz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">York, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gooden, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergo, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toone, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casey, P. J.</span><span> </span><span class="NLM_article-title">A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">4336</span><span class="NLM_x">–</span> <span class="NLM_lpage">4341</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1073%2Fpnas.0408107102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=15784746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivFCrtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=4336-4341&author=A.+M.+Winter-Vannauthor=R.+A.+Baronauthor=W.+Wongauthor=J.+dela+Cruzauthor=J.+D.+Yorkauthor=D.+M.+Goodenauthor=M.+O.+Bergoauthor=S.+G.+Youngauthor=E.+J.+Tooneauthor=P.+J.+Casey&title=A+small-molecule+inhibitor+of+isoprenylcysteine+carboxyl+methyltransferase+with+antitumor+activity+in+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells</span></div><div class="casAuthors">Winter-Vann, Ann M.; Baron, Rudi A.; Wong, Waihay; dela Cruz, June; York, John D.; Gooden, David M.; Bergo, Martin O.; Young, Stephen G.; Toone, Eric J.; Casey, Patrick J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4336-4341</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Many key regulatory proteins, including members of the Ras family of GTPases, are modified at their C terminus by a process termed prenylation.  This processing is initiated by the addn. of an isoprenoid lipid, and the proteins are further modified by a proteolytic event and methylation of the C-terminal prenylcysteine.  Although the biol. consequences of prenylation have been characterized extensively, the contributions of prenylcysteine methylation to the functions of the modified proteins are not well understood.  This reaction is catalyzed by the enzyme isoprenylcysteine carboxyl methyltransferase (Icmt).  Recent genetic disruption studies have provided strong evidence that blocking Icmt activity has profound consequences on oncogenic transformation.  Here, we report the identification of a selective small-mol. inhibitor of Icmt, 2-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]acetamide (cysmethynil).  Cysmethynil treatment results in inhibition of cell growth in an Icmt-dependent fashion, demonstrating mechanism-based activity of the compd.  Treatment of cancer cells with cysmethynil results in mislocalization of Ras and impaired epidermal growth factor signaling.  In a human colon cancer cell line, cysmethynil treatment blocks anchorage-independent growth, and this effect is reversed by overexpression of Icmt.  These findings provide a compelling rationale for development of Icmt inhibitors as another approach to anticancer drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY-1GtT0roj7Vg90H21EOLACvtfcHk0lhNsWihFx5y3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivFCrtLk%253D&md5=8cbe478e0911934e2868d5b5eb376a58</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0408107102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0408107102%26sid%3Dliteratum%253Aachs%26aulast%3DWinter-Vann%26aufirst%3DA.%2BM.%26aulast%3DBaron%26aufirst%3DR.%2BA.%26aulast%3DWong%26aufirst%3DW.%26aulast%3Ddela%2BCruz%26aufirst%3DJ.%26aulast%3DYork%26aufirst%3DJ.%2BD.%26aulast%3DGooden%26aufirst%3DD.%2BM.%26aulast%3DBergo%26aufirst%3DM.%2BO.%26aulast%3DYoung%26aufirst%3DS.%2BG.%26aulast%3DToone%26aufirst%3DE.%2BJ.%26aulast%3DCasey%26aufirst%3DP.%2BJ.%26atitle%3DA%2520small-molecule%2520inhibitor%2520of%2520isoprenylcysteine%2520carboxyl%2520methyltransferase%2520with%2520antitumor%2520activity%2520in%2520cancer%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26spage%3D4336%26epage%3D4341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Reuther, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span> </span><span class="NLM_article-title">The Ras branch of small GTPases: RAS family members don’t fall far from the tree</span> <span class="citation_source-journal">Curr. Opin. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">157</span><span class="NLM_x">–</span> <span class="NLM_lpage">165</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1016%2FS0955-0674%2899%2900071-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=10712923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD3cXitVantL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2000&pages=157-165&author=G.+W.+Reutherauthor=C.+J.+Der&title=The+Ras+branch+of+small+GTPases%3A+RAS+family+members+don%E2%80%99t+fall+far+from+the+tree"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">The Ras branch of small GTPases: Ras family members don't fall far from the tree</span></div><div class="casAuthors">Reuther, Gary W.; Der, Channing J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">157-165</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review, with ∼83 refs.  The Ras branch of the Ras superfamily consists of small GTPases most closely related to Ras and include the R-Ras, Rap, Ral, Rheb, Rin and Rit proteins.  Although our understanding of Ras signaling and biol. is now considerable, recent observations suggest that Ras function is more complex than previously believed.  First, the three Ras proteins may not be functionally identical.  Second, Ras function involves functional cross-talk with their close relatives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJoI9hhqdxJLVg90H21EOLACvtfcHk0lgoamOLBGd62Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXitVantL0%253D&md5=4e2ee4f59ac9e0e26b4489063fd2bc1a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2FS0955-0674%2899%2900071-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0955-0674%252899%252900071-X%26sid%3Dliteratum%253Aachs%26aulast%3DReuther%26aufirst%3DG.%2BW.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DThe%2520Ras%2520branch%2520of%2520small%2520GTPases%253A%2520RAS%2520family%2520members%2520don%25E2%2580%2599t%2520fall%2520far%2520from%2520the%2520tree%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D2000%26volume%3D12%26spage%3D157%26epage%3D165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Takai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matozaki, T.</span><span> </span><span class="NLM_article-title">Small GTP-binding proteins</span> <span class="citation_source-journal">Physiol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">208</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2001&pages=153-208&author=Y.+Takaiauthor=T.+Sasakiauthor=T.+Matozaki&title=Small+GTP-binding+proteins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTakai%26aufirst%3DY.%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DMatozaki%26aufirst%3DT.%26atitle%3DSmall%2520GTP-binding%2520proteins%26jtitle%3DPhysiol.%2520Rev.%26date%3D2001%26volume%3D81%26spage%3D153%26epage%3D208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Cullen, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockyer, P. J.</span><span> </span><span class="NLM_article-title">Integration of calcium and Ras signalling</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">339</span><span class="NLM_x">–</span> <span class="NLM_lpage">348</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1038%2Fnrm808" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=11988768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD38XjsFOgsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=339-348&author=P.+J.+Cullenauthor=P.+J.+Lockyer&title=Integration+of+calcium+and+Ras+signalling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Integration of calcium and ras signalling</span></div><div class="casAuthors">Cullen, P. J.; Lockyer, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">339-348</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Calcium is a universal intracellular signal that is responsible for controlling a plethora of cellular processes.  Understanding how such a simple ion can regulate so many diverse cellular processes is a key goal of calcium- and cell-biologists.  One mol. that is sensitive to changes in intracellular calcium levels is Ras.  This small GTPase operates as a binary mol. switch, and regulates cell proliferation and differentiation.  Here, we focus on examg. the link between calcium and Ras signaling and, in particular, we speculate as to how the complexity of calcium signaling could regulate Ras activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE-isSfsB4hLVg90H21EOLACvtfcHk0lgoamOLBGd62Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjsFOgsb8%253D&md5=66e291351cbea5de859eca942426c336</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fnrm808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm808%26sid%3Dliteratum%253Aachs%26aulast%3DCullen%26aufirst%3DP.%2BJ.%26aulast%3DLockyer%26aufirst%3DP.%2BJ.%26atitle%3DIntegration%2520of%2520calcium%2520and%2520Ras%2520signalling%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2002%26volume%3D3%26spage%3D339%26epage%3D348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Heldin, C. H.</span><span> </span><span class="NLM_article-title">Dimerization of cell surface receptors in signal transduction</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">–</span> <span class="NLM_lpage">223</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1016%2F0092-8674%2895%2990404-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=7834741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADyaK2MXjtlGnsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=1995&pages=213-223&author=C.+H.+Heldin&title=Dimerization+of+cell+surface+receptors+in+signal+transduction"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Dimerization of cell surface receptors in signal transduction</span></div><div class="casAuthors">Heldin, Carl-Henrik</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-23</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review, with ∼111 refs.,.  Dimerization or oligomerization have been shown to occur after binding of several polypeptide hormones, cytokines, growth factors, or growth inhibitors to their receptors.  Examples include protein tyrosine kinase receptors, cytokine receptors, antigen receptors, receptors for tumor necrosis factor and related factors, and serine/threonine kinase receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQmjNFpwPeyLVg90H21EOLACvtfcHk0lgoamOLBGd62Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjtlGnsro%253D&md5=15c49efe610770db2316f19d6c24e69d</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2895%2990404-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252895%252990404-2%26sid%3Dliteratum%253Aachs%26aulast%3DHeldin%26aufirst%3DC.%2BH.%26atitle%3DDimerization%2520of%2520cell%2520surface%2520receptors%2520in%2520signal%2520transduction%26jtitle%3DCell%26date%3D1995%26volume%3D80%26spage%3D213%26epage%3D223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Lemmon, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span> </span><span class="NLM_article-title">Regulation of signal transduction and signal diversity by receptor oligomerization</span> <span class="citation_source-journal">Trends Biochem. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">459</span><span class="NLM_x">–</span> <span class="NLM_lpage">463</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1994&pages=459-463&author=M.+A.+Lemmonauthor=J.+Schlessinger&title=Regulation+of+signal+transduction+and+signal+diversity+by+receptor+oligomerization"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLemmon%26aufirst%3DM.%2BA.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DRegulation%2520of%2520signal%2520transduction%2520and%2520signal%2520diversity%2520by%2520receptor%2520oligomerization%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D1994%26volume%3D19%26spage%3D459%26epage%3D463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Weiss, F. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daub, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">Novel mechanisms of RTK signal generation</span> <span class="citation_source-journal">Curr. Opin. Genet. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">86</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1997&pages=80-86&author=F.+U.+Weissauthor=H.+Daubauthor=A.+Ullrich&title=Novel+mechanisms+of+RTK+signal+generation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeiss%26aufirst%3DF.%2BU.%26aulast%3DDaub%26aufirst%3DH.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DNovel%2520mechanisms%2520of%2520RTK%2520signal%2520generation%26jtitle%3DCurr.%2520Opin.%2520Genet.%2520Dev.%26date%3D1997%26volume%3D7%26spage%3D80%26epage%3D86" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Schlessinger, J.</span><span> </span><span class="NLM_article-title">Cell signaling by receptor tyrosine kinases</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span><span class="NLM_x">–</span> <span class="NLM_lpage">225</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1016%2FS0092-8674%2800%2900114-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=11057895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD3cXns1Cltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2000&pages=211-225&author=J.+Schlessinger&title=Cell+signaling+by+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Cell signaling by receptor tyrosine kinases</span></div><div class="casAuthors">Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">211-225</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review, with 109 refs.  The purpose of this review is to describe general concepts underlying the mechanism of action of RTKs and the signaling pathways that they regulate, while attempting to shed light on the question of how specificity is defined by the action of RTKs, and how a specific biol. response can be generated by the diverse array of signaling pathways activated by all RTKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0AvjN2PpaVbVg90H21EOLACvtfcHk0lgi_bh2SPSf0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXns1Cltrs%253D&md5=7b4cacd2513290f3b3e6120b58647654</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2900114-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252900114-8%26sid%3Dliteratum%253Aachs%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DCell%2520signaling%2520by%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCell%26date%3D2000%26volume%3D103%26spage%3D211%26epage%3D225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Rational therapeutic intervention in cancer: kinases as drug targets</span> <span class="citation_source-journal">Curr. Opin. Genet. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">115</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=111-115&author=C.+L.+Sawyers&title=Rational+therapeutic+intervention+in+cancer%3A+kinases+as+drug+targets"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DRational%2520therapeutic%2520intervention%2520in%2520cancer%253A%2520kinases%2520as%2520drug%2520targets%26jtitle%3DCurr.%2520Opin.%2520Genet.%2520Dev.%26date%3D2002%26volume%3D12%26spage%3D111%26epage%3D115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Quilliam, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huff, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabun, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broek, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span> </span><span class="NLM_article-title">Membrane-targeting potentiates guanine nucleotide exchange factor CDC25 and SOS1 activation of Ras transforming activity</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">8512</span><span class="NLM_x">–</span> <span class="NLM_lpage">8516</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=8512-8516&author=L.+A.+Quilliamauthor=S.+Y.+Huffauthor=K.+M.+Rabunauthor=W.+Weiauthor=W.+Parkauthor=D.+Broekauthor=C.+J.+Der&title=Membrane-targeting+potentiates+guanine+nucleotide+exchange+factor+CDC25+and+SOS1+activation+of+Ras+transforming+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQuilliam%26aufirst%3DL.%2BA.%26aulast%3DHuff%26aufirst%3DS.%2BY.%26aulast%3DRabun%26aufirst%3DK.%2BM.%26aulast%3DWei%26aufirst%3DW.%26aulast%3DPark%26aufirst%3DW.%26aulast%3DBroek%26aufirst%3DD.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DMembrane-targeting%2520potentiates%2520guanine%2520nucleotide%2520exchange%2520factor%2520CDC25%2520and%2520SOS1%2520activation%2520of%2520Ras%2520transforming%2520activity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1994%26volume%3D91%26spage%3D8512%26epage%3D8516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Shields, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pruitt, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFall, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaub, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span> </span><span class="NLM_article-title">Understanding RAS: “it ain’t over ’til it’s over”</span> <span class="citation_source-journal">Trends Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">147</span><span class="NLM_x">–</span> <span class="NLM_lpage">154</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1016%2FS0962-8924%2800%2901740-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=10740269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD3cXit1Sqtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2000&pages=147-154&author=J.+M.+Shieldsauthor=K.+Pruittauthor=A.+McFallauthor=A.+Shaubauthor=C.+J.+Der&title=Understanding+RAS%3A+%E2%80%9Cit+ain%E2%80%99t+over+%E2%80%99til+it%E2%80%99s+over%E2%80%9D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding Ras: 'it ain't over 'til it's over'</span></div><div class="casAuthors">Shields, J. M.; Pruitt, K.; McFall, A.; Shaub, A.; Der, C. J.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">147-154</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review, with 55 refs.  Since 1982, Ras has been the subject of intense research scrutiny, focused on detg. the role of aberrant Ras function in human cancers and defining the mechanism by which Ras mediates its actions in normal and neoplastic cells.  The long-term goal has been to develop antagonists of Ras as novel approaches for cancer treatment.  Although impressive strides have been made in these endeavors, and our knowledge of Ras is quite extensive, it appears that we are at the beginning, rather than at the end, of fully understanding Ras function.  This review highlights new issues that have further complicated our efforts to understand Ras.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJMiQq0eD6VrVg90H21EOLACvtfcHk0lgi_bh2SPSf0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXit1Sqtr0%253D&md5=44bbbf6314ccd4abc41a1cdea02ee2f0</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2FS0962-8924%2800%2901740-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0962-8924%252800%252901740-2%26sid%3Dliteratum%253Aachs%26aulast%3DShields%26aufirst%3DJ.%2BM.%26aulast%3DPruitt%26aufirst%3DK.%26aulast%3DMcFall%26aufirst%3DA.%26aulast%3DShaub%26aufirst%3DA.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DUnderstanding%2520RAS%253A%2520%25E2%2580%259Cit%2520ain%25E2%2580%2599t%2520over%2520%25E2%2580%2599til%2520it%25E2%2580%2599s%2520over%25E2%2580%259D%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2000%26volume%3D10%26spage%3D147%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Repasky, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chenette, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span> </span><span class="NLM_article-title">Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?</span> <span class="citation_source-journal">Trends Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">639</span><span class="NLM_x">–</span> <span class="NLM_lpage">647</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1016%2Fj.tcb.2004.09.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=15519853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpt1Wgsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=639-647&author=G.+A.+Repaskyauthor=E.+J.+Chenetteauthor=C.+J.+Der&title=Renewing+the+conspiracy+theory+debate%3A+does+Raf+function+alone+to+mediate+Ras+oncogenesis%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?</span></div><div class="casAuthors">Repasky, Gretchen A.; Chenette, Emily J.; Der, Channing J.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">639-647</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Ras proteins function as signal transducers and are mutationally activated in many human cancers.  In 1993, Raf was identified as a key downstream effector of Ras signaling, and it was believed then that the primary function of Ras was simply to facilitate Raf activation.  However, the subsequent discovery of other proteins that are effectors of Ras function suggested that oncogenic activities of Ras are mediated by both Raf-dependent and Raf-independent signaling.  Further complexity arose with the identification of Ras effectors with putative tumor suppressor, rather than oncogenic, functions.  However, the recent identification of B-raf mutations in human cancers has renewed the debate regarding whether Raf activation alone promotes Ras-mediated oncogenesis.  In this article, the authors summarize the current knowledge of the contribution of Ras effectors in Ras-mediated oncogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyiIPYOakeprVg90H21EOLACvtfcHk0lgi_bh2SPSf0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpt1Wgsr0%253D&md5=b12f5644d4a3fcc3a27c25f8fc425f08</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2004.09.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2004.09.014%26sid%3Dliteratum%253Aachs%26aulast%3DRepasky%26aufirst%3DG.%2BA.%26aulast%3DChenette%26aufirst%3DE.%2BJ.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DRenewing%2520the%2520conspiracy%2520theory%2520debate%253A%2520does%2520Raf%2520function%2520alone%2520to%2520mediate%2520Ras%2520oncogenesis%253F%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2004%26volume%3D14%26spage%3D639%26epage%3D647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Leevers, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterson, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span> </span><span class="NLM_article-title">Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">369</span><span class="NLM_x">, </span> <span class="NLM_fpage">411</span><span class="NLM_x">–</span> <span class="NLM_lpage">414</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1038%2F369411a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=8196769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADyaK2cXlsFWqtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=1994&pages=411-414&author=S.+J.+Leeversauthor=H.+F.+Patersonauthor=C.+J.+Marshall&title=Requirement+for+Ras+in+Raf+activation+is+overcome+by+targeting+Raf+to+the+plasma+membrane"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane</span></div><div class="casAuthors">Leevers, Sally J.; Paterson, Hugh F.; Marshall, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">6479</span>),
    <span class="NLM_cas:pages">411-14</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">A conserved tyrosine kinase-activated signal transduction pathway has recently been identified that comprises the plasma membrane-bound small guanine-nucleotide-binding protein Ras and the protein kinases Raf, MAP-kinase kinase and MAP kinase.  GTP-bound Ras interacts directly with the amino-terminal regulatory domain of Raf, but although Ras and Raf can be coimmunopptd. from ligand-stimulated cells, Ras-GTP does not stimulate the kinase activity of Raf in vitro.  Furthermore, the authors have failed to detect Ras in prepns. of active detergent-solubilized Raf, demonstrating that once it is activated, Raf does not require Ras.  Whereas Raf is normally cytosolic, in cells expressing active Ras, Raf is assocd. with the plasma membrane.  This led the authors to investigate whether Ras is required to localize Raf to the plasma membrane in order for Raf to become activated.  The authors fused the membrane localization signal of K-Ras(4B) to the carboxy terminus of Raf.  This protein is constitutively active and can be further activated by epidermal growth factor, independently of Ras.  The authors' results indicate that Ras functions as a regulated, membrane-bound anchor for Raf, and that other signal(s) also contribute to Raf activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOG6OJ2_orRLVg90H21EOLACvtfcHk0ljEy1m0s3bSDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlsFWqtro%253D&md5=c2c7bd68c990ae117d4060a3c8b44fe9</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2F369411a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F369411a0%26sid%3Dliteratum%253Aachs%26aulast%3DLeevers%26aufirst%3DS.%2BJ.%26aulast%3DPaterson%26aufirst%3DH.%2BF.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26atitle%3DRequirement%2520for%2520Ras%2520in%2520Raf%2520activation%2520is%2520overcome%2520by%2520targeting%2520Raf%2520to%2520the%2520plasma%2520membrane%26jtitle%3DNature%26date%3D1994%26volume%3D369%26spage%3D411%26epage%3D414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Marais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Light, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterson, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span> </span><span class="NLM_article-title">Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">3136</span><span class="NLM_x">–</span> <span class="NLM_lpage">3145</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1995&pages=3136-3145&author=R.+Maraisauthor=Y.+Lightauthor=H.+F.+Patersonauthor=C.+J.+Marshall&title=Ras+recruits+Raf-1+to+the+plasma+membrane+for+activation+by+tyrosine+phosphorylation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DLight%26aufirst%3DY.%26aulast%3DPaterson%26aufirst%3DH.%2BF.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26atitle%3DRas%2520recruits%2520Raf-1%2520to%2520the%2520plasma%2520membrane%2520for%2520activation%2520by%2520tyrosine%2520phosphorylation%26jtitle%3DEMBO%2520J.%26date%3D1995%26volume%3D14%26spage%3D3136%26epage%3D3145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Finney, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrera, D.</span><span> </span><span class="NLM_article-title">Ras-Raf complexes: analyses of complexes formed in vivo</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">255</span><span class="NLM_x">, </span> <span class="NLM_fpage">310</span><span class="NLM_x">–</span> <span class="NLM_lpage">323</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=255&publication_year=1995&pages=310-323&author=R.+Finneyauthor=D.+Herrera&title=Ras-Raf+complexes%3A+analyses+of+complexes+formed+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFinney%26aufirst%3DR.%26aulast%3DHerrera%26aufirst%3DD.%26atitle%3DRas-Raf%2520complexes%253A%2520analyses%2520of%2520complexes%2520formed%2520in%2520vivo%26jtitle%3DMethods%2520Enzymol.%26date%3D1995%26volume%3D255%26spage%3D310%26epage%3D323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Johnson, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chamberlain, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. H.</span><span> </span><span class="NLM_article-title">Identification of key residues in the A-Raf kinase important for phosphoinositide lipid binding specificity</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">3432</span><span class="NLM_x">–</span> <span class="NLM_lpage">3440</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi0487692" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2005&pages=3432-3440&author=L.+M.+Johnsonauthor=K.+M.+Jamesauthor=M.+D.+Chamberlainauthor=D.+H.+Anderson&title=Identification+of+key+residues+in+the+A-Raf+kinase+important+for+phosphoinositide+lipid+binding+specificity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fbi0487692&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi0487692%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DL.%2BM.%26aulast%3DJames%26aufirst%3DK.%2BM.%26aulast%3DChamberlain%26aufirst%3DM.%2BD.%26aulast%3DAnderson%26aufirst%3DD.%2BH.%26atitle%3DIdentification%2520of%2520key%2520residues%2520in%2520the%2520A-Raf%2520kinase%2520important%2520for%2520phosphoinositide%2520lipid%2520binding%2520specificity%26jtitle%3DBiochemistry%26date%3D2005%26volume%3D44%26spage%3D3432%26epage%3D3440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dush, M.</span><span> </span><span class="NLM_article-title">Functional analysis of a phosphatidic acid binding domain in human Raf-1 kinase: mutations in the phosphatidate binding domain lead to tail and trunk abnormalities in developing zebrafish embryos</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">45690</span><span class="NLM_x">–</span> <span class="NLM_lpage">45696</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=45690-45696&author=S.+Ghoshauthor=S.+Mooreauthor=R.+M.+Bellauthor=M.+Dush&title=Functional+analysis+of+a+phosphatidic+acid+binding+domain+in+human+Raf-1+kinase%3A+mutations+in+the+phosphatidate+binding+domain+lead+to+tail+and+trunk+abnormalities+in+developing+zebrafish+embryos"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DMoore%26aufirst%3DS.%26aulast%3DBell%26aufirst%3DR.%2BM.%26aulast%3DDush%26aufirst%3DM.%26atitle%3DFunctional%2520analysis%2520of%2520a%2520phosphatidic%2520acid%2520binding%2520domain%2520in%2520human%2520Raf-1%2520kinase%253A%2520mutations%2520in%2520the%2520phosphatidate%2520binding%2520domain%2520lead%2520to%2520tail%2520and%2520trunk%2520abnormalities%2520in%2520developing%2520zebrafish%2520embryos%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D45690%26epage%3D45696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Rodriguez-Viciana, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warne, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhand, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanhaesebroeck, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gout, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waterfield, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downward, J.</span><span> </span><span class="NLM_article-title">Phosphatidylinositol-3-OH kinase as a direct target of Ras</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">527</span><span class="NLM_x">–</span> <span class="NLM_lpage">532</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=1994&pages=527-532&author=P.+Rodriguez-Vicianaauthor=P.+H.+Warneauthor=R.+Dhandauthor=B.+Vanhaesebroeckauthor=I.+Goutauthor=M.+J.+Fryauthor=M.+D.+Waterfieldauthor=J.+Downward&title=Phosphatidylinositol-3-OH+kinase+as+a+direct+target+of+Ras"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRodriguez-Viciana%26aufirst%3DP.%26aulast%3DWarne%26aufirst%3DP.%2BH.%26aulast%3DDhand%26aufirst%3DR.%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26aulast%3DGout%26aufirst%3DI.%26aulast%3DFry%26aufirst%3DM.%2BJ.%26aulast%3DWaterfield%26aufirst%3DM.%2BD.%26aulast%3DDownward%26aufirst%3DJ.%26atitle%3DPhosphatidylinositol-3-OH%2520kinase%2520as%2520a%2520direct%2520target%2520of%2520Ras%26jtitle%3DNature%26date%3D1994%26volume%3D370%26spage%3D527%26epage%3D532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Pacold, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suire, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perisic, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lara-Gonzalez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccleston, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. L.</span><span> </span><span class="NLM_article-title">Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase γ</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">931</span><span class="NLM_x">–</span> <span class="NLM_lpage">943</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2000&pages=931-943&author=M.+E.+Pacoldauthor=S.+Suireauthor=O.+Perisicauthor=S.+Lara-Gonzalezauthor=C.+T.+Davisauthor=E.+H.+Walkerauthor=P.+T.+Hawkinsauthor=L.+Stephensauthor=J.+F.+Ecclestonauthor=R.+L.+Williams&title=Crystal+structure+and+functional+analysis+of+Ras+binding+to+its+effector+phosphoinositide+3-kinase+%CE%B3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPacold%26aufirst%3DM.%2BE.%26aulast%3DSuire%26aufirst%3DS.%26aulast%3DPerisic%26aufirst%3DO.%26aulast%3DLara-Gonzalez%26aufirst%3DS.%26aulast%3DDavis%26aufirst%3DC.%2BT.%26aulast%3DWalker%26aufirst%3DE.%2BH.%26aulast%3DHawkins%26aufirst%3DP.%2BT.%26aulast%3DStephens%26aufirst%3DL.%26aulast%3DEccleston%26aufirst%3DJ.%2BF.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26atitle%3DCrystal%2520structure%2520and%2520functional%2520analysis%2520of%2520Ras%2520binding%2520to%2520its%2520effector%2520phosphoinositide%25203-kinase%2520%25CE%25B3%26jtitle%3DCell%26date%3D2000%26volume%3D103%26spage%3D931%26epage%3D943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">De Ruiter, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgering, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bos, J. L.</span><span> </span><span class="NLM_article-title">Regulation of the Forkhead transcription factor AFX by Ral-dependent phosphorylation of threonines 447 and 451</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">8225</span><span class="NLM_x">–</span> <span class="NLM_lpage">8235</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1128%2FMCB.21.23.8225-8235.2001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=11689711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD3MXotl2gurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2001&pages=8225-8235&author=N.+D.+De+Ruiterauthor=B.+M.+Burgeringauthor=J.+L.+Bos&title=Regulation+of+the+Forkhead+transcription+factor+AFX+by+Ral-dependent+phosphorylation+of+threonines+447+and+451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of the Forkhead transcription factor AFX by Ral-dependent phosphorylation of threonines 447 and 451</span></div><div class="casAuthors">De Ruiter, Nancy D.; Burgering, Boudewijn M. T.; Bos, Johannes L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">8225-8235</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">AFX is a Forkhead transcription factor that induces a G1 cell cycle arrest via upregulation of the cell cycle inhibitor p27Kip1.  Previously we have shown that protein kinase B (PKB) phosphorylates AFX causing inhibition of AFX by nuclear exclusion.  In addn., Ras, through the activation of the RalGEF-Ral pathway, induces phosphorylation of AFX.  Here we show that the Ras-Ral pathway provokes phosphorylation of threonines 447 and 451 in the C terminus of AFX.  A mutant protein in which both threonines are substituted for alanines (T447A/T451A) still responds to PKB-regulated nuclear-cytoplasmic shuttling, but transcriptional activity and consequent G1 cell cycle arrest are greatly impaired.  Furthermore, inhibition of the Ral signaling pathway abolishes both AFX-mediated transcription and regulation of p27Kip1, while activation of Ral augments AFX activity.  From these results we conclude that Ral-mediated phosphorylation of threonines 447 and 451 is required for proper activity of AFX-WT.  Interestingly, the T447A/T451A mutation did not affect the induction of transcription and G1 cell cycle arrest by the PKB-insensitive AFX-A3 mutant, suggesting that Ral-mediated phosphorylation plays a role in the regulation of AFX by PKB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVnQ2x_jSNdLVg90H21EOLACvtfcHk0lhr_eQrB9VDgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXotl2gurw%253D&md5=7bae6dbff0fe22ca3247cb0fa42fa771</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1128%2FMCB.21.23.8225-8235.2001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.21.23.8225-8235.2001%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BRuiter%26aufirst%3DN.%2BD.%26aulast%3DBurgering%26aufirst%3DB.%2BM.%26aulast%3DBos%26aufirst%3DJ.%2BL.%26atitle%3DRegulation%2520of%2520the%2520Forkhead%2520transcription%2520factor%2520AFX%2520by%2520Ral-dependent%2520phosphorylation%2520of%2520threonines%2520447%2520and%2520451%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2001%26volume%3D21%26spage%3D8225%26epage%3D8235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">González-García, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterson, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mavria, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamp, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span> </span><span class="NLM_article-title">RalGDS is required for tumor formation in a model of skin carcinogenesis</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">–</span> <span class="NLM_lpage">226</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=219-226&author=A.+Gonz%C3%A1lez-Garc%C3%ADaauthor=C.+A.+Pritchardauthor=H.+F.+Patersonauthor=G.+Mavriaauthor=G.+Stampauthor=C.+J.+Marshall&title=RalGDS+is+required+for+tumor+formation+in+a+model+of+skin+carcinogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGonz%25C3%25A1lez-Garc%25C3%25ADa%26aufirst%3DA.%26aulast%3DPritchard%26aufirst%3DC.%2BA.%26aulast%3DPaterson%26aufirst%3DH.%2BF.%26aulast%3DMavria%26aufirst%3DG.%26aulast%3DStamp%26aufirst%3DG.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26atitle%3DRalGDS%2520is%2520required%2520for%2520tumor%2520formation%2520in%2520a%2520model%2520of%2520skin%2520carcinogenesis%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26spage%3D219%26epage%3D226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Hofer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fields, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, G. S.</span><span> </span><span class="NLM_article-title">Activated Ras interacts with the Ral guanine nucleotide dissociation stimulator</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">11089</span><span class="NLM_x">–</span> <span class="NLM_lpage">11093</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=11089-11093&author=F.+Hoferauthor=S.+Fieldsauthor=C.+Schneiderauthor=G.+S.+Martin&title=Activated+Ras+interacts+with+the+Ral+guanine+nucleotide+dissociation+stimulator"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHofer%26aufirst%3DF.%26aulast%3DFields%26aufirst%3DS.%26aulast%3DSchneider%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DG.%2BS.%26atitle%3DActivated%2520Ras%2520interacts%2520with%2520the%2520Ral%2520guanine%2520nucleotide%2520dissociation%2520stimulator%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1994%26volume%3D91%26spage%3D11089%26epage%3D11093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Bittker, J. A.; Weiwer, M.; Shimada, K.; Yang, W. S.; MacPherson, L.; Dandapani, S.; Munoz, B.; Palmer, M.; Stockwell, B. R.; Schreiber, S. L.</span><span> </span><span class="NLM_article-title">Screen for RAS-Selective Lethal Compounds and VDAC Ligands—Probe 1</span>.  <span class="citation_source-book">Probe Reports from the NIH Molecular Libraries Program [Internet]</span>; <span class="NLM_publisher-name">National Center for Biotechnology Information, U.S. National Library of Medicine</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span><a href="http://www.ncbi.nlm.nih.gov/books/NBK55069/" class="extLink">http://www.ncbi.nlm.nih.gov/books/NBK55069/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=J.+A.+Bittker&author=M.+Weiwer&author=K.+Shimada&author=W.+S.+Yang&author=L.+MacPherson&author=S.+Dandapani&author=B.+Munoz&author=M.+Palmer&author=B.+R.+Stockwell&author=S.+L.+Schreiber&title=Probe+Reports+from+the+NIH+Molecular+Libraries+Program+%5BInternet%5D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DBittker%26aufirst%3DJ.%2BA.%26atitle%3DScreen%2520for%2520RAS-Selective%2520Lethal%2520Compounds%2520and%2520VDAC%2520Ligands%25E2%2580%2594Probe%25201%26btitle%3DProbe%2520Reports%2520from%2520the%2520NIH%2520Molecular%2520Libraries%2520Program%2520%255BInternet%255D%26pub%3DNational%2520Center%2520for%2520Biotechnology%2520Information%252C%2520U.S.%2520National%2520Library%2520of%2520Medicine%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Torrance, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agrawal, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogelstein, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinzler, K. W.</span><span> </span><span class="NLM_article-title">Use of isogenic human cancer cells for high-throughput screening and drug discovery</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">940</span><span class="NLM_x">–</span> <span class="NLM_lpage">945</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2001&pages=940-945&author=C.+J.+Torranceauthor=V.+Agrawalauthor=B.+Vogelsteinauthor=K.+W.+Kinzler&title=Use+of+isogenic+human+cancer+cells+for+high-throughput+screening+and+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTorrance%26aufirst%3DC.%2BJ.%26aulast%3DAgrawal%26aufirst%3DV.%26aulast%3DVogelstein%26aufirst%3DB.%26aulast%3DKinzler%26aufirst%3DK.%2BW.%26atitle%3DUse%2520of%2520isogenic%2520human%2520cancer%2520cells%2520for%2520high-throughput%2520screening%2520and%2520drug%2520discovery%26jtitle%3DNat.%2520Biotechnol.%26date%3D2001%26volume%3D19%26spage%3D940%26epage%3D945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Guo, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, B.</span><span> </span><span class="NLM_article-title">Identification of a small molecule with synthetic lethality for K-RAS and protein kinase C iota</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">7403</span><span class="NLM_x">–</span> <span class="NLM_lpage">7408</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=7403-7408&author=W.+Guoauthor=S.+Wuauthor=J.+Liuauthor=B.+Fang&title=Identification+of+a+small+molecule+with+synthetic+lethality+for+K-RAS+and+protein+kinase+C+iota"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DFang%26aufirst%3DB.%26atitle%3DIdentification%2520of%2520a%2520small%2520molecule%2520with%2520synthetic%2520lethality%2520for%2520K-RAS%2520and%2520protein%2520kinase%2520C%2520iota%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D7403%26epage%3D7408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winslow, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magendantz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouyang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowdle, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maglathin, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolliday, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacks, T.</span><span> </span><span class="NLM_article-title">Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">8773</span><span class="NLM_x">–</span> <span class="NLM_lpage">8778</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=8773-8778&author=A.+T.+Shawauthor=M.+M.+Winslowauthor=M.+Magendantzauthor=C.+Ouyangauthor=J.+Dowdleauthor=A.+Subramanianauthor=T.+A.+Lewisauthor=R.+L.+Maglathinauthor=N.+Tollidayauthor=T.+Jacks&title=Selective+killing+of+K-ras+mutant+cancer+cells+by+small+molecule+inducers+of+oxidative+stress"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DWinslow%26aufirst%3DM.%2BM.%26aulast%3DMagendantz%26aufirst%3DM.%26aulast%3DOuyang%26aufirst%3DC.%26aulast%3DDowdle%26aufirst%3DJ.%26aulast%3DSubramanian%26aufirst%3DA.%26aulast%3DLewis%26aufirst%3DT.%2BA.%26aulast%3DMaglathin%26aufirst%3DR.%2BL.%26aulast%3DTolliday%26aufirst%3DN.%26aulast%3DJacks%26aufirst%3DT.%26atitle%3DSelective%2520killing%2520of%2520K-ras%2520mutant%2520cancer%2520cells%2520by%2520small%2520molecule%2520inducers%2520of%2520oxidative%2520stress%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2011%26volume%3D108%26spage%3D8773%26epage%3D8778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Maurer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrenton, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitts, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skelton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fauber, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokoe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludlam, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowman, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannetti, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starovasnik, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellman, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, G.</span><span> </span><span class="NLM_article-title">Small-molecule ligands bind to a distinct pocket in RAS and inhibit SOS-mediated nucleotide exchange activity</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">5299</span><span class="NLM_x">–</span> <span class="NLM_lpage">5304</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1073%2Fpnas.1116510109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=22431598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BC38XlslOjsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=5299-5304&author=T.+Maurerauthor=L.+S.+Garrentonauthor=A.+Ohauthor=K.+Pittsauthor=D.+J.+Andersonauthor=N.+J.+Skeltonauthor=B.+P.+Fauberauthor=B.+Panauthor=S.+Malekauthor=D.+Stokoeauthor=M.+J.+Ludlamauthor=K.+K.+Bowmanauthor=J.+Wuauthor=A.+M.+Giannettiauthor=M.+A.+Starovasnikauthor=I.+Mellmanauthor=P.+K.+Jacksonauthor=J.+Rudolphauthor=W.+Wangauthor=G.+Fang&title=Small-molecule+ligands+bind+to+a+distinct+pocket+in+RAS+and+inhibit+SOS-mediated+nucleotide+exchange+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity</span></div><div class="casAuthors">Maurer, Till; Garrenton, Lindsay S.; Oh, Angela; Pitts, Keith; Anderson, Daniel J.; Skelton, Nicholas J.; Fauber, Benjamin P.; Pan, Borlan; Malek, Shiva; Stokoe, David; Ludlam, Mary J. C.; Bowman, Krista K.; Wu, Jiansheng; Giannetti, Anthony M.; Starovasnik, Melissa A.; Mellman, Ira; Jackson, Peter K.; Rudolph, Joachim; Wang, Weiru; Fang, Guowei</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5299-5304, S5299/1-S5299/13</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The Ras gene is frequently mutated in cancer, and mutant Ras drives tumorigenesis.  Although Ras is a central oncogene, small mols. that bind to Ras in a well-defined manner and exert inhibitory effects have not been uncovered to date.  Through an NMR-based fragment screen, we identified a group of small mols. that all bind to a common site on Ras.  High-resoln. cocrystal structures delineated a unique ligand-binding pocket on the Ras protein that is adjacent to the switch I/II regions and can be expanded upon compd. binding.  Structure anal. predicts that compd.-binding interferes with the Ras/SOS interactions.  Indeed, selected compds. inhibit SOS-mediated nucleotide exchange and prevent Ras activation by blocking the formation of intermediates of the exchange reaction.  The discovery of a small-mol. binding pocket on Ras with functional significance provides a new direction in the search of therapeutically effective inhibitors of the Ras oncoprotein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAXIzMe7yBqrVg90H21EOLACvtfcHk0lg2yddOsl_lBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlslOjsrc%253D&md5=a7210cad45154c42eb2a1faeabf88c20</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1116510109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1116510109%26sid%3Dliteratum%253Aachs%26aulast%3DMaurer%26aufirst%3DT.%26aulast%3DGarrenton%26aufirst%3DL.%2BS.%26aulast%3DOh%26aufirst%3DA.%26aulast%3DPitts%26aufirst%3DK.%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DSkelton%26aufirst%3DN.%2BJ.%26aulast%3DFauber%26aufirst%3DB.%2BP.%26aulast%3DPan%26aufirst%3DB.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DLudlam%26aufirst%3DM.%2BJ.%26aulast%3DBowman%26aufirst%3DK.%2BK.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DStarovasnik%26aufirst%3DM.%2BA.%26aulast%3DMellman%26aufirst%3DI.%26aulast%3DJackson%26aufirst%3DP.%2BK.%26aulast%3DRudolph%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DFang%26aufirst%3DG.%26atitle%3DSmall-molecule%2520ligands%2520bind%2520to%2520a%2520distinct%2520pocket%2520in%2520RAS%2520and%2520inhibit%2520SOS-mediated%2520nucleotide%2520exchange%2520activity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2012%26volume%3D109%26spage%3D5299%26epage%3D5304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Rees, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Congreve, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, R.</span><span> </span><span class="NLM_article-title">Fragment based lead discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">660</span><span class="NLM_x">–</span> <span class="NLM_lpage">672</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=660-672&author=D.+C.+Reesauthor=M.+Congreveauthor=C.+W.+Murrayauthor=R.+Carr&title=Fragment+based+lead+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DCarr%26aufirst%3DR.%26atitle%3DFragment%2520based%2520lead%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D660%26epage%3D672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Chessari, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodhead, A. J.</span><span> </span><span class="NLM_article-title">From fragment to clinical candidate—a historical perspective</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">668</span><span class="NLM_x">–</span> <span class="NLM_lpage">675</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1016%2Fj.drudis.2009.04.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=19427404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotFyktLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=668-675&author=G.+Chessariauthor=A.+J.+Woodhead&title=From+fragment+to+clinical+candidate%E2%80%94a+historical+perspective"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">From fragment to clinical candidate-a historical perspective</span></div><div class="casAuthors">Chessari, Gianni; Woodhead, Andrew J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">13/14</span>),
    <span class="NLM_cas:pages">668-675</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  As recently as ten years ago few scientists had heard of fragment screening, let alone considered low mol. wt. fragments (MW <300) with weak binding affinities to be attractive start points for drug discovery programs.  Today, however, there is widespread acceptance that these fragments can be progressed into lead series and on to become clin. candidates.  Consequently, over the past three to four years, fragment-based drug discovery has become firmly established within the biotechnol. and pharmaceutical industries as a complimentary strategy to high-throughput screening.  In this review, we give a historical perspective of how rapidly fragment-based drug discovery has developed and describe a no. of clin. compds. discovered using this approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIfibakR1lWLVg90H21EOLACvtfcHk0liYrkOEtsW6LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotFyktLo%253D&md5=1bd47b7787b1b22681466ad220eb7cd1</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2009.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2009.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DChessari%26aufirst%3DG.%26aulast%3DWoodhead%26aufirst%3DA.%2BJ.%26atitle%3DFrom%2520fragment%2520to%2520clinical%2520candidate%25E2%2580%2594a%2520historical%2520perspective%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26spage%3D668%26epage%3D675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Zartler, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mo, H.</span><span> </span><span class="NLM_article-title">Practical aspects of NMR-based fragment discovery</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1592</span><span class="NLM_x">–</span> <span class="NLM_lpage">1599</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.2174%2F156802607782341055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=17979770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVOrur7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=1592-1599&author=E.+R.+Zartlerauthor=H.+Mo&title=Practical+aspects+of+NMR-based+fragment+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Practical aspects of NMR-based fragment discovery</span></div><div class="casAuthors">Zartler, Edward R.; Mo, Huaping</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1592-1599</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Fragment-based drug discovery (FBDD) needs a biophys. assay to complement, or even replace, biochem. screening.  NMR is the best choice for this because NMR delivers many different types of data that impacts medicinal chem. decisions.  There are a multitude of different NMR methods which can be employed to these ends.  The choice of which method to use will be different for every need.  We discuss the different methods, the data they produce, and how they are best utilized in a FBDD setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqUP8IXrnvybVg90H21EOLACvtfcHk0liYrkOEtsW6LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVOrur7E&md5=b5399a10cc438cb92997e035789bb63b</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.2174%2F156802607782341055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802607782341055%26sid%3Dliteratum%253Aachs%26aulast%3DZartler%26aufirst%3DE.%2BR.%26aulast%3DMo%26aufirst%3DH.%26atitle%3DPractical%2520aspects%2520of%2520NMR-based%2520fragment%2520discovery%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D1592%26epage%3D1599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Meyer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, T.</span><span> </span><span class="NLM_article-title">NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">864</span><span class="NLM_x">–</span> <span class="NLM_lpage">890</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1002%2Fanie.200390233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitFWltL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=864-890&author=B.+Meyerauthor=T.+Peters&title=NMR+spectroscopy+techniques+for+screening+and+identifying+ligand+binding+to+protein+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors</span></div><div class="casAuthors">Meyer, Bernd; Peters, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">864-890</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Picking the locks of protein binding: NMR spectroscopic techniques for the characterization of binding processes have recently gained much attention.  Binding epitopes on the ligands and on the protein can be identified easily without the aid of crystal structures (see scheme).  Hereby, rational design of new drugs has become more accessible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNviqXqZtItbVg90H21EOLACvtfcHk0liYrkOEtsW6LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitFWltL4%253D&md5=e0b38bf974639d9414fb57e8d0def3e1</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2Fanie.200390233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200390233%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DB.%26aulast%3DPeters%26aufirst%3DT.%26atitle%3DNMR%2520spectroscopy%2520techniques%2520for%2520screening%2520and%2520identifying%2520ligand%2520binding%2520to%2520protein%2520receptors%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2003%26volume%3D42%26spage%3D864%26epage%3D890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Erlanson, D.</span><span> </span><span class="NLM_article-title">Fragments versus Ras—Part 2</span>. In  <span class="citation_source-book">Practical Fragments</span>; <span class="NLM_contrib-group">Zartler, T.; Erlanson, D.</span>, Eds.; June 6,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>BlogSpot, June 10, 2012, <a href="http://practicalfragments.blogspot.com/2012/06/fragments-versus-ras-part-2.html" class="extLink">http://practicalfragments.blogspot.com/2012/06/fragments-versus-ras-part-2.html</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=D.+Erlansonauthor=T.+Zartler&author=D.+Erlanson&title=Practical+Fragments"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DErlanson%26aufirst%3DD.%26atitle%3DFragments%2520versus%2520Ras%25E2%2580%2594Part%25202%26btitle%3DPractical%2520Fragments%26aulast%3DZartler%26aufirst%3DT.%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Sridhar, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hedley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siu, L. L.</span><span> </span><span class="NLM_article-title">Raf kinase as a target for anticancer therapeutics</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">677</span><span class="NLM_x">–</span> <span class="NLM_lpage">685</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1158%2F1535-7163.MCT-04-0297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=15827342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFegsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=677-685&author=S.+S.+Sridharauthor=D.+Hedleyauthor=L.+L.+Siu&title=Raf+kinase+as+a+target+for+anticancer+therapeutics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Raf kinase as a target for anticancer therapeutics</span></div><div class="casAuthors">Sridhar, Srikala S.; Hedley, David; Siu, Lillian L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">677-685</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The Ras-Raf-MEK-ERK (ERK) pathway is a logical therapeutic target because it represents a common downstream pathway for several key growth factor tyrosine kinase receptors which are often mutated or overexpressed in human cancers.  Although considered mainly growth-promoting, in certain contexts, this pathway also seems to be apoptosis-suppressing.  Several novel agents targeting this pathway have now been developed and are in clin. trials.  One of the most interesting new agents is BAY 43-9006.  Although initially developed as a Raf kinase inhibitor, it can also target several other important tyrosine kinases including VEGFR-2, Flt-3, and c-Kit, which contributes to its antiproliferative and antiangiogenic properties.  To date, encouraging results were seen with BAY 43-9006, particularly in renal cell cancers which are highly vascular tumors.  This review will provide an overview of the ERK signaling pathway in normal and neoplastic tissue, with a specific focus on novel therapies targeting the ERK pathway at the level of Raf kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphMFgPve1M6LVg90H21EOLACvtfcHk0lgwjZtuO4vOJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFegsLc%253D&md5=4e59ddcdb2afe92dba930b73b07ec51c</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-04-0297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-04-0297%26sid%3Dliteratum%253Aachs%26aulast%3DSridhar%26aufirst%3DS.%2BS.%26aulast%3DHedley%26aufirst%3DD.%26aulast%3DSiu%26aufirst%3DL.%2BL.%26atitle%3DRaf%2520kinase%2520as%2520a%2520target%2520for%2520anticancer%2520therapeutics%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2005%26volume%3D4%26spage%3D677%26epage%3D685" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Khosravi-Far, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westwick, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solski, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chrzanowska-Wodnicka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Aelst, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wigler, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span> </span><span class="NLM_article-title">Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">3923</span><span class="NLM_x">–</span> <span class="NLM_lpage">3933</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=8668210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADyaK28XjvVWmsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1996&pages=3923-3933&author=R.+Khosravi-Farauthor=M.+A.+Whiteauthor=J.+K.+Westwickauthor=P.+A.+Solskiauthor=M.+Chrzanowska-Wodnickaauthor=L.+Van+Aelstauthor=M.+H.+Wiglerauthor=C.+J.+Der&title=Oncogenic+Ras+activation+of+Raf%2Fmitogen-activated+protein+kinase-independent+pathways+is+sufficient+to+cause+tumorigenic+transformation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation</span></div><div class="casAuthors">Khosravi-Far, Roya; White, Michael A.; Westwick, John K.; Solski, Patricia A.; Chrzanowska-Wodnicka, Magdalena; Van Aelst, Linda; Wigler, Michael H.; Der, Channing J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3923-3933</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Substantial evidence supports a crit. role for the activation of the Raf-1/MEK/mitogen-activated protein kinase pathway in oncogenic Ras-mediated transformation.  For example, dominant neg. mutants of Raf-1, MEK, and mitogen-activated protein kinase all inhibit Ras transformation.  Furthermore, the observation that plasma membrane-localized Raf-1 exhibits the same transforming potency as oncogenic Ras suggests that Raf-1 activation alone is sufficient to mediate full Ras transforming activity.  However, the recent identification of other candidate Ras effectors (e.g., RalGDS and phosphatidylinositol-3 kinase) suggests that activation of other downstream effector-mediated signaling pathways may also mediate Ras transforming activity.  In support of this, two H-Ras effector domain mutants, H-Ras(12V, 37G) and H-Ras(12V, 40C), which are defective for Raf binding and activation, induced potent tumorigenic transformation of some strains of NIH 3T3 fibroblasts.  These Raf-binding defective mutants of H-Ras induced a transformed morphol. that was indistinguishable from that induced by activated members of Rho family proteins.  Furthermore, the transforming activities of both of these mutants were synergistically enhanced by activated Raf-1 and inhibited by the dominant neg. RhoA(19N) mutant, indicating that Ras may cause transformation that occurs via coordinate activation of Raf-dependent and -independent pathways that involves Rho family proteins.  Finally, cotransfection of H-Ras(12V, 37G) and H-Ras(12V, 40C) resulted in synergistic cooperation of their focus-forming activities, indicating that Ras activates at least two Raf-independent, Ras effector-mediated signaling events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_cWFoHWMoWrVg90H21EOLACvtfcHk0lgwjZtuO4vOJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjvVWmsro%253D&md5=dec9680e7ca532fe5ce72eb28f53293d</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKhosravi-Far%26aufirst%3DR.%26aulast%3DWhite%26aufirst%3DM.%2BA.%26aulast%3DWestwick%26aufirst%3DJ.%2BK.%26aulast%3DSolski%26aufirst%3DP.%2BA.%26aulast%3DChrzanowska-Wodnicka%26aufirst%3DM.%26aulast%3DVan%2BAelst%26aufirst%3DL.%26aulast%3DWigler%26aufirst%3DM.%2BH.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DOncogenic%2520Ras%2520activation%2520of%2520Raf%252Fmitogen-activated%2520protein%2520kinase-independent%2520pathways%2520is%2520sufficient%2520to%2520cause%2520tumorigenic%2520transformation%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1996%26volume%3D16%26spage%3D3923%26epage%3D3933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Khosravi-Far, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solski, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinch, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span> </span><span class="NLM_article-title">Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for RAS transformation</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">6443</span><span class="NLM_x">–</span> <span class="NLM_lpage">6453</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1128%2FMCB.15.11.6443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=7565796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADyaK2MXovVyksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1995&pages=6443-6453&author=R.+Khosravi-Farauthor=P.+A.+Solskiauthor=G.+J.+Clarkauthor=M.+S.+Kinchauthor=C.+J.+Der&title=Activation+of+Rac1%2C+RhoA%2C+and+mitogen-activated+protein+kinases+is+required+for+RAS+transformation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation</span></div><div class="casAuthors">Khosravi-far, Roya; Solski, Patricia A.; Clark, Geoffrey J.; Kinch, Michael S.; Der, Channing J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6443-53</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Although substantial evidence supports a crit. role for the activation of Raf-1 and mitogen-activated protein kinases (MAPKs) in oncogenic Ras-mediated transformation, recent evidence suggests that Ras may activate a second signaling pathway which involves the Ras-related proteins Rac1 and RhoA.  Consequently, the authors used three complementary approaches to det. the contribution of Rac1 and RhoA function to oncogenic Ras-mediated transformation.  First, whereas constitutively activated mutants of Rac1 and RhoA showed very weak transforming activity when transfected alone, their coexpression with a weakly transforming Raf-1 mutant caused a greater than 35-fold enhancement of transforming activity.  Second, the authors obsd. that coexpression of dominant neg. mutants of Rac1 and RhoA reduced oncogenic Ras transforming activity.  Third, activated Rac1 and RhoA further enhanced oncogenic Ras-triggered morphol. transformation, as well as growth in soft agar and cell motility.  Finally, the authors also obsd. that kinase-deficient MAPKs inhibited Ras transformation.  Taken together, these data support the possibility that oncogenic Ras activation of Rac1 and RhoA, coupled with activation of the Raf/MAPK pathway, is required to trigger the full morphogenic and mitogenic consequences of oncogenic Ras transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUEqcWdhd4prVg90H21EOLACvtfcHk0lgwjZtuO4vOJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXovVyksLk%253D&md5=4829be92810e97bad05c48faefa8780e</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1128%2FMCB.15.11.6443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.15.11.6443%26sid%3Dliteratum%253Aachs%26aulast%3DKhosravi-Far%26aufirst%3DR.%26aulast%3DSolski%26aufirst%3DP.%2BA.%26aulast%3DClark%26aufirst%3DG.%2BJ.%26aulast%3DKinch%26aufirst%3DM.%2BS.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DActivation%2520of%2520Rac1%252C%2520RhoA%252C%2520and%2520mitogen-activated%2520protein%2520kinases%2520is%2520required%2520for%2520RAS%2520transformation%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1995%26volume%3D15%26spage%3D6443%26epage%3D6453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Heim, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharifi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilger, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheulen, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeber, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strumberg, D.</span><span> </span><span class="NLM_article-title">Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006</span> <span class="citation_source-journal">Int. J. Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">616</span><span class="NLM_x">–</span> <span class="NLM_lpage">617</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=14692718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD2cXht1OjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2003&pages=616-617&author=M.+Heimauthor=M.+Sharifiauthor=R.+A.+Hilgerauthor=M.+E.+Scheulenauthor=S.+Seeberauthor=D.+Strumberg&title=Antitumor+effect+and+potentiation+or+reduction+in+cytotoxic+drug+activity+in+human+colon+carcinoma+cells+by+the+Raf+kinase+inhibitor+%28RKI%29+BAY+43-9006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006</span></div><div class="casAuthors">Heim, M.; Sharifi, M.; Hilger, R. A.; Scheulen, M. E.; Seeber, S.; Strumberg, D.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Clinical Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">616-617</span>CODEN:
                <span class="NLM_cas:coden">ICTHEK</span>;
        ISSN:<span class="NLM_cas:issn">0946-1965</span>.
    
            (<span class="NLM_cas:orgname">Dustri-Verlag Dr. Karl Feistle</span>)
        </div><div class="casAbstract">A study was conducted to evaluate the effects of combining BAY 43-9006 and cytotoxic drugs (paclitaxel, 5-FU, oxaliplatin, and SN-38) on human cancer cells using 4 sequencing protocols and to analyze the effect of RKI on colorectal cancer cells showing marked resistance against SN-38.  Results showed the additive action or moderate synergy using RKI in combination with numerous cytotoxic agents and the marked redn. of oxaliplatin activity by RKI in human carcinoma cells.  These indicate that Raf kinase activity might be important for oxaliplatin-induced cytotoxicity.  Furthermore, lacking cross-resistance between SN-38 and RKI might provide a rationale for designing clin. trials using CPT-11 in combination with BAY 43-9006 in patients with colorectal cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO-t4901dZa7Vg90H21EOLACvtfcHk0lgwjZtuO4vOJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXht1OjtA%253D%253D&md5=3913835b7d32f41af23033de33751c22</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHeim%26aufirst%3DM.%26aulast%3DSharifi%26aufirst%3DM.%26aulast%3DHilger%26aufirst%3DR.%2BA.%26aulast%3DScheulen%26aufirst%3DM.%2BE.%26aulast%3DSeeber%26aufirst%3DS.%26aulast%3DStrumberg%26aufirst%3DD.%26atitle%3DAntitumor%2520effect%2520and%2520potentiation%2520or%2520reduction%2520in%2520cytotoxic%2520drug%2520activity%2520in%2520human%2520colon%2520carcinoma%2520cells%2520by%2520the%2520Raf%2520kinase%2520inhibitor%2520%2528RKI%2529%2520BAY%252043-9006%26jtitle%3DInt.%2520J.%2520Clin.%2520Pharmacol.%2520Ther.%26date%3D2003%26volume%3D41%26spage%3D616%26epage%3D617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Wilhelm, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNabola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHugh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shujath, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gawlak, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eveleigh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adnane, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auclair, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gedrich, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voznesensky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trail, P. A.</span><span> </span><span class="NLM_article-title">BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">7099</span><span class="NLM_x">–</span> <span class="NLM_lpage">7109</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=7099-7109&author=S.+M.+Wilhelmauthor=C.+Carterauthor=L.+Tangauthor=D.+Wilkieauthor=A.+McNabolaauthor=H.+Rongauthor=C.+Chenauthor=X.+Zhangauthor=P.+Vincentauthor=M.+McHughauthor=Y.+Caoauthor=J.+Shujathauthor=S.+Gawlakauthor=D.+Eveleighauthor=B.+Rowleyauthor=L.+Liuauthor=L.+Adnaneauthor=M.+Lynchauthor=D.+Auclairauthor=I.+Taylorauthor=R.+Gedrichauthor=A.+Voznesenskyauthor=B.+Riedlauthor=L.+E.+Postauthor=G.+Bollagauthor=P.+A.+Trail&title=BAY+43-9006+exhibits+broad+spectrum+oral+antitumor+activity+and+targets+the+RAF%2FMEK%2FERK+pathway+and+receptor+tyrosine+kinases+involved+in+tumor+progression+and+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilhelm%26aufirst%3DS.%2BM.%26aulast%3DCarter%26aufirst%3DC.%26aulast%3DTang%26aufirst%3DL.%26aulast%3DWilkie%26aufirst%3DD.%26aulast%3DMcNabola%26aufirst%3DA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DVincent%26aufirst%3DP.%26aulast%3DMcHugh%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DShujath%26aufirst%3DJ.%26aulast%3DGawlak%26aufirst%3DS.%26aulast%3DEveleigh%26aufirst%3DD.%26aulast%3DRowley%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DAdnane%26aufirst%3DL.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DAuclair%26aufirst%3DD.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DGedrich%26aufirst%3DR.%26aulast%3DVoznesensky%26aufirst%3DA.%26aulast%3DRiedl%26aufirst%3DB.%26aulast%3DPost%26aufirst%3DL.%2BE.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DTrail%26aufirst%3DP.%2BA.%26atitle%3DBAY%252043-9006%2520exhibits%2520broad%2520spectrum%2520oral%2520antitumor%2520activity%2520and%2520targets%2520the%2520RAF%252FMEK%252FERK%2520pathway%2520and%2520receptor%2520tyrosine%2520kinases%2520involved%2520in%2520tumor%2520progression%2520and%2520angiogenesis%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D7099%26epage%3D7109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Koya, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otte, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blacketor, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comin-Anduix, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tumeh, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minasyan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graeber, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chodon, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span> </span><span class="NLM_article-title">BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">3928</span><span class="NLM_x">–</span> <span class="NLM_lpage">3937</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=3928-3937&author=R.+C.+Koyaauthor=S.+Mokauthor=N.+Otteauthor=K.+J.+Blacketorauthor=B.+Comin-Anduixauthor=P.+C.+Tumehauthor=A.+Minasyanauthor=N.+A.+Grahamauthor=T.+G.+Graeberauthor=T.+Chodonauthor=A.+Ribas&title=BRAF+inhibitor+vemurafenib+improves+the+antitumor+activity+of+adoptive+cell+immunotherapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKoya%26aufirst%3DR.%2BC.%26aulast%3DMok%26aufirst%3DS.%26aulast%3DOtte%26aufirst%3DN.%26aulast%3DBlacketor%26aufirst%3DK.%2BJ.%26aulast%3DComin-Anduix%26aufirst%3DB.%26aulast%3DTumeh%26aufirst%3DP.%2BC.%26aulast%3DMinasyan%26aufirst%3DA.%26aulast%3DGraham%26aufirst%3DN.%2BA.%26aulast%3DGraeber%26aufirst%3DT.%2BG.%26aulast%3DChodon%26aufirst%3DT.%26aulast%3DRibas%26aufirst%3DA.%26atitle%3DBRAF%2520inhibitor%2520vemurafenib%2520improves%2520the%2520antitumor%2520activity%2520of%2520adoptive%2520cell%2520immunotherapy%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D3928%26epage%3D3937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Holt, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logié, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Odedra, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heaton, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alferez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. D.</span><span> </span><span class="NLM_article-title">The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">858</span><span class="NLM_x">–</span> <span class="NLM_lpage">866</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1038%2Fbjc.2012.8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=22343622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1arsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2012&pages=858-866&author=S.+V.+Holtauthor=A.+Logi%C3%A9author=R.+Odedraauthor=A.+Heierauthor=S.+P.+Heatonauthor=D.+Alferezauthor=B.+R.+Daviesauthor=R.+W.+Wilkinsonauthor=P.+D.+Smith&title=The+MEK1%2F2+inhibitor%2C+selumetinib+%28AZD6244%3B+ARRY-142886%29%2C+enhances+anti-tumour+efficacy+when+combined+with+conventional+chemotherapeutic+agents+in+human+tumour+xenograft+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models</span></div><div class="casAuthors">Holt, S. V.; Logie, A.; Odedra, R.; Heier, A.; Heaton, S. P.; Alferez, D.; Davies, B. R.; Wilkinson, R. W.; Smith, P. D.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">858-866</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: The Ras/RAF/MEK/ERK pathway is frequently deregulated in cancer and a no. of inhibitors that target this pathway are currently in clin. development.  It is likely that clin. testing of these agents will be in combination with std. therapies to harness the apoptotic potential of both the agents.  To support this strategy, it has been widely obsd. that a no. of chemotherapeutics stimulate the activation of several intracellular signalling cascades including Ras/RAF/MEK/ERK.  The MEK1/2 inhibitor selumetinib has been shown to have anti-tumor activity and induce apoptotic cell death as a monotherapy.  Methods: The aim of this study was to identify agents, which would be likely to offer clin. benefit when combined with selumetinib.  Here, we used human tumor xenograft models and assessed the effects combining std. chemotherapeutic agents with selumetinib on tumor growth.  In addn., we analyzed tumor tissue to det. the mechanistic effects of these combinations.  Results: Combining selumetinib with the DNA-alkylating agent, temozolomide (TMZ), resulted in enhanced tumor growth inhibition compared with monotherapies.  Biomarker studies highlighted an increase in γH2A.X suggesting that selumetinib is able to enhance the DNA damage induced by TMZ alone.  In several models we obsd. that continuous exposure to selumetinib in combination with docetaxel results in tumor regression.  Scheduling of docetaxel before selumetinib was more beneficial than when selumetinib was dosed before docetaxel and demonstrated a pro-apoptotic phenotype.  Similar results were seen when selumetinib was combined with the Aurora B inhibitor barasertib.  Conclusion: The data presented suggests that MEK inhibition in combination with several std. chemotherapeutics or an Aurora B kinase inhibitor is a promising clin. strategy.  British Journal of Cancer (2012) 106, 858-866; doi:10.1038/bjc.2012.8 www.bjcancer.com Published online 16 Feb. 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT9m5XMlh8e7Vg90H21EOLACvtfcHk0ljU28z800DQoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1arsb0%253D&md5=1613a559df1e9e8d73c812ed48489779</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2012.8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2012.8%26sid%3Dliteratum%253Aachs%26aulast%3DHolt%26aufirst%3DS.%2BV.%26aulast%3DLogi%25C3%25A9%26aufirst%3DA.%26aulast%3DOdedra%26aufirst%3DR.%26aulast%3DHeier%26aufirst%3DA.%26aulast%3DHeaton%26aufirst%3DS.%2BP.%26aulast%3DAlferez%26aufirst%3DD.%26aulast%3DDavies%26aufirst%3DB.%2BR.%26aulast%3DWilkinson%26aufirst%3DR.%2BW.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26atitle%3DThe%2520MEK1%252F2%2520inhibitor%252C%2520selumetinib%2520%2528AZD6244%253B%2520ARRY-142886%2529%252C%2520enhances%2520anti-tumour%2520efficacy%2520when%2520combined%2520with%2520conventional%2520chemotherapeutic%2520agents%2520in%2520human%2520tumour%2520xenograft%2520models%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2012%26volume%3D106%26spage%3D858%26epage%3D866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Hoeflich, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merchant, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Den Otter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasman, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeppen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, N. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span> </span><span class="NLM_article-title">Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">210</span><span class="NLM_x">–</span> <span class="NLM_lpage">219</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1158%2F0008-5472.CAN-11-1515" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=22084396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVCltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=210-219&author=K.+P.+Hoeflichauthor=M.+Merchantauthor=C.+Orrauthor=J.+Chanauthor=D.+Den+Otterauthor=L.+Berryauthor=I.+Kasmanauthor=H.+Koeppenauthor=K.+Riceauthor=N.+Y.+Yangauthor=S.+Engstauthor=S.+Johnstonauthor=L.+S.+Friedmanauthor=M.+Belvin&title=Intermittent+administration+of+MEK+inhibitor+GDC-0973+plus+PI3K+inhibitor+GDC-0941+triggers+robust+apoptosis+and+tumor+growth+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition</span></div><div class="casAuthors">Hoeflich, Klaus P.; Merchant, Mark; Orr, Christine; Chan, Jocelyn; Den Otter, Doug; Berry, Leanne; Kasman, Ian; Koeppen, Hartmut; Rice, Ken; Yang, Nai-Ying; Engst, Stefan; Johnston, Stuart; Friedman, Lori S.; Belvin, Marcia</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">210-219</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Combinations of MAP/ERK kinase (MEK) and phosphoinositide 3-kinase (PI3K) inhibitors have shown promise in preclin. cancer models, leading to the initiation of clin. trials cotargeting these two key cancer signaling pathways.  GDC-0973, a novel selective MEK inhibitor, and GDC-0941, a class I PI3K inhibitor, are in early stage clin. trials as both single agents and in combination.  The discovery of these selective inhibitors has allowed investigation into the precise effects of combining inhibitors of two major signaling branches downstream of RAS.  Here, we investigated multiple biomarkers in the mitogen-activated protein kinase (MAPK) and PI3K pathway to search for points of convergence that explain the increased apoptosis seen in combination.  Using washout studies in vitro and alternate dosing schedules in mice, we showed that intermittent inhibition of the PI3K and MAPK pathway is sufficient for efficacy in BRAF and KRAS mutant cancer cells.  The combination of GDC-0973 with the PI3K inhibitor GDC-0941 resulted in combination efficacy in vitro and in vivo via induction of biomarkers assocd. with apoptosis, including Bcl-2 family proapoptotic regulators.  Therefore, these data suggest that continuous exposure of MEK and PI3K inhibitors in combination is not required for efficacy in preclin. cancer models and that sustained effects on downstream apoptosis biomarkers can be obsd. in response to intermittent dosing.  Cancer Res; 72(1); 210-9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokHbA7g6hLGrVg90H21EOLACvtfcHk0lj3xVV_df6y-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVCltA%253D%253D&md5=40032bf35d5e6335856a645d5c331df8</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-1515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-1515%26sid%3Dliteratum%253Aachs%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DMerchant%26aufirst%3DM.%26aulast%3DOrr%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DJ.%26aulast%3DDen%2BOtter%26aufirst%3DD.%26aulast%3DBerry%26aufirst%3DL.%26aulast%3DKasman%26aufirst%3DI.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DRice%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DN.%2BY.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DJohnston%26aufirst%3DS.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DBelvin%26aufirst%3DM.%26atitle%3DIntermittent%2520administration%2520of%2520MEK%2520inhibitor%2520GDC-0973%2520plus%2520PI3K%2520inhibitor%2520GDC-0941%2520triggers%2520robust%2520apoptosis%2520and%2520tumor%2520growth%2520inhibition%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D210%26epage%3D219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Daouti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolinsky, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Packman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Specian, A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huby, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Podlaski, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fotouhi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heimbrook, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, H.</span><span> </span><span class="NLM_article-title">Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">1924</span><span class="NLM_x">–</span> <span class="NLM_lpage">1932</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=1924-1932&author=S.+Daoutiauthor=H.+Wangauthor=W.+H.+Liauthor=B.+Higginsauthor=K.+Kolinskyauthor=K.+Packmanauthor=A.+Specianauthor=N.+Kongauthor=N.+Hubyauthor=Y.+Wenauthor=Q.+Xiangauthor=F.+J.+Podlaskiauthor=Y.+Heauthor=N.+Fotouhiauthor=D.+Heimbrookauthor=H.+Niu&title=Characterization+of+a+novel+mitogen-activated+protein+kinase+kinase+1%2F2+inhibitor+with+a+unique+mechanism+of+action+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDaouti%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DW.%2BH.%26aulast%3DHiggins%26aufirst%3DB.%26aulast%3DKolinsky%26aufirst%3DK.%26aulast%3DPackman%26aufirst%3DK.%26aulast%3DSpecian%26aufirst%3DA.%26aulast%3DKong%26aufirst%3DN.%26aulast%3DHuby%26aufirst%3DN.%26aulast%3DWen%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DQ.%26aulast%3DPodlaski%26aufirst%3DF.%2BJ.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DFotouhi%26aufirst%3DN.%26aulast%3DHeimbrook%26aufirst%3DD.%26aulast%3DNiu%26aufirst%3DH.%26atitle%3DCharacterization%2520of%2520a%2520novel%2520mitogen-activated%2520protein%2520kinase%2520kinase%25201%252F2%2520inhibitor%2520with%2520a%2520unique%2520mechanism%2520of%2520action%2520for%2520cancer%2520therapy%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D1924%26epage%3D1932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Sportsman, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaudet, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boge, A.</span><span> </span><span class="NLM_article-title">Immobilized metal ion affinity-based fluorescence polarization (IMAP): advances in kinase screening</span> <span class="citation_source-journal">Assay Drug Dev. Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">–</span> <span class="NLM_lpage">214</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1089%2F154065804323056549" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=15165516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvVSjt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2004&pages=205-214&author=J.+R.+Sportsmanauthor=E.+A.+Gaudetauthor=A.+Boge&title=Immobilized+metal+ion+affinity-based+fluorescence+polarization+%28IMAP%29%3A+advances+in+kinase+screening"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Immobilized Metal Ion Affinity-Based Fluorescence Polarization (IMAP): Advances in Kinase Screening</span></div><div class="casAuthors">Sportsman, J. Richard; Gaudet, Elizabeth A.; Boge, Annegret</div><div class="citationInfo"><span class="NLM_cas:title">Assay and Drug Development Technologies</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">205-214</span>CODEN:
                <span class="NLM_cas:coden">ADDTAR</span>;
        ISSN:<span class="NLM_cas:issn">1540-658X</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">The IMAP Fluorescence Polarization technol. is a homogeneous antibody-free method for anal. of kinases, phosphatases, and phosphodiesterases.  Recent developments to the technol. include an enhancement of the reagent system (the Progressive Binding System) that significantly expands the range of useable concns. of ATP, choices of substrates, and assay configurations.  With the new Progressive System, we are able to design multiplexed assays that allow the simultaneous detn. of multiple kinase activities.  In addn., coupled assays are now possible, allowing the assay of kinases through natural or artificial coupling through kinase cascades.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUY28ras-P37Vg90H21EOLACvtfcHk0lj3xVV_df6y-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvVSjt7c%253D&md5=df9c32895e0f7691dd08f3a5b9a052aa</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1089%2F154065804323056549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252F154065804323056549%26sid%3Dliteratum%253Aachs%26aulast%3DSportsman%26aufirst%3DJ.%2BR.%26aulast%3DGaudet%26aufirst%3DE.%2BA.%26aulast%3DBoge%26aufirst%3DA.%26atitle%3DImmobilized%2520metal%2520ion%2520affinity-based%2520fluorescence%2520polarization%2520%2528IMAP%2529%253A%2520advances%2520in%2520kinase%2520screening%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2004%26volume%3D2%26spage%3D205%26epage%3D214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span>CDAS: KinaseScreen Programs. <a href="http://www.caliperls.com/assets/011/6679.pdf" class="extLink">http://www.caliperls.com/assets/011/6679.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=CDAS%3A+KinaseScreen+Programs.+http%3A%2F%2Fwww.caliperls.com%2Fassets%2F011%2F6679.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Daouti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolinsky, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Packman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moliterni, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huby, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fotouhi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goelzer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandhu, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Railkar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heimbrook, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, H.</span><span> </span><span class="NLM_article-title">Preclinical in vivo evaluation of efficacy, pharmacokinetics, and pharmacodynamics of a novel MEK1/2 kinase inhibitor RO5068760 in multiple tumor models</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">134</span><span class="NLM_x">–</span> <span class="NLM_lpage">144</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1158%2F1535-7163.MCT-09-0601" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=20053779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktVOisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=134-144&author=S.+Daoutiauthor=B.+Higginsauthor=K.+Kolinskyauthor=K.+Packmanauthor=H.+Wangauthor=C.+Rizzoauthor=J.+Moliterniauthor=N.+Hubyauthor=N.+Fotouhiauthor=M.+Liuauthor=P.+Goelzerauthor=H.+K.+Sandhuauthor=J.+K.+Liauthor=A.+Railkarauthor=D.+Heimbrookauthor=H.+Niu&title=Preclinical+in+vivo+evaluation+of+efficacy%2C+pharmacokinetics%2C+and+pharmacodynamics+of+a+novel+MEK1%2F2+kinase+inhibitor+RO5068760+in+multiple+tumor+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical In vivo Evaluation of Efficacy, Pharmacokinetics, and Pharmacodynamics of a Novel MEK1/2 Kinase Inhibitor RO5068760 in Multiple Tumor Models</span></div><div class="casAuthors">Daouti, Sherif; Higgins, Brian; Kolinsky, Kenneth; Packman, Kathryn; Wang, Huisheng; Rizzo, Christine; Moliterni, John; Huby, Nicholas; Fotouhi, Nader; Liu, Mei; Goelzer, Petra; Sandhu, Harpreet K.; Li, Jia Kui; Railkar, Aruna; Heimbrook, David; Niu, Huifeng</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">134-144</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Targeting the Ras/Raf/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway represents a promising anticancer strategy.  Recently, we have reported a novel class of potent and selective non-ATP-competitive MEK1/2 inhibitors with a unique structure and mechanism of action.  RO5068760 is a representative of this class showing significant efficacy in a broad spectrum of tumors with aberrant mitogen-activated protein kinase pathway activation.  To understand the relationship between systemic exposures and target (MEK1/2) inhibition as well as tumor growth inhibition, the current study presents a detailed in vivo characterization of efficacy, pharmacokinetics, and pharmacodynamics of RO5068760 in multiple xenograft tumor models.  For inhibition of MEK1/2 as measured by the phosphorylated ERK levels, the estd. EC50s in plasma were 1.36 μmol/L (880 ng/mL) and 3.35 μmol/L (2168 ng/mL) in LOX melanoma and HT-29 colorectal cancer models, resp.  A similar EC50 (1.41 μmol/L or 915 ng/mL) was obsd. in monkey peripheral blood lymphocytes.  To achieve tumor growth inhibition (≥90%), an av. plasma drug concn. of 0.65 or 5.23 μmol/L was required in B-RafV600E or K-Ras mutant tumor models, resp., which were remarkably similar to the IC90 values (0.64 or 4.1 μmol/L) detd. in vitro for cellular growth inhibition.  With equiv. in vivo systemic exposures, RO5068760 showed superior efficacy in tumors harboring B-RafV600E mutation.  The plasma concn. time profiles indicate that const. p-ERK suppression (>50%) may not be required for optimal efficacy, esp. in highly responsive tumors.  This study may facilitate future clin. trial design in using biochem. markers for early proof of mechanism and in selecting the right patients and optimal dose regimen.  Mol Cancer Ther; 9(1); 134-44.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr7uzHdOgqxrVg90H21EOLACvtfcHk0lj3xVV_df6y-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktVOisw%253D%253D&md5=66fa4470c00c0fa6c2d3735d92d1f4d5</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0601%26sid%3Dliteratum%253Aachs%26aulast%3DDaouti%26aufirst%3DS.%26aulast%3DHiggins%26aufirst%3DB.%26aulast%3DKolinsky%26aufirst%3DK.%26aulast%3DPackman%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DRizzo%26aufirst%3DC.%26aulast%3DMoliterni%26aufirst%3DJ.%26aulast%3DHuby%26aufirst%3DN.%26aulast%3DFotouhi%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DGoelzer%26aufirst%3DP.%26aulast%3DSandhu%26aufirst%3DH.%2BK.%26aulast%3DLi%26aufirst%3DJ.%2BK.%26aulast%3DRailkar%26aufirst%3DA.%26aulast%3DHeimbrook%26aufirst%3DD.%26aulast%3DNiu%26aufirst%3DH.%26atitle%3DPreclinical%2520in%2520vivo%2520evaluation%2520of%2520efficacy%252C%2520pharmacokinetics%252C%2520and%2520pharmacodynamics%2520of%2520a%2520novel%2520MEK1%252F2%2520kinase%2520inhibitor%2520RO5068760%2520in%2520multiple%2520tumor%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D134%26epage%3D144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guimaraes, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upadhyay, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maira, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perera, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaur, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lightbown, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simendinger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Echeverría, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissleder, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahmood, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span> </span><span class="NLM_article-title">Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1351</span><span class="NLM_x">–</span> <span class="NLM_lpage">1356</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1038%2Fnm.1890" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=19029981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWhu7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=1351-1356&author=J.+A.+Engelmanauthor=L.+Chenauthor=X.+Tanauthor=K.+Crosbyauthor=A.+R.+Guimaraesauthor=R.+Upadhyayauthor=M.+Mairaauthor=K.+McNamaraauthor=S.+A.+Pereraauthor=Y.+Songauthor=L.+R.+Chirieacauthor=R.+Kaurauthor=A.+Lightbownauthor=J.+Simendingerauthor=T.+Liauthor=R.+F.+Paderaauthor=C.+Garc%C3%ADa-Echeverr%C3%ADaauthor=R.+Weisslederauthor=U.+Mahmoodauthor=L.+C.+Cantleyauthor=K.+K.+Wong&title=Effective+use+of+PI3K+and+MEK+inhibitors+to+treat+mutant+Kras+G12D+and+PIK3CA+H1047R+murine+lung+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers</span></div><div class="casAuthors">Engelman, Jeffrey A.; Chen, Liang; Tan, Xiaohong; Crosby, Katherine; Guimaraes, Alexander R.; Upadhyay, Rabi; Maira, Michel; McNamara, Kate; Perera, Samanthi A.; Song, Youngchul; Chirieac, Lucian R.; Kaur, Ramneet; Lightbown, Angela; Simendinger, Jessica; Li, Timothy; Padera, Robert F.; Garcia-Echeverria, Carlos; Weissleder, Ralph; Mahmood, Umar; Cantley, Lewis C.; Wong, Kwok-Kin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1351-1356</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Somatic mutations that activate phosphoinositide 3-kinase (P13K) have been identified in the p1 10-x catalytic subunit (encoded by PIK3CA).  They are most frequently obsd. in two hotspots: the helical domain (E545K and E542K) and the kinase domain (H1047R).  Although the pl 10-o mutants are transforming in vitro, their oncogenic potential has not been assessed in genetically engineered mouse models.  Furthermore, clin. trials with P13K inhibitors have recently been initiated, and it is unknown if their efficacy will be restricted to specific, genetically defined malignancies.  In this study, we engineered a mouse model of lung adenocarcinomas initiated and maintained by expression of p-110-c H 1047R.  Treatment of these tumors - with NVP-BEZ235, a dual pan-PI3K and mammalian target of rapamycin (mTOR) inhibitor in clin. development, led to labored breathing and MRI images consistent with lung tumors after marked tumor regression as shown by positron emission imaging and microscopic examn.  In contrast, mouse lung cancers driven by mutant Kras did not substantially respond to CN single-agent NVP-BEZ235.  However, when NVP-BEZ235 was combined with a mitogen-activated protein kinase kinase (MEK) inhibitor, ARRY-142886, there was marked synergy in shrinking these kras-mutant cancers.  These in vivo studies suggest that inhibitors of the PI3K-mTOR pathway may be active in cancers with PIK3CA mutations and when combined with MEK inhibitors, may effectively treat KRAS mutated lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmFCNzeJpeErVg90H21EOLACvtfcHk0ljNftsDpWUvIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWhu7rI&md5=3d9fd9c11132319c5e22807e15d592f3</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1038%2Fnm.1890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.1890%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DX.%26aulast%3DCrosby%26aufirst%3DK.%26aulast%3DGuimaraes%26aufirst%3DA.%2BR.%26aulast%3DUpadhyay%26aufirst%3DR.%26aulast%3DMaira%26aufirst%3DM.%26aulast%3DMcNamara%26aufirst%3DK.%26aulast%3DPerera%26aufirst%3DS.%2BA.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DChirieac%26aufirst%3DL.%2BR.%26aulast%3DKaur%26aufirst%3DR.%26aulast%3DLightbown%26aufirst%3DA.%26aulast%3DSimendinger%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DPadera%26aufirst%3DR.%2BF.%26aulast%3DGarc%25C3%25ADa-Echeverr%25C3%25ADa%26aufirst%3DC.%26aulast%3DWeissleder%26aufirst%3DR.%26aulast%3DMahmood%26aufirst%3DU.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DEffective%2520use%2520of%2520PI3K%2520and%2520MEK%2520inhibitors%2520to%2520treat%2520mutant%2520Kras%2520G12D%2520and%2520PIK3CA%2520H1047R%2520murine%2520lung%2520cancers%26jtitle%3DNat.%2520Med.%26date%3D2008%26volume%3D14%26spage%3D1351%26epage%3D1356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Serra, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markman, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scaltriti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eichhorn, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valero, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botero, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llonch, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atzori, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Cosimo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maira, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Echeverria, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parra, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arribas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span> </span><span class="NLM_article-title">NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">8022</span><span class="NLM_x">–</span> <span class="NLM_lpage">8030</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1158%2F0008-5472.CAN-08-1385" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=18829560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtF2msLrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=8022-8030&author=V.+Serraauthor=B.+Markmanauthor=M.+Scaltritiauthor=P.+J.+Eichhornauthor=V.+Valeroauthor=M.+Guzmanauthor=M.+L.+Boteroauthor=E.+Llonchauthor=F.+Atzoriauthor=S.+Di+Cosimoauthor=M.+Mairaauthor=C.+Garcia-Echeverriaauthor=J.+L.+Parraauthor=J.+Arribasauthor=J.+Baselga&title=NVP-BEZ235%2C+a+dual+PI3K%2FmTOR+inhibitor%2C+prevents+PI3K+signaling+and+inhibits+the+growth+of+cancer+cells+with+activating+PI3K+mutations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations</span></div><div class="casAuthors">Serra, Violeta; Markman, Ben; Scaltriti, Maurizio; Eichhorn, Pieter J. A.; Valero, Vanesa; Guzman, Marta; Botero, Maria Luisa; Llonch, Elisabeth; Atzori, Francesco; Di Cosimo, Serena; Maira, Michel; Garcia-Echeverria, Carlos; Parra, Josep Lluis; Arribas, Joaquin; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8022-8030</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Phosphatidylinositol-3-kinase (PI3K) pathway deregulation is a common event in human cancer, either through inactivation of the tumor suppressor phosphatase and tensin homolog deleted from chromosome 10 or activating mutations of p110-α.  These hotspot mutations result in oncogenic activity of the enzyme and contribute to therapeutic resistance to the anti-HER2 antibody trastuzumab.  The PI3K pathway is, therefore, an attractive target for cancer therapy.  We have studied NVP-BEZ235, a dual inhibitor of the PI3K and the downstream mammalian target of rapamycin (mTOR).  NVP-BEZ235 inhibited the activation of the downstream effectors Akt, S6 ribosomal protein, and 4EBP1 in breast cancer cells.  The antiproliferative activity of NVP-BEZ235 was superior to the allosteric selective mTOR complex inhibitor everolimus in a panel of 21 cancer cell lines of different origin and mutation status.  The described Akt activation due to mTOR inhibition was prevented by higher doses of NVP-BEZ235.  NVP-BEZ235 reversed the hyperactivation of the PI3K/mTOR pathway caused by the oncogenic mutations of p110-α, E545K, and H1047R, and inhibited the proliferation of HER2-amplified BT474 cells exogenously expressing these mutations that render them resistant to trastuzumab.  In trastuzumab-resistant BT474 H1047R breast cancer xenografts, NVP-BEZ235 inhibited PI3K signaling and had potent antitumor activity.  In treated animals, there was complete inhibition of PI3K signaling in the skin at pharmacol. active doses, suggesting that skin may serve as surrogate tissue for pharmacodynamic studies.  In summary, NVP-BEZ235 inhibits the PI3K/mTOR axis and results in antiproliferative and antitumoral activity in cancer cells with both wild-type and mutated p110-α.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlC_vqzWMDk7Vg90H21EOLACvtfcHk0ljNftsDpWUvIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtF2msLrK&md5=b5d08e989c1b619e3c0ee9437002afd7</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-1385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-1385%26sid%3Dliteratum%253Aachs%26aulast%3DSerra%26aufirst%3DV.%26aulast%3DMarkman%26aufirst%3DB.%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DEichhorn%26aufirst%3DP.%2BJ.%26aulast%3DValero%26aufirst%3DV.%26aulast%3DGuzman%26aufirst%3DM.%26aulast%3DBotero%26aufirst%3DM.%2BL.%26aulast%3DLlonch%26aufirst%3DE.%26aulast%3DAtzori%26aufirst%3DF.%26aulast%3DDi%2BCosimo%26aufirst%3DS.%26aulast%3DMaira%26aufirst%3DM.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DParra%26aufirst%3DJ.%2BL.%26aulast%3DArribas%26aufirst%3DJ.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DNVP-BEZ235%252C%2520a%2520dual%2520PI3K%252FmTOR%2520inhibitor%252C%2520prevents%2520PI3K%2520signaling%2520and%2520inhibits%2520the%2520growth%2520of%2520cancer%2520cells%2520with%2520activating%2520PI3K%2520mutations%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D8022%26epage%3D8030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Seabra, M. C.</span><span> </span><span class="NLM_article-title">Membrane association and targeting of prenylated Ras-like GTPases</span> <span class="citation_source-journal">Cell. Signalling</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">167</span><span class="NLM_x">–</span> <span class="NLM_lpage">172</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1016%2FS0898-6568%2897%2900120-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=9607139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADyaK1cXis1altb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1998&pages=167-172&author=M.+C.+Seabra&title=Membrane+association+and+targeting+of+prenylated+Ras-like+GTPases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Membrane association and targeting of prenylated Ras-like GTPases</span></div><div class="casAuthors">Seabra, Miguel C.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">167-172</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review with 59 refs. Rho.  The regulatory function of the Ras-like GTPases in diverse cellular processes, such as growth, cell movement, and protein trafficking, is critically dependent on targeting to the proper cellular membrane.  Prenylation of Ras, Rho/Rac, and Rab GTPases, defined as the covalent addn. of isoprenyl groups to cysteine residues near or at their carboxyl terminus, is the first and necessary step that leads to membrane binding and targeting of these proteins.  Recent progress on the mol. mechanisms of prenylation, membrane assocn., and targeting of Ras, Rho/Rac, and Rab proteins will be reviewed here.  The detailed understanding of these targeting mechanisms may allow future development of specific therapeutic agents that interfere with the function of each one of these proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVv6tr6JINsrVg90H21EOLACvtfcHk0lg0Smo3KuijJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXis1altb0%253D&md5=e0c744bee6c8581b4810272d0d95acf5</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2FS0898-6568%2897%2900120-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0898-6568%252897%252900120-4%26sid%3Dliteratum%253Aachs%26aulast%3DSeabra%26aufirst%3DM.%2BC.%26atitle%3DMembrane%2520association%2520and%2520targeting%2520of%2520prenylated%2520Ras-like%2520GTPases%26jtitle%3DCell.%2520Signalling%26date%3D1998%26volume%3D10%26spage%3D167%26epage%3D172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Sebti, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, A. D.</span><span> </span><span class="NLM_article-title">Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">6584</span><span class="NLM_x">–</span> <span class="NLM_lpage">6593</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=6584-6593&author=S.+M.+Sebtiauthor=A.+D.+Hamilton&title=Farnesyltransferase+and+geranylgeranyltransferase+I+inhibitors+and+cancer+therapy%3A+lessons+from+mechanism+and+bench-to-bedside+translational+studies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSebti%26aufirst%3DS.%2BM.%26aulast%3DHamilton%26aufirst%3DA.%2BD.%26atitle%3DFarnesyltransferase%2520and%2520geranylgeranyltransferase%2520I%2520inhibitors%2520and%2520cancer%2520therapy%253A%2520lessons%2520from%2520mechanism%2520and%2520bench-to-bedside%2520translational%2520studies%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D6584%26epage%3D6593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Cox, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span> </span><span class="NLM_article-title">Farnesyltransferase inhibitors: promises and realities</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">388</span><span class="NLM_x">–</span> <span class="NLM_lpage">393</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1016%2FS1471-4892%2802%2900181-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=12127871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsVGqtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=388-393&author=A.+D.+Coxauthor=C.+J.+Der&title=Farnesyltransferase+inhibitors%3A+promises+and+realities"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Farnesyltransferase inhibitors: promises and realities</span></div><div class="casAuthors">Cox, Adrienne D.; Der, Channing J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">388-393</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Farnesyltransferase inhibitors have recently shown clin. efficacy against leukemias, gliomas and even non-small-cell lung cancers, esp. when administered in combination with taxanes.  It is possible that the crit. target downstream of farnesyltransferase responsible for these effects is not either Ras or RhoB, the two most cited possibilities - but the hunt is on.  Farnesyltransferase inhibitors have anticancer activity, but their downstream targets are controversial.  Are Ras or RhoB proteins the "true targets" of these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouAFOphziJMrVg90H21EOLACvtfcHk0lg0Smo3KuijJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsVGqtL0%253D&md5=6e41bdecb34dfe5b5d0e944b35a0a8f3</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2FS1471-4892%2802%2900181-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1471-4892%252802%252900181-9%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DA.%2BD.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DFarnesyltransferase%2520inhibitors%253A%2520promises%2520and%2520realities%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2002%26volume%3D2%26spage%3D388%26epage%3D393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebti, S. M.</span><span> </span><span class="NLM_article-title">Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1467</span><span class="NLM_x">–</span> <span class="NLM_lpage">1473</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1998&pages=1467-1473&author=J.+Sunauthor=Y.+Qianauthor=A.+D.+Hamiltonauthor=S.+M.+Sebti&title=Both+farnesyltransferase+and+geranylgeranyltransferase+I+inhibitors+are+required+for+inhibition+of+oncogenic+K-Ras+prenylation+but+each+alone+is+sufficient+to+suppress+human+tumor+growth+in+nude+mouse+xenografts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DHamilton%26aufirst%3DA.%2BD.%26aulast%3DSebti%26aufirst%3DS.%2BM.%26atitle%3DBoth%2520farnesyltransferase%2520and%2520geranylgeranyltransferase%2520I%2520inhibitors%2520are%2520required%2520for%2520inhibition%2520of%2520oncogenic%2520K-Ras%2520prenylation%2520but%2520each%2520alone%2520is%2520sufficient%2520to%2520suppress%2520human%2520tumor%2520growth%2520in%2520nude%2520mouse%2520xenografts%26jtitle%3DOncogene%26date%3D1998%26volume%3D16%26spage%3D1467%26epage%3D1473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Lerner, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaskovich, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fossum, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebti, S. M.</span><span> </span><span class="NLM_article-title">Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">270</span><span class="NLM_x">, </span> <span class="NLM_fpage">26802</span><span class="NLM_x">–</span> <span class="NLM_lpage">26806</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=26802-26806&author=E.+C.+Lernerauthor=Y.+Qianauthor=M.+A.+Blaskovichauthor=R.+D.+Fossumauthor=A.+Vogtauthor=J.+Sunauthor=A.+D.+Coxauthor=C.+J.+Derauthor=A.+D.+Hamiltonauthor=S.+M.+Sebti&title=Ras+CAAX+peptidomimetic+FTI-277+selectively+blocks+oncogenic+Ras+signaling+by+inducing+cytoplasmic+accumulation+of+inactive+Ras-Raf+complexes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLerner%26aufirst%3DE.%2BC.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DBlaskovich%26aufirst%3DM.%2BA.%26aulast%3DFossum%26aufirst%3DR.%2BD.%26aulast%3DVogt%26aufirst%3DA.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DCox%26aufirst%3DA.%2BD.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26aulast%3DHamilton%26aufirst%3DA.%2BD.%26aulast%3DSebti%26aufirst%3DS.%2BM.%26atitle%3DRas%2520CAAX%2520peptidomimetic%2520FTI-277%2520selectively%2520blocks%2520oncogenic%2520Ras%2520signaling%2520by%2520inducing%2520cytoplasmic%2520accumulation%2520of%2520inactive%2520Ras-Raf%2520complexes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26spage%3D26802%26epage%3D26806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Song, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meszoely, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coffey, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietenpol, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, S. D.</span><span> </span><span class="NLM_article-title">K-Ras-independent effects of the farnesyl transferase inhibitor L-744,832 on cyclin B1/Cdc2 kinase activity, G2/M cell cycle progression and apoptosis in human pancreatic ductal adenocarcinoma cells</span> <span class="citation_source-journal">Neoplasia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">261</span><span class="NLM_x">–</span> <span class="NLM_lpage">272</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2000&pages=261-272&author=S.+Y.+Songauthor=I.+M.+Meszoelyauthor=R.+J.+Coffeyauthor=J.+A.+Pietenpolauthor=S.+D.+Leach&title=K-Ras-independent+effects+of+the+farnesyl+transferase+inhibitor+L-744%2C832+on+cyclin+B1%2FCdc2+kinase+activity%2C+G2%2FM+cell+cycle+progression+and+apoptosis+in+human+pancreatic+ductal+adenocarcinoma+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DS.%2BY.%26aulast%3DMeszoely%26aufirst%3DI.%2BM.%26aulast%3DCoffey%26aufirst%3DR.%2BJ.%26aulast%3DPietenpol%26aufirst%3DJ.%2BA.%26aulast%3DLeach%26aufirst%3DS.%2BD.%26atitle%3DK-Ras-independent%2520effects%2520of%2520the%2520farnesyl%2520transferase%2520inhibitor%2520L-744%252C832%2520on%2520cyclin%2520B1%252FCdc2%2520kinase%2520activity%252C%2520G2%252FM%2520cell%2520cycle%2520progression%2520and%2520apoptosis%2520in%2520human%2520pancreatic%2520ductal%2520adenocarcinoma%2520cells%26jtitle%3DNeoplasia%26date%3D2000%26volume%3D2%26spage%3D261%26epage%3D272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Nagasu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshimatsu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, A. M.</span><span> </span><span class="NLM_article-title">Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">5310</span><span class="NLM_x">–</span> <span class="NLM_lpage">5314</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1995&pages=5310-5314&author=T.+Nagasuauthor=K.+Yoshimatsuauthor=C.+Rowellauthor=M.+D.+Lewisauthor=A.+M.+Garcia&title=Inhibition+of+human+tumor+xenograft+growth+by+treatment+with+the+farnesyl+transferase+inhibitor+B956"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagasu%26aufirst%3DT.%26aulast%3DYoshimatsu%26aufirst%3DK.%26aulast%3DRowell%26aufirst%3DC.%26aulast%3DLewis%26aufirst%3DM.%2BD.%26aulast%3DGarcia%26aufirst%3DA.%2BM.%26atitle%3DInhibition%2520of%2520human%2520tumor%2520xenograft%2520growth%2520by%2520treatment%2520with%2520the%2520farnesyl%2520transferase%2520inhibitor%2520B956%26jtitle%3DCancer%2520Res.%26date%3D1995%26volume%3D55%26spage%3D5310%26epage%3D5314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Crespo, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohkanda, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebti, S. M.</span><span> </span><span class="NLM_article-title">The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">16161</span><span class="NLM_x">–</span> <span class="NLM_lpage">16167</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=16161-16167&author=N.+C.+Crespoauthor=J.+Ohkandaauthor=T.+J.+Yenauthor=A.+D.+Hamiltonauthor=S.+M.+Sebti&title=The+farnesyltransferase+inhibitor%2C+FTI-2153%2C+blocks+bipolar+spindle+formation+and+chromosome+alignment+and+causes+prometaphase+accumulation+during+mitosis+of+human+lung+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCrespo%26aufirst%3DN.%2BC.%26aulast%3DOhkanda%26aufirst%3DJ.%26aulast%3DYen%26aufirst%3DT.%2BJ.%26aulast%3DHamilton%26aufirst%3DA.%2BD.%26aulast%3DSebti%26aufirst%3DS.%2BM.%26atitle%3DThe%2520farnesyltransferase%2520inhibitor%252C%2520FTI-2153%252C%2520blocks%2520bipolar%2520spindle%2520formation%2520and%2520chromosome%2520alignment%2520and%2520causes%2520prometaphase%2520accumulation%2520during%2520mitosis%2520of%2520human%2520lung%2520cancer%2520cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D16161%26epage%3D16167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">Beaupre, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cepero, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obeng, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boise, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lichtenheld, M. G.</span><span> </span><span class="NLM_article-title">R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">179</span><span class="NLM_x">–</span> <span class="NLM_lpage">186</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=14985458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFCitr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=179-186&author=D.+M.+Beaupreauthor=E.+Ceperoauthor=E.+A.+Obengauthor=L.+H.+Boiseauthor=M.+G.+Lichtenheld&title=R115777+induces+Ras-independent+apoptosis+of+myeloma+cells+via+multiple+intrinsic+pathways"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways</span></div><div class="casAuthors">Beaupre, Darrin M.; Cepero, Enrique; Obeng, Esther A.; Boise, Lawrence H.; Lichtenheld, Mathias G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-186</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Ras activation is frequently obsd. in multiple myeloma either by mutation or through interleukin-6 receptor signaling.  Recently, drugs designed to inhibit Ras have shown promise in preclin. myeloma models and in clin. trials.  In this report, we characterize the pathways by which the clin. tested farnesyl transferase inhibitor (FTI) R115777 induces apoptosis in multiple myeloma cells.  Contrary to the proposed mechanistic action of FTIs, we found that R115777 induces cell death despite Ras prenylation implying participation of Ras-independent mechanism(s).  Apoptosis proceeded via an intrinsic cascade and was assocd. with an increase in the expression and activity of Bax.  Bax activation correlated with a loss of mitochondrial membrane integrity and activation of the endoplasmic reticulum (ER) stress response.  These pathways activate caspase-9 and consistent with this, cell death was prevented by caspase-9 blockade.  Interestingly, cells over-expressing Bcl-XL remained partially sensitive to R115777 despite suppression of mitochondrial membrane dysfunction and ER-related stress.  Taken together, these results indicate that R115777 induces apoptosis in a Ras-independent fashion via multiple intrinsic pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosdUKBKAfDIbVg90H21EOLACvtfcHk0liHqCdHEWpH3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFCitr8%253D&md5=0f36fe2c3351caf511152fcecf89fd9f</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBeaupre%26aufirst%3DD.%2BM.%26aulast%3DCepero%26aufirst%3DE.%26aulast%3DObeng%26aufirst%3DE.%2BA.%26aulast%3DBoise%26aufirst%3DL.%2BH.%26aulast%3DLichtenheld%26aufirst%3DM.%2BG.%26atitle%3DR115777%2520induces%2520Ras-independent%2520apoptosis%2520of%2520myeloma%2520cells%2520via%2520multiple%2520intrinsic%2520pathways%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2004%26volume%3D3%26spage%3D179%26epage%3D186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Wang, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, W. W.</span><span> </span><span class="NLM_article-title">The farnesyl protein transferase inhibitor lonafarnib (SCH66336) is an inhibitor of multidrug resistance proteins 1 and 2</span> <span class="citation_source-journal">Chemotherapy</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">303</span><span class="NLM_x">–</span> <span class="NLM_lpage">308</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2003&pages=303-308&author=E.+J.+Wangauthor=W.+W.+Johnson&title=The+farnesyl+protein+transferase+inhibitor+lonafarnib+%28SCH66336%29+is+an+inhibitor+of+multidrug+resistance+proteins+1+and+2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DE.%2BJ.%26aulast%3DJohnson%26aufirst%3DW.%2BW.%26atitle%3DThe%2520farnesyl%2520protein%2520transferase%2520inhibitor%2520lonafarnib%2520%2528SCH66336%2529%2520is%2520an%2520inhibitor%2520of%2520multidrug%2520resistance%2520proteins%25201%2520and%25202%26jtitle%3DChemotherapy%26date%3D2003%26volume%3D49%26spage%3D303%26epage%3D308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">Rose, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairchild, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monticello, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kramer, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manne, V.</span><span> </span><span class="NLM_article-title">Preclinical antitumor activity of BMS-214662.; a highly apoptotic and novel farnesyltransferase inhibitor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">7507</span><span class="NLM_x">–</span> <span class="NLM_lpage">7517</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=7507-7517&author=W.+C.+Roseauthor=F.+Y.+Leeauthor=C.+R.+Fairchildauthor=M.+Lynchauthor=T.+Monticelloauthor=R.+A.+Kramerauthor=V.+Manne&title=Preclinical+antitumor+activity+of+BMS-214662.%3B+a+highly+apoptotic+and+novel+farnesyltransferase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRose%26aufirst%3DW.%2BC.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DFairchild%26aufirst%3DC.%2BR.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DMonticello%26aufirst%3DT.%26aulast%3DKramer%26aufirst%3DR.%2BA.%26aulast%3DManne%26aufirst%3DV.%26atitle%3DPreclinical%2520antitumor%2520activity%2520of%2520BMS-214662.%253B%2520a%2520highly%2520apoptotic%2520and%2520novel%2520farnesyltransferase%2520inhibitor%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D7507%26epage%3D7517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Haluska, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dy, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span> </span><span class="NLM_article-title">Farnesyl transferase inhibitors as anticancer agents</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1685</span><span class="NLM_x">–</span> <span class="NLM_lpage">1700</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2002&pages=1685-1700&author=P.+Haluskaauthor=G.+K.+Dyauthor=A.+A.+Adjei&title=Farnesyl+transferase+inhibitors+as+anticancer+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHaluska%26aufirst%3DP.%26aulast%3DDy%26aufirst%3DG.%2BK.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DFarnesyl%2520transferase%2520inhibitors%2520as%2520anticancer%2520agents%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2002%26volume%3D38%26spage%3D1685%26epage%3D1700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">Sebti, S. M.</span><span> </span><span class="NLM_article-title">Blocked pathways: FTIs shut down oncogene signals</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 3</span><span class="NLM_x">) </span> <span class="NLM_fpage">30</span><span class="NLM_x">–</span> <span class="NLM_lpage">38</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=30-38&issue=Suppl.+3&author=S.+M.+Sebti&title=Blocked+pathways%3A+FTIs+shut+down+oncogene+signals"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSebti%26aufirst%3DS.%2BM.%26atitle%3DBlocked%2520pathways%253A%2520FTIs%2520shut%2520down%2520oncogene%2520signals%26jtitle%3DOncologist%26date%3D2003%26volume%3D8%26issue%3DSuppl.%25203%26spage%3D30%26epage%3D38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group">Whyte, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirschmeier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hockenberry, T. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nunez-Oliva, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catino, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bishop, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pai, J. K.</span><span> </span><span class="NLM_article-title">K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">272</span><span class="NLM_x">, </span> <span class="NLM_fpage">14459</span><span class="NLM_x">–</span> <span class="NLM_lpage">14464</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=14459-14464&author=D.+B.+Whyteauthor=P.+Kirschmeierauthor=T.+N.+Hockenberryauthor=I.+Nunez-Olivaauthor=L.+Jamesauthor=J.+J.+Catinoauthor=W.+R.+Bishopauthor=J.+K.+Pai&title=K-+and+N-Ras+are+geranylgeranylated+in+cells+treated+with+farnesyl+protein+transferase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWhyte%26aufirst%3DD.%2BB.%26aulast%3DKirschmeier%26aufirst%3DP.%26aulast%3DHockenberry%26aufirst%3DT.%2BN.%26aulast%3DNunez-Oliva%26aufirst%3DI.%26aulast%3DJames%26aufirst%3DL.%26aulast%3DCatino%26aufirst%3DJ.%2BJ.%26aulast%3DBishop%26aufirst%3DW.%2BR.%26aulast%3DPai%26aufirst%3DJ.%2BK.%26atitle%3DK-%2520and%2520N-Ras%2520are%2520geranylgeranylated%2520in%2520cells%2520treated%2520with%2520farnesyl%2520protein%2520transferase%2520inhibitors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26spage%3D14459%26epage%3D14464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group">Lancet, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gojo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gotlib, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liesveld, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruzek, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett-Mayer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberg, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, J. E.</span><span> </span><span class="NLM_article-title">A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">1387</span><span class="NLM_x">–</span> <span class="NLM_lpage">1394</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2007&pages=1387-1394&author=J.+E.+Lancetauthor=I.+Gojoauthor=J.+Gotlibauthor=E.+J.+Feldmanauthor=J.+Greerauthor=J.+L.+Liesveldauthor=L.+M.+Bruzekauthor=L.+Morrisauthor=Y.+Parkauthor=A.+A.+Adjeiauthor=S.+H.+Kaufmannauthor=E.+Garrett-Mayerauthor=P.+L.+Greenbergauthor=J.+J.+Wrightauthor=J.+E.+Karp&title=A+phase+2+study+of+the+farnesyltransferase+inhibitor+tipifarnib+in+poor-risk+and+elderly+patients+with+previously+untreated+acute+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLancet%26aufirst%3DJ.%2BE.%26aulast%3DGojo%26aufirst%3DI.%26aulast%3DGotlib%26aufirst%3DJ.%26aulast%3DFeldman%26aufirst%3DE.%2BJ.%26aulast%3DGreer%26aufirst%3DJ.%26aulast%3DLiesveld%26aufirst%3DJ.%2BL.%26aulast%3DBruzek%26aufirst%3DL.%2BM.%26aulast%3DMorris%26aufirst%3DL.%26aulast%3DPark%26aufirst%3DY.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26aulast%3DGarrett-Mayer%26aufirst%3DE.%26aulast%3DGreenberg%26aufirst%3DP.%2BL.%26aulast%3DWright%26aufirst%3DJ.%2BJ.%26aulast%3DKarp%26aufirst%3DJ.%2BE.%26atitle%3DA%2520phase%25202%2520study%2520of%2520the%2520farnesyltransferase%2520inhibitor%2520tipifarnib%2520in%2520poor-risk%2520and%2520elderly%2520patients%2520with%2520previously%2520untreated%2520acute%2520myelogenous%2520leukemia%26jtitle%3DBlood%26date%3D2007%26volume%3D109%26spage%3D1387%26epage%3D1394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group">Karp, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancet, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">End, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bol, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horak, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tidwell, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liesveld, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kottke, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ange, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buddharaju, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gojo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Highsmith, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belly, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohl, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rybak, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thibault, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenblatt, J.</span><span> </span><span class="NLM_article-title">Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">3361</span><span class="NLM_x">–</span> <span class="NLM_lpage">3369</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2001&pages=3361-3369&author=J.+E.+Karpauthor=J.+E.+Lancetauthor=S.+H.+Kaufmannauthor=D.+W.+Endauthor=J.+J.+Wrightauthor=K.+Bolauthor=I.+Horakauthor=M.+L.+Tidwellauthor=J.+Liesveldauthor=T.+J.+Kottkeauthor=D.+Angeauthor=L.+Buddharajuauthor=I.+Gojoauthor=W.+E.+Highsmithauthor=R.+T.+Bellyauthor=R.+J.+Hohlauthor=M.+E.+Rybakauthor=A.+Thibaultauthor=J.+Rosenblatt&title=Clinical+and+biologic+activity+of+the+farnesyltransferase+inhibitor+R115777+in+adults+with+refractory+and+relapsed+acute+leukemias%3A+a+phase+1+clinical-laboratory+correlative+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKarp%26aufirst%3DJ.%2BE.%26aulast%3DLancet%26aufirst%3DJ.%2BE.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26aulast%3DEnd%26aufirst%3DD.%2BW.%26aulast%3DWright%26aufirst%3DJ.%2BJ.%26aulast%3DBol%26aufirst%3DK.%26aulast%3DHorak%26aufirst%3DI.%26aulast%3DTidwell%26aufirst%3DM.%2BL.%26aulast%3DLiesveld%26aufirst%3DJ.%26aulast%3DKottke%26aufirst%3DT.%2BJ.%26aulast%3DAnge%26aufirst%3DD.%26aulast%3DBuddharaju%26aufirst%3DL.%26aulast%3DGojo%26aufirst%3DI.%26aulast%3DHighsmith%26aufirst%3DW.%2BE.%26aulast%3DBelly%26aufirst%3DR.%2BT.%26aulast%3DHohl%26aufirst%3DR.%2BJ.%26aulast%3DRybak%26aufirst%3DM.%2BE.%26aulast%3DThibault%26aufirst%3DA.%26aulast%3DRosenblatt%26aufirst%3DJ.%26atitle%3DClinical%2520and%2520biologic%2520activity%2520of%2520the%2520farnesyltransferase%2520inhibitor%2520R115777%2520in%2520adults%2520with%2520refractory%2520and%2520relapsed%2520acute%2520leukemias%253A%2520a%2520phase%25201%2520clinical-laboratory%2520correlative%2520trial%26jtitle%3DBlood%26date%3D2001%26volume%3D97%26spage%3D3361%26epage%3D3369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group">Karp, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gojo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancet, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett-Mayer, E.</span><span> </span><span class="NLM_article-title">Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">3077</span><span class="NLM_x">–</span> <span class="NLM_lpage">3082</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1158%2F1078-0432.CCR-07-4743" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=18483374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtVCmtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=3077-3082&author=J.+E.+Karpauthor=B.+D.+Smithauthor=I.+Gojoauthor=J.+E.+Lancetauthor=J.+Greerauthor=M.+Kleinauthor=L.+Morrisauthor=M.+J.+Levisauthor=S.+D.+Goreauthor=J.+J.+Wrightauthor=E.+Garrett-Mayer&title=Phase+II+trial+of+tipifarnib+as+maintenance+therapy+in+first+complete+remission+in+adults+with+acute+myelogenous+leukemia+and+poor-risk+features"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II Trial of Tipifarnib as Maintenance Therapy in First Complete Remission in Adults with Acute Myelogenous Leukemia and Poor-Risk Features</span></div><div class="casAuthors">Karp, Judith E.; Smith, B. Douglas; Gojo, Ivana; Lancet, Jeffrey E.; Greer, Jacqueline; Klein, Maureen; Morris, Larry; Levis, Mark J.; Gore, Steven D.; Wright, John J.; Garrett-Mayer, Elizabeth</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3077-3082</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Acute myelogenous leukemia (AML) does not have a high cure rate, particularly in patients with poor-risk features.  Such patients might benefit from addnl. therapy in complete remission (CR).  Tipifarnib is an oral farnesyltransferase inhibitor with activity in AML.  We conducted a phase II trial of maintenance tipifarnib monotherapy for 48 adults with poor-risk AML in first CR.  Tipifarnib 400 mg twice daily for 14 of 21 days was initiated after recovery from consolidation chemotherapy, for a max. of 16 cycles (48 wk).  Twenty (42%) patients completed 16 cycles, 24 (50%) were removed from study for relapse, and 4 (8%) discontinued drug prematurely for intolerance.  Nonhematol. toxicities were rare, but tipifarnib dose was reduced in 58% for myelosuppression.  Median disease-free survival (DFS) was 13.5 mo (range, 3.5-59+ months), with 30% having DFS >2 years.  Comparison of CR durations for 25 patients who received two-cycle timed sequential therapy followed by tipifarnib maintenance with 23 historically similar patients who did not receive tipifarnib showed that tipifarnib was assocd. with DFS prolongation for patients with secondary AML and adverse cytogenetics.  This study suggests that some patients with poor-risk AML, including patients with secondary AML and adverse cytogenetics, may benefit from tipifarnib maintenance therapy.  Future studies are warranted to examine alternative tipifarnib dosing and continuation beyond 16 cycles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUqycwKXKDP7Vg90H21EOLACvtfcHk0li9iVdqfAoMhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtVCmtbg%253D&md5=cae66043bc604b08d17b9439dc7c0c2e</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-4743&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-4743%26sid%3Dliteratum%253Aachs%26aulast%3DKarp%26aufirst%3DJ.%2BE.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DGojo%26aufirst%3DI.%26aulast%3DLancet%26aufirst%3DJ.%2BE.%26aulast%3DGreer%26aufirst%3DJ.%26aulast%3DKlein%26aufirst%3DM.%26aulast%3DMorris%26aufirst%3DL.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DGore%26aufirst%3DS.%2BD.%26aulast%3DWright%26aufirst%3DJ.%2BJ.%26aulast%3DGarrett-Mayer%26aufirst%3DE.%26atitle%3DPhase%2520II%2520trial%2520of%2520tipifarnib%2520as%2520maintenance%2520therapy%2520in%2520first%2520complete%2520remission%2520in%2520adults%2520with%2520acute%2520myelogenous%2520leukemia%2520and%2520poor-risk%2520features%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D3077%26epage%3D3082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albitar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurzrock, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thibault, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rackoff, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Manero, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talpaz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span> </span><span class="NLM_article-title">Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">1692</span><span class="NLM_x">–</span> <span class="NLM_lpage">1697</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2003&pages=1692-1697&author=J.+Cortesauthor=M.+Albitarauthor=D.+Thomasauthor=F.+Gilesauthor=R.+Kurzrockauthor=A.+Thibaultauthor=W.+Rackoffauthor=C.+Kollerauthor=S.+O%E2%80%99Brienauthor=G.+Garcia-Maneroauthor=M.+Talpazauthor=H.+Kantarjian&title=Efficacy+of+the+farnesyl+transferase+inhibitor+R115777+in+chronic+myeloid+leukemia+and+other+hematologic+malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DAlbitar%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DD.%26aulast%3DGiles%26aufirst%3DF.%26aulast%3DKurzrock%26aufirst%3DR.%26aulast%3DThibault%26aufirst%3DA.%26aulast%3DRackoff%26aufirst%3DW.%26aulast%3DKoller%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DGarcia-Manero%26aufirst%3DG.%26aulast%3DTalpaz%26aufirst%3DM.%26aulast%3DKantarjian%26aufirst%3DH.%26atitle%3DEfficacy%2520of%2520the%2520farnesyl%2520transferase%2520inhibitor%2520R115777%2520in%2520chronic%2520myeloid%2520leukemia%2520and%2520other%2520hematologic%2520malignancies%26jtitle%3DBlood%26date%3D2003%26volume%3D101%26spage%3D1692%26epage%3D1697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group">Mesa, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camoriano, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geyer, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlichman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardanani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasho, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finke, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tefferi, A.</span><span> </span><span class="NLM_article-title">A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1964</span><span class="NLM_x">–</span> <span class="NLM_lpage">1970</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=1964-1970&author=R.+A.+Mesaauthor=J.+K.+Camorianoauthor=S.+M.+Geyerauthor=W.+Wuauthor=S.+H.+Kaufmannauthor=C.+E.+Riveraauthor=C.+Erlichmanauthor=J.+Wrightauthor=A.+Pardananiauthor=T.+Lashoauthor=C.+Finkeauthor=C.+Y.+Liauthor=A.+Tefferi&title=A+phase+II+trial+of+tipifarnib+in+myelofibrosis%3A+primary%2C+post-polycythemia+vera+and+post-essential+thrombocythemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DCamoriano%26aufirst%3DJ.%2BK.%26aulast%3DGeyer%26aufirst%3DS.%2BM.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26aulast%3DRivera%26aufirst%3DC.%2BE.%26aulast%3DErlichman%26aufirst%3DC.%26aulast%3DWright%26aufirst%3DJ.%26aulast%3DPardanani%26aufirst%3DA.%26aulast%3DLasho%26aufirst%3DT.%26aulast%3DFinke%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DC.%2BY.%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DA%2520phase%2520II%2520trial%2520of%2520tipifarnib%2520in%2520myelofibrosis%253A%2520primary%252C%2520post-polycythemia%2520vera%2520and%2520post-essential%2520thrombocythemia%26jtitle%3DLeukemia%26date%3D2007%26volume%3D21%26spage%3D1964%26epage%3D1970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group">Kurzrock, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albitar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estey, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faderl, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Manero, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryback, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thibault, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Porre, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H. M.</span><span> </span><span class="NLM_article-title">Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1287</span><span class="NLM_x">–</span> <span class="NLM_lpage">1292</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1200%2FJCO.2004.08.082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=15051776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVGktbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2004&pages=1287-1292&author=R.+Kurzrockauthor=M.+Albitarauthor=J.+E.+Cortesauthor=E.+H.+Esteyauthor=S.+H.+Faderlauthor=G.+Garcia-Maneroauthor=D.+A.+Thomasauthor=F.+J.+Gilesauthor=M.+E.+Rybackauthor=A.+Thibaultauthor=P.+De+Porreauthor=H.+M.+Kantarjian&title=Phase+II+study+of+R115777%2C+a+farnesyl+transferase+inhibitor%2C+in+myelodysplastic+syndrome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome</span></div><div class="casAuthors">Kurzrock, Razelle; Albitar, Maher; Cortes, Jorge E.; Estey, Elihu H.; Faderl, Stefan H.; Garcia-Manero, Guillermo; Thomas, Deborah A.; Giles, Francis J.; Ryback, Mary Ellen; Thibault, Alain; de Porre, P.; Kantarjian, Hagop M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1287-1292</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">The aim was to perform a phase II study of the farnesyltransferase inhibitor R115777 (Zarnestra; Johnson and Johnson Pharmaceutical Research and Development, Raritan, NJ) in patients with myelodysplastic syndrome (MDS), using doses recommended in a phase I study in relapsed/refractory leukemia.  Patients with MDS were treated with R115777 at doses of 600 mg orally (PO) bid in cycles of 4 wk of therapy followed by a 2-wk rest period.  Dose redn. rules for toxicity were applied.  Twenty-seven of the 28 patients treated were assessable.  Three patients responded (complete remission, n = 2; partial remission, n = 1).  Responders included two patients with refractory anemia with excess blasts and one patient with refractory anemia with excess blasts in transformation.  Two of the responders had a diploid karyotype and one had multiple cytogenetic abnormalities including monosomy 5 and 7.  The starting dose of 600 mg PO bid resulted in side effects (myelosuppression, fatigue, neurotoxicity, rash, or leg pain) necessitating dose redn. (n = 4) or discontinuation of therapy (n = 7) in 11 (41%) of 27 patients during the induction period (12 wk).  Lower doses of 300 mg PO bid were well tolerated.  All responses occurred in patients who had been reduced to this dose level during the initial two cycles.  This study suggests that R115777 has modest activity in MDS patients, but that, in this patient population, 4 wk of daily doses of 600 mg PO bid is not tolerated.  Further exploration of the optimal dose/schedule and correlation with biol. end points are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopB_724LjCWLVg90H21EOLACvtfcHk0lhHHPf6uWZljQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVGktbs%253D&md5=d21e3fcffd95c92697fc085860be604c</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1200%2FJCO.2004.08.082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2004.08.082%26sid%3Dliteratum%253Aachs%26aulast%3DKurzrock%26aufirst%3DR.%26aulast%3DAlbitar%26aufirst%3DM.%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26aulast%3DEstey%26aufirst%3DE.%2BH.%26aulast%3DFaderl%26aufirst%3DS.%2BH.%26aulast%3DGarcia-Manero%26aufirst%3DG.%26aulast%3DThomas%26aufirst%3DD.%2BA.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DRyback%26aufirst%3DM.%2BE.%26aulast%3DThibault%26aufirst%3DA.%26aulast%3DDe%2BPorre%26aufirst%3DP.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26atitle%3DPhase%2520II%2520study%2520of%2520R115777%252C%2520a%2520farnesyl%2520transferase%2520inhibitor%252C%2520in%2520myelodysplastic%2520syndrome%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2004%26volume%3D22%26spage%3D1287%26epage%3D1292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group">Fenaux, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mufti, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aul, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germing, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cripe, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerstens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Porre, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurzrock, R.</span><span> </span><span class="NLM_article-title">A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">4158</span><span class="NLM_x">–</span> <span class="NLM_lpage">4163</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2007&pages=4158-4163&author=P.+Fenauxauthor=A.+Razaauthor=G.+J.+Muftiauthor=C.+Aulauthor=U.+Germingauthor=H.+Kantarjianauthor=L.+Cripeauthor=R.+Kerstensauthor=P.+De+Porreauthor=R.+Kurzrock&title=A+multicenter+phase+2+study+of+the+farnesyltransferase+inhibitor+tipifarnib+in+intermediate-+to+high-risk+myelodysplastic+syndrome"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFenaux%26aufirst%3DP.%26aulast%3DRaza%26aufirst%3DA.%26aulast%3DMufti%26aufirst%3DG.%2BJ.%26aulast%3DAul%26aufirst%3DC.%26aulast%3DGerming%26aufirst%3DU.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DCripe%26aufirst%3DL.%26aulast%3DKerstens%26aufirst%3DR.%26aulast%3DDe%2BPorre%26aufirst%3DP.%26aulast%3DKurzrock%26aufirst%3DR.%26atitle%3DA%2520multicenter%2520phase%25202%2520study%2520of%2520the%2520farnesyltransferase%2520inhibitor%2520tipifarnib%2520in%2520intermediate-%2520to%2520high-risk%2520myelodysplastic%2520syndrome%26jtitle%3DBlood%26date%3D2007%26volume%3D109%26spage%3D4158%26epage%3D4163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group">Kurzrock, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singhania, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freireich, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talpaz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebti, S. M.</span><span> </span><span class="NLM_article-title">Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">4527</span><span class="NLM_x">–</span> <span class="NLM_lpage">4534</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2003&pages=4527-4534&author=R.+Kurzrockauthor=H.+M.+Kantarjianauthor=J.+E.+Cortesauthor=N.+Singhaniaauthor=D.+A.+Thomasauthor=E.+F.+Wilsonauthor=J.+J.+Wrightauthor=E.+J.+Freireichauthor=M.+Talpazauthor=S.+M.+Sebti&title=Farnesyltransferase+inhibitor+R115777+in+myelodysplastic+syndrome%3A+clinical+and+biologic+activities+in+the+phase+1+setting"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKurzrock%26aufirst%3DR.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26aulast%3DSinghania%26aufirst%3DN.%26aulast%3DThomas%26aufirst%3DD.%2BA.%26aulast%3DWilson%26aufirst%3DE.%2BF.%26aulast%3DWright%26aufirst%3DJ.%2BJ.%26aulast%3DFreireich%26aufirst%3DE.%2BJ.%26aulast%3DTalpaz%26aufirst%3DM.%26aulast%3DSebti%26aufirst%3DS.%2BM.%26atitle%3DFarnesyltransferase%2520inhibitor%2520R115777%2520in%2520myelodysplastic%2520syndrome%253A%2520clinical%2520and%2520biologic%2520activities%2520in%2520the%2520phase%25201%2520setting%26jtitle%3DBlood%26date%3D2003%26volume%3D102%26spage%3D4527%26epage%3D4534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group">Alsina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fonseca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belle, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerbino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price-Troska, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overton, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruzek, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Djulbegovic, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantor, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greipp, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalton, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebti, S. M.</span><span> </span><span class="NLM_article-title">Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">3271</span><span class="NLM_x">–</span> <span class="NLM_lpage">3277</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2004&pages=3271-3277&author=M.+Alsinaauthor=R.+Fonsecaauthor=E.+F.+Wilsonauthor=A.+N.+Belleauthor=E.+Gerbinoauthor=T.+Price-Troskaauthor=R.+M.+Overtonauthor=G.+Ahmannauthor=L.+M.+Bruzekauthor=A.+A.+Adjeiauthor=S.+H.+Kaufmannauthor=J.+J.+Wrightauthor=D.+Sullivanauthor=B.+Djulbegovicauthor=A.+B.+Cantorauthor=P.+R.+Greippauthor=W.+S.+Daltonauthor=S.+M.+Sebti&title=Farnesyltransferase+inhibitor+tipifarnib+is+well+tolerated%2C+induces+stabilization+of+disease%2C+and+inhibits+farnesylation+and+oncogenic%2Ftumor+survival+pathways+in+patients+with+advanced+multiple+myeloma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAlsina%26aufirst%3DM.%26aulast%3DFonseca%26aufirst%3DR.%26aulast%3DWilson%26aufirst%3DE.%2BF.%26aulast%3DBelle%26aufirst%3DA.%2BN.%26aulast%3DGerbino%26aufirst%3DE.%26aulast%3DPrice-Troska%26aufirst%3DT.%26aulast%3DOverton%26aufirst%3DR.%2BM.%26aulast%3DAhmann%26aufirst%3DG.%26aulast%3DBruzek%26aufirst%3DL.%2BM.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26aulast%3DWright%26aufirst%3DJ.%2BJ.%26aulast%3DSullivan%26aufirst%3DD.%26aulast%3DDjulbegovic%26aufirst%3DB.%26aulast%3DCantor%26aufirst%3DA.%2BB.%26aulast%3DGreipp%26aufirst%3DP.%2BR.%26aulast%3DDalton%26aufirst%3DW.%2BS.%26aulast%3DSebti%26aufirst%3DS.%2BM.%26atitle%3DFarnesyltransferase%2520inhibitor%2520tipifarnib%2520is%2520well%2520tolerated%252C%2520induces%2520stabilization%2520of%2520disease%252C%2520and%2520inhibits%2520farnesylation%2520and%2520oncogenic%252Ftumor%2520survival%2520pathways%2520in%2520patients%2520with%2520advanced%2520multiple%2520myeloma%26jtitle%3DBlood%26date%3D2004%26volume%3D103%26spage%3D3271%26epage%3D3277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group">Karp, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flatten, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greer, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loegering, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricklis, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ritchie, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ironside, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talbott, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roboz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, X. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, N. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett-Mayer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, S. H.</span><span> </span><span class="NLM_article-title">Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">4841</span><span class="NLM_x">–</span> <span class="NLM_lpage">4852</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=4841-4852&author=J.+E.+Karpauthor=K.+Flattenauthor=E.+J.+Feldmanauthor=J.+M.+Greerauthor=D.+A.+Loegeringauthor=R.+M.+Ricklisauthor=L.+E.+Morrisauthor=E.+Ritchieauthor=B.+D.+Smithauthor=V.+Ironsideauthor=T.+Talbottauthor=G.+Robozauthor=S.+B.+Leauthor=X.+W.+Mengauthor=P.+A.+Schneiderauthor=N.+T.+Daiauthor=A.+A.+Adjeiauthor=S.+D.+Goreauthor=M.+J.+Levisauthor=J.+J.+Wrightauthor=E.+Garrett-Mayerauthor=S.+H.+Kaufmann&title=Active+oral+regimen+for+elderly+adults+with+newly+diagnosed+acute+myelogenous+leukemia%3A+a+preclinical+and+phase+1+trial+of+the+farnesyltransferase+inhibitor+tipifarnib+%28R115777%2C+Zarnestra%29+combined+with+etoposide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKarp%26aufirst%3DJ.%2BE.%26aulast%3DFlatten%26aufirst%3DK.%26aulast%3DFeldman%26aufirst%3DE.%2BJ.%26aulast%3DGreer%26aufirst%3DJ.%2BM.%26aulast%3DLoegering%26aufirst%3DD.%2BA.%26aulast%3DRicklis%26aufirst%3DR.%2BM.%26aulast%3DMorris%26aufirst%3DL.%2BE.%26aulast%3DRitchie%26aufirst%3DE.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DIronside%26aufirst%3DV.%26aulast%3DTalbott%26aufirst%3DT.%26aulast%3DRoboz%26aufirst%3DG.%26aulast%3DLe%26aufirst%3DS.%2BB.%26aulast%3DMeng%26aufirst%3DX.%2BW.%26aulast%3DSchneider%26aufirst%3DP.%2BA.%26aulast%3DDai%26aufirst%3DN.%2BT.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26aulast%3DGore%26aufirst%3DS.%2BD.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DWright%26aufirst%3DJ.%2BJ.%26aulast%3DGarrett-Mayer%26aufirst%3DE.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26atitle%3DActive%2520oral%2520regimen%2520for%2520elderly%2520adults%2520with%2520newly%2520diagnosed%2520acute%2520myelogenous%2520leukemia%253A%2520a%2520preclinical%2520and%2520phase%25201%2520trial%2520of%2520the%2520farnesyltransferase%2520inhibitor%2520tipifarnib%2520%2528R115777%252C%2520Zarnestra%2529%2520combined%2520with%2520etoposide%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D4841%26epage%3D4852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group">Van Cutsem, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van de Velde, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karasek, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oettle, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vervenne, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szawlowski, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoffski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verslype, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neumann, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Safran, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humblet, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez Ruixo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Von Hoff, D.</span><span> </span><span class="NLM_article-title">Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1430</span><span class="NLM_x">–</span> <span class="NLM_lpage">1438</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1200%2FJCO.2004.10.112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=15084616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpt1yjur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2004&pages=1430-1438&author=E.+Van+Cutsemauthor=H.+van+de+Veldeauthor=P.+Karasekauthor=H.+Oettleauthor=W.+L.+Vervenneauthor=A.+Szawlowskiauthor=P.+Schoffskiauthor=S.+Postauthor=C.+Verslypeauthor=H.+Neumannauthor=H.+Safranauthor=Y.+Humbletauthor=J.+Perez+Ruixoauthor=Y.+Maauthor=D.+Von+Hoff&title=Phase+III+trial+of+gemcitabine+plus+tipifarnib+compared+with+gemcitabine+plus+placebo+in+advanced+pancreatic+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer</span></div><div class="casAuthors">van Cutsem, E.; van de Velde, H.; Karasek, P.; Oettle, H.; Vervenne, W. L.; Szawlowski, A.; Schoffski, P.; Post, S.; Verslype, C.; Neumann, H.; Safran, H.; Humblet, Y.; Ruixo, J. Perez; Ma, Y.; von Hoff, D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1430-1438</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">The aim was to det. whether addn. of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777; Johnson and Johnson Pharmaceutical Research and Development, Beerse, Belgium) to std. gemcitabine therapy improves overall survival in advanced pancreatic cancer.  This randomized, double-blind, placebo-controlled study compared gemcitabine + tipifarnib vs. gemcitabine + placebo in patients with advanced pancreatic adenocarcinoma previously untreated with systemic therapy.  Tipifarnib was given at 200 mg bid orally continuously; gemcitabine was given at 1,000 mg/m2 i.v. weekly × 7 for 8 wk, then weekly × 3 every 4 wk.  The primary end point was overall survival; secondary end points included 6-mo and 1-yr survival rates, progression-free survival, response rate, safety, and quality of life.  Six hundred eighty-eight patients were enrolled.  Baseline characteristics were well balanced between the two treatment arms.  No statistically significant differences in survival parameters were obsd.  The median overall survival for the exptl. arm was 193 v 182 days for the control arm (P = .75); 6-mo and 1-yr survival rates were 53% and 27% v 49% and 24% for the control arm, resp.; median progression-free survival was 112 v 109 days for the control arm.  Ten drug-related deaths were reported for the exptl. arm and seven for the control arm.  Neutropenia and thrombocytopenia grade ≥ 3 were obsd. in 40% and 15% in the exptl. arm vs. 30% and 12% in the control arm.  Incidences of nonhematol. adverse events were similar in two groups.  The combination of gemcitabine and tipifarnib has an acceptable toxicity profile but does not prolong overall survival in advanced pancreatic cancer compared with single-agent gemcitabine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCHeE2twphB7Vg90H21EOLACvtfcHk0lgyzig_NWM2Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpt1yjur0%253D&md5=782b73146b431d999d2305268e2c2c6b</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1200%2FJCO.2004.10.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2004.10.112%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BCutsem%26aufirst%3DE.%26aulast%3Dvan%2Bde%2BVelde%26aufirst%3DH.%26aulast%3DKarasek%26aufirst%3DP.%26aulast%3DOettle%26aufirst%3DH.%26aulast%3DVervenne%26aufirst%3DW.%2BL.%26aulast%3DSzawlowski%26aufirst%3DA.%26aulast%3DSchoffski%26aufirst%3DP.%26aulast%3DPost%26aufirst%3DS.%26aulast%3DVerslype%26aufirst%3DC.%26aulast%3DNeumann%26aufirst%3DH.%26aulast%3DSafran%26aufirst%3DH.%26aulast%3DHumblet%26aufirst%3DY.%26aulast%3DPerez%2BRuixo%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DVon%2BHoff%26aufirst%3DD.%26atitle%3DPhase%2520III%2520trial%2520of%2520gemcitabine%2520plus%2520tipifarnib%2520compared%2520with%2520gemcitabine%2520plus%2520placebo%2520in%2520advanced%2520pancreatic%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2004%26volume%3D22%26spage%3D1430%26epage%3D1438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group">Lersch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Cutsem, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amado, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ehninger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heike, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerr, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothenberg, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaknoen, S. L.</span><span> </span><span class="NLM_article-title">Randomized phase II study of SCH 66336 and gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas</span> <span class="citation_source-journal">Proc. Am. Soc. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">608</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2001&pages=608&author=C.+Lerschauthor=E.+Van+Cutsemauthor=R.+Amadoauthor=G.+Ehningerauthor=M.+Heikeauthor=D.+Kerrauthor=M.+L.+Rothenbergauthor=C.+M.+Baumauthor=S.+L.+Zaknoen&title=Randomized+phase+II+study+of+SCH+66336+and+gemcitabine+in+the+treatment+of+metastatic+adenocarcinoma+of+the+pancreas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLersch%26aufirst%3DC.%26aulast%3DVan%2BCutsem%26aufirst%3DE.%26aulast%3DAmado%26aufirst%3DR.%26aulast%3DEhninger%26aufirst%3DG.%26aulast%3DHeike%26aufirst%3DM.%26aulast%3DKerr%26aufirst%3DD.%26aulast%3DRothenberg%26aufirst%3DM.%2BL.%26aulast%3DBaum%26aufirst%3DC.%2BM.%26aulast%3DZaknoen%26aufirst%3DS.%2BL.%26atitle%3DRandomized%2520phase%2520II%2520study%2520of%2520SCH%252066336%2520and%2520gemcitabine%2520in%2520the%2520treatment%2520of%2520metastatic%2520adenocarcinoma%2520of%2520the%2520pancreas%26jtitle%3DProc.%2520Am.%2520Soc.%2520Clin.%2520Oncol.%26date%3D2001%26volume%3D20%26spage%3D608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group">Sharma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kemeny, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelsen, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ilson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Reilly, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaknoen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Statkevich, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollywood, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltz, L. B.</span><span> </span><span class="NLM_article-title">A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1067</span><span class="NLM_x">–</span> <span class="NLM_lpage">1071</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1093%2Fannonc%2Fmdf173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=12176785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A280%3ADC%252BD38vitFWnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2002&pages=1067-1071&author=S.+Sharmaauthor=N.+Kemenyauthor=D.+P.+Kelsenauthor=D.+Ilsonauthor=E.+O%E2%80%99Reillyauthor=S.+Zaknoenauthor=C.+Baumauthor=P.+Statkevichauthor=E.+Hollywoodauthor=Y.+Zhuauthor=L.+B.+Saltz&title=A+phase+II+trial+of+farnesyl+protein+transferase+inhibitor+SCH+66336%2C+given+by+twice-daily+oral+administration%2C+in+patients+with+metastatic+colorectal+cancer+refractory+to+5-fluorouracil+and+irinotecan"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan</span></div><div class="casAuthors">Sharma S; Kemeny N; Kelsen D P; Ilson D; O'Reilly E; Zaknoen S; Baum C; Statkevich P; Hollywood E; Zhu Y; Saltz L B</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1067-71</span>
        ISSN:<span class="NLM_cas:issn">0923-7534</span>.
    </div><div class="casAbstract">BACKGROUND:  ras genes encode Ras proteins that are important for signal transduction in cancer cells.  Farnesyl protein transferase (FPTase) is an enzyme that is responsible for a critical post-translational modification of Ras.  PATIENTS AND METHODS:  We report the results of a phase II trial of SCH 66336, an FPTase inhibitor, in patients with metastatic colorectal cancer.  This is the first reported experience of an FPTase inhibitor in this disease.  All patients were considered refractory to first- and second-line therapy.  A total of 21 evaluable patients were treated with a starting dose of 200 mg b.i.d. given continuously.  RESULTS:  The major side-effects were fatigue (grade 1 in 42%, grade 2 in 42% and grade 3 in 14%), diarrhea (grade 1 in 23% and grade 3 in 42%) and nausea (grade 2 in 16%).  Elevations in serum creatinine (grade 2 or 3) were observed in 19% of patients and appeared to be related to dehydration induced by diarrhea.  Significant hematological toxicity was not observed (only grade 1 thrombocytopenia in 19% and grade 2 or 3 anemia in 28%).  Pharmacological studies revealed adequate mean pre-dose plasma concentrations in this group of patients on day 15 of therapy.  No objective responses were observed, although stable disease was seen in three patients for several months.  Administration of SCH 66336 was accompanied by gastrointestinal toxicity.  CONCLUSIONS:  Future development of this compound cannot be recommended as monotherapy in this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTbJLEuy3k9-hFwe7cAcrfPfW6udTcc2eb4M06qxPZX6rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38vitFWnsw%253D%253D&md5=d7f56384cef6e4d48b09ddd529611c0e</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdf173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdf173%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DKemeny%26aufirst%3DN.%26aulast%3DKelsen%26aufirst%3DD.%2BP.%26aulast%3DIlson%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DE.%26aulast%3DZaknoen%26aufirst%3DS.%26aulast%3DBaum%26aufirst%3DC.%26aulast%3DStatkevich%26aufirst%3DP.%26aulast%3DHollywood%26aufirst%3DE.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DSaltz%26aufirst%3DL.%2BB.%26atitle%3DA%2520phase%2520II%2520trial%2520of%2520farnesyl%2520protein%2520transferase%2520inhibitor%2520SCH%252066336%252C%2520given%2520by%2520twice-daily%2520oral%2520administration%252C%2520in%2520patients%2520with%2520metastatic%2520colorectal%2520cancer%2520refractory%2520to%25205-fluorouracil%2520and%2520irinotecan%26jtitle%3DAnn.%2520Oncol.%26date%3D2002%26volume%3D13%26spage%3D1067%26epage%3D1071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group">Hanrahan, E. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kies, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glisson, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khuri, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginsberg, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truong, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, E. S.</span><span> </span><span class="NLM_article-title">A phase II study of lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck</span> <span class="citation_source-journal">Am. J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">274</span><span class="NLM_x">–</span> <span class="NLM_lpage">279</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1097%2FCOC.0b013e318187dd57" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=19433965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotlShur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2009&pages=274-279&author=E.+O.+Hanrahanauthor=M.+S.+Kiesauthor=B.+S.+Glissonauthor=F.+R.+Khuriauthor=L.+Fengauthor=H.+T.+Tranauthor=L.+E.+Ginsbergauthor=M.+T.+Truongauthor=W.+K.+Hongauthor=E.+S.+Kim&title=A+phase+II+study+of+lonafarnib+%28SCH66336%29+in+patients+with+chemorefractory%2C+advanced+squamous+cell+carcinoma+of+the+head+and+neck"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II study on lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck</span></div><div class="casAuthors">Hanrahan, Emer O.; Kies, Merrill S.; Glisson, Bonnie S.; Khuri, Fadlo R.; Feng, Lei; Tran, Hai T.; Ginsberg, Lawrence E.; Truong, Mylene T.; Hong, Waun K.; Kim, Edward S.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">274-279</span>CODEN:
                <span class="NLM_cas:coden">AJCODI</span>;
        ISSN:<span class="NLM_cas:issn">0277-3732</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Treatment options for recurrent squamous cell carcinoma of the head and neck (SCCHN) following platinum-based therapy are limited.  Lonafarnib is a potent, specific inhibitor of farnesyl transferase that demonstrated marked antitumor activity as monotherapy in treatment-naive SCCHN in a phase Ib study.  A phase II study of lonafarnib was conducted to det. its efficacy and safety in patients with recurrent, platinum-refractory SCCHN.  This was an open-label, phase II, single-center study in patients with recurrent SCCHN after platinum-based therapy.  A Simon 2-stage design was used, with a plan to close the study to further accrual if <2 of the first 15 patients had objective responses.  Patients were treated with lonafarnib 200 mg twice daily (b.i.d.) by mouth continuously in 4-wk cycles.  Fifteen patients with baseline Eastern Cooperative Oncol. Group PS 0-1 and median age 57 years were enrolled.  Twelve patients had received at least 2 previous chemotherapy regimens.  Median duration of treatment with lonafarnib was 61 days.  No objective response was obsd.  Seven (47%) patients maintained stable disease through ≥3 cycles of therapy.  Median time to progression and survival time were 2.04 and 9.17 mo, resp.  Most treatment-related toxicities were grade 1-2, and there were no treatment-related deaths.  Lonafarnib at a dose of 200 mg b.i.d. was well-tolerated.  However, there were no objective responses obsd. in the first 15 patients enrolled in this study, and the study was closed to further accrual, as per predefined criteria.  Further evaluation of lonafarnib in platinum-refractory SCCHN is not planned.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3F_Lfyl-vO7Vg90H21EOLACvtfcHk0ljQn0nJWd4xtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotlShur4%253D&md5=1c6ab91e96ae5a797917399d01579e36</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1097%2FCOC.0b013e318187dd57&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCOC.0b013e318187dd57%26sid%3Dliteratum%253Aachs%26aulast%3DHanrahan%26aufirst%3DE.%2BO.%26aulast%3DKies%26aufirst%3DM.%2BS.%26aulast%3DGlisson%26aufirst%3DB.%2BS.%26aulast%3DKhuri%26aufirst%3DF.%2BR.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DTran%26aufirst%3DH.%2BT.%26aulast%3DGinsberg%26aufirst%3DL.%2BE.%26aulast%3DTruong%26aufirst%3DM.%2BT.%26aulast%3DHong%26aufirst%3DW.%2BK.%26aulast%3DKim%26aufirst%3DE.%2BS.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520lonafarnib%2520%2528SCH66336%2529%2520in%2520patients%2520with%2520chemorefractory%252C%2520advanced%2520squamous%2520cell%2520carcinoma%2520of%2520the%2520head%2520and%2520neck%26jtitle%3DAm.%2520J.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D32%26spage%3D274%26epage%3D279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group">Wong, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morse, M. A.</span><span> </span><span class="NLM_article-title">Lonafarnib for cancer and progeria</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1043</span><span class="NLM_x">–</span> <span class="NLM_lpage">1055</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=1043-1055&author=N.+S.+Wongauthor=M.+A.+Morse&title=Lonafarnib+for+cancer+and+progeria"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DN.%2BS.%26aulast%3DMorse%26aufirst%3DM.%2BA.%26atitle%3DLonafarnib%2520for%2520cancer%2520and%2520progeria%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2012%26volume%3D21%26spage%3D1043%26epage%3D1055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jabbour, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verstovsek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrajoli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Statkevich, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span> </span><span class="NLM_article-title">Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">1295</span><span class="NLM_x">–</span> <span class="NLM_lpage">1302</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=1295-1302&author=J.+Cortesauthor=E.+Jabbourauthor=G.+Q.+Daleyauthor=S.+O%E2%80%99Brienauthor=S.+Verstovsekauthor=A.+Ferrajoliauthor=C.+Kollerauthor=Y.+Zhuauthor=P.+Statkevichauthor=H.+Kantarjian&title=Phase+1+study+of+lonafarnib+%28SCH+66336%29+and+imatinib+mesylate+in+patients+with+chronic+myeloid+leukemia+who+have+failed+prior+single-agent+therapy+with+imatinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DJabbour%26aufirst%3DE.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DFerrajoli%26aufirst%3DA.%26aulast%3DKoller%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DStatkevich%26aufirst%3DP.%26aulast%3DKantarjian%26aufirst%3DH.%26atitle%3DPhase%25201%2520study%2520of%2520lonafarnib%2520%2528SCH%252066336%2529%2520and%2520imatinib%2520mesylate%2520in%2520patients%2520with%2520chronic%2520myeloid%2520leukemia%2520who%2520have%2520failed%2520prior%2520single-agent%2520therapy%2520with%2520imatinib%26jtitle%3DCancer%26date%3D2007%26volume%3D110%26spage%3D1295%26epage%3D1302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group">Theodore, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geoffrois, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vermorken, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caponigro, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiedler, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chollet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravaud, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Balincourt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacombe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fumoleau, P.</span><span> </span><span class="NLM_article-title">Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">1150</span><span class="NLM_x">–</span> <span class="NLM_lpage">1157</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2005&pages=1150-1157&author=C.+Theodoreauthor=L.+Geoffroisauthor=J.+B.+Vermorkenauthor=F.+Caponigroauthor=W.+Fiedlerauthor=P.+Cholletauthor=A.+Ravaudauthor=G.+J.+Petersauthor=C.+de+Balincourtauthor=D.+Lacombeauthor=P.+Fumoleau&title=Multicentre+EORTC+study+16997%3A+feasibility+and+phase+II+trial+of+farnesyl+transferase+inhibitor+%26+gemcitabine+combination+in+salvage+treatment+of+advanced+urothelial+tract+cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTheodore%26aufirst%3DC.%26aulast%3DGeoffrois%26aufirst%3DL.%26aulast%3DVermorken%26aufirst%3DJ.%2BB.%26aulast%3DCaponigro%26aufirst%3DF.%26aulast%3DFiedler%26aufirst%3DW.%26aulast%3DChollet%26aufirst%3DP.%26aulast%3DRavaud%26aufirst%3DA.%26aulast%3DPeters%26aufirst%3DG.%2BJ.%26aulast%3Dde%2BBalincourt%26aufirst%3DC.%26aulast%3DLacombe%26aufirst%3DD.%26aulast%3DFumoleau%26aufirst%3DP.%26atitle%3DMulticentre%2520EORTC%2520study%252016997%253A%2520feasibility%2520and%2520phase%2520II%2520trial%2520of%2520farnesyl%2520transferase%2520inhibitor%2520%2526%2520gemcitabine%2520combination%2520in%2520salvage%2520treatment%2520of%2520advanced%2520urothelial%2520tract%2520cancers%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2005%26volume%3D41%26spage%3D1150%26epage%3D1157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group">Bergo, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambroziak, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregory, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otto, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagase, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balmain, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, S. G.</span><span> </span><span class="NLM_article-title">Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">171</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1128%2FMCB.22.1.171-181.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=11739732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptlOiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2002&pages=171-181&author=M.+O.+Bergoauthor=P.+Ambroziakauthor=C.+Gregoryauthor=A.+Georgeauthor=J.+C.+Ottoauthor=E.+Kimauthor=H.+Nagaseauthor=P.+J.+Caseyauthor=A.+Balmainauthor=S.+G.+Young&title=Absence+of+the+CAAX+endoprotease+Rce1%3A+effects+on+cell+growth+and+transformation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation</span></div><div class="casAuthors">Bergo, Martin O.; Ambroziak, Patricia; Gregory, Cria; George, Amanda; Otto, James C.; Kim, Edward; Nagase, Hiroki; Casey, Patrick J.; Balmain, Allan; Young, Stephen G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">171-181</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">After isoprenylation, the Ras proteins and other CAAX proteins undergo two addnl. enzymic modifications-endoproteolytic release of the last three amino acids of the protein by the protease Rce1 and methylation of the carboxyl-terminal isoprenylcysteine by the methyltransferase Icmt.  This post-isoprenylation processing is thought to be important for the assocn. of Ras proteins with membranes.  Blocking post-isoprenylation processing, by inhibiting Rce1, has been suggested as a potential approach for retarding cell growth and blocking cellular transformation.  The objective of this study was to develop a cell culture system for addressing these issues.  We generated mice with a conditional Rce1 allele (Rce1flox) and produced Rce1flox/flox fibroblasts.  Cre-mediated excision of Rce1 (thereby producing Rce1Δ/Δ fibroblasts) eliminated Ras endoproteolytic processing and methylation and caused a partial mislocalization of truncated K-Ras and H-Ras fusion proteins within cells.  Rce1Δ/Δ fibroblasts grew more slowly than Rce1flox/flox fibroblasts.  The excision of Rce1 also reduced Ras-induced transformation, as judged by the growth of colonies in soft agar.  The excision of Rce1 from a Rce1flox/flox skin carcinoma cell line also significantly retarded the growth of cells, and this effect was exaggerated by cotreatment of the cells with a farnesyltransferase inhibitor.  These studies support the idea that interference with post-isoprenylation processing retards cell growth, limits Ras-induced transformation, and sensitizes tumor cells to a farnesyltransferase inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpa8WNtXdx5frVg90H21EOLACvtfcHk0lg7wbQqK_gwPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptlOiur4%253D&md5=179da76fc146d85df7e556dc70a104be</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1128%2FMCB.22.1.171-181.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.22.1.171-181.2002%26sid%3Dliteratum%253Aachs%26aulast%3DBergo%26aufirst%3DM.%2BO.%26aulast%3DAmbroziak%26aufirst%3DP.%26aulast%3DGregory%26aufirst%3DC.%26aulast%3DGeorge%26aufirst%3DA.%26aulast%3DOtto%26aufirst%3DJ.%2BC.%26aulast%3DKim%26aufirst%3DE.%26aulast%3DNagase%26aufirst%3DH.%26aulast%3DCasey%26aufirst%3DP.%2BJ.%26aulast%3DBalmain%26aufirst%3DA.%26aulast%3DYoung%26aufirst%3DS.%2BG.%26atitle%3DAbsence%2520of%2520the%2520CAAX%2520endoprotease%2520Rce1%253A%2520effects%2520on%2520cell%2520growth%2520and%2520transformation%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2002%26volume%3D22%26spage%3D171%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group">Manandhar, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hildebrandt, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, W. K.</span><span> </span><span class="NLM_article-title">Small-molecule inhibitors of the Rce1p CaaX protease</span> <span class="citation_source-journal">J. Biomol. Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">983</span><span class="NLM_x">–</span> <span class="NLM_lpage">993</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1177%2F1087057107307226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=17942791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht12rs7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=983-993&author=S.+P.+Manandharauthor=E.+R.+Hildebrandtauthor=W.+K.+Schmidt&title=Small-molecule+inhibitors+of+the+Rce1p+CaaX+protease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule inhibitors of the Rce1p CaaX protease</span></div><div class="casAuthors">Manandhar, Surya P.; Hildebrandt, Emily R.; Schmidt, Walter K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">983-993</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The Rce1p protease is required for the maturation of the Ras GTPase and certain other isoprenylated proteins and is considered a chemotherapeutic target.  To identify new small-mol. inhibitors of Rce1p, the authors screened the National Cancer Institute Diversity Set compd. library using in vitro assays to monitor the proteolytic processing of peptides derived from Ras and the yeast a-factor mating pheromone.  Of 46 inhibitors initially identified with a Ras-based assay, only 9 were effective in the pheromone-based assay.  The IC50 values of these 9 compds. were in the low micromolar range for both yeast (6-35 μM) and human Rce1p (0.4-46 μM).  Four compds. were somewhat Rce1p selective in that they partially inhibited the Ste24p protease and did not inhibit Ste14p isoprenylcysteine carboxyl methyltransferase, 2 enzymes also involved in the maturation of isoprenylated proteins.  The remaining 5 compds. inhibited all 3 enzymes.  The 2 most Rce1p-selective agents were ineffective trypsin inhibitors, further supporting the specificity of these agents for Rce1p.  The 5 least specific compds. formed colloidal aggregates, a proposed common feature of promiscuous inhibitors.  Interestingly, the most specific Rce1p inhibitor also formed a colloidal aggregate.  In vivo studies revealed that treatment of wild-type yeast with compd. (I) induced a Ras2p delocalization phenotype that mimics obsd. effects in rce1 ste24 null yeast.  The 9 compds. identified in this study represent new tools for understanding the enzymol. of postisoprenylation-modifying enzymes and provide new insight for the future development of Rce1p inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfMGTmaz0SkrVg90H21EOLACvtfcHk0lg7wbQqK_gwPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht12rs7rF&md5=6fec75a256a70db46d5e7a12aa4b91db</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1177%2F1087057107307226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057107307226%26sid%3Dliteratum%253Aachs%26aulast%3DManandhar%26aufirst%3DS.%2BP.%26aulast%3DHildebrandt%26aufirst%3DE.%2BR.%26aulast%3DSchmidt%26aufirst%3DW.%2BK.%26atitle%3DSmall-molecule%2520inhibitors%2520of%2520the%2520Rce1p%2520CaaX%2520protease%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2007%26volume%3D12%26spage%3D983%26epage%3D993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group">van der Hoeven, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chigurupati, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parton, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, J. F.</span><span> </span><span class="NLM_article-title">Fendiline inhibits K-Ras plasma membrane localization and blocks K-Ras signal transmission</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">237</span><span class="NLM_x">–</span> <span class="NLM_lpage">251</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1128%2FMCB.00884-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=23129805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1Sktbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=237-251&author=D.+van+der+Hoevenauthor=K.+J.+Choauthor=X.+Maauthor=S.+Chigurupatiauthor=R.+G.+Partonauthor=J.+F.+Hancock&title=Fendiline+inhibits+K-Ras+plasma+membrane+localization+and+blocks+K-Ras+signal+transmission"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Fendiline inhibits K-Ras plasma membrane localization and blocks K-Ras signal transmission</span></div><div class="casAuthors">van der Hoeven, Dharini; Cho, Kwang-jin; Ma, Xiaoping; Chigurupati, Sravanthi; Parton, Robert G.; Hancock, John F.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">237-251</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Ras proteins regulate signaling pathways important for cell growth, differentiation, and survival.  Oncogenic mutant Ras proteins are commonly expressed in human tumors, with mutations of the K-Ras isoform being most prevalent.  To be active, K-Ras must undergo posttranslational processing and assoc. with the plasma membrane.  We therefore devised a high-content screening assay to search for inhibitors of K-Ras plasma membrane assocn.  Using this assay, we identified fendiline, an L-type calcium channel blocker, as a specific inhibitor of K-Ras plasma membrane targeting with no detectable effect on the localization of H- and N-Ras.  Other classes of L-type calcium channel blockers did not mislocalize K-Ras, suggesting a mechanism that is unrelated to calcium channel blockade.  Fendilien did not inhibit K-Ras posttranslational processing but significantly reduced nanoclustering of K-Ras and redistributed K-Ras from the plasma membrane to the endoplasmic reticulum (ER), Golgi app., endosomes, and cytosol.  Fendiline significantly inhibited signaling downstream of constitutively active K-Ras and endogenous K-Ras signaling in cells transformed by oncogenic H-Ras.  Consistent with these effects, fendiline blocked the proliferation of pancreatic, colon, lung, and endometrial cancer cell lines expressing oncogenic mutant K-Ras.  Taken together, these results suggest that inhibitors of K-Ras plasma membrane localization may have utility as novel K-Ras-specific anticancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQwMRHBsb38rVg90H21EOLACvtfcHk0lg7wbQqK_gwPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1Sktbs%253D&md5=566edae36147a1c489f94e06c6caa8b1</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1128%2FMCB.00884-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00884-12%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BHoeven%26aufirst%3DD.%26aulast%3DCho%26aufirst%3DK.%2BJ.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DChigurupati%26aufirst%3DS.%26aulast%3DParton%26aufirst%3DR.%2BG.%26aulast%3DHancock%26aufirst%3DJ.%2BF.%26atitle%3DFendiline%2520inhibits%2520K-Ras%2520plasma%2520membrane%2520localization%2520and%2520blocks%2520K-Ras%2520signal%2520transmission%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2013%26volume%3D33%26spage%3D237%26epage%3D251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group">Marciano, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ben-Baruch, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marom, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egozi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haklai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kloog, Y.</span><span> </span><span class="NLM_article-title">Farnesyl derivatives of rigid carboxylic acids—inhibitors of ras-dependent cell growth</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1267</span><span class="NLM_x">–</span> <span class="NLM_lpage">1272</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00008a004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=1267-1272&author=D.+Marcianoauthor=G.+Ben-Baruchauthor=M.+Maromauthor=Y.+Egoziauthor=R.+Haklaiauthor=Y.+Kloog&title=Farnesyl+derivatives+of+rigid+carboxylic+acids%E2%80%94inhibitors+of+ras-dependent+cell+growth"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Fjm00008a004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00008a004%26sid%3Dliteratum%253Aachs%26aulast%3DMarciano%26aufirst%3DD.%26aulast%3DBen-Baruch%26aufirst%3DG.%26aulast%3DMarom%26aufirst%3DM.%26aulast%3DEgozi%26aufirst%3DY.%26aulast%3DHaklai%26aufirst%3DR.%26aulast%3DKloog%26aufirst%3DY.%26atitle%3DFarnesyl%2520derivatives%2520of%2520rigid%2520carboxylic%2520acids%25E2%2580%2594inhibitors%2520of%2520ras-dependent%2520cell%2520growth%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D1267%26epage%3D1272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group">Marom, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haklai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ben-Baruch, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marciano, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egozi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kloog, Y.</span><span> </span><span class="NLM_article-title">Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">270</span><span class="NLM_x">, </span> <span class="NLM_fpage">22263</span><span class="NLM_x">–</span> <span class="NLM_lpage">22270</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=22263-22270&author=M.+Maromauthor=R.+Haklaiauthor=G.+Ben-Baruchauthor=D.+Marcianoauthor=Y.+Egoziauthor=Y.+Kloog&title=Selective+inhibition+of+Ras-dependent+cell+growth+by+farnesylthiosalisylic+acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarom%26aufirst%3DM.%26aulast%3DHaklai%26aufirst%3DR.%26aulast%3DBen-Baruch%26aufirst%3DG.%26aulast%3DMarciano%26aufirst%3DD.%26aulast%3DEgozi%26aufirst%3DY.%26aulast%3DKloog%26aufirst%3DY.%26atitle%3DSelective%2520inhibition%2520of%2520Ras-dependent%2520cell%2520growth%2520by%2520farnesylthiosalisylic%2520acid%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26spage%3D22263%26epage%3D22270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group">Boufaied, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wioland, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falardeau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gourdeau, H.</span><span> </span><span class="NLM_article-title">TLN-4601, a novel anticancer agent, inhibits Ras signaling post Ras prenylation and before MEK activation</span> <span class="citation_source-journal">Anti-Cancer Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">543</span><span class="NLM_x">–</span> <span class="NLM_lpage">552</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=543-552&author=N.+Boufaiedauthor=M.+A.+Wiolandauthor=P.+Falardeauauthor=H.+Gourdeau&title=TLN-4601%2C+a+novel+anticancer+agent%2C+inhibits+Ras+signaling+post+Ras+prenylation+and+before+MEK+activation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoufaied%26aufirst%3DN.%26aulast%3DWioland%26aufirst%3DM.%2BA.%26aulast%3DFalardeau%26aufirst%3DP.%26aulast%3DGourdeau%26aufirst%3DH.%26atitle%3DTLN-4601%252C%2520a%2520novel%2520anticancer%2520agent%252C%2520inhibits%2520Ras%2520signaling%2520post%2520Ras%2520prenylation%2520and%2520before%2520MEK%2520activation%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2010%26volume%3D21%26spage%3D543%26epage%3D552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group">Baines, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span> </span><span class="NLM_article-title">Inhibition of Ras for cancer treatment: the search continues</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1787</span><span class="NLM_x">–</span> <span class="NLM_lpage">1808</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.4155%2Ffmc.11.121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=22004085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlertbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=1787-1808&author=A.+T.+Bainesauthor=D.+Xuauthor=C.+J.+Der&title=Inhibition+of+Ras+for+cancer+treatment%3A+the+search+continues"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Ras for cancer treatment: the search continues</span></div><div class="casAuthors">Baines, Antonio T.; Xu, Dapeng; Der, Channing J.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1787-1808</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The RAS oncogenes (HRAS, NRAS and KRAS) comprise the most frequently mutated class of oncogenes in human cancers (33%), thus stimulating intensive effort in developing anti-Ras inhibitors for cancer treatment.  Despite intensive effort, to date, no effective anti-Ras strategies have successfully made it to the clinic.  We present an overview of past and ongoing strategies to inhibit oncogenic Ras in cancer.  Since approaches to directly target mutant Ras have not been successful, most efforts have focused on indirect approaches to block Ras membrane assocn. or downstream effector signaling.  While inhibitors of effector signaling are currently under clin. evaluation, genome-wide unbiased genetic screens have identified novel directions for future anti-Ras drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGSljlfnR2TbVg90H21EOLACvtfcHk0lhEdr2P2pZO2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlertbjJ&md5=bb810b0cf2b8dc975d5a476907f5c2ec</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.4155%2Ffmc.11.121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.11.121%26sid%3Dliteratum%253Aachs%26aulast%3DBaines%26aufirst%3DA.%2BT.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DInhibition%2520of%2520Ras%2520for%2520cancer%2520treatment%253A%2520the%2520search%2520continues%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2011%26volume%3D3%26spage%3D1787%26epage%3D1808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group">Laheru, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajeshkumar, N. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McAllister, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsweig, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donehower, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimeno, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linden, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudek, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hidalgo, M.</span><span> </span><span class="NLM_article-title">Integrated preclinical and clinical development of <i>S</i>-<i>trans</i>,<i>trans</i>-farnesylthiosalicylic acid (FTS, salirasib) in pancreatic cancer</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">2391</span><span class="NLM_x">–</span> <span class="NLM_lpage">2399</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=2391-2399&author=D.+Laheruauthor=P.+Shahauthor=N.+V.+Rajeshkumarauthor=F.+McAllisterauthor=G.+Taylorauthor=H.+Goldsweigauthor=D.+T.+Leauthor=R.+Donehowerauthor=A.+Jimenoauthor=S.+Lindenauthor=M.+Zhaoauthor=D.+Songauthor=M.+A.+Rudekauthor=M.+Hidalgo&title=Integrated+preclinical+and+clinical+development+of+S-trans%2Ctrans-farnesylthiosalicylic+acid+%28FTS%2C+salirasib%29+in+pancreatic+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLaheru%26aufirst%3DD.%26aulast%3DShah%26aufirst%3DP.%26aulast%3DRajeshkumar%26aufirst%3DN.%2BV.%26aulast%3DMcAllister%26aufirst%3DF.%26aulast%3DTaylor%26aufirst%3DG.%26aulast%3DGoldsweig%26aufirst%3DH.%26aulast%3DLe%26aufirst%3DD.%2BT.%26aulast%3DDonehower%26aufirst%3DR.%26aulast%3DJimeno%26aufirst%3DA.%26aulast%3DLinden%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DSong%26aufirst%3DD.%26aulast%3DRudek%26aufirst%3DM.%2BA.%26aulast%3DHidalgo%26aufirst%3DM.%26atitle%3DIntegrated%2520preclinical%2520and%2520clinical%2520development%2520of%2520S-trans%252Ctrans-farnesylthiosalicylic%2520acid%2520%2528FTS%252C%2520salirasib%2529%2520in%2520pancreatic%2520cancer%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2012%26volume%3D30%26spage%3D2391%26epage%3D2399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizvi, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietanza, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azzoli, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krug, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginsberg, M. S.</span><span> </span><span class="NLM_article-title">A phase II trial of salirasib in patients with lung adenocarcinomas with KRAS mutations</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1435</span><span class="NLM_x">–</span> <span class="NLM_lpage">1437</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1097%2FJTO.0b013e318223c099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=21847063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A280%3ADC%252BC3MjmvV2qsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=1435-1437&author=G.+J.+Rielyauthor=M.+L.+Johnsonauthor=C.+Medinaauthor=N.+A.+Rizviauthor=V.+A.+Millerauthor=M.+G.+Krisauthor=M.+C.+Pietanzaauthor=C.+G.+Azzoliauthor=L.+M.+Krugauthor=W.+Paoauthor=M.+S.+Ginsberg&title=A+phase+II+trial+of+salirasib+in+patients+with+lung+adenocarcinomas+with+KRAS+mutations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations</span></div><div class="casAuthors">Riely Gregory J; Johnson Melissa L; Medina Chanoa; Rizvi Naiyer A; Miller Vincent A; Kris Mark G; Pietanza M Catherine; Azzoli Christopher G; Krug Lee M; Pao William; Ginsberg Michelle S</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1435-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  KRAS mutations are present in 30% of lung adenocarcinomas.  Salirasib prevents Ras membrane binding thereby blocking the function of all Ras isoforms.  This phase II study determined the activity of salirasib in patients with advanced lung adenocarcinomas with KRAS mutations.  METHODS:  Two cohorts of patients with stage IIIB/IV lung adenocarcinoma were eligible: patients with tumors with KRAS mutations who were previously treated with chemotherapy and patients receiving initial therapy who had ≥15 pack-year smoking history.  Salirasib was given orally from days 1 to 28 of a 35-day cycle.  The primary end point was the rate of nonprogression at 10 weeks.  RESULTS:  Thirty-three patients were enrolled.  Thirty patients had KRAS mutations (23 patients who were previously treated and 7/10 patients who had no prior therapy).  Of the previously treated patients, 7 of 23 (30%) had stable disease at 10 weeks, and 4 of 10 (40%) previously untreated patients had stable disease at 10 weeks.  No patient had a radiographic partial response (0% observed rate, 95% confidence interval 0-12%).  The median overall survival was not reached (>9 months) for previously untreated patients and it was 15 months for patients who received prior chemotherapy.  Diarrhea, nausea, and fatigue were the most common toxicities.  CONCLUSIONS:  Salirasib at the current dose and schedule has insufficient activity in the treatment of KRAS mutant lung adenocarcinoma to warrant further evaluation.  The successful enrollment of 30 patients with tumors with KRAS mutant lung adenocarcinoma over 15 months at a single site demonstrates that drug trials directed at a KRAS-specific genotype in lung cancer are feasible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRd97gWb8zCtINpW7w2tapOfW6udTcc2eY-8LmJnsV-Trntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MjmvV2qsA%253D%253D&md5=cf9ac4f926c6c6e5f40a2bf9c258b863</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1097%2FJTO.0b013e318223c099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0b013e318223c099%26sid%3Dliteratum%253Aachs%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DJohnson%26aufirst%3DM.%2BL.%26aulast%3DMedina%26aufirst%3DC.%26aulast%3DRizvi%26aufirst%3DN.%2BA.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DPietanza%26aufirst%3DM.%2BC.%26aulast%3DAzzoli%26aufirst%3DC.%2BG.%26aulast%3DKrug%26aufirst%3DL.%2BM.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DGinsberg%26aufirst%3DM.%2BS.%26atitle%3DA%2520phase%2520II%2520trial%2520of%2520salirasib%2520in%2520patients%2520with%2520lung%2520adenocarcinomas%2520with%2520KRAS%2520mutations%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2011%26volume%3D6%26spage%3D1435%26epage%3D1437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group">Mason, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belanger, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholas, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vallières, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kavan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desjardins, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omuro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reymond, D.</span><span> </span><span class="NLM_article-title">A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression</span> <span class="citation_source-journal">J. Neuro-Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">343</span><span class="NLM_x">–</span> <span class="NLM_lpage">349</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1007%2Fs11060-011-0747-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=22048878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A280%3ADC%252BC383ovFWrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2012&pages=343-349&author=W.+P.+Masonauthor=K.+Belangerauthor=G.+Nicholasauthor=I.+Valli%C3%A8resauthor=D.+Mathieuauthor=P.+Kavanauthor=A.+Desjardinsauthor=A.+Omuroauthor=D.+Reymond&title=A+phase+II+study+of+the+Ras-MAPK+signaling+pathway+inhibitor+TLN-4601+in+patients+with+glioblastoma+at+first+progression"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression</span></div><div class="casAuthors">Mason Warren P; Belanger Karl; Nicholas Garth; Vallieres Isabelle; Mathieu David; Kavan Petr; Desjardins Annick; Omuro Antonio; Reymond Didier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuro-oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">343-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This phase II trial was undertaken to evaluate the efficacy of TLN-4601 in patients with glioblastoma (GBM) at first progression.  TLN-4601 inhibits the Ras-MAPK signaling pathway, and in animal models crosses the blood-brain barrier and accumulates in implanted gliomas, possibly by binding specifically to the peripheral benzodiazepine receptor.  A maximum of 40 patients with recurrent GBM were to be enrolled in this study.  TLN-4601 was administered at a dose of 480 mg/m(2)/day by continuous intravenous (CIV) administration.  Each 21-day cycle consisted of a 14-day CIV administration and a 7-day recovery period.  Samples were obtained from all patients for pharmacokinetic evaluations (PK) and for Raf-1 and pERK biomarker assessment using immunohistochemistry and flow cytometry.  Following enrollment of 20 patients, this study was terminated due to a lack of efficacy.  Of 17 evaluable patients, 14 had MR scans performed after two cycles of TLN-4601.  Of these 14 patients, three had stable disease and 11 had disease progression.  Only three patients had MR scans performed after four cycles and all had evidence of radiographic progression.  Serum PKs confirmed that patients were exposed to TLN-4601 at targeted drug levels.  TLN-4601 was generally well tolerated although two patients discontinued treatment due to adverse events.  Biomarker analysis did not show consistent changes.  TLN-4601 infused via CIV at 480 mg/m(2)/day for 14 of 21 days is well tolerated by patients with progressive GBM.  However, this agent is ineffective in progressive GBM when administered as monotherapy in this schedule.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTKYvqBNi0lOukdrW1FkXG-fW6udTcc2ebLhRWEn4KUwLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383ovFWrsg%253D%253D&md5=8ab317d5679cde6b9ae1e4b10e79ef1b</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1007%2Fs11060-011-0747-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11060-011-0747-6%26sid%3Dliteratum%253Aachs%26aulast%3DMason%26aufirst%3DW.%2BP.%26aulast%3DBelanger%26aufirst%3DK.%26aulast%3DNicholas%26aufirst%3DG.%26aulast%3DValli%25C3%25A8res%26aufirst%3DI.%26aulast%3DMathieu%26aufirst%3DD.%26aulast%3DKavan%26aufirst%3DP.%26aulast%3DDesjardins%26aufirst%3DA.%26aulast%3DOmuro%26aufirst%3DA.%26aulast%3DReymond%26aufirst%3DD.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520the%2520Ras-MAPK%2520signaling%2520pathway%2520inhibitor%2520TLN-4601%2520in%2520patients%2520with%2520glioblastoma%2520at%2520first%2520progression%26jtitle%3DJ.%2520Neuro-Oncol.%26date%3D2012%26volume%3D107%26spage%3D343%26epage%3D349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heelan, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H. E.</span><span> </span><span class="NLM_article-title">KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e17</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e17&author=W.+Paoauthor=T.+Y.+Wangauthor=G.+J.+Rielyauthor=V.+A.+Millerauthor=Q.+Panauthor=M.+Ladanyiauthor=M.+F.+Zakowskiauthor=R.+T.+Heelanauthor=M.+G.+Krisauthor=H.+E.+Varmus&title=KRAS+mutations+and+primary+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DT.%2BY.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPan%26aufirst%3DQ.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DHeelan%26aufirst%3DR.%2BT.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%2BE.%26atitle%3DKRAS%2520mutations%2520and%2520primary%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3De17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emanuele, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creighton, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlabach, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westbrook, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elledge, S. J.</span><span> </span><span class="NLM_article-title">A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">137</span><span class="NLM_x">, </span> <span class="NLM_fpage">835</span><span class="NLM_x">–</span> <span class="NLM_lpage">848</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1016%2Fj.cell.2009.05.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=19490893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVCltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2009&pages=835-848&author=J.+Luoauthor=M.+J.+Emanueleauthor=D.+Liauthor=C.+J.+Creightonauthor=M.+R.+Schlabachauthor=T.+F.+Westbrookauthor=K.+K.+Wongauthor=S.+J.+Elledge&title=A+genome-wide+RNAi+screen+identifies+multiple+synthetic+lethal+interactions+with+the+Ras+oncogene"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene</span></div><div class="casAuthors">Luo, Ji; Emanuele, Michael J.; Li, Danan; Creighton, Chad J.; Schlabach, Michael R.; Westbrook, Thomas F.; Wong, Kwok-Kin; Elledge, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">835-848</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Oncogenic mutations in the small GTPase Ras are highly prevalent in cancer, but an understanding of the vulnerabilities of these cancers is lacking.  We undertook a genome-wide RNAi screen to identify synthetic lethal interactions with the KRAS oncogene.  We discovered a diverse set of proteins whose depletion selectively impaired the viability of Ras mutant cells.  Among these we obsd. a strong enrichment for genes with mitotic functions.  We describe a pathway involving the mitotic kinase PLK1, the anaphase-promoting complex/cyclosome, and the proteasome that, when inhibited, results in prometaphase accumulation and the subsequent death of Ras mutant cells.  Gene expression anal. indicates that reduced expression of genes in this pathway correlates with increased survival of patients bearing tumors with a Ras transcriptional signature.  Our results suggest a previously underappreciated role for Ras in mitotic progression and demonstrate a pharmacol. tractable pathway for the potential treatment of cancers harboring Ras mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmWFKW3XYaabVg90H21EOLACvtfcHk0liRRcnKx0JVhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVCltb4%253D&md5=f06fd1f1c469495489ad2ac7f0cab090</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DEmanuele%26aufirst%3DM.%2BJ.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCreighton%26aufirst%3DC.%2BJ.%26aulast%3DSchlabach%26aufirst%3DM.%2BR.%26aulast%3DWestbrook%26aufirst%3DT.%2BF.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DElledge%26aufirst%3DS.%2BJ.%26atitle%3DA%2520genome-wide%2520RNAi%2520screen%2520identifies%2520multiple%2520synthetic%2520lethal%2520interactions%2520with%2520the%2520Ras%2520oncogene%26jtitle%3DCell%26date%3D2009%26volume%3D137%26spage%3D835%26epage%3D848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group">Barr, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silljé, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nigg, E. A.</span><span> </span><span class="NLM_article-title">Polo-like kinases and the orchestration of cell division</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">440</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1038%2Fnrm1401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=15173822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVarsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=429-440&author=F.+A.+Barrauthor=H.+H.+Sillj%C3%A9author=E.+A.+Nigg&title=Polo-like+kinases+and+the+orchestration+of+cell+division"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Polo-like kinases and the orchestration of cell division</span></div><div class="casAuthors">Barr, Francis A.; Sillje, Herman H. W.; Nigg, Erich A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">429-441</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Polo-like kinases (Plks) are increasingly recognized as key regulators of mitosis, meiosis and cytokinesis.  In agreement with a broad range of proposed functions during cell division, Plks are subject to complex temporal and spatial control.  Recent findings are uncovering the mechanisms of Plk regulation, notably their targeting to different cellular structures through interactions with phosphorylated docking proteins.  Moreover, information is emerging on the substrate specificity of Plks and the role of individual substrates in M-phase progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLN4E8Z5Hjq7Vg90H21EOLACvtfcHk0liRRcnKx0JVhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVarsLk%253D&md5=8c11ac86d8b157dfa74ab95841e9eba0</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1038%2Fnrm1401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm1401%26sid%3Dliteratum%253Aachs%26aulast%3DBarr%26aufirst%3DF.%2BA.%26aulast%3DSillj%25C3%25A9%26aufirst%3DH.%2BH.%26aulast%3DNigg%26aufirst%3DE.%2BA.%26atitle%3DPolo-like%2520kinases%2520and%2520the%2520orchestration%2520of%2520cell%2520division%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2004%26volume%3D5%26spage%3D429%26epage%3D440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group">Strebhardt, K.</span><span> </span><span class="NLM_article-title">Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">643</span><span class="NLM_x">–</span> <span class="NLM_lpage">660</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1038%2Fnrd3184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=20671765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCktrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=643-660&author=K.+Strebhardt&title=Multifaceted+polo-like+kinases%3A+drug+targets+and+antitargets+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy</span></div><div class="casAuthors">Strebhardt, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">643-660</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The polo-like kinase 1 (PLK1) acts in concert with cyclin-dependent kinase 1-cyclin B1 and Aurora kinases to orchestrate a wide range of crit. cell cycle events.  Because PLK1 has been preclinically validated as a cancer target, small-mol. inhibitors of PLK1 have become attractive candidates for anticancer drug development.  Although the roles of the closely related PLK2, PLK3 and PLK4 in cancer are less well understood, there is evidence showing that PLK2 and PLK3 act as tumor suppressors through their functions in the p53 signalling network, which guards the cell against various stress signals.  In this article, recent insights into the biol. of PLKs will be reviewed, with an emphasis on their role in malignant transformation, and progress in the development of small-mol. PLK1 inhibitors will be examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaWCrqfphwErVg90H21EOLACvtfcHk0lhtmTeziY5WTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCktrw%253D&md5=62ab87ce3392ce187d7d62ac5f7c2679</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1038%2Fnrd3184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3184%26sid%3Dliteratum%253Aachs%26aulast%3DStrebhardt%26aufirst%3DK.%26atitle%3DMultifaceted%2520polo-like%2520kinases%253A%2520drug%2520targets%2520and%2520antitargets%2520for%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D643%26epage%3D660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group">Kumar, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molina-Arcas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steckel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">East, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diefenbacher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armenteros-Monterroso, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lassailly, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nye, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamp, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behrens, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downward, J.</span><span> </span><span class="NLM_article-title">The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">149</span><span class="NLM_x">, </span> <span class="NLM_fpage">642</span><span class="NLM_x">–</span> <span class="NLM_lpage">655</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2012&pages=642-655&author=M.+S.+Kumarauthor=D.+C.+Hancockauthor=M.+Molina-Arcasauthor=M.+Steckelauthor=P.+Eastauthor=M.+Diefenbacherauthor=E.+Armenteros-Monterrosoauthor=F.+Lassaillyauthor=N.+Matthewsauthor=E.+Nyeauthor=G.+Stampauthor=A.+Behrensauthor=J.+Downward&title=The+GATA2+transcriptional+network+is+requisite+for+RAS+oncogene-driven+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DM.%2BS.%26aulast%3DHancock%26aufirst%3DD.%2BC.%26aulast%3DMolina-Arcas%26aufirst%3DM.%26aulast%3DSteckel%26aufirst%3DM.%26aulast%3DEast%26aufirst%3DP.%26aulast%3DDiefenbacher%26aufirst%3DM.%26aulast%3DArmenteros-Monterroso%26aufirst%3DE.%26aulast%3DLassailly%26aufirst%3DF.%26aulast%3DMatthews%26aufirst%3DN.%26aulast%3DNye%26aufirst%3DE.%26aulast%3DStamp%26aufirst%3DG.%26aulast%3DBehrens%26aufirst%3DA.%26aulast%3DDownward%26aufirst%3DJ.%26atitle%3DThe%2520GATA2%2520transcriptional%2520network%2520is%2520requisite%2520for%2520RAS%2520oncogene-driven%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DCell%26date%3D2012%26volume%3D149%26spage%3D642%26epage%3D655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group">Puyol, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martín, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubus, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulero, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pizcueta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerra, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santamaría, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacid, M.</span><span> </span><span class="NLM_article-title">A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">63</span><span class="NLM_x">–</span> <span class="NLM_lpage">73</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=63-73&author=M.+Puyolauthor=A.+Mart%C3%ADnauthor=P.+Dubusauthor=F.+Muleroauthor=P.+Pizcuetaauthor=G.+Khanauthor=C.+Guerraauthor=D.+Santamar%C3%ADaauthor=M.+Barbacid&title=A+synthetic+lethal+interaction+between+K-Ras+oncogenes+and+Cdk4+unveils+a+therapeutic+strategy+for+non-small+cell+lung+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPuyol%26aufirst%3DM.%26aulast%3DMart%25C3%25ADn%26aufirst%3DA.%26aulast%3DDubus%26aufirst%3DP.%26aulast%3DMulero%26aufirst%3DF.%26aulast%3DPizcueta%26aufirst%3DP.%26aulast%3DKhan%26aufirst%3DG.%26aulast%3DGuerra%26aufirst%3DC.%26aulast%3DSantamar%25C3%25ADa%26aufirst%3DD.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DA%2520synthetic%2520lethal%2520interaction%2520between%2520K-Ras%2520oncogenes%2520and%2520Cdk4%2520unveils%2520a%2520therapeutic%2520strategy%2520for%2520non-small%2520cell%2520lung%2520carcinoma%26jtitle%3DCancer%2520Cell%26date%3D2010%26volume%3D18%26spage%3D63%26epage%3D73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Targeting the cancer kinome through polypharmacology</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1038%2Fnrc2787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=20094047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=130-137&author=Z.+A.+Knightauthor=H.+Linauthor=K.+M.+Shokat&title=Targeting+the+cancer+kinome+through+polypharmacology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cancer kinome through polypharmacology</span></div><div class="casAuthors">Knight, Zachary A.; Lin, Henry; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-137</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Kinase inhibitors are the largest class of new cancer drugs.  However, it is already apparent that most tumors can escape from the inhibition of any single kinase.  If it is necessary to inhibit multiple kinases, how do we choose which ones.  In this Opinion article, we discuss some of the strategies that are currently being used to identify new therapeutic combinations of kinase targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkDv2FeeH58rVg90H21EOLACvtfcHk0lhtmTeziY5WTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D&md5=9aaa314e54b43889e147a9f11ac77072</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1038%2Fnrc2787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2787%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DTargeting%2520the%2520cancer%2520kinome%2520through%2520polypharmacology%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D130%26epage%3D137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 76 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Zihui Liang, Qian Zhang, Yixin Nie, Xin Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Qiang Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Polarized-Electrochemiluminescence Biosensor Based on Surface Plasmon Coupling Strategy and Fluorine-Doped BN Quantum Dots. </span><span class="cited-content_cbyCitation_journal-name">Analytical Chemistry</span><span> <strong>2020,</strong> <em>92 </em>
                                    (13)
                                     , 9223-9229. <a href="https://doi.org/10.1021/acs.analchem.0c01558" title="DOI URL">https://doi.org/10.1021/acs.analchem.0c01558</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.analchem.0c01558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.analchem.0c01558%26sid%3Dliteratum%253Aachs%26jtitle%3DAnalytical%2520Chemistry%26atitle%3DPolarized-Electrochemiluminescence%252BBiosensor%252BBased%252Bon%252BSurface%252BPlasmon%252BCoupling%252BStrategy%252Band%252BFluorine-Doped%252BBN%252BQuantum%252BDots%26aulast%3DLiang%26aufirst%3DZihui%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D11042020%26date%3D15062020%26date%3D25062020%26date%3D15062020%26volume%3D92%26issue%3D13%26spage%3D9223%26epage%3D9229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Nagore
I. Marín-Ramos, Moisés Balabasquer, Francisco J. Ortega-Nogales, Iván R. Torrecillas, Ana Gil-Ordóñez, Beatriz Marcos-Ramiro, Pedro Aguilar-Garrido, Ian Cushman, Antonio Romero, Francisco J. Medrano, Consuelo Gajate, Faustino Mollinedo, Mark R. Philips, Mercedes Campillo, Miguel Gallardo, Mar Martín-Fontecha, María L. López-Rodríguez, <span class="NLM_string-name hlFld-ContribAuthor">Silvia Ortega-Gutiérrez</span>. </span><span class="cited-content_cbyCitation_article-title">A Potent Isoprenylcysteine Carboxylmethyltransferase (ICMT) Inhibitor Improves Survival in Ras-Driven Acute Myeloid Leukemia. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (13)
                                     , 6035-6046. <a href="https://doi.org/10.1021/acs.jmedchem.9b00145" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00145</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00145%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252BPotent%252BIsoprenylcysteine%252BCarboxylmethyltransferase%252B%252528ICMT%252529%252BInhibitor%252BImproves%252BSurvival%252Bin%252BRas-Driven%252BAcute%252BMyeloid%252BLeukemia%26aulast%3DMar%25C3%25ADn-Ramos%26aufirst%3DNagore%2BI.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D24012019%26date%3D19062019%26date%3D10062019%26volume%3D62%26issue%3D13%26spage%3D6035%26epage%3D6046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Seung
Min Kim, Sang Chul Shin, Eunice EunKyeong Kim, Sang-Heon Kim, Kwideok Park, Seung Ja Oh, <span class="NLM_string-name hlFld-ContribAuthor">Mihue Jang</span>. </span><span class="cited-content_cbyCitation_article-title">Simple in Vivo Gene Editing via Direct Self-Assembly of Cas9 Ribonucleoprotein Complexes for Cancer Treatment. </span><span class="cited-content_cbyCitation_journal-name">ACS Nano</span><span> <strong>2018,</strong> <em>12 </em>
                                    (8)
                                     , 7750-7760. <a href="https://doi.org/10.1021/acsnano.8b01670" title="DOI URL">https://doi.org/10.1021/acsnano.8b01670</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsnano.8b01670&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsnano.8b01670%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Nano%26atitle%3DSimple%252Bin%252BVivo%252BGene%252BEditing%252Bvia%252BDirect%252BSelf-Assembly%252Bof%252BCas9%252BRibonucleoprotein%252BComplexes%252Bfor%252BCancer%252BTreatment%26aulast%3DKim%26aufirst%3DSeung%2BMin%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D05032018%26date%3D20072018%26date%3D26072018%26date%3D20072018%26volume%3D12%26issue%3D8%26spage%3D7750%26epage%3D7760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Satoshi  Sogabe</span>, <span class="hlFld-ContribAuthor ">Yusuke  Kamada</span>, <span class="hlFld-ContribAuthor ">Masanori  Miwa</span>, <span class="hlFld-ContribAuthor ">Ayumu  Niida</span>, <span class="hlFld-ContribAuthor ">Tomoya  Sameshima</span>, <span class="hlFld-ContribAuthor ">Masahiro  Kamaura</span>, <span class="hlFld-ContribAuthor ">Kazuko  Yonemori</span>, <span class="hlFld-ContribAuthor ">Shigekazu  Sasaki</span>, <span class="hlFld-ContribAuthor ">Jun-ichi  Sakamoto</span>, and <span class="hlFld-ContribAuthor ">Kotaro  Sakamoto</span>  . </span><span class="cited-content_cbyCitation_article-title">Crystal Structure of a Human K-Ras G12D Mutant in Complex with GDP and the Cyclic Inhibitory Peptide KRpep-2d. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>8 </em>
                                    (7)
                                     , 732-736. <a href="https://doi.org/10.1021/acsmedchemlett.7b00128" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.7b00128</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.7b00128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.7b00128%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DCrystal%252BStructure%252Bof%252Ba%252BHuman%252BK-Ras%252BG12D%252BMutant%252Bin%252BComplex%252Bwith%252BGDP%252Band%252Bthe%252BCyclic%252BInhibitory%252BPeptide%252BKRpep-2d%26aulast%3DSogabe%26aufirst%3DSatoshi%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D23032017%26date%3D10052017%26date%3D15052017%26date%3D13072017%26date%3D10052017%26volume%3D8%26issue%3D7%26spage%3D732%26epage%3D736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christine E.  Kaiser</span>, <span class="hlFld-ContribAuthor ">Natalie A.  Van Ert</span>, <span class="hlFld-ContribAuthor ">Prashansa  Agrawal</span>, <span class="hlFld-ContribAuthor ">Reena  Chawla</span>, <span class="hlFld-ContribAuthor ">Danzhou  Yang</span>, and <span class="hlFld-ContribAuthor ">Laurence H.  Hurley</span>  . </span><span class="cited-content_cbyCitation_article-title">Insight into the Complexity of the i-Motif and G-Quadruplex DNA Structures Formed in the KRAS Promoter and Subsequent Drug-Induced Gene Repression. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2017,</strong> <em>139 </em>
                                    (25)
                                     , 8522-8536. <a href="https://doi.org/10.1021/jacs.7b02046" title="DOI URL">https://doi.org/10.1021/jacs.7b02046</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.7b02046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.7b02046%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DInsight%252Binto%252Bthe%252BComplexity%252Bof%252Bthe%252Bi-Motif%252Band%252BG-Quadruplex%252BDNA%252BStructures%252BFormed%252Bin%252Bthe%252BKRAS%252BPromoter%252Band%252BSubsequent%252BDrug-Induced%252BGene%252BRepression%26aulast%3DKaiser%26aufirst%3DChristine%2BE.%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D28022017%26date%3D15062017%26date%3D28062017%26date%3D01062017%26volume%3D139%26issue%3D25%26spage%3D8522%26epage%3D8536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adam M.  Levinson</span>, <span class="hlFld-ContribAuthor ">John H.  McGee</span>, <span class="hlFld-ContribAuthor ">Andrew G.  Roberts</span>, <span class="hlFld-ContribAuthor ">Gardner S.  Creech</span>, <span class="hlFld-ContribAuthor ">Ting  Wang</span>, <span class="hlFld-ContribAuthor ">Michael T.  Peterson</span>, <span class="hlFld-ContribAuthor ">Ronald C.  Hendrickson</span>, <span class="hlFld-ContribAuthor ">Gregory L.  Verdine</span>, and <span class="hlFld-ContribAuthor ">Samuel J.  Danishefsky</span>  . </span><span class="cited-content_cbyCitation_article-title">Total Chemical Synthesis and Folding of All-l and All-d Variants of Oncogenic KRas(G12V). </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2017,</strong> <em>139 </em>
                                    (22)
                                     , 7632-7639. <a href="https://doi.org/10.1021/jacs.7b02988" title="DOI URL">https://doi.org/10.1021/jacs.7b02988</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.7b02988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.7b02988%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DTotal%252BChemical%252BSynthesis%252Band%252BFolding%252Bof%252BAll-l%252Band%252BAll-d%252BVariants%252Bof%252BOncogenic%252BKRas%252528G12V%252529%26aulast%3DLevinson%26aufirst%3DAdam%2BM.%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D25032017%26date%3D22052017%26date%3D07062017%26date%3D27042017%26volume%3D139%26issue%3D22%26spage%3D7632%26epage%3D7639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shaoyong  Lu</span>, <span class="hlFld-ContribAuthor ">Hyunbum  Jang</span>, <span class="hlFld-ContribAuthor ">Serena  Muratcioglu</span>, <span class="hlFld-ContribAuthor ">Attila  Gursoy</span>, <span class="hlFld-ContribAuthor ">Ozlem  Keskin</span>, <span class="hlFld-ContribAuthor ">Ruth  Nussinov</span>, and <span class="hlFld-ContribAuthor ">Jian  Zhang</span>  . </span><span class="cited-content_cbyCitation_article-title">Ras Conformational Ensembles, Allostery, and Signaling. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2016,</strong> <em>116 </em>
                                    (11)
                                     , 6607-6665. <a href="https://doi.org/10.1021/acs.chemrev.5b00542" title="DOI URL">https://doi.org/10.1021/acs.chemrev.5b00542</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.5b00542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.5b00542%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DRas%252BConformational%252BEnsembles%25252C%252BAllostery%25252C%252Band%252BSignaling%26aulast%3DLu%26aufirst%3DShaoyong%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D15092015%26date%3D27012016%26date%3D08062016%26volume%3D116%26issue%3D11%26spage%3D6607%26epage%3D6665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dima  Kozakov</span>, <span class="hlFld-ContribAuthor ">David R.  Hall</span>, <span class="hlFld-ContribAuthor ">Raeanne L.  Napoleon</span>, <span class="hlFld-ContribAuthor ">Christine  Yueh</span>, <span class="hlFld-ContribAuthor ">Adrian  Whitty</span>, and <span class="hlFld-ContribAuthor ">Sandor  Vajda</span>  . </span><span class="cited-content_cbyCitation_article-title">New Frontiers in Druggability. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (23)
                                     , 9063-9088. <a href="https://doi.org/10.1021/acs.jmedchem.5b00586" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00586</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00586&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00586%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNew%252BFrontiers%252Bin%252BDruggability%26aulast%3DKozakov%26aufirst%3DDima%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D15042015%26date%3D11082015%26date%3D10122015%26date%3D31072015%26volume%3D58%26issue%3D23%26spage%3D9063%26epage%3D9088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alfonso  Martín-Bernabé</span>, <span class="hlFld-ContribAuthor ">Roldán  Cortés</span>, <span class="hlFld-ContribAuthor ">Sylvia G.  Lehmann</span>, <span class="hlFld-ContribAuthor ">Michel  Seve</span>, <span class="hlFld-ContribAuthor ">Marta  Cascante</span>, and <span class="hlFld-ContribAuthor ">Sandrine  Bourgoin-Voillard</span>  . </span><span class="cited-content_cbyCitation_article-title">Quantitative Proteomic Approach to Understand Metabolic Adaptation in Non-Small Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Proteome Research</span><span> <strong>2014,</strong> <em>13 </em>
                                    (11)
                                     , 4695-4704. <a href="https://doi.org/10.1021/pr500327v" title="DOI URL">https://doi.org/10.1021/pr500327v</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/pr500327v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fpr500327v%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Proteome%2520Research%26atitle%3DQuantitative%252BProteomic%252BApproach%252Bto%252BUnderstand%252BMetabolic%252BAdaptation%252Bin%252BNon-Small%252BCell%252BLung%252BCancer%26aulast%3DMart%25C3%25ADn-Bernab%25C3%25A9%26aufirst%3DAlfonso%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D31032014%26date%3D25082014%26date%3D07112014%26date%3D16072014%26volume%3D13%26issue%3D11%26spage%3D4695%26epage%3D4704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David H.  Peng</span>, <span class="hlFld-ContribAuthor ">B. Leticia  Rodriguez</span>, <span class="hlFld-ContribAuthor ">Lixia  Diao</span>, <span class="hlFld-ContribAuthor ">Pierre-Olivier  Gaudreau</span>, <span class="hlFld-ContribAuthor ">Aparna  Padhye</span>, <span class="hlFld-ContribAuthor ">Jessica M.  Konen</span>, <span class="hlFld-ContribAuthor ">Joshua K.  Ochieng</span>, <span class="hlFld-ContribAuthor ">Caleb A.  Class</span>, <span class="hlFld-ContribAuthor ">Jared J.  Fradette</span>, <span class="hlFld-ContribAuthor ">Laura  Gibson</span>, <span class="hlFld-ContribAuthor ">Limo  Chen</span>, <span class="hlFld-ContribAuthor ">Jing  Wang</span>, <span class="hlFld-ContribAuthor ">Lauren A.  Byers</span>, <span class="hlFld-ContribAuthor ">Don. L.  Gibbons</span>. </span><span class="cited-content_cbyCitation_article-title">Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers. </span><span class="cited-content_cbyCitation_journal-name">Nature Communications</span><span> <strong>2021,</strong> <em>12 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41467-021-22875-w" title="DOI URL">https://doi.org/10.1038/s41467-021-22875-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41467-021-22875-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41467-021-22875-w%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Communications%26atitle%3DTh17%252Bcells%252Bcontribute%252Bto%252Bcombination%252BMEK%252Binhibitor%252Band%252Banti-PD-L1%252Btherapy%252Bresistance%252Bin%252BKRAS%25252Fp53%252Bmutant%252Blung%252Bcancers%26aulast%3DPeng%26aufirst%3DDavid%2BH.%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pingyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Dharini  van der Hoeven</span>, <span class="hlFld-ContribAuthor ">Na  Ye</span>, <span class="hlFld-ContribAuthor ">Haiying  Chen</span>, <span class="hlFld-ContribAuthor ">Zhiqing  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaoping  Ma</span>, <span class="hlFld-ContribAuthor ">Dina  Montufar-Solis</span>, <span class="hlFld-ContribAuthor ">Kristen M.  Rehl</span>, <span class="hlFld-ContribAuthor ">Kwang-Jin  Cho</span>, <span class="hlFld-ContribAuthor ">Sabita  Thapa</span>, <span class="hlFld-ContribAuthor ">Wei  Chen</span>, <span class="hlFld-ContribAuthor ">Ransome  van der Hoeven</span>, <span class="hlFld-ContribAuthor ">Jeffrey A.  Frost</span>, <span class="hlFld-ContribAuthor ">John F.  Hancock</span>, <span class="hlFld-ContribAuthor ">Jia  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Scaffold repurposing of fendiline: Identification of potent KRAS plasma membrane localization inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>217 </em>, 113381. <a href="https://doi.org/10.1016/j.ejmech.2021.113381" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113381</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113381%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DScaffold%252Brepurposing%252Bof%252Bfendiline%25253A%252BIdentification%252Bof%252Bpotent%252BKRAS%252Bplasma%252Bmembrane%252Blocalization%252Binhibitors%26aulast%3DWang%26aufirst%3DPingyuan%26date%3D2021%26volume%3D217%26spage%3D113381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ling  Li</span>, <span class="hlFld-ContribAuthor ">Huiting  Zhao</span>, <span class="hlFld-ContribAuthor ">Hui  Liao</span>, <span class="hlFld-ContribAuthor ">Jingxuan  Chen</span>, <span class="hlFld-ContribAuthor ">Jin  Liu</span>, <span class="hlFld-ContribAuthor ">Jianjun  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel quinazoline-based covalent inhibitors of KRAS G12C with various cysteine-targeting warheads as potential anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>110 </em>, 104825. <a href="https://doi.org/10.1016/j.bioorg.2021.104825" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104825</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104825%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Bquinazoline-based%252Bcovalent%252Binhibitors%252Bof%252BKRAS%252BG12C%252Bwith%252Bvarious%252Bcysteine-targeting%252Bwarheads%252Bas%252Bpotential%252Banticancer%252Bagents%26aulast%3DLi%26aufirst%3DLing%26date%3D2021%26volume%3D110%26spage%3D104825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ruth  Nussinov</span>, <span class="hlFld-ContribAuthor ">Hyunbum  Jang</span>, <span class="hlFld-ContribAuthor ">Attila  Gursoy</span>, <span class="hlFld-ContribAuthor ">Ozlem  Keskin</span>, <span class="hlFld-ContribAuthor ">Vadim  Gaponenko</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of Nonfunctional Ras. </span><span class="cited-content_cbyCitation_journal-name">Cell Chemical Biology</span><span> <strong>2021,</strong> <em>28 </em>
                                    (2)
                                     , 121-133. <a href="https://doi.org/10.1016/j.chembiol.2020.12.012" title="DOI URL">https://doi.org/10.1016/j.chembiol.2020.12.012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2020.12.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2020.12.012%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Chemical%2520Biology%26atitle%3DInhibition%252Bof%252BNonfunctional%252BRas%26aulast%3DNussinov%26aufirst%3DRuth%26date%3D2021%26volume%3D28%26issue%3D2%26spage%3D121%26epage%3D133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Biyu  Zhang</span>, <span class="hlFld-ContribAuthor ">Lei  Yang</span>, <span class="hlFld-ContribAuthor ">Xin  Wang</span>, <span class="hlFld-ContribAuthor ">Denggang  Fu</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of a survival-related signature for sarcoma patients through integrated transcriptomic and proteomic profiling analyses. </span><span class="cited-content_cbyCitation_journal-name">Gene</span><span> <strong>2021,</strong> <em>764 </em>, 145105. <a href="https://doi.org/10.1016/j.gene.2020.145105" title="DOI URL">https://doi.org/10.1016/j.gene.2020.145105</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.gene.2020.145105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.gene.2020.145105%26sid%3Dliteratum%253Aachs%26jtitle%3DGene%26atitle%3DIdentification%252Bof%252Ba%252Bsurvival-related%252Bsignature%252Bfor%252Bsarcoma%252Bpatients%252Bthrough%252Bintegrated%252Btranscriptomic%252Band%252Bproteomic%252Bprofiling%252Banalyses%26aulast%3DZhang%26aufirst%3DBiyu%26date%3D2021%26volume%3D764%26spage%3D145105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yali  Hu</span>, <span class="hlFld-ContribAuthor ">Kunpeng  Zhang</span>, <span class="hlFld-ContribAuthor ">Xingyao  Zhu</span>, <span class="hlFld-ContribAuthor ">Xiuyan  Zheng</span>, <span class="hlFld-ContribAuthor ">Chao  Wang</span>, <span class="hlFld-ContribAuthor ">Xiao  Niu</span>, <span class="hlFld-ContribAuthor ">Teng  Jiang</span>, <span class="hlFld-ContribAuthor ">Xinhua  Ji</span>, <span class="hlFld-ContribAuthor ">Weilin  Zhao</span>, <span class="hlFld-ContribAuthor ">Lijuan  Pang</span>, <span class="hlFld-ContribAuthor ">Yan  Qi</span>, <span class="hlFld-ContribAuthor ">Feng  Li</span>, <span class="hlFld-ContribAuthor ">Li  Li</span>, <span class="hlFld-ContribAuthor ">Zhiping  Xu</span>, <span class="hlFld-ContribAuthor ">Wenyi  Gu</span>, <span class="hlFld-ContribAuthor ">Hong  Zou</span>. </span><span class="cited-content_cbyCitation_article-title">Synergistic Inhibition of Drug-Resistant Colon Cancer Growth with PI3K/mTOR Dual Inhibitor BEZ235 and Nano-Emulsioned Paclitaxel via Reducing Multidrug Resistance and Promoting Apoptosis. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Nanomedicine</span><span> <strong>2021,</strong> <em>Volume 16 </em>, 2173-2186. <a href="https://doi.org/10.2147/IJN.S290731" title="DOI URL">https://doi.org/10.2147/IJN.S290731</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2147/IJN.S290731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2147%2FIJN.S290731%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Nanomedicine%26atitle%3DSynergistic%252BInhibition%252Bof%252BDrug-Resistant%252BColon%252BCancer%252BGrowth%252Bwith%252BPI3K%25252FmTOR%252BDual%252BInhibitor%252BBEZ235%252Band%252BNano-Emulsioned%252BPaclitaxel%252Bvia%252BReducing%252BMultidrug%252BResistance%252Band%252BPromoting%252BApoptosis%26aulast%3DHu%26aufirst%3DYali%26date%3D2021%26date%3D2021%26volume%3DVolume%252016%26spage%3D2173%26epage%3D2186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Geeta Sai  Mani</span>, <span class="hlFld-ContribAuthor ">Pratibha  Anchi</span>, <span class="hlFld-ContribAuthor ">Satish  Sunkari</span>, <span class="hlFld-ContribAuthor ">Kavitha  Donthiboina</span>, <span class="hlFld-ContribAuthor ">Chandraiah  Godugu</span>, <span class="hlFld-ContribAuthor ">Nagula  Shankaraiah</span>, <span class="hlFld-ContribAuthor ">Ahmed  Kamal</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of (Z)-3-(arylamino)-1-(3-phenylimidazo[1,5-a]pyridin-1-yl)prop-2-en-1-ones as potential cytotoxic agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (18)
                                     , 127432. <a href="https://doi.org/10.1016/j.bmcl.2020.127432" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127432</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127432%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Bof%252B%252528Z%252529-3-%252528arylamino%252529-1-%2525283-phenylimidazo%25255B1%25252C5-a%25255Dpyridin-1-yl%252529prop-2-en-1-ones%252Bas%252Bpotential%252Bcytotoxic%252Bagents%26aulast%3DMani%26aufirst%3DGeeta%2BSai%26date%3D2020%26volume%3D30%26issue%3D18%26spage%3D127432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paola  Briseño-Díaz</span>, <span class="hlFld-ContribAuthor ">Dora  Emma Velez-Uriza</span>, <span class="hlFld-ContribAuthor ">Pedro  Cruz-Nova</span>, <span class="hlFld-ContribAuthor ">Martiniano  Bello Ramirez</span>, <span class="hlFld-ContribAuthor ">Jose  Correa-Basurto</span>, <span class="hlFld-ContribAuthor ">Rosaura  Hernandez-Rivas</span>, <span class="hlFld-ContribAuthor ">Ma  del Rocio Thompson Bonilla</span>, <span class="hlFld-ContribAuthor ">Miguel  Ángel Vargas Mejía</span>. </span><span class="cited-content_cbyCitation_article-title">KRas4BG12C/D/PDE6δ Heterodimeric Molecular Complex: A Target Molecular Multicomplex for the Identification and Evaluation of Nontoxic Pharmacological Compounds for the Treatment of Pancreatic Cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,<a href="https://doi.org/10.5772/intechopen.93402" title="DOI URL">https://doi.org/10.5772/intechopen.93402</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.5772/intechopen.93402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.5772%2Fintechopen.93402%26sid%3Dliteratum%253Aachs%26atitle%3DKRas4BG12C%25252FD%25252FPDE6%2525CE%2525B4%252BHeterodimeric%252BMolecular%252BComplex%25253A%252BA%252BTarget%252BMolecular%252BMulticomplex%252Bfor%252Bthe%252BIdentification%252Band%252BEvaluation%252Bof%252BNontoxic%252BPharmacological%252BCompounds%252Bfor%252Bthe%252BTreatment%252Bof%252BPancreatic%252BCancer%26aulast%3DBrise%25C3%25B1o-D%25C3%25ADaz%26aufirst%3DPaola%26date%3D2020%26date%3D2020%26pub%3DIntechOpen%26atitle%3DPancreatic%252BCancer%252B%25255BWorking%252BTitle%25255D%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kai  Chen</span>, <span class="hlFld-ContribAuthor ">Zhongjun  Shang</span>, <span class="hlFld-ContribAuthor ">Ai-lin  Dai</span>, <span class="hlFld-ContribAuthor ">Pei-ling  Dai</span>. </span><span class="cited-content_cbyCitation_article-title">Novel PI3K/Akt/mTOR pathway inhibitors plus radiotherapy: Strategy for non-small cell lung cancer with mutant RAS gene. </span><span class="cited-content_cbyCitation_journal-name">Life Sciences</span><span> <strong>2020,</strong> <em>255 </em>, 117816. <a href="https://doi.org/10.1016/j.lfs.2020.117816" title="DOI URL">https://doi.org/10.1016/j.lfs.2020.117816</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.lfs.2020.117816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.lfs.2020.117816%26sid%3Dliteratum%253Aachs%26jtitle%3DLife%2520Sciences%26atitle%3DNovel%252BPI3K%25252FAkt%25252FmTOR%252Bpathway%252Binhibitors%252Bplus%252Bradiotherapy%25253A%252BStrategy%252Bfor%252Bnon-small%252Bcell%252Blung%252Bcancer%252Bwith%252Bmutant%252BRAS%252Bgene%26aulast%3DChen%26aufirst%3DKai%26date%3D2020%26volume%3D255%26spage%3D117816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yusuke  Hirai</span>, <span class="hlFld-ContribAuthor ">Ryoko  Saeki</span>, <span class="hlFld-ContribAuthor ">Furan  Song</span>, <span class="hlFld-ContribAuthor ">Hiroyuki  Koide</span>, <span class="hlFld-ContribAuthor ">Naofumi  Fukata</span>, <span class="hlFld-ContribAuthor ">Koji  Tomita</span>, <span class="hlFld-ContribAuthor ">Noriyuki  Maeda</span>, <span class="hlFld-ContribAuthor ">Naoto  Oku</span>, <span class="hlFld-ContribAuthor ">Tomohiro  Asai</span>. </span><span class="cited-content_cbyCitation_article-title">Charge-reversible lipid derivative: A novel type of pH-responsive lipid for nanoparticle-mediated siRNA delivery. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Pharmaceutics</span><span> <strong>2020,</strong> <em>585 </em>, 119479. <a href="https://doi.org/10.1016/j.ijpharm.2020.119479" title="DOI URL">https://doi.org/10.1016/j.ijpharm.2020.119479</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijpharm.2020.119479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijpharm.2020.119479%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Pharmaceutics%26atitle%3DCharge-reversible%252Blipid%252Bderivative%25253A%252BA%252Bnovel%252Btype%252Bof%252BpH-responsive%252Blipid%252Bfor%252Bnanoparticle-mediated%252BsiRNA%252Bdelivery%26aulast%3DHirai%26aufirst%3DYusuke%26date%3D2020%26volume%3D585%26spage%3D119479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qingxia  Shu</span>, <span class="hlFld-ContribAuthor ">Fusheng  Liao</span>, <span class="hlFld-ContribAuthor ">Nian  Hong</span>, <span class="hlFld-ContribAuthor ">Lin  Cheng</span>, <span class="hlFld-ContribAuthor ">Yan  Lin</span>, <span class="hlFld-ContribAuthor ">Hanfeng  Cui</span>, <span class="hlFld-ContribAuthor ">Jia  Su</span>, <span class="hlFld-ContribAuthor ">Guangqiang  Ma</span>, <span class="hlFld-ContribAuthor ">Guobing  Wei</span>, <span class="hlFld-ContribAuthor ">Youquan  Zhong</span>, <span class="hlFld-ContribAuthor ">Jun  Xiong</span>, <span class="hlFld-ContribAuthor ">Hao  Fan</span>. </span><span class="cited-content_cbyCitation_article-title">A novel DNA sensor of homogeneous electrochemical signal amplification strategy. </span><span class="cited-content_cbyCitation_journal-name">Microchemical Journal</span><span> <strong>2020,</strong> <em>156 </em>, 104777. <a href="https://doi.org/10.1016/j.microc.2020.104777" title="DOI URL">https://doi.org/10.1016/j.microc.2020.104777</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.microc.2020.104777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.microc.2020.104777%26sid%3Dliteratum%253Aachs%26jtitle%3DMicrochemical%2520Journal%26atitle%3DA%252Bnovel%252BDNA%252Bsensor%252Bof%252Bhomogeneous%252Belectrochemical%252Bsignal%252Bamplification%252Bstrategy%26aulast%3DShu%26aufirst%3DQingxia%26date%3D2020%26volume%3D156%26spage%3D104777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arnold  Ou</span>, <span class="hlFld-ContribAuthor ">Jason W  Schmidberger</span>, <span class="hlFld-ContribAuthor ">Katie A  Wilson</span>, <span class="hlFld-ContribAuthor ">Cameron W  Evans</span>, <span class="hlFld-ContribAuthor ">Jessica A  Hargreaves</span>, <span class="hlFld-ContribAuthor ">Melanie  Grigg</span>, <span class="hlFld-ContribAuthor ">Megan L  O’Mara</span>, <span class="hlFld-ContribAuthor ">K Swaminathan  Iyer</span>, <span class="hlFld-ContribAuthor ">Charles S  Bond</span>, <span class="hlFld-ContribAuthor ">Nicole M  Smith</span>. </span><span class="cited-content_cbyCitation_article-title">High resolution crystal structure of a KRAS promoter G-quadruplex reveals a dimer with extensive poly-A π-stacking interactions for small-molecule recognition. </span><span class="cited-content_cbyCitation_journal-name">Nucleic Acids Research</span><span> <strong>2020,</strong> <em>48 </em>
                                    (10)
                                     , 5766-5776. <a href="https://doi.org/10.1093/nar/gkaa262" title="DOI URL">https://doi.org/10.1093/nar/gkaa262</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/nar/gkaa262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fnar%2Fgkaa262%26sid%3Dliteratum%253Aachs%26jtitle%3DNucleic%2520Acids%2520Research%26atitle%3DHigh%252Bresolution%252Bcrystal%252Bstructure%252Bof%252Ba%252BKRAS%252Bpromoter%252BG-quadruplex%252Breveals%252Ba%252Bdimer%252Bwith%252Bextensive%252Bpoly-A%252B%2525CF%252580-stacking%252Binteractions%252Bfor%252Bsmall-molecule%252Brecognition%26aulast%3DOu%26aufirst%3DArnold%26date%3D2020%26date%3D2020%26volume%3D48%26issue%3D10%26spage%3D5766%26epage%3D5776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tao  Wan</span>, <span class="hlFld-ContribAuthor ">Yuxuan  Chen</span>, <span class="hlFld-ContribAuthor ">Qi  Pan</span>, <span class="hlFld-ContribAuthor ">Xiaojie  Xu</span>, <span class="hlFld-ContribAuthor ">Yu  Kang</span>, <span class="hlFld-ContribAuthor ">Xue  Gao</span>, <span class="hlFld-ContribAuthor ">Feihe  Huang</span>, <span class="hlFld-ContribAuthor ">Chuanbin  Wu</span>, <span class="hlFld-ContribAuthor ">Yuan  Ping</span>. </span><span class="cited-content_cbyCitation_article-title">Genome editing of mutant KRAS through supramolecular polymer-mediated delivery of Cas9 ribonucleoprotein for colorectal cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Controlled Release</span><span> <strong>2020,</strong> <em>322 </em>, 236-247. <a href="https://doi.org/10.1016/j.jconrel.2020.03.015" title="DOI URL">https://doi.org/10.1016/j.jconrel.2020.03.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jconrel.2020.03.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jconrel.2020.03.015%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Controlled%2520Release%26atitle%3DGenome%252Bediting%252Bof%252Bmutant%252BKRAS%252Bthrough%252Bsupramolecular%252Bpolymer-mediated%252Bdelivery%252Bof%252BCas9%252Bribonucleoprotein%252Bfor%252Bcolorectal%252Bcancer%252Btherapy%26aulast%3DWan%26aufirst%3DTao%26date%3D2020%26volume%3D322%26spage%3D236%26epage%3D247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xinggang  Wu</span>, <span class="hlFld-ContribAuthor ">Mikyung  Park</span>, <span class="hlFld-ContribAuthor ">Dilara A.  Sarbassova</span>, <span class="hlFld-ContribAuthor ">Haoqiang  Ying</span>, <span class="hlFld-ContribAuthor ">Min Gyu  Lee</span>, <span class="hlFld-ContribAuthor ">Rajat  Bhattacharya</span>, <span class="hlFld-ContribAuthor ">Lee  Ellis</span>, <span class="hlFld-ContribAuthor ">Christine B.  Peterson</span>, <span class="hlFld-ContribAuthor ">Mien‐Chie  Hung</span>, <span class="hlFld-ContribAuthor ">Hui‐Kuan  Lin</span>, <span class="hlFld-ContribAuthor ">Rakhmetkazhi I.  Bersimbaev</span>, <span class="hlFld-ContribAuthor ">Min Sup  Song</span>, <span class="hlFld-ContribAuthor ">Dos D.  Sarbassov</span>. </span><span class="cited-content_cbyCitation_article-title">A chirality‐dependent action of vitamin C in suppressing Kirsten rat sarcoma mutant tumor growth by the oxidative combination: Rationale for cancer therapeutics. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Cancer</span><span> <strong>2020,</strong> <em>146 </em>
                                    (10)
                                     , 2822-2828. <a href="https://doi.org/10.1002/ijc.32658" title="DOI URL">https://doi.org/10.1002/ijc.32658</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ijc.32658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fijc.32658%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Cancer%26atitle%3DA%252Bchirality%2525E2%252580%252590dependent%252Baction%252Bof%252Bvitamin%252BC%252Bin%252Bsuppressing%252BKirsten%252Brat%252Bsarcoma%252Bmutant%252Btumor%252Bgrowth%252Bby%252Bthe%252Boxidative%252Bcombination%25253A%252BRationale%252Bfor%252Bcancer%252Btherapeutics%26aulast%3DWu%26aufirst%3DXinggang%26date%3D2020%26volume%3D146%26issue%3D10%26spage%3D2822%26epage%3D2828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Na  Ye</span>, <span class="hlFld-ContribAuthor ">Qingfeng  Xu</span>, <span class="hlFld-ContribAuthor ">Wanwan  Li</span>, <span class="hlFld-ContribAuthor ">Pingyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Jia  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in Developing K-Ras Plasma Membrane Localization Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (23)
                                     , 2114-2127. <a href="https://doi.org/10.2174/1568026619666190902145116" title="DOI URL">https://doi.org/10.2174/1568026619666190902145116</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026619666190902145116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026619666190902145116%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DRecent%252BAdvances%252Bin%252BDeveloping%252BK-Ras%252BPlasma%252BMembrane%252BLocalization%252BInhibitors%26aulast%3DYe%26aufirst%3DNa%26date%3D2019%26volume%3D19%26issue%3D23%26spage%3D2114%26epage%3D2127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fengqian  Chen</span>, <span class="hlFld-ContribAuthor ">Martin P.  Alphonse</span>, <span class="hlFld-ContribAuthor ">Yan  Liu</span>, <span class="hlFld-ContribAuthor ">Qi  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Mutant KRAS for Anticancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (23)
                                     , 2098-2113. <a href="https://doi.org/10.2174/1568026619666190902151307" title="DOI URL">https://doi.org/10.2174/1568026619666190902151307</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026619666190902151307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026619666190902151307%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252BMutant%252BKRAS%252Bfor%252BAnticancer%252BTherapy%26aulast%3DChen%26aufirst%3DFengqian%26date%3D2019%26volume%3D19%26issue%3D23%26spage%3D2098%26epage%3D2113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bingbing  Li</span>, <span class="hlFld-ContribAuthor ">Deqin  Rong</span>, <span class="hlFld-ContribAuthor ">Yuanxiang  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Protein-Protein Interaction with Covalent Small-Molecule Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (21)
                                     , 1872-1876. <a href="https://doi.org/10.2174/1568026619666191011163410" title="DOI URL">https://doi.org/10.2174/1568026619666191011163410</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026619666191011163410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026619666191011163410%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252BProtein-Protein%252BInteraction%252Bwith%252BCovalent%252BSmall-Molecule%252BInhibitors%26aulast%3DLi%26aufirst%3DBingbing%26date%3D2019%26volume%3D19%26issue%3D21%26spage%3D1872%26epage%3D1876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Congzhen  Qiao</span>, <span class="hlFld-ContribAuthor ">Gresham T  Richter</span>, <span class="hlFld-ContribAuthor ">Weijun  Pan</span>, <span class="hlFld-ContribAuthor ">Yunbo  Jin</span>, <span class="hlFld-ContribAuthor ">Xiaoxi  Lin</span>. </span><span class="cited-content_cbyCitation_article-title">Extracranial arteriovenous malformations: from bedside to bench. </span><span class="cited-content_cbyCitation_journal-name">Mutagenesis</span><span> <strong>2019,</strong> <em>127 </em><a href="https://doi.org/10.1093/mutage/gez028" title="DOI URL">https://doi.org/10.1093/mutage/gez028</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/mutage/gez028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fmutage%2Fgez028%26sid%3Dliteratum%253Aachs%26jtitle%3DMutagenesis%26atitle%3DExtracranial%252Barteriovenous%252Bmalformations%25253A%252Bfrom%252Bbedside%252Bto%252Bbench%26aulast%3DQiao%26aufirst%3DCongzhen%26date%3D2019%26date%3D2019%26volume%3D127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qi  Xiao</span>, <span class="hlFld-ContribAuthor ">Jinrong  Feng</span>, <span class="hlFld-ContribAuthor ">Jiawen  Li</span>, <span class="hlFld-ContribAuthor ">Yi  Liu</span>, <span class="hlFld-ContribAuthor ">Dan  Wang</span>, <span class="hlFld-ContribAuthor ">Shan  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">A ratiometric electrochemical biosensor for ultrasensitive and highly selective detection of the K-ras gene
              via
              exonuclease III-assisted target recycling and rolling circle amplification strategies. </span><span class="cited-content_cbyCitation_journal-name">Analytical Methods</span><span> <strong>2019,</strong> <em>11 </em>
                                    (32)
                                     , 4146-4156. <a href="https://doi.org/10.1039/C9AY01007F" title="DOI URL">https://doi.org/10.1039/C9AY01007F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9AY01007F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9AY01007F%26sid%3Dliteratum%253Aachs%26jtitle%3DAnalytical%2520Methods%26atitle%3DA%252Bratiometric%252Belectrochemical%252Bbiosensor%252Bfor%252Bultrasensitive%252Band%252Bhighly%252Bselective%252Bdetection%252Bof%252Bthe%252BK-ras%252Bgene%252Bvia%252Bexonuclease%252BIII-assisted%252Btarget%252Brecycling%252Band%252Brolling%252Bcircle%252Bamplification%252Bstrategies%26aulast%3DXiao%26aufirst%3DQi%26date%3D2019%26date%3D2019%26volume%3D11%26issue%3D32%26spage%3D4146%26epage%3D4156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shijie  Chen</span>, <span class="hlFld-ContribAuthor ">Fengyang  Li</span>, <span class="hlFld-ContribAuthor ">Dan  Xu</span>, <span class="hlFld-ContribAuthor ">Kai  Hou</span>, <span class="hlFld-ContribAuthor ">Weirong  Fang</span>, <span class="hlFld-ContribAuthor ">Yunman  Li</span>. </span><span class="cited-content_cbyCitation_article-title">The Function of RAS Mutation in Cancer and Advances in its Drug Research. </span><span class="cited-content_cbyCitation_journal-name">Current Pharmaceutical Design</span><span> <strong>2019,</strong> <em>25 </em>
                                    (10)
                                     , 1105-1114. <a href="https://doi.org/10.2174/1381612825666190506122228" title="DOI URL">https://doi.org/10.2174/1381612825666190506122228</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1381612825666190506122228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1381612825666190506122228%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Pharmaceutical%2520Design%26atitle%3DThe%252BFunction%252Bof%252BRAS%252BMutation%252Bin%252BCancer%252Band%252BAdvances%252Bin%252Bits%252BDrug%252BResearch%26aulast%3DChen%26aufirst%3DShijie%26date%3D2019%26volume%3D25%26issue%3D10%26spage%3D1105%26epage%3D1114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A.  Tirella</span>, <span class="hlFld-ContribAuthor ">K.  Kloc-Muniak</span>, <span class="hlFld-ContribAuthor ">L.  Good</span>, <span class="hlFld-ContribAuthor ">J.  Ridden</span>, <span class="hlFld-ContribAuthor ">M.  Ashford</span>, <span class="hlFld-ContribAuthor ">S.  Puri</span>, <span class="hlFld-ContribAuthor ">N.  Tirelli</span>. </span><span class="cited-content_cbyCitation_article-title">CD44 targeted delivery of siRNA by using HA-decorated nanotechnologies for KRAS silencing in cancer treatment. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Pharmaceutics</span><span> <strong>2019,</strong> <em>561 </em>, 114-123. <a href="https://doi.org/10.1016/j.ijpharm.2019.02.032" title="DOI URL">https://doi.org/10.1016/j.ijpharm.2019.02.032</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijpharm.2019.02.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijpharm.2019.02.032%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Pharmaceutics%26atitle%3DCD44%252Btargeted%252Bdelivery%252Bof%252BsiRNA%252Bby%252Busing%252BHA-decorated%252Bnanotechnologies%252Bfor%252BKRAS%252Bsilencing%252Bin%252Bcancer%252Btreatment%26aulast%3DTirella%26aufirst%3DA.%26date%3D2019%26volume%3D561%26spage%3D114%26epage%3D123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David H.  Peng</span>, <span class="hlFld-ContribAuthor ">Samrat T.  Kundu</span>, <span class="hlFld-ContribAuthor ">Jared J.  Fradette</span>, <span class="hlFld-ContribAuthor ">Lixia  Diao</span>, <span class="hlFld-ContribAuthor ">Pan  Tong</span>, <span class="hlFld-ContribAuthor ">Lauren A.  Byers</span>, <span class="hlFld-ContribAuthor ">Jing  Wang</span>, <span class="hlFld-ContribAuthor ">Jaime Rodriguez  Canales</span>, <span class="hlFld-ContribAuthor ">Pamela A.  Villalobos</span>, <span class="hlFld-ContribAuthor ">Barbara  Mino</span>, <span class="hlFld-ContribAuthor ">Yanan  Yang</span>, <span class="hlFld-ContribAuthor ">Rosalba  Minelli</span>, <span class="hlFld-ContribAuthor ">Michael D.  Peoples</span>, <span class="hlFld-ContribAuthor ">Christopher A.  Bristow</span>, <span class="hlFld-ContribAuthor ">Timothy P.  Heffernan</span>, <span class="hlFld-ContribAuthor ">Alessandro  Carugo</span>, <span class="hlFld-ContribAuthor ">Ignacio I.  Wistuba</span>, <span class="hlFld-ContribAuthor ">Don L.  Gibbons</span>. </span><span class="cited-content_cbyCitation_article-title">ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism. </span><span class="cited-content_cbyCitation_journal-name">Science Translational Medicine</span><span> <strong>2019,</strong> <em>11 </em>
                                    (483)
                                     , eaaq1238. <a href="https://doi.org/10.1126/scitranslmed.aaq1238" title="DOI URL">https://doi.org/10.1126/scitranslmed.aaq1238</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1126/scitranslmed.aaq1238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1126%2Fscitranslmed.aaq1238%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%2520Translational%2520Medicine%26atitle%3DZEB1%252Bsuppression%252Bsensitizes%252BKRAS%252Bmutant%252Bcancers%252Bto%252BMEK%252Binhibition%252Bby%252Ban%252BIL17RD-dependent%252Bmechanism%26aulast%3DPeng%26aufirst%3DDavid%2BH.%26date%3D2019%26date%3D2019%26volume%3D11%26issue%3D483%26spage%3Deaaq1238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tadeusz  Majewski</span>, <span class="hlFld-ContribAuthor ">Hui  Yao</span>, <span class="hlFld-ContribAuthor ">Jolanta  Bondaruk</span>, <span class="hlFld-ContribAuthor ">Woonbok  Chung</span>, <span class="hlFld-ContribAuthor ">Sangkyou  Lee</span>, <span class="hlFld-ContribAuthor ">June Goo  Lee</span>, <span class="hlFld-ContribAuthor ">Shizhen  Zhang</span>, <span class="hlFld-ContribAuthor ">David  Cogdell</span>, <span class="hlFld-ContribAuthor ">Guoliang  Yang</span>, <span class="hlFld-ContribAuthor ">Woonyoung  Choi</span>, <span class="hlFld-ContribAuthor ">Colin  Dinney</span>, <span class="hlFld-ContribAuthor ">H. Barton  Grossman</span>, <span class="hlFld-ContribAuthor ">Christopher  Logothetis</span>, <span class="hlFld-ContribAuthor ">Steven E.  Scherer</span>, <span class="hlFld-ContribAuthor ">Charles C.  Guo</span>, <span class="hlFld-ContribAuthor ">Li  Zhang</span>, <span class="hlFld-ContribAuthor ">Peng  Wei</span>, <span class="hlFld-ContribAuthor ">John N.  Weinstein</span>, <span class="hlFld-ContribAuthor ">Jean-Pierre  Issa</span>, <span class="hlFld-ContribAuthor ">Keith  Baggerly</span>, <span class="hlFld-ContribAuthor ">David J.  McConkey</span>, <span class="hlFld-ContribAuthor ">Bogdan  Czerniak</span>. </span><span class="cited-content_cbyCitation_article-title">Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis. </span><span class="cited-content_cbyCitation_journal-name">Cell Reports</span><span> <strong>2019,</strong> <em>26 </em>
                                    (8)
                                     , 2241-2256.e4. <a href="https://doi.org/10.1016/j.celrep.2019.01.095" title="DOI URL">https://doi.org/10.1016/j.celrep.2019.01.095</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.celrep.2019.01.095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.celrep.2019.01.095%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Reports%26atitle%3DWhole-Organ%252BGenomic%252BCharacterization%252Bof%252BMucosal%252BField%252BEffects%252BInitiating%252BBladder%252BCarcinogenesis%26aulast%3DMajewski%26aufirst%3DTadeusz%26date%3D2019%26volume%3D26%26issue%3D8%26spage%3D2241%26epage%3D2256.e4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peng  Zhao</span>, <span class="hlFld-ContribAuthor ">Hui  Chen</span>, <span class="hlFld-ContribAuthor ">Danyi  Wen</span>, <span class="hlFld-ContribAuthor ">Shuo  Mou</span>, <span class="hlFld-ContribAuthor ">Feifei  Zhang</span>, <span class="hlFld-ContribAuthor ">Shusen  Zheng</span>. </span><span class="cited-content_cbyCitation_article-title">Personalized treatment based on mini patient-derived xenografts and WES/RNA sequencing in a patient with metastatic duodenal adenocarcinoma. </span><span class="cited-content_cbyCitation_journal-name">Cancer Communications</span><span> <strong>2018,</strong> <em>38 </em>
                                    (1)
                                     , 54. <a href="https://doi.org/10.1186/s40880-018-0323-y" title="DOI URL">https://doi.org/10.1186/s40880-018-0323-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s40880-018-0323-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs40880-018-0323-y%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Communications%26atitle%3DPersonalized%252Btreatment%252Bbased%252Bon%252Bmini%252Bpatient-derived%252Bxenografts%252Band%252BWES%25252FRNA%252Bsequencing%252Bin%252Ba%252Bpatient%252Bwith%252Bmetastatic%252Bduodenal%252Badenocarcinoma%26aulast%3DZhao%26aufirst%3DPeng%26date%3D2018%26date%3D2018%26volume%3D38%26issue%3D1%26spage%3D54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dennis  Ruder</span>, <span class="hlFld-ContribAuthor ">Vassiliki  Papadimitrakopoulou</span>, <span class="hlFld-ContribAuthor ">Kazuhiko  Shien</span>, <span class="hlFld-ContribAuthor ">Carmen  Behrens</span>, <span class="hlFld-ContribAuthor ">Neda  Kalhor</span>, <span class="hlFld-ContribAuthor ">Huiqin  Chen</span>, <span class="hlFld-ContribAuthor ">Li  Shen</span>, <span class="hlFld-ContribAuthor ">J. Jack  Lee</span>, <span class="hlFld-ContribAuthor ">Waun Ki  Hong</span>, <span class="hlFld-ContribAuthor ">Ximing  Tang</span>, <span class="hlFld-ContribAuthor ">Luc  Girard</span>, <span class="hlFld-ContribAuthor ">John D.  Minna</span>, <span class="hlFld-ContribAuthor ">Lixia  Diao</span>, <span class="hlFld-ContribAuthor ">Jing  Wang</span>, <span class="hlFld-ContribAuthor ">Barbara  Mino</span>, <span class="hlFld-ContribAuthor ">Pamela  Villalobos</span>, <span class="hlFld-ContribAuthor ">Jaime  Rodriguez-Canales</span>, <span class="hlFld-ContribAuthor ">Nana E.  Hanson</span>, <span class="hlFld-ContribAuthor ">James  Sun</span>, <span class="hlFld-ContribAuthor ">Vincent  Miller</span>, <span class="hlFld-ContribAuthor ">Joel  Greenbowe</span>, <span class="hlFld-ContribAuthor ">Garrett  Frampton</span>, <span class="hlFld-ContribAuthor ">Roy S.  Herbst</span>, <span class="hlFld-ContribAuthor ">Veera  Baladandayuthapani</span>, <span class="hlFld-ContribAuthor ">Ignacio I.  Wistuba</span>, <span class="hlFld-ContribAuthor ">Julie G.  Izzo</span>. </span><span class="cited-content_cbyCitation_article-title">Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of
              RICTOR/KRAS
              -altered non-small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2018,</strong> <em>9 </em>
                                    (74)
                                     , 33995-34008. <a href="https://doi.org/10.18632/oncotarget.26129" title="DOI URL">https://doi.org/10.18632/oncotarget.26129</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.26129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.26129%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DConcomitant%252Btargeting%252Bof%252Bthe%252BmTOR%25252FMAPK%252Bpathways%25253A%252Bnovel%252Btherapeutic%252Bstrategy%252Bin%252Bsubsets%252Bof%252BRICTOR%25252FKRAS%252B-altered%252Bnon-small%252Bcell%252Blung%252Bcancer%26aulast%3DRuder%26aufirst%3DDennis%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D74%26spage%3D33995%26epage%3D34008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Charansingh H.  Gill</span>, <span class="hlFld-ContribAuthor ">Asha V.  Chate</span>, <span class="hlFld-ContribAuthor ">Gajanan Y.  Shinde</span>, <span class="hlFld-ContribAuthor ">Aniket P.  Sarkate</span>, <span class="hlFld-ContribAuthor ">Shailee V.  Tiwari</span>. </span><span class="cited-content_cbyCitation_article-title">One-pot, four-component synthesis and SAR STUDIES of spiro[pyrimido[5,4-b]quinoline-10,5′-pyrrolo[2,3-d]pyrimidine] derivatives catalyzed by β-cyclodextrin in water as potential anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Research on Chemical Intermediates</span><span> <strong>2018,</strong> <em>44 </em>
                                    (7)
                                     , 4029-4043. <a href="https://doi.org/10.1007/s11164-018-3353-9" title="DOI URL">https://doi.org/10.1007/s11164-018-3353-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11164-018-3353-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11164-018-3353-9%26sid%3Dliteratum%253Aachs%26jtitle%3DResearch%2520on%2520Chemical%2520Intermediates%26atitle%3DOne-pot%25252C%252Bfour-component%252Bsynthesis%252Band%252BSAR%252BSTUDIES%252Bof%252Bspiro%25255Bpyrimido%25255B5%25252C4-b%25255Dquinoline-10%25252C5%2525E2%252580%2525B2-pyrrolo%25255B2%25252C3-d%25255Dpyrimidine%25255D%252Bderivatives%252Bcatalyzed%252Bby%252B%2525CE%2525B2-cyclodextrin%252Bin%252Bwater%252Bas%252Bpotential%252Banticancer%252Bagents%26aulast%3DGill%26aufirst%3DCharansingh%2BH.%26date%3D2018%26date%3D2018%26volume%3D44%26issue%3D7%26spage%3D4029%26epage%3D4043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dmitri  Beglov</span>, <span class="hlFld-ContribAuthor ">David R.  Hall</span>, <span class="hlFld-ContribAuthor ">Amanda E.  Wakefield</span>, <span class="hlFld-ContribAuthor ">Lingqi  Luo</span>, <span class="hlFld-ContribAuthor ">Karen N.  Allen</span>, <span class="hlFld-ContribAuthor ">Dima  Kozakov</span>, <span class="hlFld-ContribAuthor ">Adrian  Whitty</span>, <span class="hlFld-ContribAuthor ">Sandor  Vajda</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring the structural origins of cryptic sites on proteins. </span><span class="cited-content_cbyCitation_journal-name">Proceedings of the National Academy of Sciences</span><span> <strong>2018,</strong> <em>115 </em>
                                    (15)
                                     , E3416-E3425. <a href="https://doi.org/10.1073/pnas.1711490115" title="DOI URL">https://doi.org/10.1073/pnas.1711490115</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1073/pnas.1711490115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1073%2Fpnas.1711490115%26sid%3Dliteratum%253Aachs%26jtitle%3DProceedings%2520of%2520the%2520National%2520Academy%2520of%2520Sciences%26atitle%3DExploring%252Bthe%252Bstructural%252Borigins%252Bof%252Bcryptic%252Bsites%252Bon%252Bproteins%26aulast%3DBeglov%26aufirst%3DDmitri%26date%3D2018%26date%3D2018%26volume%3D115%26issue%3D15%26spage%3DE3416%26epage%3DE3425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Donghua  Wu</span>, <span class="hlFld-ContribAuthor ">Baofeng  Zhao</span>, <span class="hlFld-ContribAuthor ">Xiaoyu  Qi</span>, <span class="hlFld-ContribAuthor ">Fang  Peng</span>, <span class="hlFld-ContribAuthor ">Hailu  Fu</span>, <span class="hlFld-ContribAuthor ">Xinming  Chi</span>, <span class="hlFld-ContribAuthor ">Qing Robert  Miao</span>, <span class="hlFld-ContribAuthor ">Shujuan  Shao</span>. </span><span class="cited-content_cbyCitation_article-title">Nogo-B receptor promotes epithelial–mesenchymal transition in non-small cell lung cancer cells through the Ras/ERK/Snail1 pathway. </span><span class="cited-content_cbyCitation_journal-name">Cancer Letters</span><span> <strong>2018,</strong> <em>418 </em>, 135-146. <a href="https://doi.org/10.1016/j.canlet.2018.01.030" title="DOI URL">https://doi.org/10.1016/j.canlet.2018.01.030</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.canlet.2018.01.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.canlet.2018.01.030%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Letters%26atitle%3DNogo-B%252Breceptor%252Bpromotes%252Bepithelial%2525E2%252580%252593mesenchymal%252Btransition%252Bin%252Bnon-small%252Bcell%252Blung%252Bcancer%252Bcells%252Bthrough%252Bthe%252BRas%25252FERK%25252FSnail1%252Bpathway%26aulast%3DWu%26aufirst%3DDonghua%26date%3D2018%26volume%3D418%26spage%3D135%26epage%3D146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tadeusz  Majewski</span>, <span class="hlFld-ContribAuthor ">Hui  Yao</span>, <span class="hlFld-ContribAuthor ">Jolanta  Bondaruk</span>, <span class="hlFld-ContribAuthor ">Woonbok  Chung</span>, <span class="hlFld-ContribAuthor ">Sangkyou  Lee</span>, <span class="hlFld-ContribAuthor ">June Goo  Lee</span>, <span class="hlFld-ContribAuthor ">Shizhen  Zhang</span>, <span class="hlFld-ContribAuthor ">David  Cogdell</span>, <span class="hlFld-ContribAuthor ">Woonyoung  Choi</span>, <span class="hlFld-ContribAuthor ">Colin  Dinney</span>, <span class="hlFld-ContribAuthor ">H. Barton  Grossman</span>, <span class="hlFld-ContribAuthor ">Steven E.  Scherer</span>, <span class="hlFld-ContribAuthor ">Charles C.  Guo</span>, <span class="hlFld-ContribAuthor ">Li  Zhang</span>, <span class="hlFld-ContribAuthor ">Peng  Wei</span>, <span class="hlFld-ContribAuthor ">John N.  Weinstein</span>, <span class="hlFld-ContribAuthor ">Jean-Pierre  Issa</span>, <span class="hlFld-ContribAuthor ">Keith  Baggerly</span>, <span class="hlFld-ContribAuthor ">David J.  McConkey</span>, <span class="hlFld-ContribAuthor ">Bogdan  Czerniak</span>. </span><span class="cited-content_cbyCitation_article-title">Whole-organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis. </span><span class="cited-content_cbyCitation_journal-name">SSRN Electronic Journal</span><span> <strong>2018,</strong> <em> </em><a href="https://doi.org/10.2139/ssrn.3188428" title="DOI URL">https://doi.org/10.2139/ssrn.3188428</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2139/ssrn.3188428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2139%2Fssrn.3188428%26sid%3Dliteratum%253Aachs%26jtitle%3DSSRN%2520Electronic%2520Journal%26atitle%3DWhole-organ%252BGenomic%252BCharacterization%252Bof%252BMucosal%252BField%252BEffects%252BInitiating%252BBladder%252BCarcinogenesis%26aulast%3DMajewski%26aufirst%3DTadeusz%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ayumu  Niida</span>, <span class="hlFld-ContribAuthor ">Shigekazu  Sasaki</span>, <span class="hlFld-ContribAuthor ">Kazuko  Yonemori</span>, <span class="hlFld-ContribAuthor ">Tomoya  Sameshima</span>, <span class="hlFld-ContribAuthor ">Masahiro  Yaguchi</span>, <span class="hlFld-ContribAuthor ">Taiji  Asami</span>, <span class="hlFld-ContribAuthor ">Kotaro  Sakamoto</span>, <span class="hlFld-ContribAuthor ">Masahiro  Kamaura</span>. </span><span class="cited-content_cbyCitation_article-title">Investigation of the structural requirements of K-Ras(G12D) selective inhibitory peptide KRpep-2d using alanine scans and cysteine bridging. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (12)
                                     , 2757-2761. <a href="https://doi.org/10.1016/j.bmcl.2017.04.063" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.04.063</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.04.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.04.063%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DInvestigation%252Bof%252Bthe%252Bstructural%252Brequirements%252Bof%252BK-Ras%252528G12D%252529%252Bselective%252Binhibitory%252Bpeptide%252BKRpep-2d%252Busing%252Balanine%252Bscans%252Band%252Bcysteine%252Bbridging%26aulast%3DNiida%26aufirst%3DAyumu%26date%3D2017%26volume%3D27%26issue%3D12%26spage%3D2757%26epage%3D2761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nagore I.  Marín-Ramos</span>, <span class="hlFld-ContribAuthor ">Carmen  Piñar</span>, <span class="hlFld-ContribAuthor ">Henar  Vázquez-Villa</span>, <span class="hlFld-ContribAuthor ">Mar  Martín-Fontecha</span>, <span class="hlFld-ContribAuthor ">Ángel  González</span>, <span class="hlFld-ContribAuthor ">Ángeles  Canales</span>, <span class="hlFld-ContribAuthor ">Sergio  Algar</span>, <span class="hlFld-ContribAuthor ">Paloma P.  Mayo</span>, <span class="hlFld-ContribAuthor ">Jesús  Jiménez-Barbero</span>, <span class="hlFld-ContribAuthor ">Consuelo  Gajate</span>, <span class="hlFld-ContribAuthor ">Faustino  Mollinedo</span>, <span class="hlFld-ContribAuthor ">Leonardo  Pardo</span>, <span class="hlFld-ContribAuthor ">Silvia  Ortega-Gutiérrez</span>, <span class="hlFld-ContribAuthor ">Alma  Viso</span>, <span class="hlFld-ContribAuthor ">María L.  López-Rodríguez</span>. </span><span class="cited-content_cbyCitation_article-title">Development of a Nucleotide Exchange Inhibitor That Impairs Ras Oncogenic Signaling. </span><span class="cited-content_cbyCitation_journal-name">Chemistry - A European Journal</span><span> <strong>2017,</strong> <em>23 </em>
                                    (7)
                                     , 1676-1685. <a href="https://doi.org/10.1002/chem.201604905" title="DOI URL">https://doi.org/10.1002/chem.201604905</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.201604905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.201604905%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520-%2520A%2520European%2520Journal%26atitle%3DDevelopment%252Bof%252Ba%252BNucleotide%252BExchange%252BInhibitor%252BThat%252BImpairs%252BRas%252BOncogenic%252BSignaling%26aulast%3DMar%25C3%25ADn-Ramos%26aufirst%3DNagore%2BI.%26date%3D2017%26date%3D2016%26volume%3D23%26issue%3D7%26spage%3D1676%26epage%3D1685" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qing  Wen</span>, <span class="hlFld-ContribAuthor ">Philip D.  Dunne</span>, <span class="hlFld-ContribAuthor ">Paul G.  O’Reilly</span>, <span class="hlFld-ContribAuthor ">Gerald  Li</span>, <span class="hlFld-ContribAuthor ">Anthony J.  Bjourson</span>, <span class="hlFld-ContribAuthor ">Darragh G.  McArt</span>, <span class="hlFld-ContribAuthor ">Peter W.  Hamilton</span>, <span class="hlFld-ContribAuthor ">Shu-Dong  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">KRAS mutant colorectal cancer gene signatures identified angiotensin II receptor blockers as potential therapies. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2017,</strong> <em>8 </em>
                                    (2)
                                     , 3206-3225. <a href="https://doi.org/10.18632/oncotarget.13884" title="DOI URL">https://doi.org/10.18632/oncotarget.13884</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.13884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.13884%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DKRAS%252Bmutant%252Bcolorectal%252Bcancer%252Bgene%252Bsignatures%252Bidentified%252Bangiotensin%252BII%252Breceptor%252Bblockers%252Bas%252Bpotential%252Btherapies%26aulast%3DWen%26aufirst%3DQing%26date%3D2017%26date%3D2016%26volume%3D8%26issue%3D2%26spage%3D3206%26epage%3D3225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guilong  Zhang</span>, <span class="hlFld-ContribAuthor ">Lukui  Chen</span>, <span class="hlFld-ContribAuthor ">Kouhong  Sun</span>, <span class="hlFld-ContribAuthor ">Ahsan Ali  Khan</span>, <span class="hlFld-ContribAuthor ">Jianghua  Yan</span>, <span class="hlFld-ContribAuthor ">Hongyi  Liu</span>, <span class="hlFld-ContribAuthor ">Ailin  Lu</span>, <span class="hlFld-ContribAuthor ">Ning  Gu</span>. </span><span class="cited-content_cbyCitation_article-title">Neuropilin-1 (NRP-1)/GIPC1 pathway mediates glioma progression. </span><span class="cited-content_cbyCitation_journal-name">Tumor Biology</span><span> <strong>2016,</strong> <em>37 </em>
                                    (10)
                                     , 13777-13788. <a href="https://doi.org/10.1007/s13277-016-5138-3" title="DOI URL">https://doi.org/10.1007/s13277-016-5138-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s13277-016-5138-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs13277-016-5138-3%26sid%3Dliteratum%253Aachs%26jtitle%3DTumor%2520Biology%26atitle%3DNeuropilin-1%252B%252528NRP-1%252529%25252FGIPC1%252Bpathway%252Bmediates%252Bglioma%252Bprogression%26aulast%3DZhang%26aufirst%3DGuilong%26date%3D2016%26date%3D2016%26volume%3D37%26issue%3D10%26spage%3D13777%26epage%3D13788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Atiye Seda Yar  Saglam</span>, <span class="hlFld-ContribAuthor ">Ebru  Alp</span>, <span class="hlFld-ContribAuthor ">Zubeyir  Elmazoglu</span>, <span class="hlFld-ContribAuthor ">Emine Sevda  Menevse</span>. </span><span class="cited-content_cbyCitation_article-title">Effect of API-1 and FR180204 on cell proliferation and apoptosis in human DLD-1 and LoVo colorectal cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Oncology Letters</span><span> <strong>2016,</strong> <em>12 </em>
                                    (4)
                                     , 2463-2474. <a href="https://doi.org/10.3892/ol.2016.4995" title="DOI URL">https://doi.org/10.3892/ol.2016.4995</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3892/ol.2016.4995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3892%2Fol.2016.4995%26sid%3Dliteratum%253Aachs%26jtitle%3DOncology%2520Letters%26atitle%3DEffect%252Bof%252BAPI-1%252Band%252BFR180204%252Bon%252Bcell%252Bproliferation%252Band%252Bapoptosis%252Bin%252Bhuman%252BDLD-1%252Band%252BLoVo%252Bcolorectal%252Bcancer%252Bcells%26aulast%3DSaglam%26aufirst%3DAtiye%2BSeda%2BYar%26date%3D2016%26date%3D2016%26volume%3D12%26issue%3D4%26spage%3D2463%26epage%3D2474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jieqiong  Wang</span>, <span class="hlFld-ContribAuthor ">Kewen  Hu</span>, <span class="hlFld-ContribAuthor ">Jiawei  Guo</span>, <span class="hlFld-ContribAuthor ">Feixiong  Cheng</span>, <span class="hlFld-ContribAuthor ">Jing  Lv</span>, <span class="hlFld-ContribAuthor ">Wenhao  Jiang</span>, <span class="hlFld-ContribAuthor ">Weiqiang  Lu</span>, <span class="hlFld-ContribAuthor ">Jinsong  Liu</span>, <span class="hlFld-ContribAuthor ">Xiufeng  Pang</span>, <span class="hlFld-ContribAuthor ">Mingyao  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK. </span><span class="cited-content_cbyCitation_journal-name">Nature Communications</span><span> <strong>2016,</strong> <em>7 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/ncomms11363" title="DOI URL">https://doi.org/10.1038/ncomms11363</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/ncomms11363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fncomms11363%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Communications%26atitle%3DSuppression%252Bof%252BKRas-mutant%252Bcancer%252Bthrough%252Bthe%252Bcombined%252Binhibition%252Bof%252BKRAS%252Bwith%252BPLK1%252Band%252BROCK%26aulast%3DWang%26aufirst%3DJieqiong%26date%3D2016%26date%3D2016%26volume%3D7%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wen  Juan</span>, <span class="hlFld-ContribAuthor ">Wanjin  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Genes</span><span> <strong>2016,</strong> <em>7 </em>
                                    (9)
                                     , 55. <a href="https://doi.org/10.3390/genes7090055" title="DOI URL">https://doi.org/10.3390/genes7090055</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/genes7090055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fgenes7090055%26sid%3Dliteratum%253Aachs%26jtitle%3DGenes%26atitle%3DTargeting%252Bthe%252BHippo%252BSignaling%252BPathway%252Bfor%252BTissue%252BRegeneration%252Band%252BCancer%252BTherapy%26aulast%3DJuan%26aufirst%3DWen%26date%3D2016%26date%3D2016%26volume%3D7%26issue%3D9%26spage%3D55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nobuo  Tsuchida</span>, <span class="hlFld-ContribAuthor ">Avaniyapuram Kannan  Murugan</span>, <span class="hlFld-ContribAuthor ">Michele  Grieco</span>. </span><span class="cited-content_cbyCitation_article-title">Kirsten Ras* oncogene: Significance of its discovery in human cancer research. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2016,</strong> <em>7 </em>
                                    (29)
                                     , 46717-46733. <a href="https://doi.org/10.18632/oncotarget.8773" title="DOI URL">https://doi.org/10.18632/oncotarget.8773</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.8773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.8773%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DKirsten%252BRas%252A%252Boncogene%25253A%252BSignificance%252Bof%252Bits%252Bdiscovery%252Bin%252Bhuman%252Bcancer%252Bresearch%26aulast%3DTsuchida%26aufirst%3DNobuo%26date%3D2016%26date%3D2016%26volume%3D7%26issue%3D29%26spage%3D46717%26epage%3D46733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ruth  Nussinov</span>, <span class="hlFld-ContribAuthor ">Serena  Muratcioglu</span>, <span class="hlFld-ContribAuthor ">Chung-Jung  Tsai</span>, <span class="hlFld-ContribAuthor ">Hyunbum  Jang</span>, <span class="hlFld-ContribAuthor ">Attila  Gursoy</span>, <span class="hlFld-ContribAuthor ">Ozlem  Keskin</span>. </span><span class="cited-content_cbyCitation_article-title">K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target?. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Targets</span><span> <strong>2016,</strong> <em>20 </em>
                                    (7)
                                     , 831-842. <a href="https://doi.org/10.1517/14728222.2016.1135131" title="DOI URL">https://doi.org/10.1517/14728222.2016.1135131</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/14728222.2016.1135131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F14728222.2016.1135131%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Targets%26atitle%3DK-Ras4B%25252Fcalmodulin%25252FPI3K%2525CE%2525B1%25253A%252BA%252Bpromising%252Bnew%252Badenocarcinoma-specific%252Bdrug%252Btarget%25253F%26aulast%3DNussinov%26aufirst%3DRuth%26date%3D2016%26date%3D2016%26volume%3D20%26issue%3D7%26spage%3D831%26epage%3D842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shun Ying  Quah</span>, <span class="hlFld-ContribAuthor ">Michelle Siying  Tan</span>, <span class="hlFld-ContribAuthor ">Yuan Han  Teh</span>, <span class="hlFld-ContribAuthor ">Johnson  Stanslas</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacological modulation of oncogenic Ras by natural products and their derivatives: Renewed hope in the discovery of novel anti-Ras drugs. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2016,</strong> <em>162 </em>, 35-57. <a href="https://doi.org/10.1016/j.pharmthera.2016.03.010" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2016.03.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2016.03.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2016.03.010%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DPharmacological%252Bmodulation%252Bof%252Boncogenic%252BRas%252Bby%252Bnatural%252Bproducts%252Band%252Btheir%252Bderivatives%25253A%252BRenewed%252Bhope%252Bin%252Bthe%252Bdiscovery%252Bof%252Bnovel%252Banti-Ras%252Bdrugs%26aulast%3DQuah%26aufirst%3DShun%2BYing%26date%3D2016%26volume%3D162%26spage%3D35%26epage%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aaron J.  Scott</span>, <span class="hlFld-ContribAuthor ">Christopher H.  Lieu</span>, <span class="hlFld-ContribAuthor ">Wells A.  Messersmith</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic Approaches to RAS Mutation. </span><span class="cited-content_cbyCitation_journal-name">The Cancer Journal</span><span> <strong>2016,</strong> <em>22 </em>
                                    (3)
                                     , 165-174. <a href="https://doi.org/10.1097/PPO.0000000000000187" title="DOI URL">https://doi.org/10.1097/PPO.0000000000000187</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/PPO.0000000000000187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FPPO.0000000000000187%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Cancer%2520Journal%26atitle%3DTherapeutic%252BApproaches%252Bto%252BRAS%252BMutation%26aulast%3DScott%26aufirst%3DAaron%2BJ.%26date%3D2016%26volume%3D22%26issue%3D3%26spage%3D165%26epage%3D174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shaoyong  Lu</span>, <span class="hlFld-ContribAuthor ">Hyunbum  Jang</span>, <span class="hlFld-ContribAuthor ">Jian  Zhang</span>, <span class="hlFld-ContribAuthor ">Ruth  Nussinov</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibitors of Ras-SOS Interactions. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2016,</strong> <em>11 </em>
                                    (8)
                                     , 814-821. <a href="https://doi.org/10.1002/cmdc.201500481" title="DOI URL">https://doi.org/10.1002/cmdc.201500481</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201500481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201500481%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DInhibitors%252Bof%252BRas-SOS%252BInteractions%26aulast%3DLu%26aufirst%3DShaoyong%26date%3D2016%26date%3D2015%26volume%3D11%26issue%3D8%26spage%3D814%26epage%3D821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">YANG  ZOU</span>, <span class="hlFld-ContribAuthor ">WEI  DENG</span>, <span class="hlFld-ContribAuthor ">FENG  WANG</span>, <span class="hlFld-ContribAuthor ">XIAO-HONG  YU</span>, <span class="hlFld-ContribAuthor ">FA-YING  LIU</span>, <span class="hlFld-ContribAuthor ">BI-CHENG  YANG</span>, <span class="hlFld-ContribAuthor ">MEI-ZHEN  HUANG</span>, <span class="hlFld-ContribAuthor ">JIU-BAI  GUO</span>, <span class="hlFld-ContribAuthor ">QIU-HUA  XIE</span>, <span class="hlFld-ContribAuthor ">MING  HE</span>, <span class="hlFld-ContribAuthor ">OU-PING  HUANG</span>. </span><span class="cited-content_cbyCitation_article-title">A novel somatic MAPK1 mutation in primary ovarian mixed germ cell tumors. </span><span class="cited-content_cbyCitation_journal-name">Oncology Reports</span><span> <strong>2016,</strong> <em>35 </em>
                                    (2)
                                     , 725-730. <a href="https://doi.org/10.3892/or.2015.4402" title="DOI URL">https://doi.org/10.3892/or.2015.4402</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3892/or.2015.4402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3892%2For.2015.4402%26sid%3Dliteratum%253Aachs%26jtitle%3DOncology%2520Reports%26atitle%3DA%252Bnovel%252Bsomatic%252BMAPK1%252Bmutation%252Bin%252Bprimary%252Bovarian%252Bmixed%252Bgerm%252Bcell%252Btumors%26aulast%3DZOU%26aufirst%3DYANG%26date%3D2016%26date%3D2015%26volume%3D35%26issue%3D2%26spage%3D725%26epage%3D730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shaoyong  Lu</span>, <span class="hlFld-ContribAuthor ">Hyunbum  Jang</span>, <span class="hlFld-ContribAuthor ">Shuo  Gu</span>, <span class="hlFld-ContribAuthor ">Jian  Zhang</span>, <span class="hlFld-ContribAuthor ">Ruth  Nussinov</span>. </span><span class="cited-content_cbyCitation_article-title">Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view. </span><span class="cited-content_cbyCitation_journal-name">Chemical Society Reviews</span><span> <strong>2016,</strong> <em>45 </em>
                                    (18)
                                     , 4929-4952. <a href="https://doi.org/10.1039/C5CS00911A" title="DOI URL">https://doi.org/10.1039/C5CS00911A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C5CS00911A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC5CS00911A%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Society%2520Reviews%26atitle%3DDrugging%252BRas%252BGTPase%25253A%252Ba%252Bcomprehensive%252Bmechanistic%252Band%252Bsignaling%252Bstructural%252Bview%26aulast%3DLu%26aufirst%3DShaoyong%26date%3D2016%26date%3D2016%26volume%3D45%26issue%3D18%26spage%3D4929%26epage%3D4952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">K. N. Visweswara  Sastry</span>, <span class="hlFld-ContribAuthor ">Sunitha Rani  Routhu</span>, <span class="hlFld-ContribAuthor ">Soma Gupta  Datta</span>, <span class="hlFld-ContribAuthor ">Narayana  Nagesh</span>, <span class="hlFld-ContribAuthor ">Bathini Nagendra  Babu</span>, <span class="hlFld-ContribAuthor ">Jagadeesh Babu  Nanubolu</span>, <span class="hlFld-ContribAuthor ">C. Ganesh  Kumar</span>, <span class="hlFld-ContribAuthor ">Ram Awatar  Maurya</span>, <span class="hlFld-ContribAuthor ">Ahmed  Kamal</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, DNA binding affinity and anticancer activity of novel 4H-benzo[g][1,2,3]triazolo[5,1-c][1,4]oxazocines. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2016,</strong> <em>14 </em>
                                    (39)
                                     , 9294-9305. <a href="https://doi.org/10.1039/C6OB01077F" title="DOI URL">https://doi.org/10.1039/C6OB01077F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6OB01077F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6OB01077F%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DSynthesis%25252C%252BDNA%252Bbinding%252Baffinity%252Band%252Banticancer%252Bactivity%252Bof%252Bnovel%252B4H-benzo%25255Bg%25255D%25255B1%25252C2%25252C3%25255Dtriazolo%25255B5%25252C1-c%25255D%25255B1%25252C4%25255Doxazocines%26aulast%3DSastry%26aufirst%3DK.%2BN.%2BVisweswara%26date%3D2016%26date%3D2016%26volume%3D14%26issue%3D39%26spage%3D9294%26epage%3D9305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haizhen  Wang</span>, <span class="hlFld-ContribAuthor ">Tao  Yang</span>, <span class="hlFld-ContribAuthor ">Xiangwei  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">5-Fluorouracil preferentially sensitizes mutant KRAS non-small cell lung carcinoma cells to TRAIL-induced apoptosis. </span><span class="cited-content_cbyCitation_journal-name">Molecular Oncology</span><span> <strong>2015,</strong> <em>9 </em>
                                    (9)
                                     , 1815-1824. <a href="https://doi.org/10.1016/j.molonc.2015.06.003" title="DOI URL">https://doi.org/10.1016/j.molonc.2015.06.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molonc.2015.06.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molonc.2015.06.003%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Oncology%26atitle%3D5-Fluorouracil%252Bpreferentially%252Bsensitizes%252Bmutant%252BKRAS%252Bnon-small%252Bcell%252Blung%252Bcarcinoma%252Bcells%252Bto%252BTRAIL-induced%252Bapoptosis%26aulast%3DWang%26aufirst%3DHaizhen%26date%3D2015%26date%3D2015%26volume%3D9%26issue%3D9%26spage%3D1815%26epage%3D1824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maen  Abdelrahim</span>, <span class="hlFld-ContribAuthor ">Scott  Kopetz</span>, <span class="hlFld-ContribAuthor ">David  Menter</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted Therapy in Solid Tumors: Colorectal Cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2015,</strong>,, 193-204. <a href="https://doi.org/10.1002/9781118468678.ch20" title="DOI URL">https://doi.org/10.1002/9781118468678.ch20</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118468678.ch20&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118468678.ch20%26sid%3Dliteratum%253Aachs%26atitle%3DTargeted%252BTherapy%252Bin%252BSolid%252BTumors%25253A%252BColorectal%252BCancer%26aulast%3DAbdelrahim%26aufirst%3DMaen%26date%3D2015%26date%3D2015%26spage%3D193%26epage%3D204%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DTargeted%252BTherapy%252Bin%252BTranslational%252BCancer%252BResearch%26aulast%3DTsimberidou%26aufirst%3DApostolia-Maria%26date%3D2015%26volume%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rhys D.  Taylor</span>, <span class="hlFld-ContribAuthor ">Anandhakumar  Chandran</span>, <span class="hlFld-ContribAuthor ">Gengo  Kashiwazaki</span>, <span class="hlFld-ContribAuthor ">Kaori  Hashiya</span>, <span class="hlFld-ContribAuthor ">Toshikazu  Bando</span>, <span class="hlFld-ContribAuthor ">Hiroki  Nagase</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Sugiyama</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Targeting of the KRAS Codon 12 Mutation Sequence by Pyrrole-Imidazole Polyamide
              seco
              -CBI Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Chemistry - A European Journal</span><span> <strong>2015,</strong> <em>21 </em>
                                    (42)
                                     , 14996-15003. <a href="https://doi.org/10.1002/chem.201501870" title="DOI URL">https://doi.org/10.1002/chem.201501870</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.201501870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.201501870%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520-%2520A%2520European%2520Journal%26atitle%3DSelective%252BTargeting%252Bof%252Bthe%252BKRAS%252BCodon%2525E2%252580%25258512%252BMutation%252BSequence%252Bby%252BPyrrole-Imidazole%252BPolyamide%252Bseco%252B-CBI%252BConjugates%26aulast%3DTaylor%26aufirst%3DRhys%2BD.%26date%3D2015%26date%3D2015%26volume%3D21%26issue%3D42%26spage%3D14996%26epage%3D15003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chada Narsimha  Reddy</span>, <span class="hlFld-ContribAuthor ">V. Lakshma  Nayak</span>, <span class="hlFld-ContribAuthor ">Geeta Sai  Mani</span>, <span class="hlFld-ContribAuthor ">Jeevak Sopanrao  Kapure</span>, <span class="hlFld-ContribAuthor ">Praveen Reddy  Adiyala</span>, <span class="hlFld-ContribAuthor ">Ram Awatar  Maurya</span>, <span class="hlFld-ContribAuthor ">Ahmed  Kamal</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of spiro[cyclopropane-1,3′-indolin]-2′-ones as potential anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (20)
                                     , 4580-4586. <a href="https://doi.org/10.1016/j.bmcl.2015.08.056" title="DOI URL">https://doi.org/10.1016/j.bmcl.2015.08.056</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2015.08.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2015.08.056%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bspiro%25255Bcyclopropane-1%25252C3%2525E2%252580%2525B2-indolin%25255D-2%2525E2%252580%2525B2-ones%252Bas%252Bpotential%252Banticancer%252Bagents%26aulast%3DReddy%26aufirst%3DChada%2BNarsimha%26date%3D2015%26volume%3D25%26issue%3D20%26spage%3D4580%26epage%3D4586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christian  Posch</span>, <span class="hlFld-ContribAuthor ">Brian D.  Cholewa</span>, <span class="hlFld-ContribAuthor ">Igor  Vujic</span>, <span class="hlFld-ContribAuthor ">Martina  Sanlorenzo</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Ma</span>, <span class="hlFld-ContribAuthor ">Sarasa T.  Kim</span>, <span class="hlFld-ContribAuthor ">Sonja  Kleffel</span>, <span class="hlFld-ContribAuthor ">Tobias  Schatton</span>, <span class="hlFld-ContribAuthor ">Klemens  Rappersberger</span>, <span class="hlFld-ContribAuthor ">Rosie  Gutteridge</span>, <span class="hlFld-ContribAuthor ">Nihal  Ahmad</span>, <span class="hlFld-ContribAuthor ">Susana  Ortiz-Urda</span>. </span><span class="cited-content_cbyCitation_article-title">Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma. </span><span class="cited-content_cbyCitation_journal-name">Journal of Investigative Dermatology</span><span> <strong>2015,</strong> <em>135 </em>
                                    (10)
                                     , 2475-2483. <a href="https://doi.org/10.1038/jid.2015.198" title="DOI URL">https://doi.org/10.1038/jid.2015.198</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/jid.2015.198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fjid.2015.198%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Investigative%2520Dermatology%26atitle%3DCombined%252BInhibition%252Bof%252BMEK%252Band%252BPlk1%252BHas%252BSynergistic%252BAntitumor%252BActivity%252Bin%252BNRAS%252BMutant%252BMelanoma%26aulast%3DPosch%26aufirst%3DChristian%26date%3D2015%26volume%3D135%26issue%3D10%26spage%3D2475%26epage%3D2483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fumi  Shima</span>, <span class="hlFld-ContribAuthor ">Shigeyuki  Matsumoto</span>, <span class="hlFld-ContribAuthor ">Yoko  Yoshikawa</span>, <span class="hlFld-ContribAuthor ">Takashi  Kawamura</span>, <span class="hlFld-ContribAuthor ">Masayuki  Isa</span>, <span class="hlFld-ContribAuthor ">Tohru  Kataoka</span>. </span><span class="cited-content_cbyCitation_article-title">Current status of the development of Ras inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biochemistry</span><span> <strong>2015,</strong> <em>158 </em>
                                    (2)
                                     , 91-99. <a href="https://doi.org/10.1093/jb/mvv060" title="DOI URL">https://doi.org/10.1093/jb/mvv060</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/jb/mvv060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fjb%2Fmvv060%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biochemistry%26atitle%3DCurrent%252Bstatus%252Bof%252Bthe%252Bdevelopment%252Bof%252BRas%252Binhibitors%26aulast%3DShima%26aufirst%3DFumi%26date%3D2015%26date%3D2015%26volume%3D158%26issue%3D2%26spage%3D91%26epage%3D99" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Victor M.  Blanco</span>, <span class="hlFld-ContribAuthor ">Tahir  Latif</span>, <span class="hlFld-ContribAuthor ">Zhengtao  Chu</span>, <span class="hlFld-ContribAuthor ">Xiaoyang  Qi</span>. </span><span class="cited-content_cbyCitation_article-title">Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles. </span><span class="cited-content_cbyCitation_journal-name">Translational Oncology</span><span> <strong>2015,</strong> <em>8 </em>
                                    (3)
                                     , 196-203. <a href="https://doi.org/10.1016/j.tranon.2015.03.011" title="DOI URL">https://doi.org/10.1016/j.tranon.2015.03.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tranon.2015.03.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tranon.2015.03.011%26sid%3Dliteratum%253Aachs%26jtitle%3DTranslational%2520Oncology%26atitle%3DImaging%252Band%252BTherapy%252Bof%252BPancreatic%252BCancer%252Bwith%252BPhosphatidylserine-Targeted%252BNanovesicles%26aulast%3DBlanco%26aufirst%3DVictor%2BM.%26date%3D2015%26volume%3D8%26issue%3D3%26spage%3D196%26epage%3D203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kendra  Marcus</span>, <span class="hlFld-ContribAuthor ">Carla  Mattos</span>. </span><span class="cited-content_cbyCitation_article-title">Direct Attack on RAS: Intramolecular Communication and Mutation-Specific Effects. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2015,</strong> <em>21 </em>
                                    (8)
                                     , 1810-1818. <a href="https://doi.org/10.1158/1078-0432.CCR-14-2148" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-14-2148</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-14-2148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-14-2148%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DDirect%252BAttack%252Bon%252BRAS%25253A%252BIntramolecular%252BCommunication%252Band%252BMutation-Specific%252BEffects%26aulast%3DMarcus%26aufirst%3DKendra%26date%3D2015%26date%3D2015%26volume%3D21%26issue%3D8%26spage%3D1810%26epage%3D1818" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marcian E.  Van Dort</span>, <span class="hlFld-ContribAuthor ">Stefanie  Galbán</span>, <span class="hlFld-ContribAuthor ">Hanxiao  Wang</span>, <span class="hlFld-ContribAuthor ">Judith  Sebolt-Leopold</span>, <span class="hlFld-ContribAuthor ">Christopher  Whitehead</span>, <span class="hlFld-ContribAuthor ">Hao  Hong</span>, <span class="hlFld-ContribAuthor ">Alnawaz  Rehemtulla</span>, <span class="hlFld-ContribAuthor ">Brian D.  Ross</span>. </span><span class="cited-content_cbyCitation_article-title">Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2015,</strong> <em>23 </em>
                                    (7)
                                     , 1386-1394. <a href="https://doi.org/10.1016/j.bmc.2015.02.053" title="DOI URL">https://doi.org/10.1016/j.bmc.2015.02.053</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2015.02.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2015.02.053%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDual%252Binhibition%252Bof%252Ballosteric%252Bmitogen-activated%252Bprotein%252Bkinase%252B%252528MEK%252529%252Band%252Bphosphatidylinositol%252B3-kinase%252B%252528PI3K%252529%252Boncogenic%252Btargets%252Bwith%252Ba%252Bbifunctional%252Binhibitor%26aulast%3DVan%2BDort%26aufirst%3DMarcian%2BE.%26date%3D2015%26volume%3D23%26issue%3D7%26spage%3D1386%26epage%3D1394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kyle  Knickelbein</span>, <span class="hlFld-ContribAuthor ">Lin  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer. </span><span class="cited-content_cbyCitation_journal-name">Genes & Diseases</span><span> <strong>2015,</strong> <em>2 </em>
                                    (1)
                                     , 4-12. <a href="https://doi.org/10.1016/j.gendis.2014.10.002" title="DOI URL">https://doi.org/10.1016/j.gendis.2014.10.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.gendis.2014.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.gendis.2014.10.002%26sid%3Dliteratum%253Aachs%26jtitle%3DGenes%2520%2526%2520Diseases%26atitle%3DMutant%252BKRAS%252Bas%252Ba%252Bcritical%252Bdeterminant%252Bof%252Bthe%252Btherapeutic%252Bresponse%252Bof%252Bcolorectal%252Bcancer%26aulast%3DKnickelbein%26aufirst%3DKyle%26date%3D2015%26volume%3D2%26issue%3D1%26spage%3D4%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoying  Wang</span>, <span class="hlFld-ContribAuthor ">Guofang  Shu</span>, <span class="hlFld-ContribAuthor ">Chanchan  Gao</span>, <span class="hlFld-ContribAuthor ">Yu  Yang</span>, <span class="hlFld-ContribAuthor ">Qian  Xu</span>, <span class="hlFld-ContribAuthor ">Meng  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">Electrochemical biosensor based on functional composite nanofibers for detection of K-ras gene via multiple signal amplification strategy. </span><span class="cited-content_cbyCitation_journal-name">Analytical Biochemistry</span><span> <strong>2014,</strong> <em>466 </em>, 51-58. <a href="https://doi.org/10.1016/j.ab.2014.08.023" title="DOI URL">https://doi.org/10.1016/j.ab.2014.08.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ab.2014.08.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ab.2014.08.023%26sid%3Dliteratum%253Aachs%26jtitle%3DAnalytical%2520Biochemistry%26atitle%3DElectrochemical%252Bbiosensor%252Bbased%252Bon%252Bfunctional%252Bcomposite%252Bnanofibers%252Bfor%252Bdetection%252Bof%252BK-ras%252Bgene%252Bvia%252Bmultiple%252Bsignal%252Bamplification%252Bstrategy%26aulast%3DWang%26aufirst%3DXiaoying%26date%3D2014%26volume%3D466%26spage%3D51%26epage%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Punit  Upadhyaya</span>, <span class="hlFld-ContribAuthor ">Ziqing  Qian</span>, <span class="hlFld-ContribAuthor ">Nurlaila A.A.  Habir</span>, <span class="hlFld-ContribAuthor ">Dehua  Pei</span>. </span><span class="cited-content_cbyCitation_article-title">Direct Ras inhibitors identified from a structurally rigidified bicyclic peptide library. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2014,</strong> <em>70 </em>
                                    (42)
                                     , 7714-7720. <a href="https://doi.org/10.1016/j.tet.2014.05.113" title="DOI URL">https://doi.org/10.1016/j.tet.2014.05.113</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2014.05.113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2014.05.113%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DDirect%252BRas%252Binhibitors%252Bidentified%252Bfrom%252Ba%252Bstructurally%252Brigidified%252Bbicyclic%252Bpeptide%252Blibrary%26aulast%3DUpadhyaya%26aufirst%3DPunit%26date%3D2014%26volume%3D70%26issue%3D42%26spage%3D7714%26epage%3D7720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jochen  Spiegel</span>, <span class="hlFld-ContribAuthor ">Philipp M  Cromm</span>, <span class="hlFld-ContribAuthor ">Gunther  Zimmermann</span>, <span class="hlFld-ContribAuthor ">Tom N  Grossmann</span>, <span class="hlFld-ContribAuthor ">Herbert  Waldmann</span>. </span><span class="cited-content_cbyCitation_article-title">Small-molecule modulation of Ras signaling. </span><span class="cited-content_cbyCitation_journal-name">Nature Chemical Biology</span><span> <strong>2014,</strong> <em>10 </em>
                                    (8)
                                     , 613-622. <a href="https://doi.org/10.1038/nchembio.1560" title="DOI URL">https://doi.org/10.1038/nchembio.1560</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nchembio.1560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnchembio.1560%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Chemical%2520Biology%26atitle%3DSmall-molecule%252Bmodulation%252Bof%252BRas%252Bsignaling%26aulast%3DSpiegel%26aufirst%3DJochen%26date%3D2014%26date%3D2014%26volume%3D10%26issue%3D8%26spage%3D613%26epage%3D622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jessica R.  Maximino</span>, <span class="hlFld-ContribAuthor ">Gabriela P.  de Oliveira</span>, <span class="hlFld-ContribAuthor ">Chrystian J.  Alves</span>, <span class="hlFld-ContribAuthor ">Gerson  Chadi</span>. </span><span class="cited-content_cbyCitation_article-title">Deregulated expression of cytoskeleton related genes in the spinal cord and sciatic nerve of presymptomatic SOD1G93A Amyotrophic Lateral Sclerosis mouse model. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cellular Neuroscience</span><span> <strong>2014,</strong> <em>8 </em><a href="https://doi.org/10.3389/fncel.2014.00148" title="DOI URL">https://doi.org/10.3389/fncel.2014.00148</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fncel.2014.00148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffncel.2014.00148%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cellular%2520Neuroscience%26atitle%3DDeregulated%252Bexpression%252Bof%252Bcytoskeleton%252Brelated%252Bgenes%252Bin%252Bthe%252Bspinal%252Bcord%252Band%252Bsciatic%252Bnerve%252Bof%252Bpresymptomatic%252BSOD1G93A%252BAmyotrophic%252BLateral%252BSclerosis%252Bmouse%252Bmodel%26aulast%3DMaximino%26aufirst%3DJessica%2BR.%26date%3D2014%26date%3D2014%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">W.  Zhang</span>, <span class="hlFld-ContribAuthor ">N.  Nandakumar</span>, <span class="hlFld-ContribAuthor ">Y.  Shi</span>, <span class="hlFld-ContribAuthor ">M.  Manzano</span>, <span class="hlFld-ContribAuthor ">A.  Smith</span>, <span class="hlFld-ContribAuthor ">G.  Graham</span>, <span class="hlFld-ContribAuthor ">S.  Gupta</span>, <span class="hlFld-ContribAuthor ">E. E.  Vietsch</span>, <span class="hlFld-ContribAuthor ">S. Z.  Laughlin</span>, <span class="hlFld-ContribAuthor ">M.  Wadhwa</span>, <span class="hlFld-ContribAuthor ">M.  Chetram</span>, <span class="hlFld-ContribAuthor ">M.  Joshi</span>, <span class="hlFld-ContribAuthor ">F.  Wang</span>, <span class="hlFld-ContribAuthor ">B.  Kallakury</span>, <span class="hlFld-ContribAuthor ">J.  Toretsky</span>, <span class="hlFld-ContribAuthor ">A.  Wellstein</span>, <span class="hlFld-ContribAuthor ">C.  Yi</span>. </span><span class="cited-content_cbyCitation_article-title">Downstream of Mutant KRAS, the Transcription Regulator YAP Is Essential for Neoplastic Progression to Pancreatic Ductal Adenocarcinoma. </span><span class="cited-content_cbyCitation_journal-name">Science Signaling</span><span> <strong>2014,</strong> <em>7 </em>
                                    (324)
                                     , ra42-ra42. <a href="https://doi.org/10.1126/scisignal.2005049" title="DOI URL">https://doi.org/10.1126/scisignal.2005049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1126/scisignal.2005049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1126%2Fscisignal.2005049%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%2520Signaling%26atitle%3DDownstream%252Bof%252BMutant%252BKRAS%25252C%252Bthe%252BTranscription%252BRegulator%252BYAP%252BIs%252BEssential%252Bfor%252BNeoplastic%252BProgression%252Bto%252BPancreatic%252BDuctal%252BAdenocarcinoma%26aulast%3DZhang%26aufirst%3DW.%26date%3D2014%26date%3D2014%26volume%3D7%26issue%3D324%26spage%3Dra42%26epage%3Dra42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nilufer  Avci</span>, <span class="hlFld-ContribAuthor ">Gulsah  Cecener</span>, <span class="hlFld-ContribAuthor ">Adem  Deligonul</span>, <span class="hlFld-ContribAuthor ">Elif  Erturk</span>, <span class="hlFld-ContribAuthor ">Berrin  Tunca</span>, <span class="hlFld-ContribAuthor ">Unal  Egeli</span>, <span class="hlFld-ContribAuthor ">Gulcin  Tezcan</span>, <span class="hlFld-ContribAuthor ">Elif Ulker  Akyildiz</span>, <span class="hlFld-ContribAuthor ">Ahmet Sami  Bayram</span>, <span class="hlFld-ContribAuthor ">Cengiz  Gebitekin</span>, <span class="hlFld-ContribAuthor ">Ender  Kurt</span>, <span class="hlFld-ContribAuthor ">Turkkan  Evrensel</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Markers for Patients with Thymic Malignancies: not Feasible at Present?. </span><span class="cited-content_cbyCitation_journal-name">Asian Pacific Journal of Cancer Prevention</span><span> <strong>2014,</strong> <em>15 </em>
                                    (8)
                                     , 3457-3460. <a href="https://doi.org/10.7314/APJCP.2014.15.8.3457" title="DOI URL">https://doi.org/10.7314/APJCP.2014.15.8.3457</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.7314/APJCP.2014.15.8.3457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.7314%2FAPJCP.2014.15.8.3457%26sid%3Dliteratum%253Aachs%26jtitle%3DAsian%2520Pacific%2520Journal%2520of%2520Cancer%2520Prevention%26atitle%3DMolecular%252BMarkers%252Bfor%252BPatients%252Bwith%252BThymic%252BMalignancies%25253A%252Bnot%252BFeasible%252Bat%252BPresent%25253F%26aulast%3DAvci%26aufirst%3DNilufer%26date%3D2014%26volume%3D15%26issue%3D8%26spage%3D3457%26epage%3D3460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nathan  Schuld</span>, <span class="hlFld-ContribAuthor ">Andrew  Hauser</span>, <span class="hlFld-ContribAuthor ">Adam  Gastonguay</span>, <span class="hlFld-ContribAuthor ">Jessica  Wilson</span>, <span class="hlFld-ContribAuthor ">Ellen  Lorimer</span>, <span class="hlFld-ContribAuthor ">Carol  Williams</span>. </span><span class="cited-content_cbyCitation_article-title">SmgGDS-558 regulates the cell cycle in pancreatic, non-small cell lung, and breast cancers. </span><span class="cited-content_cbyCitation_journal-name">Cell Cycle</span><span> <strong>2014,</strong> <em>13 </em>
                                    (6)
                                     , 941-952. <a href="https://doi.org/10.4161/cc.27804" title="DOI URL">https://doi.org/10.4161/cc.27804</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4161/cc.27804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4161%2Fcc.27804%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Cycle%26atitle%3DSmgGDS-558%252Bregulates%252Bthe%252Bcell%252Bcycle%252Bin%252Bpancreatic%25252C%252Bnon-small%252Bcell%252Blung%25252C%252Band%252Bbreast%252Bcancers%26aulast%3DSchuld%26aufirst%3DNathan%26date%3D2014%26date%3D2014%26volume%3D13%26issue%3D6%26spage%3D941%26epage%3D952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jia  Gao</span>, <span class="hlFld-ContribAuthor ">Rongsheng  Ma</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Na  Wang</span>, <span class="hlFld-ContribAuthor ">Ryan  Sasaki</span>, <span class="hlFld-ContribAuthor ">David  Snyderman</span>, <span class="hlFld-ContribAuthor ">Jihui  Wu</span>, <span class="hlFld-ContribAuthor ">Ke  Ruan</span>, . </span><span class="cited-content_cbyCitation_article-title">Automated NMR Fragment Based Screening Identified a Novel Interface Blocker to the LARG/RhoA Complex. </span><span class="cited-content_cbyCitation_journal-name">PLoS ONE</span><span> <strong>2014,</strong> <em>9 </em>
                                    (2)
                                     , e88098. <a href="https://doi.org/10.1371/journal.pone.0088098" title="DOI URL">https://doi.org/10.1371/journal.pone.0088098</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0088098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0088098%26sid%3Dliteratum%253Aachs%26jtitle%3DPLoS%2520ONE%26atitle%3DAutomated%252BNMR%252BFragment%252BBased%252BScreening%252BIdentified%252Ba%252BNovel%252BInterface%252BBlocker%252Bto%252Bthe%252BLARG%25252FRhoA%252BComplex%26aulast%3DGao%26aufirst%3DJia%26date%3D2014%26date%3D2014%26volume%3D9%26issue%3D2%26spage%3De88098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rhys Dylan  Taylor</span>, <span class="hlFld-ContribAuthor ">Sefan  Asamitsu</span>, <span class="hlFld-ContribAuthor ">Tomohiro  Takenaka</span>, <span class="hlFld-ContribAuthor ">Makoto  Yamamoto</span>, <span class="hlFld-ContribAuthor ">Kaori  Hashiya</span>, <span class="hlFld-ContribAuthor ">Yusuke  Kawamoto</span>, <span class="hlFld-ContribAuthor ">Toshikazu  Bando</span>, <span class="hlFld-ContribAuthor ">Hiroki  Nagase</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Sugiyama</span>. </span><span class="cited-content_cbyCitation_article-title">Sequence-Specific DNA Alkylation Targeting for Kras Codon 13 Mutation by Pyrrole-Imidazole Polyamide
              seco
              -CBI Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Chemistry - A European Journal</span><span> <strong>2014,</strong> <em>20 </em>
                                    (5)
                                     , 1310-1317. <a href="https://doi.org/10.1002/chem.201303295" title="DOI URL">https://doi.org/10.1002/chem.201303295</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.201303295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.201303295%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520-%2520A%2520European%2520Journal%26atitle%3DSequence-Specific%252BDNA%252BAlkylation%252BTargeting%252Bfor%252BKras%252BCodon%2525E2%252580%25258513%252BMutation%252Bby%252BPyrrole-Imidazole%252BPolyamide%252Bseco%252B-CBI%252BConjugates%26aulast%3DTaylor%26aufirst%3DRhys%2BDylan%26date%3D2014%26date%3D2013%26volume%3D20%26issue%3D5%26spage%3D1310%26epage%3D1317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Timothy John  Perren</span>, <span class="hlFld-ContribAuthor ">Faisal  Al-Terkait</span>, <span class="hlFld-ContribAuthor ">Sheryl  Sim</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in the Medical Management of Ovarian Cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,, 77-107. <a href="https://doi.org/10.1007/978-1-4471-2942-4_4" title="DOI URL">https://doi.org/10.1007/978-1-4471-2942-4_4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-1-4471-2942-4_4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-1-4471-2942-4_4%26sid%3Dliteratum%253Aachs%26atitle%3DAdvances%252Bin%252Bthe%252BMedical%252BManagement%252Bof%252BOvarian%252BCancer%26aulast%3DPerren%26aufirst%3DTimothy%2BJohn%26date%3D2014%26date%3D2014%26spage%3D77%26epage%3D107%26pub%3DSpringer%2520London%26atitle%3DPathology%252Bof%252Bthe%252BOvary%25252C%252BFallopian%252BTube%252Band%252BPeritoneum%26aulast%3DWilkinson%26aufirst%3DNafisa%26date%3D2014%26volume%3D120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Raymond R.  Mattingly</span>. </span><span class="cited-content_cbyCitation_article-title">Activated Ras as a Therapeutic Target: Constraints on Directly Targeting Ras Isoforms and Wild-Type versus Mutated Proteins. </span><span class="cited-content_cbyCitation_journal-name">ISRN Oncology</span><span> <strong>2013,</strong> <em>2013 </em>, 1-14. <a href="https://doi.org/10.1155/2013/536529" title="DOI URL">https://doi.org/10.1155/2013/536529</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1155/2013/536529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1155%2F2013%2F536529%26sid%3Dliteratum%253Aachs%26jtitle%3DISRN%2520Oncology%26atitle%3DActivated%252BRas%252Bas%252Ba%252BTherapeutic%252BTarget%25253A%252BConstraints%252Bon%252BDirectly%252BTargeting%252BRas%252BIsoforms%252Band%252BWild-Type%252Bversus%252BMutated%252BProteins%26aulast%3DMattingly%26aufirst%3DRaymond%2BR.%26date%3D2013%26volume%3D2013%26spage%3D1%26epage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brendan  Frett</span>, <span class="hlFld-ContribAuthor ">Yuanxiang  Wang</span>, <span class="hlFld-ContribAuthor ">Hong-yu  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the K-Ras/PDE
              δ
              Protein-Protein Interaction: The Solution for Ras-Driven Cancers or Just Another Therapeutic Mirage?. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2013,</strong> <em>26 </em>, n/a-n/a. <a href="https://doi.org/10.1002/cmdc.201300311" title="DOI URL">https://doi.org/10.1002/cmdc.201300311</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201300311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201300311%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DTargeting%252Bthe%252BK-Ras%25252FPDE%252B%2525CE%2525B4%252BProtein-Protein%252BInteraction%25253A%252BThe%252BSolution%252Bfor%252BRas-Driven%252BCancers%252Bor%252BJust%252BAnother%252BTherapeutic%252BMirage%25253F%26aulast%3DFrett%26aufirst%3DBrendan%26date%3D2013%26date%3D2013%26volume%3D26%26spage%3Dn%252Fa%26epage%3Dn%252Fa" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jonathan M.  Cooper</span>, <span class="hlFld-ContribAuthor ">Brian O.  Bodemann</span>, <span class="hlFld-ContribAuthor ">Michael A.  White</span>. </span><span class="cited-content_cbyCitation_article-title">The RalGEF/Ral Pathway. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2013,</strong>,, 137-156. <a href="https://doi.org/10.1016/B978-0-12-420146-0.00006-8" title="DOI URL">https://doi.org/10.1016/B978-0-12-420146-0.00006-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-420146-0.00006-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-420146-0.00006-8%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BRalGEF%25252FRal%252BPathway%26aulast%3DCooper%26aufirst%3DJonathan%2BM.%26date%3D2013%26spage%3D137%26epage%3D156%26pub%3DElsevier%26atitle%3DInhibitors%252Bof%252Bthe%252BRas%252Bsuperfamily%252BG-proteins%25252C%252BPart%252BB%26date%3D2013%26volume%3D34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_null" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/medium/jm-2012-017706_0017.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/medium/jm-2012-017706_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Post-translational processing of RAS proteins. Farnesyltransferase (FTase) catalyzes the transfer of a farnesyl group to the terminal cysteine of new synthesized RAS proteins. Next, the three C-terminal amino acids are cleaved by the endopeptidase RAS-converting enzyme 1 (RCE1). Carboxymethylation of of the terminal cysteine residue is accomplished by isoprenylcysteine carboxylmethyltransferase 1 (ICMT1). Finally, palmitoyl transferase (PTase) transfers a palmitoyl group to C-terminal cysteine residues of HRAS, NRAS, and the KRAS-4A isoform.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/medium/jm-2012-017706_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Upstream signaling of RAS. Activated growth-factor-recptor tyrosine kinases undergo autophosphorylation and interact with the adaptor proteins SHC and GRB2. These proteins associate with various GEFs which exchange GDP for GTP, thereby activating the RAS protein. GAPs stimulate the RAS protein’s intrinsic GTPase activity, causing the hydrolysis of GTP to GDP, thereby inactivating the protein.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/medium/jm-2012-017706_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Downstream signaling of RAS. Ras interacts with a number of downstream effectors. The main ones include RAF protein kinases, phosphoinositide 3-kinases (PI3Ks), guanine nucleotide exchange factors for the RAS-related protein Ral (RalGDS), and phospholipase Cε (PLCε).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/medium/jm-2012-017706_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structures of <b>1</b>, <b>2</b>, <b>3</b>, and <b>4</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/medium/jm-2012-017706_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Structure of <b>5</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/medium/jm-2012-017706_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structures of <b>6</b> and <b>7</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/medium/jm-2012-017706_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (a) Structures of compounds shown to interfere with the KRAS/SOS interaction. (b) Overlay of <b>8</b> (pink) and a compound similar to <b>11</b> (teal) in the hydrophobic binding pocket of KRAS. Reproduced with permission of D. Erlanson.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/medium/jm-2012-017706_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Structures of <b>12</b>, <b>13</b>, <b>14</b>, and <b>15</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/medium/jm-2012-017706_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Structures of <b>16</b>, <b>17</b>, and <b>18</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/medium/jm-2012-017706_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Structures of selected farnesyltransferse inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/medium/jm-2012-017706_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Structures of RCE1 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/medium/jm-2012-017706_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Structure of <b>31</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/medium/jm-2012-017706_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0014.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Structures of <b>32</b>, <b>33</b>, and <b>34</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/medium/jm-2012-017706_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0015.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Structures that are active in the KRAS mutant synthetic lethal assays.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/medium/jm-2012-017706_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0016.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Structures of <b>41</b> and <b>42</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-13/jm3017706/production/images/large/jm-2012-017706_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm3017706&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i19">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31415" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31415" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 120 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Wennerberg, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossman, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span> </span><span class="NLM_article-title">The Ras superfamily at a glance</span> <span class="citation_source-journal">J. Cell Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">843</span><span class="NLM_x">–</span> <span class="NLM_lpage">846</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1242%2Fjcs.01660" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=15731001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjs12msb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2005&pages=843-846&author=K.+Wennerbergauthor=K.+L.+Rossmanauthor=C.+J.+Der&title=The+Ras+superfamily+at+a+glance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The Ras superfamily at a glance</span></div><div class="casAuthors">Wennerberg, Krister; Rossman, Kent L.; Der, Channing J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">843-846</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  The Ras superfamily of small guanosine triphosphatases (GTPases) comprise over 150 human members, with evolutionarily conserved orthologs found in Drosophila, C. elegans, S. cerevisiae, S. pombe, Dictyostelium and plants.  The Ras oncogene proteins are the founding members of this family, which is divided into five major branches on the basis of sequence and functional similarities: Ras, Rho, Rab, Ran, and Arf.  The basic structural features of Ras proteins, with respect to specific Ras sequences, are presented to highlight the general properties of this family of proteins and discuss features that distinguish the various branches of the superfamily from Ras.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGYkOKxB2I8LVg90H21EOLACvtfcHk0ljJOQAyg9zCfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjs12msb8%253D&md5=be429610b9e8581c5517194e2ebaad06</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1242%2Fjcs.01660&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.01660%26sid%3Dliteratum%253Aachs%26aulast%3DWennerberg%26aufirst%3DK.%26aulast%3DRossman%26aufirst%3DK.%2BL.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DThe%2520Ras%2520superfamily%2520at%2520a%2520glance%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2005%26volume%3D118%26spage%3D843%26epage%3D846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Adjei, A. A.</span><span> </span><span class="NLM_article-title">Blocking oncogenic Ras signaling for cancer therapy</span> <span class="citation_source-journal">J. Natl. Cancer. Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">1062</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1093%2Fjnci%2F93.14.1062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=11459867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD3MXls1Ojtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2001&pages=1062-1074&author=A.+A.+Adjei&title=Blocking+oncogenic+Ras+signaling+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Blocking oncogenic ras signaling for cancer therapy</span></div><div class="casAuthors">Adjei, Alex A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1062-1074</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  The Ras gene product is a monomeric membrane-localized G protein of 21 kd that functions as a mol. switch linking receptor and nonreceptor tyrosine kinase activation to downstream cytoplasmic or nuclear events.  Each mammalian cell contains at least 3 distinct ras proto-oncogenes encoding closely related, but distinct proteins.  Activating mutations in these Ras proteins result in constitutive signaling, thereby stimulating cell proliferation and inhibiting apoptosis.  Oncogenic mutations in the ras gene are present in approx. 30% of all human cancers.  K-ras mutations occur frequently in non-small-cell lung, colorectal, and pancreatic carcinomas; H-ras mutations are common in bladder, kidney, and thyroid carcinomas; N-ras mutations are found in melanoma, hepatocellular carcinoma, and hematol. malignancies.  The ras-signaling pathway has attracted considerable attention as a target for anticancer therapy because of its important role in carcinogenesis.  In this review, the physiol. and biochem. properties of the Ras proteins, their mechanism of cell signaling, and their relation to human cancer will be discussed.  Novel cancer therapeutic approaches based on the inhibition of Ras-mediated signaling, including inhibition of Ras processing, inhibition of Ras protein synthesis, and blockage of downstream Ras effectors, will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3KGaz7MPcrLVg90H21EOLACvtfcHk0ljJOQAyg9zCfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXls1Ojtrg%253D&md5=583d951206daaf33f2ee369eb43910a5</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F93.14.1062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F93.14.1062%26sid%3Dliteratum%253Aachs%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DBlocking%2520oncogenic%2520Ras%2520signaling%2520for%2520cancer%2520therapy%26jtitle%3DJ.%2520Natl.%2520Cancer.%2520Inst.%26date%3D2001%26volume%3D93%26spage%3D1062%26epage%3D1074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Karnoub, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, R. A.</span><span> </span><span class="NLM_article-title">Ras oncogenes: split personalities</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">517</span><span class="NLM_x">–</span> <span class="NLM_lpage">531</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1038%2Fnrm2438" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=18568040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsFGnsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=517-531&author=A.+E.+Karnoubauthor=R.+A.+Weinberg&title=Ras+oncogenes%3A+split+personalities"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Ras oncogenes: split personalities</span></div><div class="casAuthors">Karnoub, Antoine E.; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">517-531</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Extensive research over the past 30 years has revealed the involvement of Ras not only in tumorigenesis but also in many developmental disorders.  The complexity of the mol. and cell biol. mechanisms of action of Ras proteins indicates that much remains to be learns.  Extensive research on the Ras proteins and their functions in cell physiol. over the past 30 years has led to numerous insights that have revealed the involvement of Ras not only in tumorigenesis but also in many developmental disorders.  Despite great strides in our understanding of the mol. and cellular mechanisms of action of the Ras proteins, the expanding roster of their downstream effectors and the complexity of the signaling cascades that they regulate indicate that much remains to be learns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocptUdlhqaM7Vg90H21EOLACvtfcHk0ljDN-2qFAqOIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsFGnsr0%253D&md5=9de78b17b953b2560238d7a98f3bea6a</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrm2438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2438%26sid%3Dliteratum%253Aachs%26aulast%3DKarnoub%26aufirst%3DA.%2BE.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DRas%2520oncogenes%253A%2520split%2520personalities%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2008%26volume%3D9%26spage%3D517%26epage%3D531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Friday, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span> </span><span class="NLM_article-title">K-ras as a target for cancer therapy</span> <span class="citation_source-journal">Biochim. Biophys. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">1756</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">144</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1756&publication_year=2005&pages=127-144&author=B.+B.+Fridayauthor=A.+A.+Adjei&title=K-ras+as+a+target+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFriday%26aufirst%3DB.%2BB.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DK-ras%2520as%2520a%2520target%2520for%2520cancer%2520therapy%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D2005%26volume%3D1756%26spage%3D127%26epage%3D144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Pylayeva-Gupta, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grabocka, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bar-Sagi, D.</span><span> </span><span class="NLM_article-title">RAS oncogenes: weaving a tumorigenic web</span> <span class="citation_source-journal">Nat. Rev., Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">761</span><span class="NLM_x">–</span> <span class="NLM_lpage">774</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1038%2Fnrc3106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=21993244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlSkur7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=761-774&author=Y.+Pylayeva-Guptaauthor=E.+Grabockaauthor=D.+Bar-Sagi&title=RAS+oncogenes%3A+weaving+a+tumorigenic+web"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">RAS oncogenes: weaving a tumorigenic web</span></div><div class="casAuthors">Pylayeva-Gupta, Yuliya; Grabocka, Elda; Bar-Sagi, Dafna</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">761-774</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  RAS proteins are essential components of signalling pathways that emanate from cell surface receptors.  Oncogenic activation of these proteins owing to missense mutations is frequently detected in several types of cancer.  A wealth of biochem. and genetic studies indicates that RAS proteins control a complex mol. circuitry that consists of a wide array of interconnecting pathways.  In this Review, we describe how RAS oncogenes exploit their extensive signalling reach to affect multiple cellular processes that drive tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdHRt0jsiXtLVg90H21EOLACvtfcHk0ljDN-2qFAqOIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlSkur7K&md5=d1be47023ab43a30cb81e71cb92bc0aa</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrc3106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3106%26sid%3Dliteratum%253Aachs%26aulast%3DPylayeva-Gupta%26aufirst%3DY.%26aulast%3DGrabocka%26aufirst%3DE.%26aulast%3DBar-Sagi%26aufirst%3DD.%26atitle%3DRAS%2520oncogenes%253A%2520weaving%2520a%2520tumorigenic%2520web%26jtitle%3DNat.%2520Rev.%252C%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D761%26epage%3D774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Downward, J.</span><span> </span><span class="NLM_article-title">Targeting RAS signalling pathways in cancer therapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1038%2Fnrc969" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=12509763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD38XpvVertbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=11-22&author=J.+Downward&title=Targeting+RAS+signalling+pathways+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting RAS signalling pathways in cancer therapy</span></div><div class="casAuthors">Downward, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-22</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The RAS proteins control signaling pathways that are key regulators of several aspects of normal cell growth and malignant transformation.  They are aberrant in most human tumors due to activating mutations in the RAS genes themselves or to alterations in upstream or downstream signaling components.  Rational therapies that target the RAS pathways might inhibit tumor growth, survival and spread.  Several of these new therapeutic agents are showing promise in the clinic and many more are being developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwKF9JX2sXtbVg90H21EOLACvtfcHk0ljDN-2qFAqOIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpvVertbo%253D&md5=85ea9312480c3ca01f2a94faae7b84e7</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrc969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc969%26sid%3Dliteratum%253Aachs%26aulast%3DDownward%26aufirst%3DJ.%26atitle%3DTargeting%2520RAS%2520signalling%2520pathways%2520in%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2003%26volume%3D3%26spage%3D11%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Podsypanina, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beverly, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H. E.</span><span> </span><span class="NLM_article-title">Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">5242</span><span class="NLM_x">–</span> <span class="NLM_lpage">5247</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=5242-5247&author=K.+Podsypaninaauthor=K.+Politiauthor=L.+J.+Beverlyauthor=H.+E.+Varmus&title=Oncogene+cooperation+in+tumor+maintenance+and+tumor+recurrence+in+mouse+mammary+tumors+induced+by+Myc+and+mutant+Kras"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPodsypanina%26aufirst%3DK.%26aulast%3DPoliti%26aufirst%3DK.%26aulast%3DBeverly%26aufirst%3DL.%2BJ.%26aulast%3DVarmus%26aufirst%3DH.%2BE.%26atitle%3DOncogene%2520cooperation%2520in%2520tumor%2520maintenance%2520and%2520tumor%2520recurrence%2520in%2520mouse%2520mammary%2520tumors%2520induced%2520by%2520Myc%2520and%2520mutant%2520Kras%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D5242%26epage%3D5247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Chin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pomerantz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holash, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bardeesy, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Hagan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pantginis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horner, J. W.,  2nd.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordon-Cardo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yancopoulos, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DePinho, R. A.</span><span> </span><span class="NLM_article-title">Essential role for oncogenic Ras in tumour maintenance</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">400</span><span class="NLM_x">, </span> <span class="NLM_fpage">468</span><span class="NLM_x">–</span> <span class="NLM_lpage">472</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=400&publication_year=1999&pages=468-472&author=L.+Chinauthor=A.+Tamauthor=J.+Pomerantzauthor=M.+Wongauthor=J.+Holashauthor=N.+Bardeesyauthor=Q.+Shenauthor=R.+O%E2%80%99Haganauthor=J.+Pantginisauthor=H.+Zhouauthor=J.+W.+Hornerauthor=C.+Cordon-Cardoauthor=G.+D.+Yancopoulosauthor=R.+A.+DePinho&title=Essential+role+for+oncogenic+Ras+in+tumour+maintenance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChin%26aufirst%3DL.%26aulast%3DTam%26aufirst%3DA.%26aulast%3DPomerantz%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DM.%26aulast%3DHolash%26aufirst%3DJ.%26aulast%3DBardeesy%26aufirst%3DN.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DO%25E2%2580%2599Hagan%26aufirst%3DR.%26aulast%3DPantginis%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DHorner%26aufirst%3DJ.%2BW.%26aulast%3DCordon-Cardo%26aufirst%3DC.%26aulast%3DYancopoulos%26aufirst%3DG.%2BD.%26aulast%3DDePinho%26aufirst%3DR.%2BA.%26atitle%3DEssential%2520role%2520for%2520oncogenic%2520Ras%2520in%2520tumour%2520maintenance%26jtitle%3DNature%26date%3D1999%26volume%3D400%26spage%3D468%26epage%3D472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Gysin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCormick, F.</span><span> </span><span class="NLM_article-title">Therapeutic strategies for targeting ras proteins</span> <span class="citation_source-journal">Genes Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">359</span><span class="NLM_x">–</span> <span class="NLM_lpage">372</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1177%2F1947601911412376" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=21779505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvFWlsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=359-372&author=S.+Gysinauthor=M.+Saltauthor=A.+Youngauthor=F.+McCormick&title=Therapeutic+strategies+for+targeting+ras+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic strategies for targeting Ras proteins</span></div><div class="casAuthors">Gysin, Stephan; Salt, Megan; Young, Amy; McCormick, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">359-372</span>CODEN:
                <span class="NLM_cas:coden">GCEAAY</span>;
        ISSN:<span class="NLM_cas:issn">1947-6019</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Ras genes are frequently activated in cancer.  Attempts to develop drugs that target mutant Ras proteins have, so far, been unsuccessful.  Tumors bearing these mutations, therefore, remain among the most difficult to treat.  Most efforts to block activated Ras have focused on pathways downstream.  Drugs that inhibit Raf kinase have shown clin. benefit in the treatment of malignant melanoma.  However, these drugs have failed to show clin. benefit in Ras mutant tumors.  It remains unclear to what extent Ras depends on Raf kinase for transforming activity, even though Raf proteins bind directly to Ras and are certainly major effectors of Ras action in normal cells and in development.  Furthermore, Raf kinase inhibitors can lead to paradoxical activation of the MAPK pathway.  MEK inhibitors block the Ras-MAPK pathway, but often activate the PI3'-kinase, and have shown little clin. benefit as single agents.  This activation is mediated by EGF-R and other receptor tyrosine kinases through relief of a neg. feedback loop from ERK.  Drug combinations that target multiple points within the Ras signaling network are likely to be necessary to achieve substantial clin. benefit.  Other effectors may also contribute to Ras signaling and provide a source of targets.  In addn., unbiased screens for genes necessary for Ras transformation have revealed new potential targets and have added to our understanding of Ras cancer biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTnzEvjaufXrVg90H21EOLACvtfcHk0liKPKlYe-pfgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvFWlsbY%253D&md5=f680dda525256c8388e417d45ebe4299</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1177%2F1947601911412376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1947601911412376%26sid%3Dliteratum%253Aachs%26aulast%3DGysin%26aufirst%3DS.%26aulast%3DSalt%26aufirst%3DM.%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DMcCormick%26aufirst%3DF.%26atitle%3DTherapeutic%2520strategies%2520for%2520targeting%2520ras%2520proteins%26jtitle%3DGenes%2520Cancer%26date%3D2011%26volume%3D2%26spage%3D359%26epage%3D372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Sun, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burns, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olejniczak, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waterson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossanese, O. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fesik, S. W.</span><span> </span><span class="NLM_article-title">Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">6140</span><span class="NLM_x">–</span> <span class="NLM_lpage">6143</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1002%2Fanie.201201358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BC38Xms1entr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=6140-6143&author=Q.+Sunauthor=J.+P.+Burkeauthor=J.+Phanauthor=M.+C.+Burnsauthor=E.+T.+Olejniczakauthor=A.+G.+Watersonauthor=T.+Leeauthor=O.+W.+Rossaneseauthor=S.+W.+Fesik&title=Discovery+of+small+molecules+that+bind+to+K-Ras+and+inhibit+Sos-mediated+activation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-Mediated Activation</span></div><div class="casAuthors">Sun, Qi; Burke, Jason P.; Phan, Jason; Burns, Michael C.; Olejniczak, Edward T.; Waterson, Alex G.; Lee, Taekyu; Rossanese, Olivia W.; Fesik, Stephen W.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">6140-6143, S6140/1-S6140/17</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">K-Ras inhibition represents an attractive therapeutic strategy for many cancers.  We report on the discovery of novel small mols. that bind directly to K-Ras between switch I and switch II and inhibit Sos-catalyzed K-Ras activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpy5Cx7BSO1pLVg90H21EOLACvtfcHk0liKPKlYe-pfgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xms1entr4%253D&md5=7d579523462aaf7eac1890643f91fab3</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fanie.201201358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201201358%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DBurke%26aufirst%3DJ.%2BP.%26aulast%3DPhan%26aufirst%3DJ.%26aulast%3DBurns%26aufirst%3DM.%2BC.%26aulast%3DOlejniczak%26aufirst%3DE.%2BT.%26aulast%3DWaterson%26aufirst%3DA.%2BG.%26aulast%3DLee%26aufirst%3DT.%26aulast%3DRossanese%26aufirst%3DO.%2BW.%26aulast%3DFesik%26aufirst%3DS.%2BW.%26atitle%3DDiscovery%2520of%2520small%2520molecules%2520that%2520bind%2520to%2520K-Ras%2520and%2520inhibit%2520Sos-mediated%2520activation%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2012%26volume%3D51%26spage%3D6140%26epage%3D6143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Fletcher, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, A. D.</span><span> </span><span class="NLM_article-title">Targeting protein–protein interactions by rational design: mimicry of protein surfaces</span> <span class="citation_source-journal">J. R. Soc. Interface</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">215</span><span class="NLM_x">–</span> <span class="NLM_lpage">233</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1098%2Frsif.2006.0115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=16849232" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD2sXls1Cltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=215-233&author=S.+Fletcherauthor=A.+D.+Hamilton&title=Targeting+protein%E2%80%93protein+interactions+by+rational+design%3A+mimicry+of+protein+surfaces"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting protein-protein interactions by rational design: mimicry of protein surfaces</span></div><div class="casAuthors">Fletcher, Steven; Hamilton, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Royal Society, Interface</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">215-233</span>CODEN:
                <span class="NLM_cas:coden">JRSICU</span>;
        ISSN:<span class="NLM_cas:issn">1742-5689</span>.
    
            (<span class="NLM_cas:orgname">Royal Society</span>)
        </div><div class="casAbstract">A review.  Protein-protein interactions play key roles in a range of biol. processes, and are therefore important targets for the design of novel therapeutics.  Unlike in the design of enzyme active site inhibitors, the disruption of protein-protein interactions is far more challenging, due to such factors as the large interfacial areas involved and the relatively flat and featureless topologies of these surfaces.  Nevertheless, in spite of such challenges, there has been considerable progress in recent years.  In this review, we discuss this progress in the context of mimicry of protein surfaces: targeting protein-protein interactions by rational design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxKr4YNJ6khLVg90H21EOLACvtfcHk0liKPKlYe-pfgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXls1Cltg%253D%253D&md5=e4a7eaf80e4e81291d504a9aef85ad02</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1098%2Frsif.2006.0115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frsif.2006.0115%26sid%3Dliteratum%253Aachs%26aulast%3DFletcher%26aufirst%3DS.%26aulast%3DHamilton%26aufirst%3DA.%2BD.%26atitle%3DTargeting%2520protein%25E2%2580%2593protein%2520interactions%2520by%2520rational%2520design%253A%2520mimicry%2520of%2520protein%2520surfaces%26jtitle%3DJ.%2520R.%2520Soc.%2520Interface%26date%3D2006%26volume%3D3%26spage%3D215%26epage%3D233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Ghobrial, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span> </span><span class="NLM_article-title">Inhibitors of the ras oncogene as therapeutic targets</span> <span class="citation_source-journal">Hematol. Oncol. Clin. North Am.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1065</span><span class="NLM_x">–</span> <span class="NLM_lpage">1088</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1016%2FS0889-8588%2802%2900050-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=12512383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A280%3ADC%252BD3s%252FgsleitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2002&pages=1065-1088&author=I.+M.+Ghobrialauthor=A.+A.+Adjei&title=Inhibitors+of+the+ras+oncogene+as+therapeutic+targets"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of the ras oncogene as therapeutic targets</span></div><div class="casAuthors">Ghobrial Irene M; Adjei Alex A</div><div class="citationInfo"><span class="NLM_cas:title">Hematology/oncology clinics of North America</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1065-88</span>
        ISSN:<span class="NLM_cas:issn">0889-8588</span>.
    </div><div class="casAbstract">Advances in our understanding of the molecular pathways and genetic mutations that control tumor cell proliferation and metastasis present an opportunity to develop novel, mechanism-based therapeutic strategies.  Ras mutations are the most frequently activated oncogenes in human tumors, with over 30% expressing ras mutations.  Molecular dissection of the signaling pathway and the mechanisms of ras anchorage, post-translational modification, and downstream effector signaling of ras now under intensive investigation will help us to design additional methods for ras-directed therapy in an effort to reach an optimal treatment for human tumors that will most likely comprise a combination of modalities targeted at the different underlying genetic defects.  The successes and limitations of ras-targeted therapies must be viewed in light of the increasing understanding of the complexity of the ras-signaling pathway.  Only now are we beginning to discover the many functions of this integrated pathway, such as the differences between the actions of various ras isoforms that may affect our choice of therapeutic approach.  Many of these Ras therapeutic targets have shown success in preclinical studies, and some have shown efficacy in clinical trials with minimal toxicities.  Compounds that block ras-transforming activity without affecting normal ras function seem more attractive for the future development of ras-targeted therapy.  FTIs may partially fulfill such requirements.  Based on their specific, novel, and mechanism-based action; minimal toxicity; and encouraging responses in clinical trials, the development of Ras therapeutic targets as single agents or in combination with conventional chemotherapy and radiotherapy should be pursued.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5fkskOa0PLDQLBVDQn4bCfW6udTcc2eaxkiii9dX7x7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3s%252FgsleitA%253D%253D&md5=322dbf27931d9e5130d5df1bd2715cab</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS0889-8588%2802%2900050-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0889-8588%252802%252900050-3%26sid%3Dliteratum%253Aachs%26aulast%3DGhobrial%26aufirst%3DI.%2BM.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DInhibitors%2520of%2520the%2520ras%2520oncogene%2520as%2520therapeutic%2520targets%26jtitle%3DHematol.%2520Oncol.%2520Clin.%2520North%2520Am.%26date%3D2002%26volume%3D16%26spage%3D1065%26epage%3D1088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Adjei, A. A.</span><span> </span><span class="NLM_article-title">Farnesyltransferase inhibitors</span> <span class="citation_source-journal">Cancer Chemother. Biol. Response Modif.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">149</span><span class="NLM_x">–</span> <span class="NLM_lpage">164</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=11686012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlvVWjsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2001&pages=149-164&author=A.+A.+Adjei&title=Farnesyltransferase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Farnesyltransferase inhibitors</span></div><div class="casAuthors">Adjei, Alex A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Biological Response Modifiers</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">149-164</span>CODEN:
                <span class="NLM_cas:coden">CCBAED</span>;
        ISSN:<span class="NLM_cas:issn">0921-4410</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review discusses the development, preclin. pharmacol., mechanism of action, clin. studies, and toxicity profile of farnesyltransferase inhibitors (FTIs).  Farnesyltransferase inhibition was envisioned as a strategy for interfering with ras-dependent cell transformation, thus, various FTIs have been developed.  Four FTIs are in clin. trials worldwide, with several more at different levels of preclin. development.  Two of these, R115777 and SCH66336, are orally active heterocyclic compds. and are in phase II studies.  The other two agents, L778123 and BMS214662, are administered i.v. and are in phase I trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpkHrVNdV-arVg90H21EOLACvtfcHk0lgV5td9CXAXsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlvVWjsrc%253D&md5=43f49e89ed99f7e8b038e053a144f14b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DFarnesyltransferase%2520inhibitors%26jtitle%3DCancer%2520Chemother.%2520Biol.%2520Response%2520Modif.%26date%3D2001%26volume%3D19%26spage%3D149%26epage%3D164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Cho, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. I.</span><span> </span><span class="NLM_article-title">Chemistry and biology of Ras farnesyltransferase</span> <span class="citation_source-journal">Arch. Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">759</span><span class="NLM_x">–</span> <span class="NLM_lpage">769</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1007%2FBF02976989" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=12510823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD3sXht1answ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2002&pages=759-769&author=K.+N.+Choauthor=K.+I.+Lee&title=Chemistry+and+biology+of+Ras+farnesyltransferase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Chemistry and biology of Ras farnesyltransferase</span></div><div class="casAuthors">Cho, Kwang-Nym; Lee, Kee-In</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Pharmacal Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">759-769</span>CODEN:
                <span class="NLM_cas:coden">APHRDQ</span>;
        ISSN:<span class="NLM_cas:issn">0253-6269</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Korea</span>)
        </div><div class="casAbstract">A review.  Mutated forms of ras are found in many human tumors and the rate of incidence is significantly higher in colon and pancreatic cancers.  The protein product from the ras oncogene is a small G-protein, p21ras (Ras) that is known to play a key role in the signal transduction cascade and cell differentiation and proliferation.  Mutated Ras is unable to regulate itself and remains constantly activated, leading to uncontrolled cell growth.  The function of Ras in signal transduction requires its location near the growth factor receptor at the cell membrane.  However, Ras does not have a transmembrane domain.  Ras requires farnesylation to increase its hydrophobicity and subsequent plasma membrane assocn. for its transforming activity.  This key post-translational modification is catalyzed by the enzyme Ras farnesyltransferase (FTase), which transfers a farnesyl group from farnesylpyrophosphate to the C-terminal cysteine of the Ras protein.  The requirement has focused attention on FTase as a target for therapeutic intervention.  Selective inhibition of FTase will prevent Ras protein from assocn. with the plasma membrane, leading to a disruption of oncogenic Ras function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFTfS6GqBY1bVg90H21EOLACvtfcHk0lgV5td9CXAXsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXht1answ%253D%253D&md5=bfb36fbd490be4bf060dae517bd16735</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1007%2FBF02976989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF02976989%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DK.%2BN.%26aulast%3DLee%26aufirst%3DK.%2BI.%26atitle%3DChemistry%2520and%2520biology%2520of%2520Ras%2520farnesyltransferase%26jtitle%3DArch.%2520Pharm.%2520Res.%26date%3D2002%26volume%3D25%26spage%3D759%26epage%3D769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Casey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solski, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buss, J. E.</span><span> </span><span class="NLM_article-title">p21ras is modified by a farnesyl isoprenoid</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">8323</span><span class="NLM_x">–</span> <span class="NLM_lpage">8327</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=1989&pages=8323-8327&author=P.+J.+Caseyauthor=P.+A.+Solskiauthor=C.+J.+Derauthor=J.+E.+Buss&title=p21ras+is+modified+by+a+farnesyl+isoprenoid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCasey%26aufirst%3DP.%2BJ.%26aulast%3DSolski%26aufirst%3DP.%2BA.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26aulast%3DBuss%26aufirst%3DJ.%2BE.%26atitle%3Dp21ras%2520is%2520modified%2520by%2520a%2520farnesyl%2520isoprenoid%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1989%26volume%3D86%26spage%3D8323%26epage%3D8327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Cox, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span> </span><span class="NLM_article-title">Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?</span> <span class="citation_source-journal">Biochim. Biophys. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">1333</span><span class="NLM_x">, </span> <span class="NLM_fpage">F51</span><span class="NLM_x">–</span> <span class="NLM_lpage">F71</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1333&publication_year=1997&pages=F51-F71&author=A.+D.+Coxauthor=C.+J.+Der&title=Farnesyltransferase+inhibitors+and+cancer+treatment%3A+targeting+simply+Ras%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DA.%2BD.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DFarnesyltransferase%2520inhibitors%2520and%2520cancer%2520treatment%253A%2520targeting%2520simply%2520Ras%253F%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D1997%26volume%3D1333%26spage%3DF51%26epage%3DF71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Hancock, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magee, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Childs, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span> </span><span class="NLM_article-title">All RAS proteins are polyisoprenylated but only some are palmitoylated</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1167</span><span class="NLM_x">–</span> <span class="NLM_lpage">1177</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1016%2F0092-8674%2889%2990054-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=2661017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADyaL1MXkvFansr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1989&pages=1167-1177&author=J.+F.+Hancockauthor=A.+I.+Mageeauthor=J.+E.+Childsauthor=C.+J.+Marshall&title=All+RAS+proteins+are+polyisoprenylated+but+only+some+are+palmitoylated"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">All ras proteins are polyisoprenylated but only some are palmitoylated</span></div><div class="casAuthors">Hancock, John F.; Magee, Anthony I.; Childs, Julie E.; Marshall, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1167-77</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">The C-terminal CAAX motif of the yeast mating factors is modified by proteolysis to remove the 3 terminal amino acids (-AAX) leaving a C-terminal cysteine residue that is polyisoprenylated and carboxylmethylated.  Here it is shown that all gene ras proteins are polyisoprenylated on their C-terminal cysteine (Cys186).  Mutational anal. shows palmitoylation does not take place on Cys186 as previously thought but on cysteine residues contained in the hypervariable domain of some ras proteins.  The major expressed form of c-K-ras (exon 4B) does not have a cysteine residue immediately upstream of Cys186 and is not palmitoylated.  Polyisoprenylated but nonpalmitoylated H-ras proteins are biol. active and assoc. weakly with cell membranes.  Palmitoylation increases the avidity of this binding and enhances their transforming activity.  Polyisoprenylation is essential for biol. activity as inhibiting the biosynthesis of polyisoprenoids abolishes membrane assocn. of p21ras.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkbozglr8QdrVg90H21EOLACvtfcHk0ljaDizavIokVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXkvFansr8%253D&md5=0294ca0eafe10cf138ab55e5dfa294ac</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2889%2990054-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252889%252990054-8%26sid%3Dliteratum%253Aachs%26aulast%3DHancock%26aufirst%3DJ.%2BF.%26aulast%3DMagee%26aufirst%3DA.%2BI.%26aulast%3DChilds%26aufirst%3DJ.%2BE.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26atitle%3DAll%2520RAS%2520proteins%2520are%2520polyisoprenylated%2520but%2520only%2520some%2520are%2520palmitoylated%26jtitle%3DCell%26date%3D1989%26volume%3D57%26spage%3D1167%26epage%3D1177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Hancock, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span> </span><span class="NLM_article-title">A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">133</span><span class="NLM_x">–</span> <span class="NLM_lpage">139</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1016%2F0092-8674%2890%2990294-O" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=2208277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADyaK3cXmt1KltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=1990&pages=133-139&author=J.+F.+Hancockauthor=H.+Patersonauthor=C.+J.+Marshall&title=A+polybasic+domain+or+palmitoylation+is+required+in+addition+to+the+CAAX+motif+to+localize+p21ras+to+the+plasma+membrane"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane</span></div><div class="casAuthors">Hancock, John F.; Peterson, Hugh; Marshall, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">133-9</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">The C-terminal CAAX (C-cysteine, A = aliph., and X = any amino acid) motif of ras proteins undergoes a triplet of posttranslational modifications that are required for membrane assocn.  The CAAX motif lies immediately C-terminal to the hypervariable domain, a region of 20 amino acids that distinguishes the ras proteins from each other.  The hypervariable domains of p21H-ras, p21N-ras and p21K-ras(A) contain sites for palmitoylation, which are shown to combine with the CAAX motif to target specific plasma membrane localization.  Within the hypervariable domain of p21K-ras(B), which is not palmitoylated, a novel plasma membrane targeting signal consisting of a polybasic domain that also acts in combination with the CAAX motif has been identified.  One function of the hypervariable domains of p21ras is therefore to provide different signals for plasma membrane localization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmJT7cPVTh97Vg90H21EOLACvtfcHk0ljaDizavIokVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXmt1KltLs%253D&md5=3dceb53c12512e4e70f3c9291ac3598e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2890%2990294-O&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252890%252990294-O%26sid%3Dliteratum%253Aachs%26aulast%3DHancock%26aufirst%3DJ.%2BF.%26aulast%3DPaterson%26aufirst%3DH.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26atitle%3DA%2520polybasic%2520domain%2520or%2520palmitoylation%2520is%2520required%2520in%2520addition%2520to%2520the%2520CAAX%2520motif%2520to%2520localize%2520p21ras%2520to%2520the%2520plasma%2520membrane%26jtitle%3DCell%26date%3D1990%26volume%3D63%26spage%3D133%26epage%3D139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Boyartchuk, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashby, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rine, J.</span><span> </span><span class="NLM_article-title">Modulation of Ras and a-factor function by carboxyl-terminal proteolysis</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">275</span><span class="NLM_x">, </span> <span class="NLM_fpage">1796</span><span class="NLM_x">–</span> <span class="NLM_lpage">1800</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=1997&pages=1796-1800&author=V.+L.+Boyartchukauthor=M.+N.+Ashbyauthor=J.+Rine&title=Modulation+of+Ras+and+a-factor+function+by+carboxyl-terminal+proteolysis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoyartchuk%26aufirst%3DV.%2BL.%26aulast%3DAshby%26aufirst%3DM.%2BN.%26aulast%3DRine%26aufirst%3DJ.%26atitle%3DModulation%2520of%2520Ras%2520and%2520a-factor%2520function%2520by%2520carboxyl-terminal%2520proteolysis%26jtitle%3DScience%26date%3D1997%26volume%3D275%26spage%3D1796%26epage%3D1800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Otto, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casey, P. J.</span><span> </span><span class="NLM_article-title">Cloning and characterization of a mammalian prenyl protein-specific protease</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">274</span><span class="NLM_x">, </span> <span class="NLM_fpage">8379</span><span class="NLM_x">–</span> <span class="NLM_lpage">8382</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=8379-8382&author=J.+C.+Ottoauthor=E.+Kimauthor=S.+G.+Youngauthor=P.+J.+Casey&title=Cloning+and+characterization+of+a+mammalian+prenyl+protein-specific+protease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOtto%26aufirst%3DJ.%2BC.%26aulast%3DKim%26aufirst%3DE.%26aulast%3DYoung%26aufirst%3DS.%2BG.%26aulast%3DCasey%26aufirst%3DP.%2BJ.%26atitle%3DCloning%2520and%2520characterization%2520of%2520a%2520mammalian%2520prenyl%2520protein-specific%2520protease%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26spage%3D8379%26epage%3D8382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Clarke, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogel, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deschenes, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stock, J.</span><span> </span><span class="NLM_article-title">Posttranslational modification of the Ha-ras oncogene protein: evidence for a third class of protein carboxyl methyltransferases</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">4643</span><span class="NLM_x">–</span> <span class="NLM_lpage">4647</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=1988&pages=4643-4647&author=S.+Clarkeauthor=J.+P.+Vogelauthor=R.+J.+Deschenesauthor=J.+Stock&title=Posttranslational+modification+of+the+Ha-ras+oncogene+protein%3A+evidence+for+a+third+class+of+protein+carboxyl+methyltransferases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DClarke%26aufirst%3DS.%26aulast%3DVogel%26aufirst%3DJ.%2BP.%26aulast%3DDeschenes%26aufirst%3DR.%2BJ.%26aulast%3DStock%26aufirst%3DJ.%26atitle%3DPosttranslational%2520modification%2520of%2520the%2520Ha-ras%2520oncogene%2520protein%253A%2520evidence%2520for%2520a%2520third%2520class%2520of%2520protein%2520carboxyl%2520methyltransferases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1988%26volume%3D85%26spage%3D4643%26epage%3D4647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Hrycyna, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sapperstein, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelis, S.</span><span> </span><span class="NLM_article-title">The <i>Saccharomyces cerevisiae</i> STE14 gene encodes a methyltransferase that mediates C-terminal methylation of a-factor and RAS proteins</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1699</span><span class="NLM_x">–</span> <span class="NLM_lpage">1709</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1991&pages=1699-1709&author=C.+A.+Hrycynaauthor=S.+K.+Sappersteinauthor=S.+Clarkeauthor=S.+Michaelis&title=The+Saccharomyces+cerevisiae+STE14+gene+encodes+a+methyltransferase+that+mediates+C-terminal+methylation+of+a-factor+and+RAS+proteins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHrycyna%26aufirst%3DC.%2BA.%26aulast%3DSapperstein%26aufirst%3DS.%2BK.%26aulast%3DClarke%26aufirst%3DS.%26aulast%3DMichaelis%26aufirst%3DS.%26atitle%3DThe%2520Saccharomyces%2520cerevisiae%2520STE14%2520gene%2520encodes%2520a%2520methyltransferase%2520that%2520mediates%2520C-terminal%2520methylation%2520of%2520a-factor%2520and%2520RAS%2520proteins%26jtitle%3DEMBO%2520J.%26date%3D1991%26volume%3D10%26spage%3D1699%26epage%3D1709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Dai, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choy, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiu, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slivka, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steitz, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philips, M. R.</span><span> </span><span class="NLM_article-title">Mammalian prenylcysteine carboxyl methyltransferase is in the endoplasmic reticulum</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">273</span><span class="NLM_x">, </span> <span class="NLM_fpage">15030</span><span class="NLM_x">–</span> <span class="NLM_lpage">15034</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1998&pages=15030-15034&author=Q.+Daiauthor=E.+Choyauthor=V.+Chiuauthor=J.+Romanoauthor=S.+R.+Slivkaauthor=S.+A.+Steitzauthor=S.+Michaelisauthor=M.+R.+Philips&title=Mammalian+prenylcysteine+carboxyl+methyltransferase+is+in+the+endoplasmic+reticulum"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DQ.%26aulast%3DChoy%26aufirst%3DE.%26aulast%3DChiu%26aufirst%3DV.%26aulast%3DRomano%26aufirst%3DJ.%26aulast%3DSlivka%26aufirst%3DS.%2BR.%26aulast%3DSteitz%26aufirst%3DS.%2BA.%26aulast%3DMichaelis%26aufirst%3DS.%26aulast%3DPhilips%26aufirst%3DM.%2BR.%26atitle%3DMammalian%2520prenylcysteine%2520carboxyl%2520methyltransferase%2520is%2520in%2520the%2520endoplasmic%2520reticulum%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1998%26volume%3D273%26spage%3D15030%26epage%3D15034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Appels, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beijnen, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schellens, J. H.</span><span> </span><span class="NLM_article-title">Development of farnesyl transferase inhibitors: a review</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">565</span><span class="NLM_x">–</span> <span class="NLM_lpage">578</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=565-578&author=N.+M.+Appelsauthor=J.+H.+Beijnenauthor=J.+H.+Schellens&title=Development+of+farnesyl+transferase+inhibitors%3A+a+review"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAppels%26aufirst%3DN.%2BM.%26aulast%3DBeijnen%26aufirst%3DJ.%2BH.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26atitle%3DDevelopment%2520of%2520farnesyl%2520transferase%2520inhibitors%253A%2520a%2520review%26jtitle%3DOncologist%26date%3D2005%26volume%3D10%26spage%3D565%26epage%3D578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Wright, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philips, M. R.</span><span> </span><span class="NLM_article-title">Thematic review series: lipid posttranslational modifications. CAAX modification and membrane targeting of Ras</span> <span class="citation_source-journal">J. Lipid Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">883</span><span class="NLM_x">–</span> <span class="NLM_lpage">891</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2006&pages=883-891&author=L.+P.+Wrightauthor=M.+R.+Philips&title=Thematic+review+series%3A+lipid+posttranslational+modifications.+CAAX+modification+and+membrane+targeting+of+Ras"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWright%26aufirst%3DL.%2BP.%26aulast%3DPhilips%26aufirst%3DM.%2BR.%26atitle%3DThematic%2520review%2520series%253A%2520lipid%2520posttranslational%2520modifications.%2520CAAX%2520modification%2520and%2520membrane%2520targeting%2520of%2520Ras%26jtitle%3DJ.%2520Lipid%2520Res.%26date%3D2006%26volume%3D47%26spage%3D883%26epage%3D891" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Manandhar, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hildebrandt, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santangelo, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, W. K.</span><span> </span><span class="NLM_article-title">Chemical inhibition of CaaX protease activity disrupts yeast Ras localization</span> <span class="citation_source-journal">Yeast</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">327</span><span class="NLM_x">–</span> <span class="NLM_lpage">343</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2010&pages=327-343&author=S.+P.+Manandharauthor=E.+R.+Hildebrandtauthor=W.+H.+Jacobsenauthor=G.+M.+Santangeloauthor=W.+K.+Schmidt&title=Chemical+inhibition+of+CaaX+protease+activity+disrupts+yeast+Ras+localization"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DManandhar%26aufirst%3DS.%2BP.%26aulast%3DHildebrandt%26aufirst%3DE.%2BR.%26aulast%3DJacobsen%26aufirst%3DW.%2BH.%26aulast%3DSantangelo%26aufirst%3DG.%2BM.%26aulast%3DSchmidt%26aufirst%3DW.%2BK.%26atitle%3DChemical%2520inhibition%2520of%2520CaaX%2520protease%2520activity%2520disrupts%2520yeast%2520Ras%2520localization%26jtitle%3DYeast%26date%3D2010%26volume%3D27%26spage%3D327%26epage%3D343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Winter-Vann, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baron, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">dela Cruz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">York, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gooden, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergo, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toone, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casey, P. J.</span><span> </span><span class="NLM_article-title">A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">4336</span><span class="NLM_x">–</span> <span class="NLM_lpage">4341</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1073%2Fpnas.0408107102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=15784746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivFCrtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=4336-4341&author=A.+M.+Winter-Vannauthor=R.+A.+Baronauthor=W.+Wongauthor=J.+dela+Cruzauthor=J.+D.+Yorkauthor=D.+M.+Goodenauthor=M.+O.+Bergoauthor=S.+G.+Youngauthor=E.+J.+Tooneauthor=P.+J.+Casey&title=A+small-molecule+inhibitor+of+isoprenylcysteine+carboxyl+methyltransferase+with+antitumor+activity+in+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells</span></div><div class="casAuthors">Winter-Vann, Ann M.; Baron, Rudi A.; Wong, Waihay; dela Cruz, June; York, John D.; Gooden, David M.; Bergo, Martin O.; Young, Stephen G.; Toone, Eric J.; Casey, Patrick J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4336-4341</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Many key regulatory proteins, including members of the Ras family of GTPases, are modified at their C terminus by a process termed prenylation.  This processing is initiated by the addn. of an isoprenoid lipid, and the proteins are further modified by a proteolytic event and methylation of the C-terminal prenylcysteine.  Although the biol. consequences of prenylation have been characterized extensively, the contributions of prenylcysteine methylation to the functions of the modified proteins are not well understood.  This reaction is catalyzed by the enzyme isoprenylcysteine carboxyl methyltransferase (Icmt).  Recent genetic disruption studies have provided strong evidence that blocking Icmt activity has profound consequences on oncogenic transformation.  Here, we report the identification of a selective small-mol. inhibitor of Icmt, 2-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]acetamide (cysmethynil).  Cysmethynil treatment results in inhibition of cell growth in an Icmt-dependent fashion, demonstrating mechanism-based activity of the compd.  Treatment of cancer cells with cysmethynil results in mislocalization of Ras and impaired epidermal growth factor signaling.  In a human colon cancer cell line, cysmethynil treatment blocks anchorage-independent growth, and this effect is reversed by overexpression of Icmt.  These findings provide a compelling rationale for development of Icmt inhibitors as another approach to anticancer drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY-1GtT0roj7Vg90H21EOLACvtfcHk0ljhWk7YYmu1RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivFCrtLk%253D&md5=8cbe478e0911934e2868d5b5eb376a58</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0408107102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0408107102%26sid%3Dliteratum%253Aachs%26aulast%3DWinter-Vann%26aufirst%3DA.%2BM.%26aulast%3DBaron%26aufirst%3DR.%2BA.%26aulast%3DWong%26aufirst%3DW.%26aulast%3Ddela%2BCruz%26aufirst%3DJ.%26aulast%3DYork%26aufirst%3DJ.%2BD.%26aulast%3DGooden%26aufirst%3DD.%2BM.%26aulast%3DBergo%26aufirst%3DM.%2BO.%26aulast%3DYoung%26aufirst%3DS.%2BG.%26aulast%3DToone%26aufirst%3DE.%2BJ.%26aulast%3DCasey%26aufirst%3DP.%2BJ.%26atitle%3DA%2520small-molecule%2520inhibitor%2520of%2520isoprenylcysteine%2520carboxyl%2520methyltransferase%2520with%2520antitumor%2520activity%2520in%2520cancer%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26spage%3D4336%26epage%3D4341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Reuther, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span> </span><span class="NLM_article-title">The Ras branch of small GTPases: RAS family members don’t fall far from the tree</span> <span class="citation_source-journal">Curr. Opin. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">157</span><span class="NLM_x">–</span> <span class="NLM_lpage">165</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1016%2FS0955-0674%2899%2900071-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=10712923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD3cXitVantL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2000&pages=157-165&author=G.+W.+Reutherauthor=C.+J.+Der&title=The+Ras+branch+of+small+GTPases%3A+RAS+family+members+don%E2%80%99t+fall+far+from+the+tree"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">The Ras branch of small GTPases: Ras family members don't fall far from the tree</span></div><div class="casAuthors">Reuther, Gary W.; Der, Channing J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">157-165</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review, with ∼83 refs.  The Ras branch of the Ras superfamily consists of small GTPases most closely related to Ras and include the R-Ras, Rap, Ral, Rheb, Rin and Rit proteins.  Although our understanding of Ras signaling and biol. is now considerable, recent observations suggest that Ras function is more complex than previously believed.  First, the three Ras proteins may not be functionally identical.  Second, Ras function involves functional cross-talk with their close relatives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJoI9hhqdxJLVg90H21EOLACvtfcHk0ljhWk7YYmu1RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXitVantL0%253D&md5=4e2ee4f59ac9e0e26b4489063fd2bc1a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2FS0955-0674%2899%2900071-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0955-0674%252899%252900071-X%26sid%3Dliteratum%253Aachs%26aulast%3DReuther%26aufirst%3DG.%2BW.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DThe%2520Ras%2520branch%2520of%2520small%2520GTPases%253A%2520RAS%2520family%2520members%2520don%25E2%2580%2599t%2520fall%2520far%2520from%2520the%2520tree%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D2000%26volume%3D12%26spage%3D157%26epage%3D165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Takai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matozaki, T.</span><span> </span><span class="NLM_article-title">Small GTP-binding proteins</span> <span class="citation_source-journal">Physiol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">208</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2001&pages=153-208&author=Y.+Takaiauthor=T.+Sasakiauthor=T.+Matozaki&title=Small+GTP-binding+proteins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTakai%26aufirst%3DY.%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DMatozaki%26aufirst%3DT.%26atitle%3DSmall%2520GTP-binding%2520proteins%26jtitle%3DPhysiol.%2520Rev.%26date%3D2001%26volume%3D81%26spage%3D153%26epage%3D208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Cullen, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockyer, P. J.</span><span> </span><span class="NLM_article-title">Integration of calcium and Ras signalling</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">339</span><span class="NLM_x">–</span> <span class="NLM_lpage">348</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1038%2Fnrm808" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=11988768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD38XjsFOgsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=339-348&author=P.+J.+Cullenauthor=P.+J.+Lockyer&title=Integration+of+calcium+and+Ras+signalling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Integration of calcium and ras signalling</span></div><div class="casAuthors">Cullen, P. J.; Lockyer, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">339-348</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Calcium is a universal intracellular signal that is responsible for controlling a plethora of cellular processes.  Understanding how such a simple ion can regulate so many diverse cellular processes is a key goal of calcium- and cell-biologists.  One mol. that is sensitive to changes in intracellular calcium levels is Ras.  This small GTPase operates as a binary mol. switch, and regulates cell proliferation and differentiation.  Here, we focus on examg. the link between calcium and Ras signaling and, in particular, we speculate as to how the complexity of calcium signaling could regulate Ras activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE-isSfsB4hLVg90H21EOLACvtfcHk0li5wVJjCTIyzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjsFOgsb8%253D&md5=66e291351cbea5de859eca942426c336</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fnrm808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm808%26sid%3Dliteratum%253Aachs%26aulast%3DCullen%26aufirst%3DP.%2BJ.%26aulast%3DLockyer%26aufirst%3DP.%2BJ.%26atitle%3DIntegration%2520of%2520calcium%2520and%2520Ras%2520signalling%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2002%26volume%3D3%26spage%3D339%26epage%3D348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Heldin, C. H.</span><span> </span><span class="NLM_article-title">Dimerization of cell surface receptors in signal transduction</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">–</span> <span class="NLM_lpage">223</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1016%2F0092-8674%2895%2990404-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=7834741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADyaK2MXjtlGnsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=1995&pages=213-223&author=C.+H.+Heldin&title=Dimerization+of+cell+surface+receptors+in+signal+transduction"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Dimerization of cell surface receptors in signal transduction</span></div><div class="casAuthors">Heldin, Carl-Henrik</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-23</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review, with ∼111 refs.,.  Dimerization or oligomerization have been shown to occur after binding of several polypeptide hormones, cytokines, growth factors, or growth inhibitors to their receptors.  Examples include protein tyrosine kinase receptors, cytokine receptors, antigen receptors, receptors for tumor necrosis factor and related factors, and serine/threonine kinase receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQmjNFpwPeyLVg90H21EOLACvtfcHk0li5wVJjCTIyzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjtlGnsro%253D&md5=15c49efe610770db2316f19d6c24e69d</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2895%2990404-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252895%252990404-2%26sid%3Dliteratum%253Aachs%26aulast%3DHeldin%26aufirst%3DC.%2BH.%26atitle%3DDimerization%2520of%2520cell%2520surface%2520receptors%2520in%2520signal%2520transduction%26jtitle%3DCell%26date%3D1995%26volume%3D80%26spage%3D213%26epage%3D223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Lemmon, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span> </span><span class="NLM_article-title">Regulation of signal transduction and signal diversity by receptor oligomerization</span> <span class="citation_source-journal">Trends Biochem. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">459</span><span class="NLM_x">–</span> <span class="NLM_lpage">463</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1994&pages=459-463&author=M.+A.+Lemmonauthor=J.+Schlessinger&title=Regulation+of+signal+transduction+and+signal+diversity+by+receptor+oligomerization"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLemmon%26aufirst%3DM.%2BA.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DRegulation%2520of%2520signal%2520transduction%2520and%2520signal%2520diversity%2520by%2520receptor%2520oligomerization%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D1994%26volume%3D19%26spage%3D459%26epage%3D463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Weiss, F. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daub, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">Novel mechanisms of RTK signal generation</span> <span class="citation_source-journal">Curr. Opin. Genet. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">86</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1997&pages=80-86&author=F.+U.+Weissauthor=H.+Daubauthor=A.+Ullrich&title=Novel+mechanisms+of+RTK+signal+generation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeiss%26aufirst%3DF.%2BU.%26aulast%3DDaub%26aufirst%3DH.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DNovel%2520mechanisms%2520of%2520RTK%2520signal%2520generation%26jtitle%3DCurr.%2520Opin.%2520Genet.%2520Dev.%26date%3D1997%26volume%3D7%26spage%3D80%26epage%3D86" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Schlessinger, J.</span><span> </span><span class="NLM_article-title">Cell signaling by receptor tyrosine kinases</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span><span class="NLM_x">–</span> <span class="NLM_lpage">225</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1016%2FS0092-8674%2800%2900114-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=11057895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD3cXns1Cltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2000&pages=211-225&author=J.+Schlessinger&title=Cell+signaling+by+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Cell signaling by receptor tyrosine kinases</span></div><div class="casAuthors">Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">211-225</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review, with 109 refs.  The purpose of this review is to describe general concepts underlying the mechanism of action of RTKs and the signaling pathways that they regulate, while attempting to shed light on the question of how specificity is defined by the action of RTKs, and how a specific biol. response can be generated by the diverse array of signaling pathways activated by all RTKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0AvjN2PpaVbVg90H21EOLACvtfcHk0li5wVJjCTIyzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXns1Cltrs%253D&md5=7b4cacd2513290f3b3e6120b58647654</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2900114-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252900114-8%26sid%3Dliteratum%253Aachs%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DCell%2520signaling%2520by%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCell%26date%3D2000%26volume%3D103%26spage%3D211%26epage%3D225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Rational therapeutic intervention in cancer: kinases as drug targets</span> <span class="citation_source-journal">Curr. Opin. Genet. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">115</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=111-115&author=C.+L.+Sawyers&title=Rational+therapeutic+intervention+in+cancer%3A+kinases+as+drug+targets"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DRational%2520therapeutic%2520intervention%2520in%2520cancer%253A%2520kinases%2520as%2520drug%2520targets%26jtitle%3DCurr.%2520Opin.%2520Genet.%2520Dev.%26date%3D2002%26volume%3D12%26spage%3D111%26epage%3D115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Quilliam, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huff, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabun, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broek, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span> </span><span class="NLM_article-title">Membrane-targeting potentiates guanine nucleotide exchange factor CDC25 and SOS1 activation of Ras transforming activity</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">8512</span><span class="NLM_x">–</span> <span class="NLM_lpage">8516</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=8512-8516&author=L.+A.+Quilliamauthor=S.+Y.+Huffauthor=K.+M.+Rabunauthor=W.+Weiauthor=W.+Parkauthor=D.+Broekauthor=C.+J.+Der&title=Membrane-targeting+potentiates+guanine+nucleotide+exchange+factor+CDC25+and+SOS1+activation+of+Ras+transforming+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQuilliam%26aufirst%3DL.%2BA.%26aulast%3DHuff%26aufirst%3DS.%2BY.%26aulast%3DRabun%26aufirst%3DK.%2BM.%26aulast%3DWei%26aufirst%3DW.%26aulast%3DPark%26aufirst%3DW.%26aulast%3DBroek%26aufirst%3DD.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DMembrane-targeting%2520potentiates%2520guanine%2520nucleotide%2520exchange%2520factor%2520CDC25%2520and%2520SOS1%2520activation%2520of%2520Ras%2520transforming%2520activity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1994%26volume%3D91%26spage%3D8512%26epage%3D8516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Shields, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pruitt, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFall, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaub, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span> </span><span class="NLM_article-title">Understanding RAS: “it ain’t over ’til it’s over”</span> <span class="citation_source-journal">Trends Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">147</span><span class="NLM_x">–</span> <span class="NLM_lpage">154</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1016%2FS0962-8924%2800%2901740-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=10740269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD3cXit1Sqtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2000&pages=147-154&author=J.+M.+Shieldsauthor=K.+Pruittauthor=A.+McFallauthor=A.+Shaubauthor=C.+J.+Der&title=Understanding+RAS%3A+%E2%80%9Cit+ain%E2%80%99t+over+%E2%80%99til+it%E2%80%99s+over%E2%80%9D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding Ras: 'it ain't over 'til it's over'</span></div><div class="casAuthors">Shields, J. M.; Pruitt, K.; McFall, A.; Shaub, A.; Der, C. J.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">147-154</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review, with 55 refs.  Since 1982, Ras has been the subject of intense research scrutiny, focused on detg. the role of aberrant Ras function in human cancers and defining the mechanism by which Ras mediates its actions in normal and neoplastic cells.  The long-term goal has been to develop antagonists of Ras as novel approaches for cancer treatment.  Although impressive strides have been made in these endeavors, and our knowledge of Ras is quite extensive, it appears that we are at the beginning, rather than at the end, of fully understanding Ras function.  This review highlights new issues that have further complicated our efforts to understand Ras.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJMiQq0eD6VrVg90H21EOLACvtfcHk0lg0hWp1Xrs_5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXit1Sqtr0%253D&md5=44bbbf6314ccd4abc41a1cdea02ee2f0</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2FS0962-8924%2800%2901740-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0962-8924%252800%252901740-2%26sid%3Dliteratum%253Aachs%26aulast%3DShields%26aufirst%3DJ.%2BM.%26aulast%3DPruitt%26aufirst%3DK.%26aulast%3DMcFall%26aufirst%3DA.%26aulast%3DShaub%26aufirst%3DA.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DUnderstanding%2520RAS%253A%2520%25E2%2580%259Cit%2520ain%25E2%2580%2599t%2520over%2520%25E2%2580%2599til%2520it%25E2%2580%2599s%2520over%25E2%2580%259D%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2000%26volume%3D10%26spage%3D147%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Repasky, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chenette, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span> </span><span class="NLM_article-title">Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?</span> <span class="citation_source-journal">Trends Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">639</span><span class="NLM_x">–</span> <span class="NLM_lpage">647</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1016%2Fj.tcb.2004.09.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=15519853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpt1Wgsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=639-647&author=G.+A.+Repaskyauthor=E.+J.+Chenetteauthor=C.+J.+Der&title=Renewing+the+conspiracy+theory+debate%3A+does+Raf+function+alone+to+mediate+Ras+oncogenesis%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?</span></div><div class="casAuthors">Repasky, Gretchen A.; Chenette, Emily J.; Der, Channing J.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">639-647</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Ras proteins function as signal transducers and are mutationally activated in many human cancers.  In 1993, Raf was identified as a key downstream effector of Ras signaling, and it was believed then that the primary function of Ras was simply to facilitate Raf activation.  However, the subsequent discovery of other proteins that are effectors of Ras function suggested that oncogenic activities of Ras are mediated by both Raf-dependent and Raf-independent signaling.  Further complexity arose with the identification of Ras effectors with putative tumor suppressor, rather than oncogenic, functions.  However, the recent identification of B-raf mutations in human cancers has renewed the debate regarding whether Raf activation alone promotes Ras-mediated oncogenesis.  In this article, the authors summarize the current knowledge of the contribution of Ras effectors in Ras-mediated oncogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyiIPYOakeprVg90H21EOLACvtfcHk0lg0hWp1Xrs_5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpt1Wgsr0%253D&md5=b12f5644d4a3fcc3a27c25f8fc425f08</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2004.09.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2004.09.014%26sid%3Dliteratum%253Aachs%26aulast%3DRepasky%26aufirst%3DG.%2BA.%26aulast%3DChenette%26aufirst%3DE.%2BJ.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DRenewing%2520the%2520conspiracy%2520theory%2520debate%253A%2520does%2520Raf%2520function%2520alone%2520to%2520mediate%2520Ras%2520oncogenesis%253F%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2004%26volume%3D14%26spage%3D639%26epage%3D647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Leevers, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterson, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span> </span><span class="NLM_article-title">Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">369</span><span class="NLM_x">, </span> <span class="NLM_fpage">411</span><span class="NLM_x">–</span> <span class="NLM_lpage">414</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1038%2F369411a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=8196769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADyaK2cXlsFWqtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=1994&pages=411-414&author=S.+J.+Leeversauthor=H.+F.+Patersonauthor=C.+J.+Marshall&title=Requirement+for+Ras+in+Raf+activation+is+overcome+by+targeting+Raf+to+the+plasma+membrane"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane</span></div><div class="casAuthors">Leevers, Sally J.; Paterson, Hugh F.; Marshall, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">6479</span>),
    <span class="NLM_cas:pages">411-14</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">A conserved tyrosine kinase-activated signal transduction pathway has recently been identified that comprises the plasma membrane-bound small guanine-nucleotide-binding protein Ras and the protein kinases Raf, MAP-kinase kinase and MAP kinase.  GTP-bound Ras interacts directly with the amino-terminal regulatory domain of Raf, but although Ras and Raf can be coimmunopptd. from ligand-stimulated cells, Ras-GTP does not stimulate the kinase activity of Raf in vitro.  Furthermore, the authors have failed to detect Ras in prepns. of active detergent-solubilized Raf, demonstrating that once it is activated, Raf does not require Ras.  Whereas Raf is normally cytosolic, in cells expressing active Ras, Raf is assocd. with the plasma membrane.  This led the authors to investigate whether Ras is required to localize Raf to the plasma membrane in order for Raf to become activated.  The authors fused the membrane localization signal of K-Ras(4B) to the carboxy terminus of Raf.  This protein is constitutively active and can be further activated by epidermal growth factor, independently of Ras.  The authors' results indicate that Ras functions as a regulated, membrane-bound anchor for Raf, and that other signal(s) also contribute to Raf activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOG6OJ2_orRLVg90H21EOLACvtfcHk0lg0hWp1Xrs_5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlsFWqtro%253D&md5=c2c7bd68c990ae117d4060a3c8b44fe9</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2F369411a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F369411a0%26sid%3Dliteratum%253Aachs%26aulast%3DLeevers%26aufirst%3DS.%2BJ.%26aulast%3DPaterson%26aufirst%3DH.%2BF.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26atitle%3DRequirement%2520for%2520Ras%2520in%2520Raf%2520activation%2520is%2520overcome%2520by%2520targeting%2520Raf%2520to%2520the%2520plasma%2520membrane%26jtitle%3DNature%26date%3D1994%26volume%3D369%26spage%3D411%26epage%3D414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Marais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Light, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterson, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span> </span><span class="NLM_article-title">Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">3136</span><span class="NLM_x">–</span> <span class="NLM_lpage">3145</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1995&pages=3136-3145&author=R.+Maraisauthor=Y.+Lightauthor=H.+F.+Patersonauthor=C.+J.+Marshall&title=Ras+recruits+Raf-1+to+the+plasma+membrane+for+activation+by+tyrosine+phosphorylation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DLight%26aufirst%3DY.%26aulast%3DPaterson%26aufirst%3DH.%2BF.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26atitle%3DRas%2520recruits%2520Raf-1%2520to%2520the%2520plasma%2520membrane%2520for%2520activation%2520by%2520tyrosine%2520phosphorylation%26jtitle%3DEMBO%2520J.%26date%3D1995%26volume%3D14%26spage%3D3136%26epage%3D3145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Finney, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrera, D.</span><span> </span><span class="NLM_article-title">Ras-Raf complexes: analyses of complexes formed in vivo</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">255</span><span class="NLM_x">, </span> <span class="NLM_fpage">310</span><span class="NLM_x">–</span> <span class="NLM_lpage">323</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=255&publication_year=1995&pages=310-323&author=R.+Finneyauthor=D.+Herrera&title=Ras-Raf+complexes%3A+analyses+of+complexes+formed+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFinney%26aufirst%3DR.%26aulast%3DHerrera%26aufirst%3DD.%26atitle%3DRas-Raf%2520complexes%253A%2520analyses%2520of%2520complexes%2520formed%2520in%2520vivo%26jtitle%3DMethods%2520Enzymol.%26date%3D1995%26volume%3D255%26spage%3D310%26epage%3D323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Johnson, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chamberlain, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. H.</span><span> </span><span class="NLM_article-title">Identification of key residues in the A-Raf kinase important for phosphoinositide lipid binding specificity</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">3432</span><span class="NLM_x">–</span> <span class="NLM_lpage">3440</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi0487692" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2005&pages=3432-3440&author=L.+M.+Johnsonauthor=K.+M.+Jamesauthor=M.+D.+Chamberlainauthor=D.+H.+Anderson&title=Identification+of+key+residues+in+the+A-Raf+kinase+important+for+phosphoinositide+lipid+binding+specificity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fbi0487692&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi0487692%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DL.%2BM.%26aulast%3DJames%26aufirst%3DK.%2BM.%26aulast%3DChamberlain%26aufirst%3DM.%2BD.%26aulast%3DAnderson%26aufirst%3DD.%2BH.%26atitle%3DIdentification%2520of%2520key%2520residues%2520in%2520the%2520A-Raf%2520kinase%2520important%2520for%2520phosphoinositide%2520lipid%2520binding%2520specificity%26jtitle%3DBiochemistry%26date%3D2005%26volume%3D44%26spage%3D3432%26epage%3D3440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dush, M.</span><span> </span><span class="NLM_article-title">Functional analysis of a phosphatidic acid binding domain in human Raf-1 kinase: mutations in the phosphatidate binding domain lead to tail and trunk abnormalities in developing zebrafish embryos</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">45690</span><span class="NLM_x">–</span> <span class="NLM_lpage">45696</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=45690-45696&author=S.+Ghoshauthor=S.+Mooreauthor=R.+M.+Bellauthor=M.+Dush&title=Functional+analysis+of+a+phosphatidic+acid+binding+domain+in+human+Raf-1+kinase%3A+mutations+in+the+phosphatidate+binding+domain+lead+to+tail+and+trunk+abnormalities+in+developing+zebrafish+embryos"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DMoore%26aufirst%3DS.%26aulast%3DBell%26aufirst%3DR.%2BM.%26aulast%3DDush%26aufirst%3DM.%26atitle%3DFunctional%2520analysis%2520of%2520a%2520phosphatidic%2520acid%2520binding%2520domain%2520in%2520human%2520Raf-1%2520kinase%253A%2520mutations%2520in%2520the%2520phosphatidate%2520binding%2520domain%2520lead%2520to%2520tail%2520and%2520trunk%2520abnormalities%2520in%2520developing%2520zebrafish%2520embryos%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D45690%26epage%3D45696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Rodriguez-Viciana, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warne, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhand, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanhaesebroeck, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gout, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waterfield, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downward, J.</span><span> </span><span class="NLM_article-title">Phosphatidylinositol-3-OH kinase as a direct target of Ras</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">527</span><span class="NLM_x">–</span> <span class="NLM_lpage">532</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=1994&pages=527-532&author=P.+Rodriguez-Vicianaauthor=P.+H.+Warneauthor=R.+Dhandauthor=B.+Vanhaesebroeckauthor=I.+Goutauthor=M.+J.+Fryauthor=M.+D.+Waterfieldauthor=J.+Downward&title=Phosphatidylinositol-3-OH+kinase+as+a+direct+target+of+Ras"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRodriguez-Viciana%26aufirst%3DP.%26aulast%3DWarne%26aufirst%3DP.%2BH.%26aulast%3DDhand%26aufirst%3DR.%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26aulast%3DGout%26aufirst%3DI.%26aulast%3DFry%26aufirst%3DM.%2BJ.%26aulast%3DWaterfield%26aufirst%3DM.%2BD.%26aulast%3DDownward%26aufirst%3DJ.%26atitle%3DPhosphatidylinositol-3-OH%2520kinase%2520as%2520a%2520direct%2520target%2520of%2520Ras%26jtitle%3DNature%26date%3D1994%26volume%3D370%26spage%3D527%26epage%3D532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Pacold, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suire, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perisic, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lara-Gonzalez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccleston, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. L.</span><span> </span><span class="NLM_article-title">Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase γ</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">931</span><span class="NLM_x">–</span> <span class="NLM_lpage">943</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2000&pages=931-943&author=M.+E.+Pacoldauthor=S.+Suireauthor=O.+Perisicauthor=S.+Lara-Gonzalezauthor=C.+T.+Davisauthor=E.+H.+Walkerauthor=P.+T.+Hawkinsauthor=L.+Stephensauthor=J.+F.+Ecclestonauthor=R.+L.+Williams&title=Crystal+structure+and+functional+analysis+of+Ras+binding+to+its+effector+phosphoinositide+3-kinase+%CE%B3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPacold%26aufirst%3DM.%2BE.%26aulast%3DSuire%26aufirst%3DS.%26aulast%3DPerisic%26aufirst%3DO.%26aulast%3DLara-Gonzalez%26aufirst%3DS.%26aulast%3DDavis%26aufirst%3DC.%2BT.%26aulast%3DWalker%26aufirst%3DE.%2BH.%26aulast%3DHawkins%26aufirst%3DP.%2BT.%26aulast%3DStephens%26aufirst%3DL.%26aulast%3DEccleston%26aufirst%3DJ.%2BF.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26atitle%3DCrystal%2520structure%2520and%2520functional%2520analysis%2520of%2520Ras%2520binding%2520to%2520its%2520effector%2520phosphoinositide%25203-kinase%2520%25CE%25B3%26jtitle%3DCell%26date%3D2000%26volume%3D103%26spage%3D931%26epage%3D943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">De Ruiter, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgering, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bos, J. L.</span><span> </span><span class="NLM_article-title">Regulation of the Forkhead transcription factor AFX by Ral-dependent phosphorylation of threonines 447 and 451</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">8225</span><span class="NLM_x">–</span> <span class="NLM_lpage">8235</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1128%2FMCB.21.23.8225-8235.2001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=11689711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD3MXotl2gurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2001&pages=8225-8235&author=N.+D.+De+Ruiterauthor=B.+M.+Burgeringauthor=J.+L.+Bos&title=Regulation+of+the+Forkhead+transcription+factor+AFX+by+Ral-dependent+phosphorylation+of+threonines+447+and+451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of the Forkhead transcription factor AFX by Ral-dependent phosphorylation of threonines 447 and 451</span></div><div class="casAuthors">De Ruiter, Nancy D.; Burgering, Boudewijn M. T.; Bos, Johannes L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">8225-8235</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">AFX is a Forkhead transcription factor that induces a G1 cell cycle arrest via upregulation of the cell cycle inhibitor p27Kip1.  Previously we have shown that protein kinase B (PKB) phosphorylates AFX causing inhibition of AFX by nuclear exclusion.  In addn., Ras, through the activation of the RalGEF-Ral pathway, induces phosphorylation of AFX.  Here we show that the Ras-Ral pathway provokes phosphorylation of threonines 447 and 451 in the C terminus of AFX.  A mutant protein in which both threonines are substituted for alanines (T447A/T451A) still responds to PKB-regulated nuclear-cytoplasmic shuttling, but transcriptional activity and consequent G1 cell cycle arrest are greatly impaired.  Furthermore, inhibition of the Ral signaling pathway abolishes both AFX-mediated transcription and regulation of p27Kip1, while activation of Ral augments AFX activity.  From these results we conclude that Ral-mediated phosphorylation of threonines 447 and 451 is required for proper activity of AFX-WT.  Interestingly, the T447A/T451A mutation did not affect the induction of transcription and G1 cell cycle arrest by the PKB-insensitive AFX-A3 mutant, suggesting that Ral-mediated phosphorylation plays a role in the regulation of AFX by PKB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVnQ2x_jSNdLVg90H21EOLACvtfcHk0liQZBHvhRtR2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXotl2gurw%253D&md5=7bae6dbff0fe22ca3247cb0fa42fa771</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1128%2FMCB.21.23.8225-8235.2001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.21.23.8225-8235.2001%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BRuiter%26aufirst%3DN.%2BD.%26aulast%3DBurgering%26aufirst%3DB.%2BM.%26aulast%3DBos%26aufirst%3DJ.%2BL.%26atitle%3DRegulation%2520of%2520the%2520Forkhead%2520transcription%2520factor%2520AFX%2520by%2520Ral-dependent%2520phosphorylation%2520of%2520threonines%2520447%2520and%2520451%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2001%26volume%3D21%26spage%3D8225%26epage%3D8235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">González-García, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterson, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mavria, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamp, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span> </span><span class="NLM_article-title">RalGDS is required for tumor formation in a model of skin carcinogenesis</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">–</span> <span class="NLM_lpage">226</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=219-226&author=A.+Gonz%C3%A1lez-Garc%C3%ADaauthor=C.+A.+Pritchardauthor=H.+F.+Patersonauthor=G.+Mavriaauthor=G.+Stampauthor=C.+J.+Marshall&title=RalGDS+is+required+for+tumor+formation+in+a+model+of+skin+carcinogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGonz%25C3%25A1lez-Garc%25C3%25ADa%26aufirst%3DA.%26aulast%3DPritchard%26aufirst%3DC.%2BA.%26aulast%3DPaterson%26aufirst%3DH.%2BF.%26aulast%3DMavria%26aufirst%3DG.%26aulast%3DStamp%26aufirst%3DG.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26atitle%3DRalGDS%2520is%2520required%2520for%2520tumor%2520formation%2520in%2520a%2520model%2520of%2520skin%2520carcinogenesis%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26spage%3D219%26epage%3D226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Hofer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fields, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, G. S.</span><span> </span><span class="NLM_article-title">Activated Ras interacts with the Ral guanine nucleotide dissociation stimulator</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">11089</span><span class="NLM_x">–</span> <span class="NLM_lpage">11093</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=11089-11093&author=F.+Hoferauthor=S.+Fieldsauthor=C.+Schneiderauthor=G.+S.+Martin&title=Activated+Ras+interacts+with+the+Ral+guanine+nucleotide+dissociation+stimulator"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHofer%26aufirst%3DF.%26aulast%3DFields%26aufirst%3DS.%26aulast%3DSchneider%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DG.%2BS.%26atitle%3DActivated%2520Ras%2520interacts%2520with%2520the%2520Ral%2520guanine%2520nucleotide%2520dissociation%2520stimulator%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1994%26volume%3D91%26spage%3D11089%26epage%3D11093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Bittker, J. A.; Weiwer, M.; Shimada, K.; Yang, W. S.; MacPherson, L.; Dandapani, S.; Munoz, B.; Palmer, M.; Stockwell, B. R.; Schreiber, S. L.</span><span> </span><span class="NLM_article-title">Screen for RAS-Selective Lethal Compounds and VDAC Ligands—Probe 1</span>.  <span class="citation_source-book">Probe Reports from the NIH Molecular Libraries Program [Internet]</span>; <span class="NLM_publisher-name">National Center for Biotechnology Information, U.S. National Library of Medicine</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span><a href="http://www.ncbi.nlm.nih.gov/books/NBK55069/" class="extLink">http://www.ncbi.nlm.nih.gov/books/NBK55069/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=J.+A.+Bittker&author=M.+Weiwer&author=K.+Shimada&author=W.+S.+Yang&author=L.+MacPherson&author=S.+Dandapani&author=B.+Munoz&author=M.+Palmer&author=B.+R.+Stockwell&author=S.+L.+Schreiber&title=Probe+Reports+from+the+NIH+Molecular+Libraries+Program+%5BInternet%5D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DBittker%26aufirst%3DJ.%2BA.%26atitle%3DScreen%2520for%2520RAS-Selective%2520Lethal%2520Compounds%2520and%2520VDAC%2520Ligands%25E2%2580%2594Probe%25201%26btitle%3DProbe%2520Reports%2520from%2520the%2520NIH%2520Molecular%2520Libraries%2520Program%2520%255BInternet%255D%26pub%3DNational%2520Center%2520for%2520Biotechnology%2520Information%252C%2520U.S.%2520National%2520Library%2520of%2520Medicine%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Torrance, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agrawal, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogelstein, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinzler, K. W.</span><span> </span><span class="NLM_article-title">Use of isogenic human cancer cells for high-throughput screening and drug discovery</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">940</span><span class="NLM_x">–</span> <span class="NLM_lpage">945</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2001&pages=940-945&author=C.+J.+Torranceauthor=V.+Agrawalauthor=B.+Vogelsteinauthor=K.+W.+Kinzler&title=Use+of+isogenic+human+cancer+cells+for+high-throughput+screening+and+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTorrance%26aufirst%3DC.%2BJ.%26aulast%3DAgrawal%26aufirst%3DV.%26aulast%3DVogelstein%26aufirst%3DB.%26aulast%3DKinzler%26aufirst%3DK.%2BW.%26atitle%3DUse%2520of%2520isogenic%2520human%2520cancer%2520cells%2520for%2520high-throughput%2520screening%2520and%2520drug%2520discovery%26jtitle%3DNat.%2520Biotechnol.%26date%3D2001%26volume%3D19%26spage%3D940%26epage%3D945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Guo, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, B.</span><span> </span><span class="NLM_article-title">Identification of a small molecule with synthetic lethality for K-RAS and protein kinase C iota</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">7403</span><span class="NLM_x">–</span> <span class="NLM_lpage">7408</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=7403-7408&author=W.+Guoauthor=S.+Wuauthor=J.+Liuauthor=B.+Fang&title=Identification+of+a+small+molecule+with+synthetic+lethality+for+K-RAS+and+protein+kinase+C+iota"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DFang%26aufirst%3DB.%26atitle%3DIdentification%2520of%2520a%2520small%2520molecule%2520with%2520synthetic%2520lethality%2520for%2520K-RAS%2520and%2520protein%2520kinase%2520C%2520iota%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D7403%26epage%3D7408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winslow, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magendantz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouyang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowdle, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maglathin, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolliday, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacks, T.</span><span> </span><span class="NLM_article-title">Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">8773</span><span class="NLM_x">–</span> <span class="NLM_lpage">8778</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=8773-8778&author=A.+T.+Shawauthor=M.+M.+Winslowauthor=M.+Magendantzauthor=C.+Ouyangauthor=J.+Dowdleauthor=A.+Subramanianauthor=T.+A.+Lewisauthor=R.+L.+Maglathinauthor=N.+Tollidayauthor=T.+Jacks&title=Selective+killing+of+K-ras+mutant+cancer+cells+by+small+molecule+inducers+of+oxidative+stress"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DWinslow%26aufirst%3DM.%2BM.%26aulast%3DMagendantz%26aufirst%3DM.%26aulast%3DOuyang%26aufirst%3DC.%26aulast%3DDowdle%26aufirst%3DJ.%26aulast%3DSubramanian%26aufirst%3DA.%26aulast%3DLewis%26aufirst%3DT.%2BA.%26aulast%3DMaglathin%26aufirst%3DR.%2BL.%26aulast%3DTolliday%26aufirst%3DN.%26aulast%3DJacks%26aufirst%3DT.%26atitle%3DSelective%2520killing%2520of%2520K-ras%2520mutant%2520cancer%2520cells%2520by%2520small%2520molecule%2520inducers%2520of%2520oxidative%2520stress%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2011%26volume%3D108%26spage%3D8773%26epage%3D8778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Maurer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrenton, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitts, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skelton, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fauber, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokoe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludlam, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowman, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannetti, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starovasnik, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellman, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, G.</span><span> </span><span class="NLM_article-title">Small-molecule ligands bind to a distinct pocket in RAS and inhibit SOS-mediated nucleotide exchange activity</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">5299</span><span class="NLM_x">–</span> <span class="NLM_lpage">5304</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1073%2Fpnas.1116510109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=22431598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BC38XlslOjsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=5299-5304&author=T.+Maurerauthor=L.+S.+Garrentonauthor=A.+Ohauthor=K.+Pittsauthor=D.+J.+Andersonauthor=N.+J.+Skeltonauthor=B.+P.+Fauberauthor=B.+Panauthor=S.+Malekauthor=D.+Stokoeauthor=M.+J.+Ludlamauthor=K.+K.+Bowmanauthor=J.+Wuauthor=A.+M.+Giannettiauthor=M.+A.+Starovasnikauthor=I.+Mellmanauthor=P.+K.+Jacksonauthor=J.+Rudolphauthor=W.+Wangauthor=G.+Fang&title=Small-molecule+ligands+bind+to+a+distinct+pocket+in+RAS+and+inhibit+SOS-mediated+nucleotide+exchange+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity</span></div><div class="casAuthors">Maurer, Till; Garrenton, Lindsay S.; Oh, Angela; Pitts, Keith; Anderson, Daniel J.; Skelton, Nicholas J.; Fauber, Benjamin P.; Pan, Borlan; Malek, Shiva; Stokoe, David; Ludlam, Mary J. C.; Bowman, Krista K.; Wu, Jiansheng; Giannetti, Anthony M.; Starovasnik, Melissa A.; Mellman, Ira; Jackson, Peter K.; Rudolph, Joachim; Wang, Weiru; Fang, Guowei</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5299-5304, S5299/1-S5299/13</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The Ras gene is frequently mutated in cancer, and mutant Ras drives tumorigenesis.  Although Ras is a central oncogene, small mols. that bind to Ras in a well-defined manner and exert inhibitory effects have not been uncovered to date.  Through an NMR-based fragment screen, we identified a group of small mols. that all bind to a common site on Ras.  High-resoln. cocrystal structures delineated a unique ligand-binding pocket on the Ras protein that is adjacent to the switch I/II regions and can be expanded upon compd. binding.  Structure anal. predicts that compd.-binding interferes with the Ras/SOS interactions.  Indeed, selected compds. inhibit SOS-mediated nucleotide exchange and prevent Ras activation by blocking the formation of intermediates of the exchange reaction.  The discovery of a small-mol. binding pocket on Ras with functional significance provides a new direction in the search of therapeutically effective inhibitors of the Ras oncoprotein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAXIzMe7yBqrVg90H21EOLACvtfcHk0lhCLb3i6z_d4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlslOjsrc%253D&md5=a7210cad45154c42eb2a1faeabf88c20</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1116510109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1116510109%26sid%3Dliteratum%253Aachs%26aulast%3DMaurer%26aufirst%3DT.%26aulast%3DGarrenton%26aufirst%3DL.%2BS.%26aulast%3DOh%26aufirst%3DA.%26aulast%3DPitts%26aufirst%3DK.%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DSkelton%26aufirst%3DN.%2BJ.%26aulast%3DFauber%26aufirst%3DB.%2BP.%26aulast%3DPan%26aufirst%3DB.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DLudlam%26aufirst%3DM.%2BJ.%26aulast%3DBowman%26aufirst%3DK.%2BK.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DStarovasnik%26aufirst%3DM.%2BA.%26aulast%3DMellman%26aufirst%3DI.%26aulast%3DJackson%26aufirst%3DP.%2BK.%26aulast%3DRudolph%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DFang%26aufirst%3DG.%26atitle%3DSmall-molecule%2520ligands%2520bind%2520to%2520a%2520distinct%2520pocket%2520in%2520RAS%2520and%2520inhibit%2520SOS-mediated%2520nucleotide%2520exchange%2520activity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2012%26volume%3D109%26spage%3D5299%26epage%3D5304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Rees, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Congreve, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, R.</span><span> </span><span class="NLM_article-title">Fragment based lead discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">660</span><span class="NLM_x">–</span> <span class="NLM_lpage">672</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=660-672&author=D.+C.+Reesauthor=M.+Congreveauthor=C.+W.+Murrayauthor=R.+Carr&title=Fragment+based+lead+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DCarr%26aufirst%3DR.%26atitle%3DFragment%2520based%2520lead%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D660%26epage%3D672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Chessari, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodhead, A. J.</span><span> </span><span class="NLM_article-title">From fragment to clinical candidate—a historical perspective</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">668</span><span class="NLM_x">–</span> <span class="NLM_lpage">675</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1016%2Fj.drudis.2009.04.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=19427404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotFyktLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=668-675&author=G.+Chessariauthor=A.+J.+Woodhead&title=From+fragment+to+clinical+candidate%E2%80%94a+historical+perspective"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">From fragment to clinical candidate-a historical perspective</span></div><div class="casAuthors">Chessari, Gianni; Woodhead, Andrew J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">13/14</span>),
    <span class="NLM_cas:pages">668-675</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  As recently as ten years ago few scientists had heard of fragment screening, let alone considered low mol. wt. fragments (MW <300) with weak binding affinities to be attractive start points for drug discovery programs.  Today, however, there is widespread acceptance that these fragments can be progressed into lead series and on to become clin. candidates.  Consequently, over the past three to four years, fragment-based drug discovery has become firmly established within the biotechnol. and pharmaceutical industries as a complimentary strategy to high-throughput screening.  In this review, we give a historical perspective of how rapidly fragment-based drug discovery has developed and describe a no. of clin. compds. discovered using this approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIfibakR1lWLVg90H21EOLACvtfcHk0lipBoIFe044IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotFyktLo%253D&md5=1bd47b7787b1b22681466ad220eb7cd1</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2009.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2009.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DChessari%26aufirst%3DG.%26aulast%3DWoodhead%26aufirst%3DA.%2BJ.%26atitle%3DFrom%2520fragment%2520to%2520clinical%2520candidate%25E2%2580%2594a%2520historical%2520perspective%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26spage%3D668%26epage%3D675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Zartler, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mo, H.</span><span> </span><span class="NLM_article-title">Practical aspects of NMR-based fragment discovery</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1592</span><span class="NLM_x">–</span> <span class="NLM_lpage">1599</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.2174%2F156802607782341055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=17979770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVOrur7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=1592-1599&author=E.+R.+Zartlerauthor=H.+Mo&title=Practical+aspects+of+NMR-based+fragment+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Practical aspects of NMR-based fragment discovery</span></div><div class="casAuthors">Zartler, Edward R.; Mo, Huaping</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1592-1599</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Fragment-based drug discovery (FBDD) needs a biophys. assay to complement, or even replace, biochem. screening.  NMR is the best choice for this because NMR delivers many different types of data that impacts medicinal chem. decisions.  There are a multitude of different NMR methods which can be employed to these ends.  The choice of which method to use will be different for every need.  We discuss the different methods, the data they produce, and how they are best utilized in a FBDD setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqUP8IXrnvybVg90H21EOLACvtfcHk0lipBoIFe044IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVOrur7E&md5=b5399a10cc438cb92997e035789bb63b</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.2174%2F156802607782341055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802607782341055%26sid%3Dliteratum%253Aachs%26aulast%3DZartler%26aufirst%3DE.%2BR.%26aulast%3DMo%26aufirst%3DH.%26atitle%3DPractical%2520aspects%2520of%2520NMR-based%2520fragment%2520discovery%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D1592%26epage%3D1599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Meyer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, T.</span><span> </span><span class="NLM_article-title">NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">864</span><span class="NLM_x">–</span> <span class="NLM_lpage">890</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1002%2Fanie.200390233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitFWltL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=864-890&author=B.+Meyerauthor=T.+Peters&title=NMR+spectroscopy+techniques+for+screening+and+identifying+ligand+binding+to+protein+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors</span></div><div class="casAuthors">Meyer, Bernd; Peters, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">864-890</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Picking the locks of protein binding: NMR spectroscopic techniques for the characterization of binding processes have recently gained much attention.  Binding epitopes on the ligands and on the protein can be identified easily without the aid of crystal structures (see scheme).  Hereby, rational design of new drugs has become more accessible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNviqXqZtItbVg90H21EOLACvtfcHk0lipBoIFe044IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitFWltL4%253D&md5=e0b38bf974639d9414fb57e8d0def3e1</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2Fanie.200390233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200390233%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DB.%26aulast%3DPeters%26aufirst%3DT.%26atitle%3DNMR%2520spectroscopy%2520techniques%2520for%2520screening%2520and%2520identifying%2520ligand%2520binding%2520to%2520protein%2520receptors%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2003%26volume%3D42%26spage%3D864%26epage%3D890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Erlanson, D.</span><span> </span><span class="NLM_article-title">Fragments versus Ras—Part 2</span>. In  <span class="citation_source-book">Practical Fragments</span>; <span class="NLM_contrib-group">Zartler, T.; Erlanson, D.</span>, Eds.; June 6,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>BlogSpot, June 10, 2012, <a href="http://practicalfragments.blogspot.com/2012/06/fragments-versus-ras-part-2.html" class="extLink">http://practicalfragments.blogspot.com/2012/06/fragments-versus-ras-part-2.html</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=D.+Erlansonauthor=T.+Zartler&author=D.+Erlanson&title=Practical+Fragments"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DErlanson%26aufirst%3DD.%26atitle%3DFragments%2520versus%2520Ras%25E2%2580%2594Part%25202%26btitle%3DPractical%2520Fragments%26aulast%3DZartler%26aufirst%3DT.%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Sridhar, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hedley, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siu, L. L.</span><span> </span><span class="NLM_article-title">Raf kinase as a target for anticancer therapeutics</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">677</span><span class="NLM_x">–</span> <span class="NLM_lpage">685</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1158%2F1535-7163.MCT-04-0297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=15827342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFegsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=677-685&author=S.+S.+Sridharauthor=D.+Hedleyauthor=L.+L.+Siu&title=Raf+kinase+as+a+target+for+anticancer+therapeutics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Raf kinase as a target for anticancer therapeutics</span></div><div class="casAuthors">Sridhar, Srikala S.; Hedley, David; Siu, Lillian L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">677-685</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The Ras-Raf-MEK-ERK (ERK) pathway is a logical therapeutic target because it represents a common downstream pathway for several key growth factor tyrosine kinase receptors which are often mutated or overexpressed in human cancers.  Although considered mainly growth-promoting, in certain contexts, this pathway also seems to be apoptosis-suppressing.  Several novel agents targeting this pathway have now been developed and are in clin. trials.  One of the most interesting new agents is BAY 43-9006.  Although initially developed as a Raf kinase inhibitor, it can also target several other important tyrosine kinases including VEGFR-2, Flt-3, and c-Kit, which contributes to its antiproliferative and antiangiogenic properties.  To date, encouraging results were seen with BAY 43-9006, particularly in renal cell cancers which are highly vascular tumors.  This review will provide an overview of the ERK signaling pathway in normal and neoplastic tissue, with a specific focus on novel therapies targeting the ERK pathway at the level of Raf kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphMFgPve1M6LVg90H21EOLACvtfcHk0liI7M7sOzFqnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFegsLc%253D&md5=4e59ddcdb2afe92dba930b73b07ec51c</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-04-0297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-04-0297%26sid%3Dliteratum%253Aachs%26aulast%3DSridhar%26aufirst%3DS.%2BS.%26aulast%3DHedley%26aufirst%3DD.%26aulast%3DSiu%26aufirst%3DL.%2BL.%26atitle%3DRaf%2520kinase%2520as%2520a%2520target%2520for%2520anticancer%2520therapeutics%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2005%26volume%3D4%26spage%3D677%26epage%3D685" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Khosravi-Far, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westwick, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solski, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chrzanowska-Wodnicka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Aelst, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wigler, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span> </span><span class="NLM_article-title">Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">3923</span><span class="NLM_x">–</span> <span class="NLM_lpage">3933</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=8668210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADyaK28XjvVWmsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1996&pages=3923-3933&author=R.+Khosravi-Farauthor=M.+A.+Whiteauthor=J.+K.+Westwickauthor=P.+A.+Solskiauthor=M.+Chrzanowska-Wodnickaauthor=L.+Van+Aelstauthor=M.+H.+Wiglerauthor=C.+J.+Der&title=Oncogenic+Ras+activation+of+Raf%2Fmitogen-activated+protein+kinase-independent+pathways+is+sufficient+to+cause+tumorigenic+transformation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation</span></div><div class="casAuthors">Khosravi-Far, Roya; White, Michael A.; Westwick, John K.; Solski, Patricia A.; Chrzanowska-Wodnicka, Magdalena; Van Aelst, Linda; Wigler, Michael H.; Der, Channing J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3923-3933</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Substantial evidence supports a crit. role for the activation of the Raf-1/MEK/mitogen-activated protein kinase pathway in oncogenic Ras-mediated transformation.  For example, dominant neg. mutants of Raf-1, MEK, and mitogen-activated protein kinase all inhibit Ras transformation.  Furthermore, the observation that plasma membrane-localized Raf-1 exhibits the same transforming potency as oncogenic Ras suggests that Raf-1 activation alone is sufficient to mediate full Ras transforming activity.  However, the recent identification of other candidate Ras effectors (e.g., RalGDS and phosphatidylinositol-3 kinase) suggests that activation of other downstream effector-mediated signaling pathways may also mediate Ras transforming activity.  In support of this, two H-Ras effector domain mutants, H-Ras(12V, 37G) and H-Ras(12V, 40C), which are defective for Raf binding and activation, induced potent tumorigenic transformation of some strains of NIH 3T3 fibroblasts.  These Raf-binding defective mutants of H-Ras induced a transformed morphol. that was indistinguishable from that induced by activated members of Rho family proteins.  Furthermore, the transforming activities of both of these mutants were synergistically enhanced by activated Raf-1 and inhibited by the dominant neg. RhoA(19N) mutant, indicating that Ras may cause transformation that occurs via coordinate activation of Raf-dependent and -independent pathways that involves Rho family proteins.  Finally, cotransfection of H-Ras(12V, 37G) and H-Ras(12V, 40C) resulted in synergistic cooperation of their focus-forming activities, indicating that Ras activates at least two Raf-independent, Ras effector-mediated signaling events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_cWFoHWMoWrVg90H21EOLACvtfcHk0liI7M7sOzFqnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjvVWmsro%253D&md5=dec9680e7ca532fe5ce72eb28f53293d</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKhosravi-Far%26aufirst%3DR.%26aulast%3DWhite%26aufirst%3DM.%2BA.%26aulast%3DWestwick%26aufirst%3DJ.%2BK.%26aulast%3DSolski%26aufirst%3DP.%2BA.%26aulast%3DChrzanowska-Wodnicka%26aufirst%3DM.%26aulast%3DVan%2BAelst%26aufirst%3DL.%26aulast%3DWigler%26aufirst%3DM.%2BH.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DOncogenic%2520Ras%2520activation%2520of%2520Raf%252Fmitogen-activated%2520protein%2520kinase-independent%2520pathways%2520is%2520sufficient%2520to%2520cause%2520tumorigenic%2520transformation%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1996%26volume%3D16%26spage%3D3923%26epage%3D3933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Khosravi-Far, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solski, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinch, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span> </span><span class="NLM_article-title">Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for RAS transformation</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">6443</span><span class="NLM_x">–</span> <span class="NLM_lpage">6453</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1128%2FMCB.15.11.6443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=7565796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADyaK2MXovVyksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1995&pages=6443-6453&author=R.+Khosravi-Farauthor=P.+A.+Solskiauthor=G.+J.+Clarkauthor=M.+S.+Kinchauthor=C.+J.+Der&title=Activation+of+Rac1%2C+RhoA%2C+and+mitogen-activated+protein+kinases+is+required+for+RAS+transformation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation</span></div><div class="casAuthors">Khosravi-far, Roya; Solski, Patricia A.; Clark, Geoffrey J.; Kinch, Michael S.; Der, Channing J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6443-53</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Although substantial evidence supports a crit. role for the activation of Raf-1 and mitogen-activated protein kinases (MAPKs) in oncogenic Ras-mediated transformation, recent evidence suggests that Ras may activate a second signaling pathway which involves the Ras-related proteins Rac1 and RhoA.  Consequently, the authors used three complementary approaches to det. the contribution of Rac1 and RhoA function to oncogenic Ras-mediated transformation.  First, whereas constitutively activated mutants of Rac1 and RhoA showed very weak transforming activity when transfected alone, their coexpression with a weakly transforming Raf-1 mutant caused a greater than 35-fold enhancement of transforming activity.  Second, the authors obsd. that coexpression of dominant neg. mutants of Rac1 and RhoA reduced oncogenic Ras transforming activity.  Third, activated Rac1 and RhoA further enhanced oncogenic Ras-triggered morphol. transformation, as well as growth in soft agar and cell motility.  Finally, the authors also obsd. that kinase-deficient MAPKs inhibited Ras transformation.  Taken together, these data support the possibility that oncogenic Ras activation of Rac1 and RhoA, coupled with activation of the Raf/MAPK pathway, is required to trigger the full morphogenic and mitogenic consequences of oncogenic Ras transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUEqcWdhd4prVg90H21EOLACvtfcHk0liI7M7sOzFqnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXovVyksLk%253D&md5=4829be92810e97bad05c48faefa8780e</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1128%2FMCB.15.11.6443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.15.11.6443%26sid%3Dliteratum%253Aachs%26aulast%3DKhosravi-Far%26aufirst%3DR.%26aulast%3DSolski%26aufirst%3DP.%2BA.%26aulast%3DClark%26aufirst%3DG.%2BJ.%26aulast%3DKinch%26aufirst%3DM.%2BS.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DActivation%2520of%2520Rac1%252C%2520RhoA%252C%2520and%2520mitogen-activated%2520protein%2520kinases%2520is%2520required%2520for%2520RAS%2520transformation%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1995%26volume%3D15%26spage%3D6443%26epage%3D6453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Heim, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharifi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilger, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheulen, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeber, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strumberg, D.</span><span> </span><span class="NLM_article-title">Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006</span> <span class="citation_source-journal">Int. J. Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">616</span><span class="NLM_x">–</span> <span class="NLM_lpage">617</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=14692718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD2cXht1OjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2003&pages=616-617&author=M.+Heimauthor=M.+Sharifiauthor=R.+A.+Hilgerauthor=M.+E.+Scheulenauthor=S.+Seeberauthor=D.+Strumberg&title=Antitumor+effect+and+potentiation+or+reduction+in+cytotoxic+drug+activity+in+human+colon+carcinoma+cells+by+the+Raf+kinase+inhibitor+%28RKI%29+BAY+43-9006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006</span></div><div class="casAuthors">Heim, M.; Sharifi, M.; Hilger, R. A.; Scheulen, M. E.; Seeber, S.; Strumberg, D.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Clinical Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">616-617</span>CODEN:
                <span class="NLM_cas:coden">ICTHEK</span>;
        ISSN:<span class="NLM_cas:issn">0946-1965</span>.
    
            (<span class="NLM_cas:orgname">Dustri-Verlag Dr. Karl Feistle</span>)
        </div><div class="casAbstract">A study was conducted to evaluate the effects of combining BAY 43-9006 and cytotoxic drugs (paclitaxel, 5-FU, oxaliplatin, and SN-38) on human cancer cells using 4 sequencing protocols and to analyze the effect of RKI on colorectal cancer cells showing marked resistance against SN-38.  Results showed the additive action or moderate synergy using RKI in combination with numerous cytotoxic agents and the marked redn. of oxaliplatin activity by RKI in human carcinoma cells.  These indicate that Raf kinase activity might be important for oxaliplatin-induced cytotoxicity.  Furthermore, lacking cross-resistance between SN-38 and RKI might provide a rationale for designing clin. trials using CPT-11 in combination with BAY 43-9006 in patients with colorectal cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO-t4901dZa7Vg90H21EOLACvtfcHk0ljyJgAEs5PwNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXht1OjtA%253D%253D&md5=3913835b7d32f41af23033de33751c22</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHeim%26aufirst%3DM.%26aulast%3DSharifi%26aufirst%3DM.%26aulast%3DHilger%26aufirst%3DR.%2BA.%26aulast%3DScheulen%26aufirst%3DM.%2BE.%26aulast%3DSeeber%26aufirst%3DS.%26aulast%3DStrumberg%26aufirst%3DD.%26atitle%3DAntitumor%2520effect%2520and%2520potentiation%2520or%2520reduction%2520in%2520cytotoxic%2520drug%2520activity%2520in%2520human%2520colon%2520carcinoma%2520cells%2520by%2520the%2520Raf%2520kinase%2520inhibitor%2520%2528RKI%2529%2520BAY%252043-9006%26jtitle%3DInt.%2520J.%2520Clin.%2520Pharmacol.%2520Ther.%26date%3D2003%26volume%3D41%26spage%3D616%26epage%3D617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Wilhelm, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNabola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHugh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shujath, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gawlak, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eveleigh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adnane, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auclair, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gedrich, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voznesensky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trail, P. A.</span><span> </span><span class="NLM_article-title">BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">7099</span><span class="NLM_x">–</span> <span class="NLM_lpage">7109</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=7099-7109&author=S.+M.+Wilhelmauthor=C.+Carterauthor=L.+Tangauthor=D.+Wilkieauthor=A.+McNabolaauthor=H.+Rongauthor=C.+Chenauthor=X.+Zhangauthor=P.+Vincentauthor=M.+McHughauthor=Y.+Caoauthor=J.+Shujathauthor=S.+Gawlakauthor=D.+Eveleighauthor=B.+Rowleyauthor=L.+Liuauthor=L.+Adnaneauthor=M.+Lynchauthor=D.+Auclairauthor=I.+Taylorauthor=R.+Gedrichauthor=A.+Voznesenskyauthor=B.+Riedlauthor=L.+E.+Postauthor=G.+Bollagauthor=P.+A.+Trail&title=BAY+43-9006+exhibits+broad+spectrum+oral+antitumor+activity+and+targets+the+RAF%2FMEK%2FERK+pathway+and+receptor+tyrosine+kinases+involved+in+tumor+progression+and+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilhelm%26aufirst%3DS.%2BM.%26aulast%3DCarter%26aufirst%3DC.%26aulast%3DTang%26aufirst%3DL.%26aulast%3DWilkie%26aufirst%3DD.%26aulast%3DMcNabola%26aufirst%3DA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DVincent%26aufirst%3DP.%26aulast%3DMcHugh%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DShujath%26aufirst%3DJ.%26aulast%3DGawlak%26aufirst%3DS.%26aulast%3DEveleigh%26aufirst%3DD.%26aulast%3DRowley%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DAdnane%26aufirst%3DL.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DAuclair%26aufirst%3DD.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DGedrich%26aufirst%3DR.%26aulast%3DVoznesensky%26aufirst%3DA.%26aulast%3DRiedl%26aufirst%3DB.%26aulast%3DPost%26aufirst%3DL.%2BE.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DTrail%26aufirst%3DP.%2BA.%26atitle%3DBAY%252043-9006%2520exhibits%2520broad%2520spectrum%2520oral%2520antitumor%2520activity%2520and%2520targets%2520the%2520RAF%252FMEK%252FERK%2520pathway%2520and%2520receptor%2520tyrosine%2520kinases%2520involved%2520in%2520tumor%2520progression%2520and%2520angiogenesis%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D7099%26epage%3D7109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Koya, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otte, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blacketor, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comin-Anduix, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tumeh, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minasyan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graeber, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chodon, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span> </span><span class="NLM_article-title">BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">3928</span><span class="NLM_x">–</span> <span class="NLM_lpage">3937</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=3928-3937&author=R.+C.+Koyaauthor=S.+Mokauthor=N.+Otteauthor=K.+J.+Blacketorauthor=B.+Comin-Anduixauthor=P.+C.+Tumehauthor=A.+Minasyanauthor=N.+A.+Grahamauthor=T.+G.+Graeberauthor=T.+Chodonauthor=A.+Ribas&title=BRAF+inhibitor+vemurafenib+improves+the+antitumor+activity+of+adoptive+cell+immunotherapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKoya%26aufirst%3DR.%2BC.%26aulast%3DMok%26aufirst%3DS.%26aulast%3DOtte%26aufirst%3DN.%26aulast%3DBlacketor%26aufirst%3DK.%2BJ.%26aulast%3DComin-Anduix%26aufirst%3DB.%26aulast%3DTumeh%26aufirst%3DP.%2BC.%26aulast%3DMinasyan%26aufirst%3DA.%26aulast%3DGraham%26aufirst%3DN.%2BA.%26aulast%3DGraeber%26aufirst%3DT.%2BG.%26aulast%3DChodon%26aufirst%3DT.%26aulast%3DRibas%26aufirst%3DA.%26atitle%3DBRAF%2520inhibitor%2520vemurafenib%2520improves%2520the%2520antitumor%2520activity%2520of%2520adoptive%2520cell%2520immunotherapy%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D3928%26epage%3D3937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Holt, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logié, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Odedra, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heaton, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alferez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P. D.</span><span> </span><span class="NLM_article-title">The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">858</span><span class="NLM_x">–</span> <span class="NLM_lpage">866</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1038%2Fbjc.2012.8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=22343622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1arsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2012&pages=858-866&author=S.+V.+Holtauthor=A.+Logi%C3%A9author=R.+Odedraauthor=A.+Heierauthor=S.+P.+Heatonauthor=D.+Alferezauthor=B.+R.+Daviesauthor=R.+W.+Wilkinsonauthor=P.+D.+Smith&title=The+MEK1%2F2+inhibitor%2C+selumetinib+%28AZD6244%3B+ARRY-142886%29%2C+enhances+anti-tumour+efficacy+when+combined+with+conventional+chemotherapeutic+agents+in+human+tumour+xenograft+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models</span></div><div class="casAuthors">Holt, S. V.; Logie, A.; Odedra, R.; Heier, A.; Heaton, S. P.; Alferez, D.; Davies, B. R.; Wilkinson, R. W.; Smith, P. D.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">858-866</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: The Ras/RAF/MEK/ERK pathway is frequently deregulated in cancer and a no. of inhibitors that target this pathway are currently in clin. development.  It is likely that clin. testing of these agents will be in combination with std. therapies to harness the apoptotic potential of both the agents.  To support this strategy, it has been widely obsd. that a no. of chemotherapeutics stimulate the activation of several intracellular signalling cascades including Ras/RAF/MEK/ERK.  The MEK1/2 inhibitor selumetinib has been shown to have anti-tumor activity and induce apoptotic cell death as a monotherapy.  Methods: The aim of this study was to identify agents, which would be likely to offer clin. benefit when combined with selumetinib.  Here, we used human tumor xenograft models and assessed the effects combining std. chemotherapeutic agents with selumetinib on tumor growth.  In addn., we analyzed tumor tissue to det. the mechanistic effects of these combinations.  Results: Combining selumetinib with the DNA-alkylating agent, temozolomide (TMZ), resulted in enhanced tumor growth inhibition compared with monotherapies.  Biomarker studies highlighted an increase in γH2A.X suggesting that selumetinib is able to enhance the DNA damage induced by TMZ alone.  In several models we obsd. that continuous exposure to selumetinib in combination with docetaxel results in tumor regression.  Scheduling of docetaxel before selumetinib was more beneficial than when selumetinib was dosed before docetaxel and demonstrated a pro-apoptotic phenotype.  Similar results were seen when selumetinib was combined with the Aurora B inhibitor barasertib.  Conclusion: The data presented suggests that MEK inhibition in combination with several std. chemotherapeutics or an Aurora B kinase inhibitor is a promising clin. strategy.  British Journal of Cancer (2012) 106, 858-866; doi:10.1038/bjc.2012.8 www.bjcancer.com Published online 16 Feb. 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT9m5XMlh8e7Vg90H21EOLACvtfcHk0ljyJgAEs5PwNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1arsb0%253D&md5=1613a559df1e9e8d73c812ed48489779</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2012.8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2012.8%26sid%3Dliteratum%253Aachs%26aulast%3DHolt%26aufirst%3DS.%2BV.%26aulast%3DLogi%25C3%25A9%26aufirst%3DA.%26aulast%3DOdedra%26aufirst%3DR.%26aulast%3DHeier%26aufirst%3DA.%26aulast%3DHeaton%26aufirst%3DS.%2BP.%26aulast%3DAlferez%26aufirst%3DD.%26aulast%3DDavies%26aufirst%3DB.%2BR.%26aulast%3DWilkinson%26aufirst%3DR.%2BW.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26atitle%3DThe%2520MEK1%252F2%2520inhibitor%252C%2520selumetinib%2520%2528AZD6244%253B%2520ARRY-142886%2529%252C%2520enhances%2520anti-tumour%2520efficacy%2520when%2520combined%2520with%2520conventional%2520chemotherapeutic%2520agents%2520in%2520human%2520tumour%2520xenograft%2520models%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2012%26volume%3D106%26spage%3D858%26epage%3D866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Hoeflich, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merchant, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Den Otter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasman, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeppen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, N. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span> </span><span class="NLM_article-title">Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">210</span><span class="NLM_x">–</span> <span class="NLM_lpage">219</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1158%2F0008-5472.CAN-11-1515" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=22084396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVCltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=210-219&author=K.+P.+Hoeflichauthor=M.+Merchantauthor=C.+Orrauthor=J.+Chanauthor=D.+Den+Otterauthor=L.+Berryauthor=I.+Kasmanauthor=H.+Koeppenauthor=K.+Riceauthor=N.+Y.+Yangauthor=S.+Engstauthor=S.+Johnstonauthor=L.+S.+Friedmanauthor=M.+Belvin&title=Intermittent+administration+of+MEK+inhibitor+GDC-0973+plus+PI3K+inhibitor+GDC-0941+triggers+robust+apoptosis+and+tumor+growth+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition</span></div><div class="casAuthors">Hoeflich, Klaus P.; Merchant, Mark; Orr, Christine; Chan, Jocelyn; Den Otter, Doug; Berry, Leanne; Kasman, Ian; Koeppen, Hartmut; Rice, Ken; Yang, Nai-Ying; Engst, Stefan; Johnston, Stuart; Friedman, Lori S.; Belvin, Marcia</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">210-219</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Combinations of MAP/ERK kinase (MEK) and phosphoinositide 3-kinase (PI3K) inhibitors have shown promise in preclin. cancer models, leading to the initiation of clin. trials cotargeting these two key cancer signaling pathways.  GDC-0973, a novel selective MEK inhibitor, and GDC-0941, a class I PI3K inhibitor, are in early stage clin. trials as both single agents and in combination.  The discovery of these selective inhibitors has allowed investigation into the precise effects of combining inhibitors of two major signaling branches downstream of RAS.  Here, we investigated multiple biomarkers in the mitogen-activated protein kinase (MAPK) and PI3K pathway to search for points of convergence that explain the increased apoptosis seen in combination.  Using washout studies in vitro and alternate dosing schedules in mice, we showed that intermittent inhibition of the PI3K and MAPK pathway is sufficient for efficacy in BRAF and KRAS mutant cancer cells.  The combination of GDC-0973 with the PI3K inhibitor GDC-0941 resulted in combination efficacy in vitro and in vivo via induction of biomarkers assocd. with apoptosis, including Bcl-2 family proapoptotic regulators.  Therefore, these data suggest that continuous exposure of MEK and PI3K inhibitors in combination is not required for efficacy in preclin. cancer models and that sustained effects on downstream apoptosis biomarkers can be obsd. in response to intermittent dosing.  Cancer Res; 72(1); 210-9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokHbA7g6hLGrVg90H21EOLACvtfcHk0ljUeETGBJsXgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVCltA%253D%253D&md5=40032bf35d5e6335856a645d5c331df8</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-1515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-1515%26sid%3Dliteratum%253Aachs%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DMerchant%26aufirst%3DM.%26aulast%3DOrr%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DJ.%26aulast%3DDen%2BOtter%26aufirst%3DD.%26aulast%3DBerry%26aufirst%3DL.%26aulast%3DKasman%26aufirst%3DI.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DRice%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DN.%2BY.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DJohnston%26aufirst%3DS.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DBelvin%26aufirst%3DM.%26atitle%3DIntermittent%2520administration%2520of%2520MEK%2520inhibitor%2520GDC-0973%2520plus%2520PI3K%2520inhibitor%2520GDC-0941%2520triggers%2520robust%2520apoptosis%2520and%2520tumor%2520growth%2520inhibition%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D210%26epage%3D219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Daouti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolinsky, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Packman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Specian, A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huby, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Podlaski, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fotouhi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heimbrook, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, H.</span><span> </span><span class="NLM_article-title">Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">1924</span><span class="NLM_x">–</span> <span class="NLM_lpage">1932</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=1924-1932&author=S.+Daoutiauthor=H.+Wangauthor=W.+H.+Liauthor=B.+Higginsauthor=K.+Kolinskyauthor=K.+Packmanauthor=A.+Specianauthor=N.+Kongauthor=N.+Hubyauthor=Y.+Wenauthor=Q.+Xiangauthor=F.+J.+Podlaskiauthor=Y.+Heauthor=N.+Fotouhiauthor=D.+Heimbrookauthor=H.+Niu&title=Characterization+of+a+novel+mitogen-activated+protein+kinase+kinase+1%2F2+inhibitor+with+a+unique+mechanism+of+action+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDaouti%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DW.%2BH.%26aulast%3DHiggins%26aufirst%3DB.%26aulast%3DKolinsky%26aufirst%3DK.%26aulast%3DPackman%26aufirst%3DK.%26aulast%3DSpecian%26aufirst%3DA.%26aulast%3DKong%26aufirst%3DN.%26aulast%3DHuby%26aufirst%3DN.%26aulast%3DWen%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DQ.%26aulast%3DPodlaski%26aufirst%3DF.%2BJ.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DFotouhi%26aufirst%3DN.%26aulast%3DHeimbrook%26aufirst%3DD.%26aulast%3DNiu%26aufirst%3DH.%26atitle%3DCharacterization%2520of%2520a%2520novel%2520mitogen-activated%2520protein%2520kinase%2520kinase%25201%252F2%2520inhibitor%2520with%2520a%2520unique%2520mechanism%2520of%2520action%2520for%2520cancer%2520therapy%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D1924%26epage%3D1932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Sportsman, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaudet, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boge, A.</span><span> </span><span class="NLM_article-title">Immobilized metal ion affinity-based fluorescence polarization (IMAP): advances in kinase screening</span> <span class="citation_source-journal">Assay Drug Dev. Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">–</span> <span class="NLM_lpage">214</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1089%2F154065804323056549" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=15165516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvVSjt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2004&pages=205-214&author=J.+R.+Sportsmanauthor=E.+A.+Gaudetauthor=A.+Boge&title=Immobilized+metal+ion+affinity-based+fluorescence+polarization+%28IMAP%29%3A+advances+in+kinase+screening"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Immobilized Metal Ion Affinity-Based Fluorescence Polarization (IMAP): Advances in Kinase Screening</span></div><div class="casAuthors">Sportsman, J. Richard; Gaudet, Elizabeth A.; Boge, Annegret</div><div class="citationInfo"><span class="NLM_cas:title">Assay and Drug Development Technologies</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">205-214</span>CODEN:
                <span class="NLM_cas:coden">ADDTAR</span>;
        ISSN:<span class="NLM_cas:issn">1540-658X</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">The IMAP Fluorescence Polarization technol. is a homogeneous antibody-free method for anal. of kinases, phosphatases, and phosphodiesterases.  Recent developments to the technol. include an enhancement of the reagent system (the Progressive Binding System) that significantly expands the range of useable concns. of ATP, choices of substrates, and assay configurations.  With the new Progressive System, we are able to design multiplexed assays that allow the simultaneous detn. of multiple kinase activities.  In addn., coupled assays are now possible, allowing the assay of kinases through natural or artificial coupling through kinase cascades.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUY28ras-P37Vg90H21EOLACvtfcHk0ljUeETGBJsXgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvVSjt7c%253D&md5=df9c32895e0f7691dd08f3a5b9a052aa</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1089%2F154065804323056549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252F154065804323056549%26sid%3Dliteratum%253Aachs%26aulast%3DSportsman%26aufirst%3DJ.%2BR.%26aulast%3DGaudet%26aufirst%3DE.%2BA.%26aulast%3DBoge%26aufirst%3DA.%26atitle%3DImmobilized%2520metal%2520ion%2520affinity-based%2520fluorescence%2520polarization%2520%2528IMAP%2529%253A%2520advances%2520in%2520kinase%2520screening%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2004%26volume%3D2%26spage%3D205%26epage%3D214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span>CDAS: KinaseScreen Programs. <a href="http://www.caliperls.com/assets/011/6679.pdf" class="extLink">http://www.caliperls.com/assets/011/6679.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=CDAS%3A+KinaseScreen+Programs.+http%3A%2F%2Fwww.caliperls.com%2Fassets%2F011%2F6679.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Daouti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolinsky, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Packman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moliterni, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huby, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fotouhi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goelzer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandhu, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Railkar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heimbrook, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, H.</span><span> </span><span class="NLM_article-title">Preclinical in vivo evaluation of efficacy, pharmacokinetics, and pharmacodynamics of a novel MEK1/2 kinase inhibitor RO5068760 in multiple tumor models</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">134</span><span class="NLM_x">–</span> <span class="NLM_lpage">144</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1158%2F1535-7163.MCT-09-0601" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=20053779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktVOisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=134-144&author=S.+Daoutiauthor=B.+Higginsauthor=K.+Kolinskyauthor=K.+Packmanauthor=H.+Wangauthor=C.+Rizzoauthor=J.+Moliterniauthor=N.+Hubyauthor=N.+Fotouhiauthor=M.+Liuauthor=P.+Goelzerauthor=H.+K.+Sandhuauthor=J.+K.+Liauthor=A.+Railkarauthor=D.+Heimbrookauthor=H.+Niu&title=Preclinical+in+vivo+evaluation+of+efficacy%2C+pharmacokinetics%2C+and+pharmacodynamics+of+a+novel+MEK1%2F2+kinase+inhibitor+RO5068760+in+multiple+tumor+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical In vivo Evaluation of Efficacy, Pharmacokinetics, and Pharmacodynamics of a Novel MEK1/2 Kinase Inhibitor RO5068760 in Multiple Tumor Models</span></div><div class="casAuthors">Daouti, Sherif; Higgins, Brian; Kolinsky, Kenneth; Packman, Kathryn; Wang, Huisheng; Rizzo, Christine; Moliterni, John; Huby, Nicholas; Fotouhi, Nader; Liu, Mei; Goelzer, Petra; Sandhu, Harpreet K.; Li, Jia Kui; Railkar, Aruna; Heimbrook, David; Niu, Huifeng</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">134-144</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Targeting the Ras/Raf/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway represents a promising anticancer strategy.  Recently, we have reported a novel class of potent and selective non-ATP-competitive MEK1/2 inhibitors with a unique structure and mechanism of action.  RO5068760 is a representative of this class showing significant efficacy in a broad spectrum of tumors with aberrant mitogen-activated protein kinase pathway activation.  To understand the relationship between systemic exposures and target (MEK1/2) inhibition as well as tumor growth inhibition, the current study presents a detailed in vivo characterization of efficacy, pharmacokinetics, and pharmacodynamics of RO5068760 in multiple xenograft tumor models.  For inhibition of MEK1/2 as measured by the phosphorylated ERK levels, the estd. EC50s in plasma were 1.36 μmol/L (880 ng/mL) and 3.35 μmol/L (2168 ng/mL) in LOX melanoma and HT-29 colorectal cancer models, resp.  A similar EC50 (1.41 μmol/L or 915 ng/mL) was obsd. in monkey peripheral blood lymphocytes.  To achieve tumor growth inhibition (≥90%), an av. plasma drug concn. of 0.65 or 5.23 μmol/L was required in B-RafV600E or K-Ras mutant tumor models, resp., which were remarkably similar to the IC90 values (0.64 or 4.1 μmol/L) detd. in vitro for cellular growth inhibition.  With equiv. in vivo systemic exposures, RO5068760 showed superior efficacy in tumors harboring B-RafV600E mutation.  The plasma concn. time profiles indicate that const. p-ERK suppression (>50%) may not be required for optimal efficacy, esp. in highly responsive tumors.  This study may facilitate future clin. trial design in using biochem. markers for early proof of mechanism and in selecting the right patients and optimal dose regimen.  Mol Cancer Ther; 9(1); 134-44.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr7uzHdOgqxrVg90H21EOLACvtfcHk0ljcbgNhY-ad-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktVOisw%253D%253D&md5=66fa4470c00c0fa6c2d3735d92d1f4d5</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0601%26sid%3Dliteratum%253Aachs%26aulast%3DDaouti%26aufirst%3DS.%26aulast%3DHiggins%26aufirst%3DB.%26aulast%3DKolinsky%26aufirst%3DK.%26aulast%3DPackman%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DRizzo%26aufirst%3DC.%26aulast%3DMoliterni%26aufirst%3DJ.%26aulast%3DHuby%26aufirst%3DN.%26aulast%3DFotouhi%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DGoelzer%26aufirst%3DP.%26aulast%3DSandhu%26aufirst%3DH.%2BK.%26aulast%3DLi%26aufirst%3DJ.%2BK.%26aulast%3DRailkar%26aufirst%3DA.%26aulast%3DHeimbrook%26aufirst%3DD.%26aulast%3DNiu%26aufirst%3DH.%26atitle%3DPreclinical%2520in%2520vivo%2520evaluation%2520of%2520efficacy%252C%2520pharmacokinetics%252C%2520and%2520pharmacodynamics%2520of%2520a%2520novel%2520MEK1%252F2%2520kinase%2520inhibitor%2520RO5068760%2520in%2520multiple%2520tumor%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D134%26epage%3D144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guimaraes, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upadhyay, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maira, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perera, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaur, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lightbown, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simendinger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Echeverría, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissleder, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahmood, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span> </span><span class="NLM_article-title">Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1351</span><span class="NLM_x">–</span> <span class="NLM_lpage">1356</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1038%2Fnm.1890" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=19029981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWhu7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=1351-1356&author=J.+A.+Engelmanauthor=L.+Chenauthor=X.+Tanauthor=K.+Crosbyauthor=A.+R.+Guimaraesauthor=R.+Upadhyayauthor=M.+Mairaauthor=K.+McNamaraauthor=S.+A.+Pereraauthor=Y.+Songauthor=L.+R.+Chirieacauthor=R.+Kaurauthor=A.+Lightbownauthor=J.+Simendingerauthor=T.+Liauthor=R.+F.+Paderaauthor=C.+Garc%C3%ADa-Echeverr%C3%ADaauthor=R.+Weisslederauthor=U.+Mahmoodauthor=L.+C.+Cantleyauthor=K.+K.+Wong&title=Effective+use+of+PI3K+and+MEK+inhibitors+to+treat+mutant+Kras+G12D+and+PIK3CA+H1047R+murine+lung+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers</span></div><div class="casAuthors">Engelman, Jeffrey A.; Chen, Liang; Tan, Xiaohong; Crosby, Katherine; Guimaraes, Alexander R.; Upadhyay, Rabi; Maira, Michel; McNamara, Kate; Perera, Samanthi A.; Song, Youngchul; Chirieac, Lucian R.; Kaur, Ramneet; Lightbown, Angela; Simendinger, Jessica; Li, Timothy; Padera, Robert F.; Garcia-Echeverria, Carlos; Weissleder, Ralph; Mahmood, Umar; Cantley, Lewis C.; Wong, Kwok-Kin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1351-1356</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Somatic mutations that activate phosphoinositide 3-kinase (P13K) have been identified in the p1 10-x catalytic subunit (encoded by PIK3CA).  They are most frequently obsd. in two hotspots: the helical domain (E545K and E542K) and the kinase domain (H1047R).  Although the pl 10-o mutants are transforming in vitro, their oncogenic potential has not been assessed in genetically engineered mouse models.  Furthermore, clin. trials with P13K inhibitors have recently been initiated, and it is unknown if their efficacy will be restricted to specific, genetically defined malignancies.  In this study, we engineered a mouse model of lung adenocarcinomas initiated and maintained by expression of p-110-c H 1047R.  Treatment of these tumors - with NVP-BEZ235, a dual pan-PI3K and mammalian target of rapamycin (mTOR) inhibitor in clin. development, led to labored breathing and MRI images consistent with lung tumors after marked tumor regression as shown by positron emission imaging and microscopic examn.  In contrast, mouse lung cancers driven by mutant Kras did not substantially respond to CN single-agent NVP-BEZ235.  However, when NVP-BEZ235 was combined with a mitogen-activated protein kinase kinase (MEK) inhibitor, ARRY-142886, there was marked synergy in shrinking these kras-mutant cancers.  These in vivo studies suggest that inhibitors of the PI3K-mTOR pathway may be active in cancers with PIK3CA mutations and when combined with MEK inhibitors, may effectively treat KRAS mutated lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmFCNzeJpeErVg90H21EOLACvtfcHk0ljcbgNhY-ad-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWhu7rI&md5=3d9fd9c11132319c5e22807e15d592f3</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1038%2Fnm.1890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.1890%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DX.%26aulast%3DCrosby%26aufirst%3DK.%26aulast%3DGuimaraes%26aufirst%3DA.%2BR.%26aulast%3DUpadhyay%26aufirst%3DR.%26aulast%3DMaira%26aufirst%3DM.%26aulast%3DMcNamara%26aufirst%3DK.%26aulast%3DPerera%26aufirst%3DS.%2BA.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DChirieac%26aufirst%3DL.%2BR.%26aulast%3DKaur%26aufirst%3DR.%26aulast%3DLightbown%26aufirst%3DA.%26aulast%3DSimendinger%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DPadera%26aufirst%3DR.%2BF.%26aulast%3DGarc%25C3%25ADa-Echeverr%25C3%25ADa%26aufirst%3DC.%26aulast%3DWeissleder%26aufirst%3DR.%26aulast%3DMahmood%26aufirst%3DU.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DEffective%2520use%2520of%2520PI3K%2520and%2520MEK%2520inhibitors%2520to%2520treat%2520mutant%2520Kras%2520G12D%2520and%2520PIK3CA%2520H1047R%2520murine%2520lung%2520cancers%26jtitle%3DNat.%2520Med.%26date%3D2008%26volume%3D14%26spage%3D1351%26epage%3D1356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Serra, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markman, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scaltriti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eichhorn, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valero, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botero, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llonch, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atzori, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Cosimo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maira, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Echeverria, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parra, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arribas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span> </span><span class="NLM_article-title">NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">8022</span><span class="NLM_x">–</span> <span class="NLM_lpage">8030</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1158%2F0008-5472.CAN-08-1385" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=18829560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtF2msLrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=8022-8030&author=V.+Serraauthor=B.+Markmanauthor=M.+Scaltritiauthor=P.+J.+Eichhornauthor=V.+Valeroauthor=M.+Guzmanauthor=M.+L.+Boteroauthor=E.+Llonchauthor=F.+Atzoriauthor=S.+Di+Cosimoauthor=M.+Mairaauthor=C.+Garcia-Echeverriaauthor=J.+L.+Parraauthor=J.+Arribasauthor=J.+Baselga&title=NVP-BEZ235%2C+a+dual+PI3K%2FmTOR+inhibitor%2C+prevents+PI3K+signaling+and+inhibits+the+growth+of+cancer+cells+with+activating+PI3K+mutations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations</span></div><div class="casAuthors">Serra, Violeta; Markman, Ben; Scaltriti, Maurizio; Eichhorn, Pieter J. A.; Valero, Vanesa; Guzman, Marta; Botero, Maria Luisa; Llonch, Elisabeth; Atzori, Francesco; Di Cosimo, Serena; Maira, Michel; Garcia-Echeverria, Carlos; Parra, Josep Lluis; Arribas, Joaquin; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8022-8030</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Phosphatidylinositol-3-kinase (PI3K) pathway deregulation is a common event in human cancer, either through inactivation of the tumor suppressor phosphatase and tensin homolog deleted from chromosome 10 or activating mutations of p110-α.  These hotspot mutations result in oncogenic activity of the enzyme and contribute to therapeutic resistance to the anti-HER2 antibody trastuzumab.  The PI3K pathway is, therefore, an attractive target for cancer therapy.  We have studied NVP-BEZ235, a dual inhibitor of the PI3K and the downstream mammalian target of rapamycin (mTOR).  NVP-BEZ235 inhibited the activation of the downstream effectors Akt, S6 ribosomal protein, and 4EBP1 in breast cancer cells.  The antiproliferative activity of NVP-BEZ235 was superior to the allosteric selective mTOR complex inhibitor everolimus in a panel of 21 cancer cell lines of different origin and mutation status.  The described Akt activation due to mTOR inhibition was prevented by higher doses of NVP-BEZ235.  NVP-BEZ235 reversed the hyperactivation of the PI3K/mTOR pathway caused by the oncogenic mutations of p110-α, E545K, and H1047R, and inhibited the proliferation of HER2-amplified BT474 cells exogenously expressing these mutations that render them resistant to trastuzumab.  In trastuzumab-resistant BT474 H1047R breast cancer xenografts, NVP-BEZ235 inhibited PI3K signaling and had potent antitumor activity.  In treated animals, there was complete inhibition of PI3K signaling in the skin at pharmacol. active doses, suggesting that skin may serve as surrogate tissue for pharmacodynamic studies.  In summary, NVP-BEZ235 inhibits the PI3K/mTOR axis and results in antiproliferative and antitumoral activity in cancer cells with both wild-type and mutated p110-α.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlC_vqzWMDk7Vg90H21EOLACvtfcHk0ljcbgNhY-ad-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtF2msLrK&md5=b5d08e989c1b619e3c0ee9437002afd7</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-1385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-1385%26sid%3Dliteratum%253Aachs%26aulast%3DSerra%26aufirst%3DV.%26aulast%3DMarkman%26aufirst%3DB.%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DEichhorn%26aufirst%3DP.%2BJ.%26aulast%3DValero%26aufirst%3DV.%26aulast%3DGuzman%26aufirst%3DM.%26aulast%3DBotero%26aufirst%3DM.%2BL.%26aulast%3DLlonch%26aufirst%3DE.%26aulast%3DAtzori%26aufirst%3DF.%26aulast%3DDi%2BCosimo%26aufirst%3DS.%26aulast%3DMaira%26aufirst%3DM.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DParra%26aufirst%3DJ.%2BL.%26aulast%3DArribas%26aufirst%3DJ.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DNVP-BEZ235%252C%2520a%2520dual%2520PI3K%252FmTOR%2520inhibitor%252C%2520prevents%2520PI3K%2520signaling%2520and%2520inhibits%2520the%2520growth%2520of%2520cancer%2520cells%2520with%2520activating%2520PI3K%2520mutations%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D8022%26epage%3D8030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Seabra, M. C.</span><span> </span><span class="NLM_article-title">Membrane association and targeting of prenylated Ras-like GTPases</span> <span class="citation_source-journal">Cell. Signalling</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">167</span><span class="NLM_x">–</span> <span class="NLM_lpage">172</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1016%2FS0898-6568%2897%2900120-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=9607139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADyaK1cXis1altb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1998&pages=167-172&author=M.+C.+Seabra&title=Membrane+association+and+targeting+of+prenylated+Ras-like+GTPases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Membrane association and targeting of prenylated Ras-like GTPases</span></div><div class="casAuthors">Seabra, Miguel C.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">167-172</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review with 59 refs. Rho.  The regulatory function of the Ras-like GTPases in diverse cellular processes, such as growth, cell movement, and protein trafficking, is critically dependent on targeting to the proper cellular membrane.  Prenylation of Ras, Rho/Rac, and Rab GTPases, defined as the covalent addn. of isoprenyl groups to cysteine residues near or at their carboxyl terminus, is the first and necessary step that leads to membrane binding and targeting of these proteins.  Recent progress on the mol. mechanisms of prenylation, membrane assocn., and targeting of Ras, Rho/Rac, and Rab proteins will be reviewed here.  The detailed understanding of these targeting mechanisms may allow future development of specific therapeutic agents that interfere with the function of each one of these proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVv6tr6JINsrVg90H21EOLACvtfcHk0lhNMbsbpHdVyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXis1altb0%253D&md5=e0c744bee6c8581b4810272d0d95acf5</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2FS0898-6568%2897%2900120-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0898-6568%252897%252900120-4%26sid%3Dliteratum%253Aachs%26aulast%3DSeabra%26aufirst%3DM.%2BC.%26atitle%3DMembrane%2520association%2520and%2520targeting%2520of%2520prenylated%2520Ras-like%2520GTPases%26jtitle%3DCell.%2520Signalling%26date%3D1998%26volume%3D10%26spage%3D167%26epage%3D172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Sebti, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, A. D.</span><span> </span><span class="NLM_article-title">Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">6584</span><span class="NLM_x">–</span> <span class="NLM_lpage">6593</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=6584-6593&author=S.+M.+Sebtiauthor=A.+D.+Hamilton&title=Farnesyltransferase+and+geranylgeranyltransferase+I+inhibitors+and+cancer+therapy%3A+lessons+from+mechanism+and+bench-to-bedside+translational+studies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSebti%26aufirst%3DS.%2BM.%26aulast%3DHamilton%26aufirst%3DA.%2BD.%26atitle%3DFarnesyltransferase%2520and%2520geranylgeranyltransferase%2520I%2520inhibitors%2520and%2520cancer%2520therapy%253A%2520lessons%2520from%2520mechanism%2520and%2520bench-to-bedside%2520translational%2520studies%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D6584%26epage%3D6593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Cox, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span> </span><span class="NLM_article-title">Farnesyltransferase inhibitors: promises and realities</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">388</span><span class="NLM_x">–</span> <span class="NLM_lpage">393</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1016%2FS1471-4892%2802%2900181-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=12127871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsVGqtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=388-393&author=A.+D.+Coxauthor=C.+J.+Der&title=Farnesyltransferase+inhibitors%3A+promises+and+realities"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Farnesyltransferase inhibitors: promises and realities</span></div><div class="casAuthors">Cox, Adrienne D.; Der, Channing J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">388-393</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Farnesyltransferase inhibitors have recently shown clin. efficacy against leukemias, gliomas and even non-small-cell lung cancers, esp. when administered in combination with taxanes.  It is possible that the crit. target downstream of farnesyltransferase responsible for these effects is not either Ras or RhoB, the two most cited possibilities - but the hunt is on.  Farnesyltransferase inhibitors have anticancer activity, but their downstream targets are controversial.  Are Ras or RhoB proteins the "true targets" of these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouAFOphziJMrVg90H21EOLACvtfcHk0lhNMbsbpHdVyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsVGqtL0%253D&md5=6e41bdecb34dfe5b5d0e944b35a0a8f3</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2FS1471-4892%2802%2900181-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1471-4892%252802%252900181-9%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DA.%2BD.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DFarnesyltransferase%2520inhibitors%253A%2520promises%2520and%2520realities%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2002%26volume%3D2%26spage%3D388%26epage%3D393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebti, S. M.</span><span> </span><span class="NLM_article-title">Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1467</span><span class="NLM_x">–</span> <span class="NLM_lpage">1473</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1998&pages=1467-1473&author=J.+Sunauthor=Y.+Qianauthor=A.+D.+Hamiltonauthor=S.+M.+Sebti&title=Both+farnesyltransferase+and+geranylgeranyltransferase+I+inhibitors+are+required+for+inhibition+of+oncogenic+K-Ras+prenylation+but+each+alone+is+sufficient+to+suppress+human+tumor+growth+in+nude+mouse+xenografts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DHamilton%26aufirst%3DA.%2BD.%26aulast%3DSebti%26aufirst%3DS.%2BM.%26atitle%3DBoth%2520farnesyltransferase%2520and%2520geranylgeranyltransferase%2520I%2520inhibitors%2520are%2520required%2520for%2520inhibition%2520of%2520oncogenic%2520K-Ras%2520prenylation%2520but%2520each%2520alone%2520is%2520sufficient%2520to%2520suppress%2520human%2520tumor%2520growth%2520in%2520nude%2520mouse%2520xenografts%26jtitle%3DOncogene%26date%3D1998%26volume%3D16%26spage%3D1467%26epage%3D1473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Lerner, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaskovich, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fossum, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebti, S. M.</span><span> </span><span class="NLM_article-title">Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">270</span><span class="NLM_x">, </span> <span class="NLM_fpage">26802</span><span class="NLM_x">–</span> <span class="NLM_lpage">26806</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=26802-26806&author=E.+C.+Lernerauthor=Y.+Qianauthor=M.+A.+Blaskovichauthor=R.+D.+Fossumauthor=A.+Vogtauthor=J.+Sunauthor=A.+D.+Coxauthor=C.+J.+Derauthor=A.+D.+Hamiltonauthor=S.+M.+Sebti&title=Ras+CAAX+peptidomimetic+FTI-277+selectively+blocks+oncogenic+Ras+signaling+by+inducing+cytoplasmic+accumulation+of+inactive+Ras-Raf+complexes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLerner%26aufirst%3DE.%2BC.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DBlaskovich%26aufirst%3DM.%2BA.%26aulast%3DFossum%26aufirst%3DR.%2BD.%26aulast%3DVogt%26aufirst%3DA.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DCox%26aufirst%3DA.%2BD.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26aulast%3DHamilton%26aufirst%3DA.%2BD.%26aulast%3DSebti%26aufirst%3DS.%2BM.%26atitle%3DRas%2520CAAX%2520peptidomimetic%2520FTI-277%2520selectively%2520blocks%2520oncogenic%2520Ras%2520signaling%2520by%2520inducing%2520cytoplasmic%2520accumulation%2520of%2520inactive%2520Ras-Raf%2520complexes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26spage%3D26802%26epage%3D26806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Song, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meszoely, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coffey, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietenpol, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, S. D.</span><span> </span><span class="NLM_article-title">K-Ras-independent effects of the farnesyl transferase inhibitor L-744,832 on cyclin B1/Cdc2 kinase activity, G2/M cell cycle progression and apoptosis in human pancreatic ductal adenocarcinoma cells</span> <span class="citation_source-journal">Neoplasia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">261</span><span class="NLM_x">–</span> <span class="NLM_lpage">272</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2000&pages=261-272&author=S.+Y.+Songauthor=I.+M.+Meszoelyauthor=R.+J.+Coffeyauthor=J.+A.+Pietenpolauthor=S.+D.+Leach&title=K-Ras-independent+effects+of+the+farnesyl+transferase+inhibitor+L-744%2C832+on+cyclin+B1%2FCdc2+kinase+activity%2C+G2%2FM+cell+cycle+progression+and+apoptosis+in+human+pancreatic+ductal+adenocarcinoma+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DS.%2BY.%26aulast%3DMeszoely%26aufirst%3DI.%2BM.%26aulast%3DCoffey%26aufirst%3DR.%2BJ.%26aulast%3DPietenpol%26aufirst%3DJ.%2BA.%26aulast%3DLeach%26aufirst%3DS.%2BD.%26atitle%3DK-Ras-independent%2520effects%2520of%2520the%2520farnesyl%2520transferase%2520inhibitor%2520L-744%252C832%2520on%2520cyclin%2520B1%252FCdc2%2520kinase%2520activity%252C%2520G2%252FM%2520cell%2520cycle%2520progression%2520and%2520apoptosis%2520in%2520human%2520pancreatic%2520ductal%2520adenocarcinoma%2520cells%26jtitle%3DNeoplasia%26date%3D2000%26volume%3D2%26spage%3D261%26epage%3D272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Nagasu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshimatsu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, A. M.</span><span> </span><span class="NLM_article-title">Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">5310</span><span class="NLM_x">–</span> <span class="NLM_lpage">5314</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1995&pages=5310-5314&author=T.+Nagasuauthor=K.+Yoshimatsuauthor=C.+Rowellauthor=M.+D.+Lewisauthor=A.+M.+Garcia&title=Inhibition+of+human+tumor+xenograft+growth+by+treatment+with+the+farnesyl+transferase+inhibitor+B956"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagasu%26aufirst%3DT.%26aulast%3DYoshimatsu%26aufirst%3DK.%26aulast%3DRowell%26aufirst%3DC.%26aulast%3DLewis%26aufirst%3DM.%2BD.%26aulast%3DGarcia%26aufirst%3DA.%2BM.%26atitle%3DInhibition%2520of%2520human%2520tumor%2520xenograft%2520growth%2520by%2520treatment%2520with%2520the%2520farnesyl%2520transferase%2520inhibitor%2520B956%26jtitle%3DCancer%2520Res.%26date%3D1995%26volume%3D55%26spage%3D5310%26epage%3D5314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Crespo, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohkanda, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebti, S. M.</span><span> </span><span class="NLM_article-title">The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">16161</span><span class="NLM_x">–</span> <span class="NLM_lpage">16167</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=16161-16167&author=N.+C.+Crespoauthor=J.+Ohkandaauthor=T.+J.+Yenauthor=A.+D.+Hamiltonauthor=S.+M.+Sebti&title=The+farnesyltransferase+inhibitor%2C+FTI-2153%2C+blocks+bipolar+spindle+formation+and+chromosome+alignment+and+causes+prometaphase+accumulation+during+mitosis+of+human+lung+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCrespo%26aufirst%3DN.%2BC.%26aulast%3DOhkanda%26aufirst%3DJ.%26aulast%3DYen%26aufirst%3DT.%2BJ.%26aulast%3DHamilton%26aufirst%3DA.%2BD.%26aulast%3DSebti%26aufirst%3DS.%2BM.%26atitle%3DThe%2520farnesyltransferase%2520inhibitor%252C%2520FTI-2153%252C%2520blocks%2520bipolar%2520spindle%2520formation%2520and%2520chromosome%2520alignment%2520and%2520causes%2520prometaphase%2520accumulation%2520during%2520mitosis%2520of%2520human%2520lung%2520cancer%2520cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D16161%26epage%3D16167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">Beaupre, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cepero, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obeng, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boise, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lichtenheld, M. G.</span><span> </span><span class="NLM_article-title">R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">179</span><span class="NLM_x">–</span> <span class="NLM_lpage">186</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=14985458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFCitr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=179-186&author=D.+M.+Beaupreauthor=E.+Ceperoauthor=E.+A.+Obengauthor=L.+H.+Boiseauthor=M.+G.+Lichtenheld&title=R115777+induces+Ras-independent+apoptosis+of+myeloma+cells+via+multiple+intrinsic+pathways"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways</span></div><div class="casAuthors">Beaupre, Darrin M.; Cepero, Enrique; Obeng, Esther A.; Boise, Lawrence H.; Lichtenheld, Mathias G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-186</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Ras activation is frequently obsd. in multiple myeloma either by mutation or through interleukin-6 receptor signaling.  Recently, drugs designed to inhibit Ras have shown promise in preclin. myeloma models and in clin. trials.  In this report, we characterize the pathways by which the clin. tested farnesyl transferase inhibitor (FTI) R115777 induces apoptosis in multiple myeloma cells.  Contrary to the proposed mechanistic action of FTIs, we found that R115777 induces cell death despite Ras prenylation implying participation of Ras-independent mechanism(s).  Apoptosis proceeded via an intrinsic cascade and was assocd. with an increase in the expression and activity of Bax.  Bax activation correlated with a loss of mitochondrial membrane integrity and activation of the endoplasmic reticulum (ER) stress response.  These pathways activate caspase-9 and consistent with this, cell death was prevented by caspase-9 blockade.  Interestingly, cells over-expressing Bcl-XL remained partially sensitive to R115777 despite suppression of mitochondrial membrane dysfunction and ER-related stress.  Taken together, these results indicate that R115777 induces apoptosis in a Ras-independent fashion via multiple intrinsic pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosdUKBKAfDIbVg90H21EOLACvtfcHk0lgEPcE4sYHydw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFCitr8%253D&md5=0f36fe2c3351caf511152fcecf89fd9f</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBeaupre%26aufirst%3DD.%2BM.%26aulast%3DCepero%26aufirst%3DE.%26aulast%3DObeng%26aufirst%3DE.%2BA.%26aulast%3DBoise%26aufirst%3DL.%2BH.%26aulast%3DLichtenheld%26aufirst%3DM.%2BG.%26atitle%3DR115777%2520induces%2520Ras-independent%2520apoptosis%2520of%2520myeloma%2520cells%2520via%2520multiple%2520intrinsic%2520pathways%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2004%26volume%3D3%26spage%3D179%26epage%3D186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Wang, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, W. W.</span><span> </span><span class="NLM_article-title">The farnesyl protein transferase inhibitor lonafarnib (SCH66336) is an inhibitor of multidrug resistance proteins 1 and 2</span> <span class="citation_source-journal">Chemotherapy</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">303</span><span class="NLM_x">–</span> <span class="NLM_lpage">308</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2003&pages=303-308&author=E.+J.+Wangauthor=W.+W.+Johnson&title=The+farnesyl+protein+transferase+inhibitor+lonafarnib+%28SCH66336%29+is+an+inhibitor+of+multidrug+resistance+proteins+1+and+2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DE.%2BJ.%26aulast%3DJohnson%26aufirst%3DW.%2BW.%26atitle%3DThe%2520farnesyl%2520protein%2520transferase%2520inhibitor%2520lonafarnib%2520%2528SCH66336%2529%2520is%2520an%2520inhibitor%2520of%2520multidrug%2520resistance%2520proteins%25201%2520and%25202%26jtitle%3DChemotherapy%26date%3D2003%26volume%3D49%26spage%3D303%26epage%3D308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">Rose, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairchild, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monticello, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kramer, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manne, V.</span><span> </span><span class="NLM_article-title">Preclinical antitumor activity of BMS-214662.; a highly apoptotic and novel farnesyltransferase inhibitor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">7507</span><span class="NLM_x">–</span> <span class="NLM_lpage">7517</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=7507-7517&author=W.+C.+Roseauthor=F.+Y.+Leeauthor=C.+R.+Fairchildauthor=M.+Lynchauthor=T.+Monticelloauthor=R.+A.+Kramerauthor=V.+Manne&title=Preclinical+antitumor+activity+of+BMS-214662.%3B+a+highly+apoptotic+and+novel+farnesyltransferase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRose%26aufirst%3DW.%2BC.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DFairchild%26aufirst%3DC.%2BR.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DMonticello%26aufirst%3DT.%26aulast%3DKramer%26aufirst%3DR.%2BA.%26aulast%3DManne%26aufirst%3DV.%26atitle%3DPreclinical%2520antitumor%2520activity%2520of%2520BMS-214662.%253B%2520a%2520highly%2520apoptotic%2520and%2520novel%2520farnesyltransferase%2520inhibitor%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D7507%26epage%3D7517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Haluska, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dy, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span> </span><span class="NLM_article-title">Farnesyl transferase inhibitors as anticancer agents</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1685</span><span class="NLM_x">–</span> <span class="NLM_lpage">1700</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2002&pages=1685-1700&author=P.+Haluskaauthor=G.+K.+Dyauthor=A.+A.+Adjei&title=Farnesyl+transferase+inhibitors+as+anticancer+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHaluska%26aufirst%3DP.%26aulast%3DDy%26aufirst%3DG.%2BK.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DFarnesyl%2520transferase%2520inhibitors%2520as%2520anticancer%2520agents%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2002%26volume%3D38%26spage%3D1685%26epage%3D1700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">Sebti, S. M.</span><span> </span><span class="NLM_article-title">Blocked pathways: FTIs shut down oncogene signals</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 3</span><span class="NLM_x">) </span> <span class="NLM_fpage">30</span><span class="NLM_x">–</span> <span class="NLM_lpage">38</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=30-38&issue=Suppl.+3&author=S.+M.+Sebti&title=Blocked+pathways%3A+FTIs+shut+down+oncogene+signals"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSebti%26aufirst%3DS.%2BM.%26atitle%3DBlocked%2520pathways%253A%2520FTIs%2520shut%2520down%2520oncogene%2520signals%26jtitle%3DOncologist%26date%3D2003%26volume%3D8%26issue%3DSuppl.%25203%26spage%3D30%26epage%3D38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group">Whyte, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirschmeier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hockenberry, T. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nunez-Oliva, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catino, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bishop, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pai, J. K.</span><span> </span><span class="NLM_article-title">K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">272</span><span class="NLM_x">, </span> <span class="NLM_fpage">14459</span><span class="NLM_x">–</span> <span class="NLM_lpage">14464</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=14459-14464&author=D.+B.+Whyteauthor=P.+Kirschmeierauthor=T.+N.+Hockenberryauthor=I.+Nunez-Olivaauthor=L.+Jamesauthor=J.+J.+Catinoauthor=W.+R.+Bishopauthor=J.+K.+Pai&title=K-+and+N-Ras+are+geranylgeranylated+in+cells+treated+with+farnesyl+protein+transferase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWhyte%26aufirst%3DD.%2BB.%26aulast%3DKirschmeier%26aufirst%3DP.%26aulast%3DHockenberry%26aufirst%3DT.%2BN.%26aulast%3DNunez-Oliva%26aufirst%3DI.%26aulast%3DJames%26aufirst%3DL.%26aulast%3DCatino%26aufirst%3DJ.%2BJ.%26aulast%3DBishop%26aufirst%3DW.%2BR.%26aulast%3DPai%26aufirst%3DJ.%2BK.%26atitle%3DK-%2520and%2520N-Ras%2520are%2520geranylgeranylated%2520in%2520cells%2520treated%2520with%2520farnesyl%2520protein%2520transferase%2520inhibitors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26spage%3D14459%26epage%3D14464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group">Lancet, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gojo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gotlib, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liesveld, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruzek, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett-Mayer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberg, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, J. E.</span><span> </span><span class="NLM_article-title">A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">1387</span><span class="NLM_x">–</span> <span class="NLM_lpage">1394</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2007&pages=1387-1394&author=J.+E.+Lancetauthor=I.+Gojoauthor=J.+Gotlibauthor=E.+J.+Feldmanauthor=J.+Greerauthor=J.+L.+Liesveldauthor=L.+M.+Bruzekauthor=L.+Morrisauthor=Y.+Parkauthor=A.+A.+Adjeiauthor=S.+H.+Kaufmannauthor=E.+Garrett-Mayerauthor=P.+L.+Greenbergauthor=J.+J.+Wrightauthor=J.+E.+Karp&title=A+phase+2+study+of+the+farnesyltransferase+inhibitor+tipifarnib+in+poor-risk+and+elderly+patients+with+previously+untreated+acute+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLancet%26aufirst%3DJ.%2BE.%26aulast%3DGojo%26aufirst%3DI.%26aulast%3DGotlib%26aufirst%3DJ.%26aulast%3DFeldman%26aufirst%3DE.%2BJ.%26aulast%3DGreer%26aufirst%3DJ.%26aulast%3DLiesveld%26aufirst%3DJ.%2BL.%26aulast%3DBruzek%26aufirst%3DL.%2BM.%26aulast%3DMorris%26aufirst%3DL.%26aulast%3DPark%26aufirst%3DY.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26aulast%3DGarrett-Mayer%26aufirst%3DE.%26aulast%3DGreenberg%26aufirst%3DP.%2BL.%26aulast%3DWright%26aufirst%3DJ.%2BJ.%26aulast%3DKarp%26aufirst%3DJ.%2BE.%26atitle%3DA%2520phase%25202%2520study%2520of%2520the%2520farnesyltransferase%2520inhibitor%2520tipifarnib%2520in%2520poor-risk%2520and%2520elderly%2520patients%2520with%2520previously%2520untreated%2520acute%2520myelogenous%2520leukemia%26jtitle%3DBlood%26date%3D2007%26volume%3D109%26spage%3D1387%26epage%3D1394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group">Karp, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancet, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">End, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bol, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horak, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tidwell, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liesveld, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kottke, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ange, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buddharaju, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gojo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Highsmith, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belly, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohl, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rybak, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thibault, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenblatt, J.</span><span> </span><span class="NLM_article-title">Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">3361</span><span class="NLM_x">–</span> <span class="NLM_lpage">3369</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2001&pages=3361-3369&author=J.+E.+Karpauthor=J.+E.+Lancetauthor=S.+H.+Kaufmannauthor=D.+W.+Endauthor=J.+J.+Wrightauthor=K.+Bolauthor=I.+Horakauthor=M.+L.+Tidwellauthor=J.+Liesveldauthor=T.+J.+Kottkeauthor=D.+Angeauthor=L.+Buddharajuauthor=I.+Gojoauthor=W.+E.+Highsmithauthor=R.+T.+Bellyauthor=R.+J.+Hohlauthor=M.+E.+Rybakauthor=A.+Thibaultauthor=J.+Rosenblatt&title=Clinical+and+biologic+activity+of+the+farnesyltransferase+inhibitor+R115777+in+adults+with+refractory+and+relapsed+acute+leukemias%3A+a+phase+1+clinical-laboratory+correlative+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKarp%26aufirst%3DJ.%2BE.%26aulast%3DLancet%26aufirst%3DJ.%2BE.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26aulast%3DEnd%26aufirst%3DD.%2BW.%26aulast%3DWright%26aufirst%3DJ.%2BJ.%26aulast%3DBol%26aufirst%3DK.%26aulast%3DHorak%26aufirst%3DI.%26aulast%3DTidwell%26aufirst%3DM.%2BL.%26aulast%3DLiesveld%26aufirst%3DJ.%26aulast%3DKottke%26aufirst%3DT.%2BJ.%26aulast%3DAnge%26aufirst%3DD.%26aulast%3DBuddharaju%26aufirst%3DL.%26aulast%3DGojo%26aufirst%3DI.%26aulast%3DHighsmith%26aufirst%3DW.%2BE.%26aulast%3DBelly%26aufirst%3DR.%2BT.%26aulast%3DHohl%26aufirst%3DR.%2BJ.%26aulast%3DRybak%26aufirst%3DM.%2BE.%26aulast%3DThibault%26aufirst%3DA.%26aulast%3DRosenblatt%26aufirst%3DJ.%26atitle%3DClinical%2520and%2520biologic%2520activity%2520of%2520the%2520farnesyltransferase%2520inhibitor%2520R115777%2520in%2520adults%2520with%2520refractory%2520and%2520relapsed%2520acute%2520leukemias%253A%2520a%2520phase%25201%2520clinical-laboratory%2520correlative%2520trial%26jtitle%3DBlood%26date%3D2001%26volume%3D97%26spage%3D3361%26epage%3D3369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group">Karp, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gojo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancet, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett-Mayer, E.</span><span> </span><span class="NLM_article-title">Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">3077</span><span class="NLM_x">–</span> <span class="NLM_lpage">3082</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1158%2F1078-0432.CCR-07-4743" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=18483374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtVCmtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=3077-3082&author=J.+E.+Karpauthor=B.+D.+Smithauthor=I.+Gojoauthor=J.+E.+Lancetauthor=J.+Greerauthor=M.+Kleinauthor=L.+Morrisauthor=M.+J.+Levisauthor=S.+D.+Goreauthor=J.+J.+Wrightauthor=E.+Garrett-Mayer&title=Phase+II+trial+of+tipifarnib+as+maintenance+therapy+in+first+complete+remission+in+adults+with+acute+myelogenous+leukemia+and+poor-risk+features"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II Trial of Tipifarnib as Maintenance Therapy in First Complete Remission in Adults with Acute Myelogenous Leukemia and Poor-Risk Features</span></div><div class="casAuthors">Karp, Judith E.; Smith, B. Douglas; Gojo, Ivana; Lancet, Jeffrey E.; Greer, Jacqueline; Klein, Maureen; Morris, Larry; Levis, Mark J.; Gore, Steven D.; Wright, John J.; Garrett-Mayer, Elizabeth</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3077-3082</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Acute myelogenous leukemia (AML) does not have a high cure rate, particularly in patients with poor-risk features.  Such patients might benefit from addnl. therapy in complete remission (CR).  Tipifarnib is an oral farnesyltransferase inhibitor with activity in AML.  We conducted a phase II trial of maintenance tipifarnib monotherapy for 48 adults with poor-risk AML in first CR.  Tipifarnib 400 mg twice daily for 14 of 21 days was initiated after recovery from consolidation chemotherapy, for a max. of 16 cycles (48 wk).  Twenty (42%) patients completed 16 cycles, 24 (50%) were removed from study for relapse, and 4 (8%) discontinued drug prematurely for intolerance.  Nonhematol. toxicities were rare, but tipifarnib dose was reduced in 58% for myelosuppression.  Median disease-free survival (DFS) was 13.5 mo (range, 3.5-59+ months), with 30% having DFS >2 years.  Comparison of CR durations for 25 patients who received two-cycle timed sequential therapy followed by tipifarnib maintenance with 23 historically similar patients who did not receive tipifarnib showed that tipifarnib was assocd. with DFS prolongation for patients with secondary AML and adverse cytogenetics.  This study suggests that some patients with poor-risk AML, including patients with secondary AML and adverse cytogenetics, may benefit from tipifarnib maintenance therapy.  Future studies are warranted to examine alternative tipifarnib dosing and continuation beyond 16 cycles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUqycwKXKDP7Vg90H21EOLACvtfcHk0liKwXKdKDkRCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtVCmtbg%253D&md5=cae66043bc604b08d17b9439dc7c0c2e</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-4743&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-4743%26sid%3Dliteratum%253Aachs%26aulast%3DKarp%26aufirst%3DJ.%2BE.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DGojo%26aufirst%3DI.%26aulast%3DLancet%26aufirst%3DJ.%2BE.%26aulast%3DGreer%26aufirst%3DJ.%26aulast%3DKlein%26aufirst%3DM.%26aulast%3DMorris%26aufirst%3DL.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DGore%26aufirst%3DS.%2BD.%26aulast%3DWright%26aufirst%3DJ.%2BJ.%26aulast%3DGarrett-Mayer%26aufirst%3DE.%26atitle%3DPhase%2520II%2520trial%2520of%2520tipifarnib%2520as%2520maintenance%2520therapy%2520in%2520first%2520complete%2520remission%2520in%2520adults%2520with%2520acute%2520myelogenous%2520leukemia%2520and%2520poor-risk%2520features%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D3077%26epage%3D3082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albitar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurzrock, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thibault, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rackoff, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Manero, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talpaz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span> </span><span class="NLM_article-title">Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">1692</span><span class="NLM_x">–</span> <span class="NLM_lpage">1697</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2003&pages=1692-1697&author=J.+Cortesauthor=M.+Albitarauthor=D.+Thomasauthor=F.+Gilesauthor=R.+Kurzrockauthor=A.+Thibaultauthor=W.+Rackoffauthor=C.+Kollerauthor=S.+O%E2%80%99Brienauthor=G.+Garcia-Maneroauthor=M.+Talpazauthor=H.+Kantarjian&title=Efficacy+of+the+farnesyl+transferase+inhibitor+R115777+in+chronic+myeloid+leukemia+and+other+hematologic+malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DAlbitar%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DD.%26aulast%3DGiles%26aufirst%3DF.%26aulast%3DKurzrock%26aufirst%3DR.%26aulast%3DThibault%26aufirst%3DA.%26aulast%3DRackoff%26aufirst%3DW.%26aulast%3DKoller%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DGarcia-Manero%26aufirst%3DG.%26aulast%3DTalpaz%26aufirst%3DM.%26aulast%3DKantarjian%26aufirst%3DH.%26atitle%3DEfficacy%2520of%2520the%2520farnesyl%2520transferase%2520inhibitor%2520R115777%2520in%2520chronic%2520myeloid%2520leukemia%2520and%2520other%2520hematologic%2520malignancies%26jtitle%3DBlood%26date%3D2003%26volume%3D101%26spage%3D1692%26epage%3D1697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group">Mesa, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camoriano, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geyer, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlichman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardanani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasho, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finke, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tefferi, A.</span><span> </span><span class="NLM_article-title">A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1964</span><span class="NLM_x">–</span> <span class="NLM_lpage">1970</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=1964-1970&author=R.+A.+Mesaauthor=J.+K.+Camorianoauthor=S.+M.+Geyerauthor=W.+Wuauthor=S.+H.+Kaufmannauthor=C.+E.+Riveraauthor=C.+Erlichmanauthor=J.+Wrightauthor=A.+Pardananiauthor=T.+Lashoauthor=C.+Finkeauthor=C.+Y.+Liauthor=A.+Tefferi&title=A+phase+II+trial+of+tipifarnib+in+myelofibrosis%3A+primary%2C+post-polycythemia+vera+and+post-essential+thrombocythemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DCamoriano%26aufirst%3DJ.%2BK.%26aulast%3DGeyer%26aufirst%3DS.%2BM.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26aulast%3DRivera%26aufirst%3DC.%2BE.%26aulast%3DErlichman%26aufirst%3DC.%26aulast%3DWright%26aufirst%3DJ.%26aulast%3DPardanani%26aufirst%3DA.%26aulast%3DLasho%26aufirst%3DT.%26aulast%3DFinke%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DC.%2BY.%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DA%2520phase%2520II%2520trial%2520of%2520tipifarnib%2520in%2520myelofibrosis%253A%2520primary%252C%2520post-polycythemia%2520vera%2520and%2520post-essential%2520thrombocythemia%26jtitle%3DLeukemia%26date%3D2007%26volume%3D21%26spage%3D1964%26epage%3D1970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group">Kurzrock, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albitar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estey, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faderl, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Manero, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryback, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thibault, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Porre, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H. M.</span><span> </span><span class="NLM_article-title">Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1287</span><span class="NLM_x">–</span> <span class="NLM_lpage">1292</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1200%2FJCO.2004.08.082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=15051776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVGktbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2004&pages=1287-1292&author=R.+Kurzrockauthor=M.+Albitarauthor=J.+E.+Cortesauthor=E.+H.+Esteyauthor=S.+H.+Faderlauthor=G.+Garcia-Maneroauthor=D.+A.+Thomasauthor=F.+J.+Gilesauthor=M.+E.+Rybackauthor=A.+Thibaultauthor=P.+De+Porreauthor=H.+M.+Kantarjian&title=Phase+II+study+of+R115777%2C+a+farnesyl+transferase+inhibitor%2C+in+myelodysplastic+syndrome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome</span></div><div class="casAuthors">Kurzrock, Razelle; Albitar, Maher; Cortes, Jorge E.; Estey, Elihu H.; Faderl, Stefan H.; Garcia-Manero, Guillermo; Thomas, Deborah A.; Giles, Francis J.; Ryback, Mary Ellen; Thibault, Alain; de Porre, P.; Kantarjian, Hagop M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1287-1292</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">The aim was to perform a phase II study of the farnesyltransferase inhibitor R115777 (Zarnestra; Johnson and Johnson Pharmaceutical Research and Development, Raritan, NJ) in patients with myelodysplastic syndrome (MDS), using doses recommended in a phase I study in relapsed/refractory leukemia.  Patients with MDS were treated with R115777 at doses of 600 mg orally (PO) bid in cycles of 4 wk of therapy followed by a 2-wk rest period.  Dose redn. rules for toxicity were applied.  Twenty-seven of the 28 patients treated were assessable.  Three patients responded (complete remission, n = 2; partial remission, n = 1).  Responders included two patients with refractory anemia with excess blasts and one patient with refractory anemia with excess blasts in transformation.  Two of the responders had a diploid karyotype and one had multiple cytogenetic abnormalities including monosomy 5 and 7.  The starting dose of 600 mg PO bid resulted in side effects (myelosuppression, fatigue, neurotoxicity, rash, or leg pain) necessitating dose redn. (n = 4) or discontinuation of therapy (n = 7) in 11 (41%) of 27 patients during the induction period (12 wk).  Lower doses of 300 mg PO bid were well tolerated.  All responses occurred in patients who had been reduced to this dose level during the initial two cycles.  This study suggests that R115777 has modest activity in MDS patients, but that, in this patient population, 4 wk of daily doses of 600 mg PO bid is not tolerated.  Further exploration of the optimal dose/schedule and correlation with biol. end points are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopB_724LjCWLVg90H21EOLACvtfcHk0lgh3MivibAA6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVGktbs%253D&md5=d21e3fcffd95c92697fc085860be604c</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1200%2FJCO.2004.08.082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2004.08.082%26sid%3Dliteratum%253Aachs%26aulast%3DKurzrock%26aufirst%3DR.%26aulast%3DAlbitar%26aufirst%3DM.%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26aulast%3DEstey%26aufirst%3DE.%2BH.%26aulast%3DFaderl%26aufirst%3DS.%2BH.%26aulast%3DGarcia-Manero%26aufirst%3DG.%26aulast%3DThomas%26aufirst%3DD.%2BA.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DRyback%26aufirst%3DM.%2BE.%26aulast%3DThibault%26aufirst%3DA.%26aulast%3DDe%2BPorre%26aufirst%3DP.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26atitle%3DPhase%2520II%2520study%2520of%2520R115777%252C%2520a%2520farnesyl%2520transferase%2520inhibitor%252C%2520in%2520myelodysplastic%2520syndrome%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2004%26volume%3D22%26spage%3D1287%26epage%3D1292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group">Fenaux, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mufti, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aul, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germing, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cripe, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerstens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Porre, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurzrock, R.</span><span> </span><span class="NLM_article-title">A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">4158</span><span class="NLM_x">–</span> <span class="NLM_lpage">4163</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2007&pages=4158-4163&author=P.+Fenauxauthor=A.+Razaauthor=G.+J.+Muftiauthor=C.+Aulauthor=U.+Germingauthor=H.+Kantarjianauthor=L.+Cripeauthor=R.+Kerstensauthor=P.+De+Porreauthor=R.+Kurzrock&title=A+multicenter+phase+2+study+of+the+farnesyltransferase+inhibitor+tipifarnib+in+intermediate-+to+high-risk+myelodysplastic+syndrome"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFenaux%26aufirst%3DP.%26aulast%3DRaza%26aufirst%3DA.%26aulast%3DMufti%26aufirst%3DG.%2BJ.%26aulast%3DAul%26aufirst%3DC.%26aulast%3DGerming%26aufirst%3DU.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DCripe%26aufirst%3DL.%26aulast%3DKerstens%26aufirst%3DR.%26aulast%3DDe%2BPorre%26aufirst%3DP.%26aulast%3DKurzrock%26aufirst%3DR.%26atitle%3DA%2520multicenter%2520phase%25202%2520study%2520of%2520the%2520farnesyltransferase%2520inhibitor%2520tipifarnib%2520in%2520intermediate-%2520to%2520high-risk%2520myelodysplastic%2520syndrome%26jtitle%3DBlood%26date%3D2007%26volume%3D109%26spage%3D4158%26epage%3D4163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group">Kurzrock, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singhania, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freireich, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talpaz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebti, S. M.</span><span> </span><span class="NLM_article-title">Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">4527</span><span class="NLM_x">–</span> <span class="NLM_lpage">4534</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2003&pages=4527-4534&author=R.+Kurzrockauthor=H.+M.+Kantarjianauthor=J.+E.+Cortesauthor=N.+Singhaniaauthor=D.+A.+Thomasauthor=E.+F.+Wilsonauthor=J.+J.+Wrightauthor=E.+J.+Freireichauthor=M.+Talpazauthor=S.+M.+Sebti&title=Farnesyltransferase+inhibitor+R115777+in+myelodysplastic+syndrome%3A+clinical+and+biologic+activities+in+the+phase+1+setting"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKurzrock%26aufirst%3DR.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26aulast%3DSinghania%26aufirst%3DN.%26aulast%3DThomas%26aufirst%3DD.%2BA.%26aulast%3DWilson%26aufirst%3DE.%2BF.%26aulast%3DWright%26aufirst%3DJ.%2BJ.%26aulast%3DFreireich%26aufirst%3DE.%2BJ.%26aulast%3DTalpaz%26aufirst%3DM.%26aulast%3DSebti%26aufirst%3DS.%2BM.%26atitle%3DFarnesyltransferase%2520inhibitor%2520R115777%2520in%2520myelodysplastic%2520syndrome%253A%2520clinical%2520and%2520biologic%2520activities%2520in%2520the%2520phase%25201%2520setting%26jtitle%3DBlood%26date%3D2003%26volume%3D102%26spage%3D4527%26epage%3D4534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group">Alsina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fonseca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belle, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerbino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price-Troska, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overton, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruzek, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Djulbegovic, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantor, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greipp, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalton, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebti, S. M.</span><span> </span><span class="NLM_article-title">Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">3271</span><span class="NLM_x">–</span> <span class="NLM_lpage">3277</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2004&pages=3271-3277&author=M.+Alsinaauthor=R.+Fonsecaauthor=E.+F.+Wilsonauthor=A.+N.+Belleauthor=E.+Gerbinoauthor=T.+Price-Troskaauthor=R.+M.+Overtonauthor=G.+Ahmannauthor=L.+M.+Bruzekauthor=A.+A.+Adjeiauthor=S.+H.+Kaufmannauthor=J.+J.+Wrightauthor=D.+Sullivanauthor=B.+Djulbegovicauthor=A.+B.+Cantorauthor=P.+R.+Greippauthor=W.+S.+Daltonauthor=S.+M.+Sebti&title=Farnesyltransferase+inhibitor+tipifarnib+is+well+tolerated%2C+induces+stabilization+of+disease%2C+and+inhibits+farnesylation+and+oncogenic%2Ftumor+survival+pathways+in+patients+with+advanced+multiple+myeloma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAlsina%26aufirst%3DM.%26aulast%3DFonseca%26aufirst%3DR.%26aulast%3DWilson%26aufirst%3DE.%2BF.%26aulast%3DBelle%26aufirst%3DA.%2BN.%26aulast%3DGerbino%26aufirst%3DE.%26aulast%3DPrice-Troska%26aufirst%3DT.%26aulast%3DOverton%26aufirst%3DR.%2BM.%26aulast%3DAhmann%26aufirst%3DG.%26aulast%3DBruzek%26aufirst%3DL.%2BM.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26aulast%3DWright%26aufirst%3DJ.%2BJ.%26aulast%3DSullivan%26aufirst%3DD.%26aulast%3DDjulbegovic%26aufirst%3DB.%26aulast%3DCantor%26aufirst%3DA.%2BB.%26aulast%3DGreipp%26aufirst%3DP.%2BR.%26aulast%3DDalton%26aufirst%3DW.%2BS.%26aulast%3DSebti%26aufirst%3DS.%2BM.%26atitle%3DFarnesyltransferase%2520inhibitor%2520tipifarnib%2520is%2520well%2520tolerated%252C%2520induces%2520stabilization%2520of%2520disease%252C%2520and%2520inhibits%2520farnesylation%2520and%2520oncogenic%252Ftumor%2520survival%2520pathways%2520in%2520patients%2520with%2520advanced%2520multiple%2520myeloma%26jtitle%3DBlood%26date%3D2004%26volume%3D103%26spage%3D3271%26epage%3D3277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group">Karp, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flatten, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greer, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loegering, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricklis, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ritchie, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ironside, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talbott, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roboz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, X. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, N. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett-Mayer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, S. H.</span><span> </span><span class="NLM_article-title">Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">4841</span><span class="NLM_x">–</span> <span class="NLM_lpage">4852</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=4841-4852&author=J.+E.+Karpauthor=K.+Flattenauthor=E.+J.+Feldmanauthor=J.+M.+Greerauthor=D.+A.+Loegeringauthor=R.+M.+Ricklisauthor=L.+E.+Morrisauthor=E.+Ritchieauthor=B.+D.+Smithauthor=V.+Ironsideauthor=T.+Talbottauthor=G.+Robozauthor=S.+B.+Leauthor=X.+W.+Mengauthor=P.+A.+Schneiderauthor=N.+T.+Daiauthor=A.+A.+Adjeiauthor=S.+D.+Goreauthor=M.+J.+Levisauthor=J.+J.+Wrightauthor=E.+Garrett-Mayerauthor=S.+H.+Kaufmann&title=Active+oral+regimen+for+elderly+adults+with+newly+diagnosed+acute+myelogenous+leukemia%3A+a+preclinical+and+phase+1+trial+of+the+farnesyltransferase+inhibitor+tipifarnib+%28R115777%2C+Zarnestra%29+combined+with+etoposide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKarp%26aufirst%3DJ.%2BE.%26aulast%3DFlatten%26aufirst%3DK.%26aulast%3DFeldman%26aufirst%3DE.%2BJ.%26aulast%3DGreer%26aufirst%3DJ.%2BM.%26aulast%3DLoegering%26aufirst%3DD.%2BA.%26aulast%3DRicklis%26aufirst%3DR.%2BM.%26aulast%3DMorris%26aufirst%3DL.%2BE.%26aulast%3DRitchie%26aufirst%3DE.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DIronside%26aufirst%3DV.%26aulast%3DTalbott%26aufirst%3DT.%26aulast%3DRoboz%26aufirst%3DG.%26aulast%3DLe%26aufirst%3DS.%2BB.%26aulast%3DMeng%26aufirst%3DX.%2BW.%26aulast%3DSchneider%26aufirst%3DP.%2BA.%26aulast%3DDai%26aufirst%3DN.%2BT.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26aulast%3DGore%26aufirst%3DS.%2BD.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DWright%26aufirst%3DJ.%2BJ.%26aulast%3DGarrett-Mayer%26aufirst%3DE.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26atitle%3DActive%2520oral%2520regimen%2520for%2520elderly%2520adults%2520with%2520newly%2520diagnosed%2520acute%2520myelogenous%2520leukemia%253A%2520a%2520preclinical%2520and%2520phase%25201%2520trial%2520of%2520the%2520farnesyltransferase%2520inhibitor%2520tipifarnib%2520%2528R115777%252C%2520Zarnestra%2529%2520combined%2520with%2520etoposide%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D4841%26epage%3D4852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group">Van Cutsem, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van de Velde, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karasek, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oettle, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vervenne, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szawlowski, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoffski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verslype, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neumann, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Safran, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humblet, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez Ruixo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Von Hoff, D.</span><span> </span><span class="NLM_article-title">Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1430</span><span class="NLM_x">–</span> <span class="NLM_lpage">1438</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1200%2FJCO.2004.10.112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=15084616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpt1yjur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2004&pages=1430-1438&author=E.+Van+Cutsemauthor=H.+van+de+Veldeauthor=P.+Karasekauthor=H.+Oettleauthor=W.+L.+Vervenneauthor=A.+Szawlowskiauthor=P.+Schoffskiauthor=S.+Postauthor=C.+Verslypeauthor=H.+Neumannauthor=H.+Safranauthor=Y.+Humbletauthor=J.+Perez+Ruixoauthor=Y.+Maauthor=D.+Von+Hoff&title=Phase+III+trial+of+gemcitabine+plus+tipifarnib+compared+with+gemcitabine+plus+placebo+in+advanced+pancreatic+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer</span></div><div class="casAuthors">van Cutsem, E.; van de Velde, H.; Karasek, P.; Oettle, H.; Vervenne, W. L.; Szawlowski, A.; Schoffski, P.; Post, S.; Verslype, C.; Neumann, H.; Safran, H.; Humblet, Y.; Ruixo, J. Perez; Ma, Y.; von Hoff, D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1430-1438</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">The aim was to det. whether addn. of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777; Johnson and Johnson Pharmaceutical Research and Development, Beerse, Belgium) to std. gemcitabine therapy improves overall survival in advanced pancreatic cancer.  This randomized, double-blind, placebo-controlled study compared gemcitabine + tipifarnib vs. gemcitabine + placebo in patients with advanced pancreatic adenocarcinoma previously untreated with systemic therapy.  Tipifarnib was given at 200 mg bid orally continuously; gemcitabine was given at 1,000 mg/m2 i.v. weekly × 7 for 8 wk, then weekly × 3 every 4 wk.  The primary end point was overall survival; secondary end points included 6-mo and 1-yr survival rates, progression-free survival, response rate, safety, and quality of life.  Six hundred eighty-eight patients were enrolled.  Baseline characteristics were well balanced between the two treatment arms.  No statistically significant differences in survival parameters were obsd.  The median overall survival for the exptl. arm was 193 v 182 days for the control arm (P = .75); 6-mo and 1-yr survival rates were 53% and 27% v 49% and 24% for the control arm, resp.; median progression-free survival was 112 v 109 days for the control arm.  Ten drug-related deaths were reported for the exptl. arm and seven for the control arm.  Neutropenia and thrombocytopenia grade ≥ 3 were obsd. in 40% and 15% in the exptl. arm vs. 30% and 12% in the control arm.  Incidences of nonhematol. adverse events were similar in two groups.  The combination of gemcitabine and tipifarnib has an acceptable toxicity profile but does not prolong overall survival in advanced pancreatic cancer compared with single-agent gemcitabine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCHeE2twphB7Vg90H21EOLACvtfcHk0ljwW5w7YWhnZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpt1yjur0%253D&md5=782b73146b431d999d2305268e2c2c6b</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1200%2FJCO.2004.10.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2004.10.112%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BCutsem%26aufirst%3DE.%26aulast%3Dvan%2Bde%2BVelde%26aufirst%3DH.%26aulast%3DKarasek%26aufirst%3DP.%26aulast%3DOettle%26aufirst%3DH.%26aulast%3DVervenne%26aufirst%3DW.%2BL.%26aulast%3DSzawlowski%26aufirst%3DA.%26aulast%3DSchoffski%26aufirst%3DP.%26aulast%3DPost%26aufirst%3DS.%26aulast%3DVerslype%26aufirst%3DC.%26aulast%3DNeumann%26aufirst%3DH.%26aulast%3DSafran%26aufirst%3DH.%26aulast%3DHumblet%26aufirst%3DY.%26aulast%3DPerez%2BRuixo%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DVon%2BHoff%26aufirst%3DD.%26atitle%3DPhase%2520III%2520trial%2520of%2520gemcitabine%2520plus%2520tipifarnib%2520compared%2520with%2520gemcitabine%2520plus%2520placebo%2520in%2520advanced%2520pancreatic%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2004%26volume%3D22%26spage%3D1430%26epage%3D1438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group">Lersch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Cutsem, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amado, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ehninger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heike, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerr, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothenberg, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaknoen, S. L.</span><span> </span><span class="NLM_article-title">Randomized phase II study of SCH 66336 and gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas</span> <span class="citation_source-journal">Proc. Am. Soc. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">608</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2001&pages=608&author=C.+Lerschauthor=E.+Van+Cutsemauthor=R.+Amadoauthor=G.+Ehningerauthor=M.+Heikeauthor=D.+Kerrauthor=M.+L.+Rothenbergauthor=C.+M.+Baumauthor=S.+L.+Zaknoen&title=Randomized+phase+II+study+of+SCH+66336+and+gemcitabine+in+the+treatment+of+metastatic+adenocarcinoma+of+the+pancreas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLersch%26aufirst%3DC.%26aulast%3DVan%2BCutsem%26aufirst%3DE.%26aulast%3DAmado%26aufirst%3DR.%26aulast%3DEhninger%26aufirst%3DG.%26aulast%3DHeike%26aufirst%3DM.%26aulast%3DKerr%26aufirst%3DD.%26aulast%3DRothenberg%26aufirst%3DM.%2BL.%26aulast%3DBaum%26aufirst%3DC.%2BM.%26aulast%3DZaknoen%26aufirst%3DS.%2BL.%26atitle%3DRandomized%2520phase%2520II%2520study%2520of%2520SCH%252066336%2520and%2520gemcitabine%2520in%2520the%2520treatment%2520of%2520metastatic%2520adenocarcinoma%2520of%2520the%2520pancreas%26jtitle%3DProc.%2520Am.%2520Soc.%2520Clin.%2520Oncol.%26date%3D2001%26volume%3D20%26spage%3D608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group">Sharma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kemeny, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelsen, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ilson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Reilly, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaknoen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Statkevich, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollywood, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltz, L. B.</span><span> </span><span class="NLM_article-title">A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1067</span><span class="NLM_x">–</span> <span class="NLM_lpage">1071</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1093%2Fannonc%2Fmdf173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=12176785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A280%3ADC%252BD38vitFWnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2002&pages=1067-1071&author=S.+Sharmaauthor=N.+Kemenyauthor=D.+P.+Kelsenauthor=D.+Ilsonauthor=E.+O%E2%80%99Reillyauthor=S.+Zaknoenauthor=C.+Baumauthor=P.+Statkevichauthor=E.+Hollywoodauthor=Y.+Zhuauthor=L.+B.+Saltz&title=A+phase+II+trial+of+farnesyl+protein+transferase+inhibitor+SCH+66336%2C+given+by+twice-daily+oral+administration%2C+in+patients+with+metastatic+colorectal+cancer+refractory+to+5-fluorouracil+and+irinotecan"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan</span></div><div class="casAuthors">Sharma S; Kemeny N; Kelsen D P; Ilson D; O'Reilly E; Zaknoen S; Baum C; Statkevich P; Hollywood E; Zhu Y; Saltz L B</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1067-71</span>
        ISSN:<span class="NLM_cas:issn">0923-7534</span>.
    </div><div class="casAbstract">BACKGROUND:  ras genes encode Ras proteins that are important for signal transduction in cancer cells.  Farnesyl protein transferase (FPTase) is an enzyme that is responsible for a critical post-translational modification of Ras.  PATIENTS AND METHODS:  We report the results of a phase II trial of SCH 66336, an FPTase inhibitor, in patients with metastatic colorectal cancer.  This is the first reported experience of an FPTase inhibitor in this disease.  All patients were considered refractory to first- and second-line therapy.  A total of 21 evaluable patients were treated with a starting dose of 200 mg b.i.d. given continuously.  RESULTS:  The major side-effects were fatigue (grade 1 in 42%, grade 2 in 42% and grade 3 in 14%), diarrhea (grade 1 in 23% and grade 3 in 42%) and nausea (grade 2 in 16%).  Elevations in serum creatinine (grade 2 or 3) were observed in 19% of patients and appeared to be related to dehydration induced by diarrhea.  Significant hematological toxicity was not observed (only grade 1 thrombocytopenia in 19% and grade 2 or 3 anemia in 28%).  Pharmacological studies revealed adequate mean pre-dose plasma concentrations in this group of patients on day 15 of therapy.  No objective responses were observed, although stable disease was seen in three patients for several months.  Administration of SCH 66336 was accompanied by gastrointestinal toxicity.  CONCLUSIONS:  Future development of this compound cannot be recommended as monotherapy in this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTbJLEuy3k9-hFwe7cAcrfPfW6udTcc2eYhLiusiwmuA7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38vitFWnsw%253D%253D&md5=d7f56384cef6e4d48b09ddd529611c0e</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdf173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdf173%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DKemeny%26aufirst%3DN.%26aulast%3DKelsen%26aufirst%3DD.%2BP.%26aulast%3DIlson%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DE.%26aulast%3DZaknoen%26aufirst%3DS.%26aulast%3DBaum%26aufirst%3DC.%26aulast%3DStatkevich%26aufirst%3DP.%26aulast%3DHollywood%26aufirst%3DE.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DSaltz%26aufirst%3DL.%2BB.%26atitle%3DA%2520phase%2520II%2520trial%2520of%2520farnesyl%2520protein%2520transferase%2520inhibitor%2520SCH%252066336%252C%2520given%2520by%2520twice-daily%2520oral%2520administration%252C%2520in%2520patients%2520with%2520metastatic%2520colorectal%2520cancer%2520refractory%2520to%25205-fluorouracil%2520and%2520irinotecan%26jtitle%3DAnn.%2520Oncol.%26date%3D2002%26volume%3D13%26spage%3D1067%26epage%3D1071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group">Hanrahan, E. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kies, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glisson, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khuri, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginsberg, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truong, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, E. S.</span><span> </span><span class="NLM_article-title">A phase II study of lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck</span> <span class="citation_source-journal">Am. J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">274</span><span class="NLM_x">–</span> <span class="NLM_lpage">279</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1097%2FCOC.0b013e318187dd57" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=19433965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotlShur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2009&pages=274-279&author=E.+O.+Hanrahanauthor=M.+S.+Kiesauthor=B.+S.+Glissonauthor=F.+R.+Khuriauthor=L.+Fengauthor=H.+T.+Tranauthor=L.+E.+Ginsbergauthor=M.+T.+Truongauthor=W.+K.+Hongauthor=E.+S.+Kim&title=A+phase+II+study+of+lonafarnib+%28SCH66336%29+in+patients+with+chemorefractory%2C+advanced+squamous+cell+carcinoma+of+the+head+and+neck"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II study on lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck</span></div><div class="casAuthors">Hanrahan, Emer O.; Kies, Merrill S.; Glisson, Bonnie S.; Khuri, Fadlo R.; Feng, Lei; Tran, Hai T.; Ginsberg, Lawrence E.; Truong, Mylene T.; Hong, Waun K.; Kim, Edward S.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">274-279</span>CODEN:
                <span class="NLM_cas:coden">AJCODI</span>;
        ISSN:<span class="NLM_cas:issn">0277-3732</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Treatment options for recurrent squamous cell carcinoma of the head and neck (SCCHN) following platinum-based therapy are limited.  Lonafarnib is a potent, specific inhibitor of farnesyl transferase that demonstrated marked antitumor activity as monotherapy in treatment-naive SCCHN in a phase Ib study.  A phase II study of lonafarnib was conducted to det. its efficacy and safety in patients with recurrent, platinum-refractory SCCHN.  This was an open-label, phase II, single-center study in patients with recurrent SCCHN after platinum-based therapy.  A Simon 2-stage design was used, with a plan to close the study to further accrual if <2 of the first 15 patients had objective responses.  Patients were treated with lonafarnib 200 mg twice daily (b.i.d.) by mouth continuously in 4-wk cycles.  Fifteen patients with baseline Eastern Cooperative Oncol. Group PS 0-1 and median age 57 years were enrolled.  Twelve patients had received at least 2 previous chemotherapy regimens.  Median duration of treatment with lonafarnib was 61 days.  No objective response was obsd.  Seven (47%) patients maintained stable disease through ≥3 cycles of therapy.  Median time to progression and survival time were 2.04 and 9.17 mo, resp.  Most treatment-related toxicities were grade 1-2, and there were no treatment-related deaths.  Lonafarnib at a dose of 200 mg b.i.d. was well-tolerated.  However, there were no objective responses obsd. in the first 15 patients enrolled in this study, and the study was closed to further accrual, as per predefined criteria.  Further evaluation of lonafarnib in platinum-refractory SCCHN is not planned.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3F_Lfyl-vO7Vg90H21EOLACvtfcHk0lhO1hAmsIaq4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotlShur4%253D&md5=1c6ab91e96ae5a797917399d01579e36</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1097%2FCOC.0b013e318187dd57&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCOC.0b013e318187dd57%26sid%3Dliteratum%253Aachs%26aulast%3DHanrahan%26aufirst%3DE.%2BO.%26aulast%3DKies%26aufirst%3DM.%2BS.%26aulast%3DGlisson%26aufirst%3DB.%2BS.%26aulast%3DKhuri%26aufirst%3DF.%2BR.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DTran%26aufirst%3DH.%2BT.%26aulast%3DGinsberg%26aufirst%3DL.%2BE.%26aulast%3DTruong%26aufirst%3DM.%2BT.%26aulast%3DHong%26aufirst%3DW.%2BK.%26aulast%3DKim%26aufirst%3DE.%2BS.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520lonafarnib%2520%2528SCH66336%2529%2520in%2520patients%2520with%2520chemorefractory%252C%2520advanced%2520squamous%2520cell%2520carcinoma%2520of%2520the%2520head%2520and%2520neck%26jtitle%3DAm.%2520J.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D32%26spage%3D274%26epage%3D279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group">Wong, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morse, M. A.</span><span> </span><span class="NLM_article-title">Lonafarnib for cancer and progeria</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1043</span><span class="NLM_x">–</span> <span class="NLM_lpage">1055</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=1043-1055&author=N.+S.+Wongauthor=M.+A.+Morse&title=Lonafarnib+for+cancer+and+progeria"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DN.%2BS.%26aulast%3DMorse%26aufirst%3DM.%2BA.%26atitle%3DLonafarnib%2520for%2520cancer%2520and%2520progeria%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2012%26volume%3D21%26spage%3D1043%26epage%3D1055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jabbour, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verstovsek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrajoli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Statkevich, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span> </span><span class="NLM_article-title">Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">1295</span><span class="NLM_x">–</span> <span class="NLM_lpage">1302</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=1295-1302&author=J.+Cortesauthor=E.+Jabbourauthor=G.+Q.+Daleyauthor=S.+O%E2%80%99Brienauthor=S.+Verstovsekauthor=A.+Ferrajoliauthor=C.+Kollerauthor=Y.+Zhuauthor=P.+Statkevichauthor=H.+Kantarjian&title=Phase+1+study+of+lonafarnib+%28SCH+66336%29+and+imatinib+mesylate+in+patients+with+chronic+myeloid+leukemia+who+have+failed+prior+single-agent+therapy+with+imatinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DJabbour%26aufirst%3DE.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DFerrajoli%26aufirst%3DA.%26aulast%3DKoller%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DStatkevich%26aufirst%3DP.%26aulast%3DKantarjian%26aufirst%3DH.%26atitle%3DPhase%25201%2520study%2520of%2520lonafarnib%2520%2528SCH%252066336%2529%2520and%2520imatinib%2520mesylate%2520in%2520patients%2520with%2520chronic%2520myeloid%2520leukemia%2520who%2520have%2520failed%2520prior%2520single-agent%2520therapy%2520with%2520imatinib%26jtitle%3DCancer%26date%3D2007%26volume%3D110%26spage%3D1295%26epage%3D1302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group">Theodore, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geoffrois, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vermorken, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caponigro, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiedler, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chollet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravaud, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Balincourt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacombe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fumoleau, P.</span><span> </span><span class="NLM_article-title">Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">1150</span><span class="NLM_x">–</span> <span class="NLM_lpage">1157</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2005&pages=1150-1157&author=C.+Theodoreauthor=L.+Geoffroisauthor=J.+B.+Vermorkenauthor=F.+Caponigroauthor=W.+Fiedlerauthor=P.+Cholletauthor=A.+Ravaudauthor=G.+J.+Petersauthor=C.+de+Balincourtauthor=D.+Lacombeauthor=P.+Fumoleau&title=Multicentre+EORTC+study+16997%3A+feasibility+and+phase+II+trial+of+farnesyl+transferase+inhibitor+%26+gemcitabine+combination+in+salvage+treatment+of+advanced+urothelial+tract+cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTheodore%26aufirst%3DC.%26aulast%3DGeoffrois%26aufirst%3DL.%26aulast%3DVermorken%26aufirst%3DJ.%2BB.%26aulast%3DCaponigro%26aufirst%3DF.%26aulast%3DFiedler%26aufirst%3DW.%26aulast%3DChollet%26aufirst%3DP.%26aulast%3DRavaud%26aufirst%3DA.%26aulast%3DPeters%26aufirst%3DG.%2BJ.%26aulast%3Dde%2BBalincourt%26aufirst%3DC.%26aulast%3DLacombe%26aufirst%3DD.%26aulast%3DFumoleau%26aufirst%3DP.%26atitle%3DMulticentre%2520EORTC%2520study%252016997%253A%2520feasibility%2520and%2520phase%2520II%2520trial%2520of%2520farnesyl%2520transferase%2520inhibitor%2520%2526%2520gemcitabine%2520combination%2520in%2520salvage%2520treatment%2520of%2520advanced%2520urothelial%2520tract%2520cancers%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2005%26volume%3D41%26spage%3D1150%26epage%3D1157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group">Bergo, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambroziak, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregory, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otto, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagase, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balmain, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, S. G.</span><span> </span><span class="NLM_article-title">Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">171</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1128%2FMCB.22.1.171-181.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=11739732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptlOiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2002&pages=171-181&author=M.+O.+Bergoauthor=P.+Ambroziakauthor=C.+Gregoryauthor=A.+Georgeauthor=J.+C.+Ottoauthor=E.+Kimauthor=H.+Nagaseauthor=P.+J.+Caseyauthor=A.+Balmainauthor=S.+G.+Young&title=Absence+of+the+CAAX+endoprotease+Rce1%3A+effects+on+cell+growth+and+transformation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation</span></div><div class="casAuthors">Bergo, Martin O.; Ambroziak, Patricia; Gregory, Cria; George, Amanda; Otto, James C.; Kim, Edward; Nagase, Hiroki; Casey, Patrick J.; Balmain, Allan; Young, Stephen G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">171-181</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">After isoprenylation, the Ras proteins and other CAAX proteins undergo two addnl. enzymic modifications-endoproteolytic release of the last three amino acids of the protein by the protease Rce1 and methylation of the carboxyl-terminal isoprenylcysteine by the methyltransferase Icmt.  This post-isoprenylation processing is thought to be important for the assocn. of Ras proteins with membranes.  Blocking post-isoprenylation processing, by inhibiting Rce1, has been suggested as a potential approach for retarding cell growth and blocking cellular transformation.  The objective of this study was to develop a cell culture system for addressing these issues.  We generated mice with a conditional Rce1 allele (Rce1flox) and produced Rce1flox/flox fibroblasts.  Cre-mediated excision of Rce1 (thereby producing Rce1Δ/Δ fibroblasts) eliminated Ras endoproteolytic processing and methylation and caused a partial mislocalization of truncated K-Ras and H-Ras fusion proteins within cells.  Rce1Δ/Δ fibroblasts grew more slowly than Rce1flox/flox fibroblasts.  The excision of Rce1 also reduced Ras-induced transformation, as judged by the growth of colonies in soft agar.  The excision of Rce1 from a Rce1flox/flox skin carcinoma cell line also significantly retarded the growth of cells, and this effect was exaggerated by cotreatment of the cells with a farnesyltransferase inhibitor.  These studies support the idea that interference with post-isoprenylation processing retards cell growth, limits Ras-induced transformation, and sensitizes tumor cells to a farnesyltransferase inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpa8WNtXdx5frVg90H21EOLACvtfcHk0lgZ3H5q2qPFnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptlOiur4%253D&md5=179da76fc146d85df7e556dc70a104be</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1128%2FMCB.22.1.171-181.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.22.1.171-181.2002%26sid%3Dliteratum%253Aachs%26aulast%3DBergo%26aufirst%3DM.%2BO.%26aulast%3DAmbroziak%26aufirst%3DP.%26aulast%3DGregory%26aufirst%3DC.%26aulast%3DGeorge%26aufirst%3DA.%26aulast%3DOtto%26aufirst%3DJ.%2BC.%26aulast%3DKim%26aufirst%3DE.%26aulast%3DNagase%26aufirst%3DH.%26aulast%3DCasey%26aufirst%3DP.%2BJ.%26aulast%3DBalmain%26aufirst%3DA.%26aulast%3DYoung%26aufirst%3DS.%2BG.%26atitle%3DAbsence%2520of%2520the%2520CAAX%2520endoprotease%2520Rce1%253A%2520effects%2520on%2520cell%2520growth%2520and%2520transformation%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2002%26volume%3D22%26spage%3D171%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group">Manandhar, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hildebrandt, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, W. K.</span><span> </span><span class="NLM_article-title">Small-molecule inhibitors of the Rce1p CaaX protease</span> <span class="citation_source-journal">J. Biomol. Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">983</span><span class="NLM_x">–</span> <span class="NLM_lpage">993</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1177%2F1087057107307226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=17942791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht12rs7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=983-993&author=S.+P.+Manandharauthor=E.+R.+Hildebrandtauthor=W.+K.+Schmidt&title=Small-molecule+inhibitors+of+the+Rce1p+CaaX+protease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule inhibitors of the Rce1p CaaX protease</span></div><div class="casAuthors">Manandhar, Surya P.; Hildebrandt, Emily R.; Schmidt, Walter K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">983-993</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The Rce1p protease is required for the maturation of the Ras GTPase and certain other isoprenylated proteins and is considered a chemotherapeutic target.  To identify new small-mol. inhibitors of Rce1p, the authors screened the National Cancer Institute Diversity Set compd. library using in vitro assays to monitor the proteolytic processing of peptides derived from Ras and the yeast a-factor mating pheromone.  Of 46 inhibitors initially identified with a Ras-based assay, only 9 were effective in the pheromone-based assay.  The IC50 values of these 9 compds. were in the low micromolar range for both yeast (6-35 μM) and human Rce1p (0.4-46 μM).  Four compds. were somewhat Rce1p selective in that they partially inhibited the Ste24p protease and did not inhibit Ste14p isoprenylcysteine carboxyl methyltransferase, 2 enzymes also involved in the maturation of isoprenylated proteins.  The remaining 5 compds. inhibited all 3 enzymes.  The 2 most Rce1p-selective agents were ineffective trypsin inhibitors, further supporting the specificity of these agents for Rce1p.  The 5 least specific compds. formed colloidal aggregates, a proposed common feature of promiscuous inhibitors.  Interestingly, the most specific Rce1p inhibitor also formed a colloidal aggregate.  In vivo studies revealed that treatment of wild-type yeast with compd. (I) induced a Ras2p delocalization phenotype that mimics obsd. effects in rce1 ste24 null yeast.  The 9 compds. identified in this study represent new tools for understanding the enzymol. of postisoprenylation-modifying enzymes and provide new insight for the future development of Rce1p inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfMGTmaz0SkrVg90H21EOLACvtfcHk0lgofIYIJogstA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht12rs7rF&md5=6fec75a256a70db46d5e7a12aa4b91db</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1177%2F1087057107307226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057107307226%26sid%3Dliteratum%253Aachs%26aulast%3DManandhar%26aufirst%3DS.%2BP.%26aulast%3DHildebrandt%26aufirst%3DE.%2BR.%26aulast%3DSchmidt%26aufirst%3DW.%2BK.%26atitle%3DSmall-molecule%2520inhibitors%2520of%2520the%2520Rce1p%2520CaaX%2520protease%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2007%26volume%3D12%26spage%3D983%26epage%3D993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group">van der Hoeven, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chigurupati, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parton, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, J. F.</span><span> </span><span class="NLM_article-title">Fendiline inhibits K-Ras plasma membrane localization and blocks K-Ras signal transmission</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">237</span><span class="NLM_x">–</span> <span class="NLM_lpage">251</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1128%2FMCB.00884-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=23129805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1Sktbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=237-251&author=D.+van+der+Hoevenauthor=K.+J.+Choauthor=X.+Maauthor=S.+Chigurupatiauthor=R.+G.+Partonauthor=J.+F.+Hancock&title=Fendiline+inhibits+K-Ras+plasma+membrane+localization+and+blocks+K-Ras+signal+transmission"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Fendiline inhibits K-Ras plasma membrane localization and blocks K-Ras signal transmission</span></div><div class="casAuthors">van der Hoeven, Dharini; Cho, Kwang-jin; Ma, Xiaoping; Chigurupati, Sravanthi; Parton, Robert G.; Hancock, John F.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">237-251</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Ras proteins regulate signaling pathways important for cell growth, differentiation, and survival.  Oncogenic mutant Ras proteins are commonly expressed in human tumors, with mutations of the K-Ras isoform being most prevalent.  To be active, K-Ras must undergo posttranslational processing and assoc. with the plasma membrane.  We therefore devised a high-content screening assay to search for inhibitors of K-Ras plasma membrane assocn.  Using this assay, we identified fendiline, an L-type calcium channel blocker, as a specific inhibitor of K-Ras plasma membrane targeting with no detectable effect on the localization of H- and N-Ras.  Other classes of L-type calcium channel blockers did not mislocalize K-Ras, suggesting a mechanism that is unrelated to calcium channel blockade.  Fendilien did not inhibit K-Ras posttranslational processing but significantly reduced nanoclustering of K-Ras and redistributed K-Ras from the plasma membrane to the endoplasmic reticulum (ER), Golgi app., endosomes, and cytosol.  Fendiline significantly inhibited signaling downstream of constitutively active K-Ras and endogenous K-Ras signaling in cells transformed by oncogenic H-Ras.  Consistent with these effects, fendiline blocked the proliferation of pancreatic, colon, lung, and endometrial cancer cell lines expressing oncogenic mutant K-Ras.  Taken together, these results suggest that inhibitors of K-Ras plasma membrane localization may have utility as novel K-Ras-specific anticancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQwMRHBsb38rVg90H21EOLACvtfcHk0lgofIYIJogstA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1Sktbs%253D&md5=566edae36147a1c489f94e06c6caa8b1</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1128%2FMCB.00884-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00884-12%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BHoeven%26aufirst%3DD.%26aulast%3DCho%26aufirst%3DK.%2BJ.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DChigurupati%26aufirst%3DS.%26aulast%3DParton%26aufirst%3DR.%2BG.%26aulast%3DHancock%26aufirst%3DJ.%2BF.%26atitle%3DFendiline%2520inhibits%2520K-Ras%2520plasma%2520membrane%2520localization%2520and%2520blocks%2520K-Ras%2520signal%2520transmission%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2013%26volume%3D33%26spage%3D237%26epage%3D251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group">Marciano, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ben-Baruch, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marom, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egozi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haklai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kloog, Y.</span><span> </span><span class="NLM_article-title">Farnesyl derivatives of rigid carboxylic acids—inhibitors of ras-dependent cell growth</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1267</span><span class="NLM_x">–</span> <span class="NLM_lpage">1272</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00008a004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=1267-1272&author=D.+Marcianoauthor=G.+Ben-Baruchauthor=M.+Maromauthor=Y.+Egoziauthor=R.+Haklaiauthor=Y.+Kloog&title=Farnesyl+derivatives+of+rigid+carboxylic+acids%E2%80%94inhibitors+of+ras-dependent+cell+growth"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Fjm00008a004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00008a004%26sid%3Dliteratum%253Aachs%26aulast%3DMarciano%26aufirst%3DD.%26aulast%3DBen-Baruch%26aufirst%3DG.%26aulast%3DMarom%26aufirst%3DM.%26aulast%3DEgozi%26aufirst%3DY.%26aulast%3DHaklai%26aufirst%3DR.%26aulast%3DKloog%26aufirst%3DY.%26atitle%3DFarnesyl%2520derivatives%2520of%2520rigid%2520carboxylic%2520acids%25E2%2580%2594inhibitors%2520of%2520ras-dependent%2520cell%2520growth%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D1267%26epage%3D1272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group">Marom, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haklai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ben-Baruch, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marciano, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egozi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kloog, Y.</span><span> </span><span class="NLM_article-title">Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">270</span><span class="NLM_x">, </span> <span class="NLM_fpage">22263</span><span class="NLM_x">–</span> <span class="NLM_lpage">22270</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=22263-22270&author=M.+Maromauthor=R.+Haklaiauthor=G.+Ben-Baruchauthor=D.+Marcianoauthor=Y.+Egoziauthor=Y.+Kloog&title=Selective+inhibition+of+Ras-dependent+cell+growth+by+farnesylthiosalisylic+acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarom%26aufirst%3DM.%26aulast%3DHaklai%26aufirst%3DR.%26aulast%3DBen-Baruch%26aufirst%3DG.%26aulast%3DMarciano%26aufirst%3DD.%26aulast%3DEgozi%26aufirst%3DY.%26aulast%3DKloog%26aufirst%3DY.%26atitle%3DSelective%2520inhibition%2520of%2520Ras-dependent%2520cell%2520growth%2520by%2520farnesylthiosalisylic%2520acid%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26spage%3D22263%26epage%3D22270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group">Boufaied, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wioland, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falardeau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gourdeau, H.</span><span> </span><span class="NLM_article-title">TLN-4601, a novel anticancer agent, inhibits Ras signaling post Ras prenylation and before MEK activation</span> <span class="citation_source-journal">Anti-Cancer Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">543</span><span class="NLM_x">–</span> <span class="NLM_lpage">552</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=543-552&author=N.+Boufaiedauthor=M.+A.+Wiolandauthor=P.+Falardeauauthor=H.+Gourdeau&title=TLN-4601%2C+a+novel+anticancer+agent%2C+inhibits+Ras+signaling+post+Ras+prenylation+and+before+MEK+activation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoufaied%26aufirst%3DN.%26aulast%3DWioland%26aufirst%3DM.%2BA.%26aulast%3DFalardeau%26aufirst%3DP.%26aulast%3DGourdeau%26aufirst%3DH.%26atitle%3DTLN-4601%252C%2520a%2520novel%2520anticancer%2520agent%252C%2520inhibits%2520Ras%2520signaling%2520post%2520Ras%2520prenylation%2520and%2520before%2520MEK%2520activation%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2010%26volume%3D21%26spage%3D543%26epage%3D552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group">Baines, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span> </span><span class="NLM_article-title">Inhibition of Ras for cancer treatment: the search continues</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1787</span><span class="NLM_x">–</span> <span class="NLM_lpage">1808</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.4155%2Ffmc.11.121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=22004085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlertbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=1787-1808&author=A.+T.+Bainesauthor=D.+Xuauthor=C.+J.+Der&title=Inhibition+of+Ras+for+cancer+treatment%3A+the+search+continues"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Ras for cancer treatment: the search continues</span></div><div class="casAuthors">Baines, Antonio T.; Xu, Dapeng; Der, Channing J.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1787-1808</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The RAS oncogenes (HRAS, NRAS and KRAS) comprise the most frequently mutated class of oncogenes in human cancers (33%), thus stimulating intensive effort in developing anti-Ras inhibitors for cancer treatment.  Despite intensive effort, to date, no effective anti-Ras strategies have successfully made it to the clinic.  We present an overview of past and ongoing strategies to inhibit oncogenic Ras in cancer.  Since approaches to directly target mutant Ras have not been successful, most efforts have focused on indirect approaches to block Ras membrane assocn. or downstream effector signaling.  While inhibitors of effector signaling are currently under clin. evaluation, genome-wide unbiased genetic screens have identified novel directions for future anti-Ras drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGSljlfnR2TbVg90H21EOLACvtfcHk0liOfT9wogPHvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlertbjJ&md5=bb810b0cf2b8dc975d5a476907f5c2ec</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.4155%2Ffmc.11.121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.11.121%26sid%3Dliteratum%253Aachs%26aulast%3DBaines%26aufirst%3DA.%2BT.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DInhibition%2520of%2520Ras%2520for%2520cancer%2520treatment%253A%2520the%2520search%2520continues%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2011%26volume%3D3%26spage%3D1787%26epage%3D1808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group">Laheru, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajeshkumar, N. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McAllister, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsweig, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donehower, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimeno, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linden, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudek, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hidalgo, M.</span><span> </span><span class="NLM_article-title">Integrated preclinical and clinical development of <i>S</i>-<i>trans</i>,<i>trans</i>-farnesylthiosalicylic acid (FTS, salirasib) in pancreatic cancer</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">2391</span><span class="NLM_x">–</span> <span class="NLM_lpage">2399</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=2391-2399&author=D.+Laheruauthor=P.+Shahauthor=N.+V.+Rajeshkumarauthor=F.+McAllisterauthor=G.+Taylorauthor=H.+Goldsweigauthor=D.+T.+Leauthor=R.+Donehowerauthor=A.+Jimenoauthor=S.+Lindenauthor=M.+Zhaoauthor=D.+Songauthor=M.+A.+Rudekauthor=M.+Hidalgo&title=Integrated+preclinical+and+clinical+development+of+S-trans%2Ctrans-farnesylthiosalicylic+acid+%28FTS%2C+salirasib%29+in+pancreatic+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLaheru%26aufirst%3DD.%26aulast%3DShah%26aufirst%3DP.%26aulast%3DRajeshkumar%26aufirst%3DN.%2BV.%26aulast%3DMcAllister%26aufirst%3DF.%26aulast%3DTaylor%26aufirst%3DG.%26aulast%3DGoldsweig%26aufirst%3DH.%26aulast%3DLe%26aufirst%3DD.%2BT.%26aulast%3DDonehower%26aufirst%3DR.%26aulast%3DJimeno%26aufirst%3DA.%26aulast%3DLinden%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DSong%26aufirst%3DD.%26aulast%3DRudek%26aufirst%3DM.%2BA.%26aulast%3DHidalgo%26aufirst%3DM.%26atitle%3DIntegrated%2520preclinical%2520and%2520clinical%2520development%2520of%2520S-trans%252Ctrans-farnesylthiosalicylic%2520acid%2520%2528FTS%252C%2520salirasib%2529%2520in%2520pancreatic%2520cancer%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2012%26volume%3D30%26spage%3D2391%26epage%3D2399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizvi, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietanza, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azzoli, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krug, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginsberg, M. S.</span><span> </span><span class="NLM_article-title">A phase II trial of salirasib in patients with lung adenocarcinomas with KRAS mutations</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1435</span><span class="NLM_x">–</span> <span class="NLM_lpage">1437</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1097%2FJTO.0b013e318223c099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=21847063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A280%3ADC%252BC3MjmvV2qsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=1435-1437&author=G.+J.+Rielyauthor=M.+L.+Johnsonauthor=C.+Medinaauthor=N.+A.+Rizviauthor=V.+A.+Millerauthor=M.+G.+Krisauthor=M.+C.+Pietanzaauthor=C.+G.+Azzoliauthor=L.+M.+Krugauthor=W.+Paoauthor=M.+S.+Ginsberg&title=A+phase+II+trial+of+salirasib+in+patients+with+lung+adenocarcinomas+with+KRAS+mutations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations</span></div><div class="casAuthors">Riely Gregory J; Johnson Melissa L; Medina Chanoa; Rizvi Naiyer A; Miller Vincent A; Kris Mark G; Pietanza M Catherine; Azzoli Christopher G; Krug Lee M; Pao William; Ginsberg Michelle S</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1435-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  KRAS mutations are present in 30% of lung adenocarcinomas.  Salirasib prevents Ras membrane binding thereby blocking the function of all Ras isoforms.  This phase II study determined the activity of salirasib in patients with advanced lung adenocarcinomas with KRAS mutations.  METHODS:  Two cohorts of patients with stage IIIB/IV lung adenocarcinoma were eligible: patients with tumors with KRAS mutations who were previously treated with chemotherapy and patients receiving initial therapy who had ≥15 pack-year smoking history.  Salirasib was given orally from days 1 to 28 of a 35-day cycle.  The primary end point was the rate of nonprogression at 10 weeks.  RESULTS:  Thirty-three patients were enrolled.  Thirty patients had KRAS mutations (23 patients who were previously treated and 7/10 patients who had no prior therapy).  Of the previously treated patients, 7 of 23 (30%) had stable disease at 10 weeks, and 4 of 10 (40%) previously untreated patients had stable disease at 10 weeks.  No patient had a radiographic partial response (0% observed rate, 95% confidence interval 0-12%).  The median overall survival was not reached (>9 months) for previously untreated patients and it was 15 months for patients who received prior chemotherapy.  Diarrhea, nausea, and fatigue were the most common toxicities.  CONCLUSIONS:  Salirasib at the current dose and schedule has insufficient activity in the treatment of KRAS mutant lung adenocarcinoma to warrant further evaluation.  The successful enrollment of 30 patients with tumors with KRAS mutant lung adenocarcinoma over 15 months at a single site demonstrates that drug trials directed at a KRAS-specific genotype in lung cancer are feasible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRd97gWb8zCtINpW7w2tapOfW6udTcc2ebV1MiXMT9Gk7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MjmvV2qsA%253D%253D&md5=cf9ac4f926c6c6e5f40a2bf9c258b863</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1097%2FJTO.0b013e318223c099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0b013e318223c099%26sid%3Dliteratum%253Aachs%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DJohnson%26aufirst%3DM.%2BL.%26aulast%3DMedina%26aufirst%3DC.%26aulast%3DRizvi%26aufirst%3DN.%2BA.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DPietanza%26aufirst%3DM.%2BC.%26aulast%3DAzzoli%26aufirst%3DC.%2BG.%26aulast%3DKrug%26aufirst%3DL.%2BM.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DGinsberg%26aufirst%3DM.%2BS.%26atitle%3DA%2520phase%2520II%2520trial%2520of%2520salirasib%2520in%2520patients%2520with%2520lung%2520adenocarcinomas%2520with%2520KRAS%2520mutations%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2011%26volume%3D6%26spage%3D1435%26epage%3D1437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group">Mason, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belanger, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholas, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vallières, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kavan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desjardins, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omuro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reymond, D.</span><span> </span><span class="NLM_article-title">A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression</span> <span class="citation_source-journal">J. Neuro-Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">343</span><span class="NLM_x">–</span> <span class="NLM_lpage">349</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1007%2Fs11060-011-0747-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=22048878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A280%3ADC%252BC383ovFWrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2012&pages=343-349&author=W.+P.+Masonauthor=K.+Belangerauthor=G.+Nicholasauthor=I.+Valli%C3%A8resauthor=D.+Mathieuauthor=P.+Kavanauthor=A.+Desjardinsauthor=A.+Omuroauthor=D.+Reymond&title=A+phase+II+study+of+the+Ras-MAPK+signaling+pathway+inhibitor+TLN-4601+in+patients+with+glioblastoma+at+first+progression"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression</span></div><div class="casAuthors">Mason Warren P; Belanger Karl; Nicholas Garth; Vallieres Isabelle; Mathieu David; Kavan Petr; Desjardins Annick; Omuro Antonio; Reymond Didier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuro-oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">343-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This phase II trial was undertaken to evaluate the efficacy of TLN-4601 in patients with glioblastoma (GBM) at first progression.  TLN-4601 inhibits the Ras-MAPK signaling pathway, and in animal models crosses the blood-brain barrier and accumulates in implanted gliomas, possibly by binding specifically to the peripheral benzodiazepine receptor.  A maximum of 40 patients with recurrent GBM were to be enrolled in this study.  TLN-4601 was administered at a dose of 480 mg/m(2)/day by continuous intravenous (CIV) administration.  Each 21-day cycle consisted of a 14-day CIV administration and a 7-day recovery period.  Samples were obtained from all patients for pharmacokinetic evaluations (PK) and for Raf-1 and pERK biomarker assessment using immunohistochemistry and flow cytometry.  Following enrollment of 20 patients, this study was terminated due to a lack of efficacy.  Of 17 evaluable patients, 14 had MR scans performed after two cycles of TLN-4601.  Of these 14 patients, three had stable disease and 11 had disease progression.  Only three patients had MR scans performed after four cycles and all had evidence of radiographic progression.  Serum PKs confirmed that patients were exposed to TLN-4601 at targeted drug levels.  TLN-4601 was generally well tolerated although two patients discontinued treatment due to adverse events.  Biomarker analysis did not show consistent changes.  TLN-4601 infused via CIV at 480 mg/m(2)/day for 14 of 21 days is well tolerated by patients with progressive GBM.  However, this agent is ineffective in progressive GBM when administered as monotherapy in this schedule.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTKYvqBNi0lOukdrW1FkXG-fW6udTcc2eYZ64cEBq7Bc7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383ovFWrsg%253D%253D&md5=8ab317d5679cde6b9ae1e4b10e79ef1b</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1007%2Fs11060-011-0747-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11060-011-0747-6%26sid%3Dliteratum%253Aachs%26aulast%3DMason%26aufirst%3DW.%2BP.%26aulast%3DBelanger%26aufirst%3DK.%26aulast%3DNicholas%26aufirst%3DG.%26aulast%3DValli%25C3%25A8res%26aufirst%3DI.%26aulast%3DMathieu%26aufirst%3DD.%26aulast%3DKavan%26aufirst%3DP.%26aulast%3DDesjardins%26aufirst%3DA.%26aulast%3DOmuro%26aufirst%3DA.%26aulast%3DReymond%26aufirst%3DD.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520the%2520Ras-MAPK%2520signaling%2520pathway%2520inhibitor%2520TLN-4601%2520in%2520patients%2520with%2520glioblastoma%2520at%2520first%2520progression%26jtitle%3DJ.%2520Neuro-Oncol.%26date%3D2012%26volume%3D107%26spage%3D343%26epage%3D349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heelan, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H. E.</span><span> </span><span class="NLM_article-title">KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e17</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e17&author=W.+Paoauthor=T.+Y.+Wangauthor=G.+J.+Rielyauthor=V.+A.+Millerauthor=Q.+Panauthor=M.+Ladanyiauthor=M.+F.+Zakowskiauthor=R.+T.+Heelanauthor=M.+G.+Krisauthor=H.+E.+Varmus&title=KRAS+mutations+and+primary+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DT.%2BY.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPan%26aufirst%3DQ.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DHeelan%26aufirst%3DR.%2BT.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%2BE.%26atitle%3DKRAS%2520mutations%2520and%2520primary%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3De17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emanuele, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Creighton, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlabach, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westbrook, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elledge, S. J.</span><span> </span><span class="NLM_article-title">A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">137</span><span class="NLM_x">, </span> <span class="NLM_fpage">835</span><span class="NLM_x">–</span> <span class="NLM_lpage">848</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1016%2Fj.cell.2009.05.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=19490893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVCltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2009&pages=835-848&author=J.+Luoauthor=M.+J.+Emanueleauthor=D.+Liauthor=C.+J.+Creightonauthor=M.+R.+Schlabachauthor=T.+F.+Westbrookauthor=K.+K.+Wongauthor=S.+J.+Elledge&title=A+genome-wide+RNAi+screen+identifies+multiple+synthetic+lethal+interactions+with+the+Ras+oncogene"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene</span></div><div class="casAuthors">Luo, Ji; Emanuele, Michael J.; Li, Danan; Creighton, Chad J.; Schlabach, Michael R.; Westbrook, Thomas F.; Wong, Kwok-Kin; Elledge, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">835-848</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Oncogenic mutations in the small GTPase Ras are highly prevalent in cancer, but an understanding of the vulnerabilities of these cancers is lacking.  We undertook a genome-wide RNAi screen to identify synthetic lethal interactions with the KRAS oncogene.  We discovered a diverse set of proteins whose depletion selectively impaired the viability of Ras mutant cells.  Among these we obsd. a strong enrichment for genes with mitotic functions.  We describe a pathway involving the mitotic kinase PLK1, the anaphase-promoting complex/cyclosome, and the proteasome that, when inhibited, results in prometaphase accumulation and the subsequent death of Ras mutant cells.  Gene expression anal. indicates that reduced expression of genes in this pathway correlates with increased survival of patients bearing tumors with a Ras transcriptional signature.  Our results suggest a previously underappreciated role for Ras in mitotic progression and demonstrate a pharmacol. tractable pathway for the potential treatment of cancers harboring Ras mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmWFKW3XYaabVg90H21EOLACvtfcHk0litfG6qz-Ncow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVCltb4%253D&md5=f06fd1f1c469495489ad2ac7f0cab090</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DEmanuele%26aufirst%3DM.%2BJ.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCreighton%26aufirst%3DC.%2BJ.%26aulast%3DSchlabach%26aufirst%3DM.%2BR.%26aulast%3DWestbrook%26aufirst%3DT.%2BF.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DElledge%26aufirst%3DS.%2BJ.%26atitle%3DA%2520genome-wide%2520RNAi%2520screen%2520identifies%2520multiple%2520synthetic%2520lethal%2520interactions%2520with%2520the%2520Ras%2520oncogene%26jtitle%3DCell%26date%3D2009%26volume%3D137%26spage%3D835%26epage%3D848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group">Barr, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silljé, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nigg, E. A.</span><span> </span><span class="NLM_article-title">Polo-like kinases and the orchestration of cell division</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">440</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1038%2Fnrm1401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=15173822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVarsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=429-440&author=F.+A.+Barrauthor=H.+H.+Sillj%C3%A9author=E.+A.+Nigg&title=Polo-like+kinases+and+the+orchestration+of+cell+division"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Polo-like kinases and the orchestration of cell division</span></div><div class="casAuthors">Barr, Francis A.; Sillje, Herman H. W.; Nigg, Erich A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">429-441</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Polo-like kinases (Plks) are increasingly recognized as key regulators of mitosis, meiosis and cytokinesis.  In agreement with a broad range of proposed functions during cell division, Plks are subject to complex temporal and spatial control.  Recent findings are uncovering the mechanisms of Plk regulation, notably their targeting to different cellular structures through interactions with phosphorylated docking proteins.  Moreover, information is emerging on the substrate specificity of Plks and the role of individual substrates in M-phase progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLN4E8Z5Hjq7Vg90H21EOLACvtfcHk0li5YFTe4Ijl2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVarsLk%253D&md5=8c11ac86d8b157dfa74ab95841e9eba0</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1038%2Fnrm1401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm1401%26sid%3Dliteratum%253Aachs%26aulast%3DBarr%26aufirst%3DF.%2BA.%26aulast%3DSillj%25C3%25A9%26aufirst%3DH.%2BH.%26aulast%3DNigg%26aufirst%3DE.%2BA.%26atitle%3DPolo-like%2520kinases%2520and%2520the%2520orchestration%2520of%2520cell%2520division%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2004%26volume%3D5%26spage%3D429%26epage%3D440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group">Strebhardt, K.</span><span> </span><span class="NLM_article-title">Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">643</span><span class="NLM_x">–</span> <span class="NLM_lpage">660</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1038%2Fnrd3184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=20671765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCktrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=643-660&author=K.+Strebhardt&title=Multifaceted+polo-like+kinases%3A+drug+targets+and+antitargets+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy</span></div><div class="casAuthors">Strebhardt, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">643-660</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The polo-like kinase 1 (PLK1) acts in concert with cyclin-dependent kinase 1-cyclin B1 and Aurora kinases to orchestrate a wide range of crit. cell cycle events.  Because PLK1 has been preclinically validated as a cancer target, small-mol. inhibitors of PLK1 have become attractive candidates for anticancer drug development.  Although the roles of the closely related PLK2, PLK3 and PLK4 in cancer are less well understood, there is evidence showing that PLK2 and PLK3 act as tumor suppressors through their functions in the p53 signalling network, which guards the cell against various stress signals.  In this article, recent insights into the biol. of PLKs will be reviewed, with an emphasis on their role in malignant transformation, and progress in the development of small-mol. PLK1 inhibitors will be examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaWCrqfphwErVg90H21EOLACvtfcHk0li5YFTe4Ijl2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCktrw%253D&md5=62ab87ce3392ce187d7d62ac5f7c2679</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1038%2Fnrd3184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3184%26sid%3Dliteratum%253Aachs%26aulast%3DStrebhardt%26aufirst%3DK.%26atitle%3DMultifaceted%2520polo-like%2520kinases%253A%2520drug%2520targets%2520and%2520antitargets%2520for%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D643%26epage%3D660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group">Kumar, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molina-Arcas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steckel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">East, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diefenbacher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armenteros-Monterroso, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lassailly, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nye, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamp, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behrens, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downward, J.</span><span> </span><span class="NLM_article-title">The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">149</span><span class="NLM_x">, </span> <span class="NLM_fpage">642</span><span class="NLM_x">–</span> <span class="NLM_lpage">655</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2012&pages=642-655&author=M.+S.+Kumarauthor=D.+C.+Hancockauthor=M.+Molina-Arcasauthor=M.+Steckelauthor=P.+Eastauthor=M.+Diefenbacherauthor=E.+Armenteros-Monterrosoauthor=F.+Lassaillyauthor=N.+Matthewsauthor=E.+Nyeauthor=G.+Stampauthor=A.+Behrensauthor=J.+Downward&title=The+GATA2+transcriptional+network+is+requisite+for+RAS+oncogene-driven+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DM.%2BS.%26aulast%3DHancock%26aufirst%3DD.%2BC.%26aulast%3DMolina-Arcas%26aufirst%3DM.%26aulast%3DSteckel%26aufirst%3DM.%26aulast%3DEast%26aufirst%3DP.%26aulast%3DDiefenbacher%26aufirst%3DM.%26aulast%3DArmenteros-Monterroso%26aufirst%3DE.%26aulast%3DLassailly%26aufirst%3DF.%26aulast%3DMatthews%26aufirst%3DN.%26aulast%3DNye%26aufirst%3DE.%26aulast%3DStamp%26aufirst%3DG.%26aulast%3DBehrens%26aufirst%3DA.%26aulast%3DDownward%26aufirst%3DJ.%26atitle%3DThe%2520GATA2%2520transcriptional%2520network%2520is%2520requisite%2520for%2520RAS%2520oncogene-driven%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DCell%26date%3D2012%26volume%3D149%26spage%3D642%26epage%3D655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group">Puyol, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martín, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubus, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulero, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pizcueta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerra, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santamaría, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacid, M.</span><span> </span><span class="NLM_article-title">A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">63</span><span class="NLM_x">–</span> <span class="NLM_lpage">73</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=63-73&author=M.+Puyolauthor=A.+Mart%C3%ADnauthor=P.+Dubusauthor=F.+Muleroauthor=P.+Pizcuetaauthor=G.+Khanauthor=C.+Guerraauthor=D.+Santamar%C3%ADaauthor=M.+Barbacid&title=A+synthetic+lethal+interaction+between+K-Ras+oncogenes+and+Cdk4+unveils+a+therapeutic+strategy+for+non-small+cell+lung+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPuyol%26aufirst%3DM.%26aulast%3DMart%25C3%25ADn%26aufirst%3DA.%26aulast%3DDubus%26aufirst%3DP.%26aulast%3DMulero%26aufirst%3DF.%26aulast%3DPizcueta%26aufirst%3DP.%26aulast%3DKhan%26aufirst%3DG.%26aulast%3DGuerra%26aufirst%3DC.%26aulast%3DSantamar%25C3%25ADa%26aufirst%3DD.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DA%2520synthetic%2520lethal%2520interaction%2520between%2520K-Ras%2520oncogenes%2520and%2520Cdk4%2520unveils%2520a%2520therapeutic%2520strategy%2520for%2520non-small%2520cell%2520lung%2520carcinoma%26jtitle%3DCancer%2520Cell%26date%3D2010%26volume%3D18%26spage%3D63%26epage%3D73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Targeting the cancer kinome through polypharmacology</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Fjm3017706&amp;key=10.1038%2Fnrc2787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Fjm3017706&amp;key=20094047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Fjm3017706&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=130-137&author=Z.+A.+Knightauthor=H.+Linauthor=K.+M.+Shokat&title=Targeting+the+cancer+kinome+through+polypharmacology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cancer kinome through polypharmacology</span></div><div class="casAuthors">Knight, Zachary A.; Lin, Henry; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-137</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Kinase inhibitors are the largest class of new cancer drugs.  However, it is already apparent that most tumors can escape from the inhibition of any single kinase.  If it is necessary to inhibit multiple kinases, how do we choose which ones.  In this Opinion article, we discuss some of the strategies that are currently being used to identify new therapeutic combinations of kinase targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkDv2FeeH58rVg90H21EOLACvtfcHk0ljbcvItAatucw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D&md5=9aaa314e54b43889e147a9f11ac77072</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1038%2Fnrc2787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2787%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DTargeting%2520the%2520cancer%2520kinome%2520through%2520polypharmacology%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D130%26epage%3D137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm3017706&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2013.56.issue-13%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Fjm3017706%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm3017706" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677b0f579e443c2e","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
